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Abstract 
An understanding of the underlying mechanisms by which proteins engage and communicate within 
the complex cellular environment is critical to the elucidation of the molecular basis of disease states 
and the development of safer, more efficacious drug therapies. Diverse cellular functions, including 
replication, transcription, cell growth and intracellular signal transduction, are governed by extensive 
networks of protein-protein interactions (PPIs). Disruption of the finely-tuned cellular networks due 
to the formation of aberrant or unregulated PPIs is implicated in the development and progression 
of cancer. As a result, over the last decade, PPI modulation has developed as an attractive molecular 
target for novel cancer therapies and as a powerful research tool in chemical biology to provide 
insight into the cellular transformations involved in carcinogenesis.  
 
Chapter 1 provides a review of the physiological importance of PPIs and the role they play in the 
development and progression of cancer. A summary of the challenges associated with targeting PPIs 
is given, highlighting the changing perception regarding the drugabbility of PPIs and the 
technological and conceptual advances driving this transformation. A brief overview of the 
approaches used to identify PPI modulators links the reader to the appropriate chapter for further 
discussion and utilisation of a selection of these methods. 
 
Chapter 2 describes the application of a virtual screening approach to discover PPI modulators. In 
particular, the development of an in silico – in vitro screening method to identify modulators of the 
protein interactome of the AAA+ protein reptin. The synthesis and optimisation of two hit 
compounds is outlined, with a discussion of their predicted binding modes, mode of action, potential 
as chemical tools and lead molecules for an anti-cancer drug discovery programme.  
 
Chapter 3 highlights the potential to discover PPI modulators from Nature’s rich source of 
structurally complex, bioactive molecules. A synthetic approach to a sub-family of tetramic acid 
natural products is outlined, involving the development of a short, asymmetric synthesis of 
unnatural 4,4-disubstituted glutamic acid derivatives. The first total syntheses of the potent 
siderophore harzianic acid and the PAC3 PPI inhibitor JBIR-22 are reported. In addition, the potential 
role of a Diels-Alderase enzyme in the biosynthesis of JBIR-22 and the development of a chiral 
catalysed intramolecular Diels-Alder of an advanced JBIR-22 intermediate is investigated. 
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Chapter 4 discusses the use of structure based design techniques in the development of PPI 
modulators. The process involved in the design of two series of inhibitors of PICK PDZ domain 
mediated interactions is outlined. This leads to the development and optimisation of synthetic 
routes to both series of inhibitors, including the utilisation of a strategic sp3-sp2 cross coupling 
reaction. Finally, preliminary biological assessment of the inhibitors is reported.  
 
Chapter 5 gives a brief overview of high-throughput screening (HTS) methods used to identify PPI 
modulators. The utilisation of a forward chemical genetics screen to identify the p53 activator MJ05 
is described. A racemic and asymmetric route to MJ05 is developed and biochemical analysis of the 
two enantiomers of MJ05 is reported including the investigation of MJ05 as an adjuvant therapy for 
the treatment of cancer. 
 
Chapter 6 provides a general overview of the outcome of the different approaches used in this 
research to discover PPI modulators. Particular emphasis is placed on the development of chemical 
tools for the elucidation and dissection of the physiological role of protein-protein interactions and 
the identification of novel drug targets, in addition to the identification of lead molecules for PPI 
drug development programmes. 
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1 General Introduction 
 
Landmark technological and conceptual advances in biochemistry, molecular cell biology and 
genomic technologies have progressively transformed contemporary understanding of the extensive 
and responsive protein interaction networks which regulate essential cellular processes.1 Genome-
wide proteomic studies have heightened awareness of the significant and ubiquitous role of protein-
protein interactions (PPIs) in cellular physiology.2 Critical cellular functions, including replication, 
transcription, cell growth and intracellular signal transduction, are all governed either by finely-
tuned PPI mediated transient protein interactions or by the formation of dynamic multiprotein 
complexes.3,4 An understanding of the underlying mechanisms of how proteins engage and 
communicate within the extensive cellular network has allowed the elucidation of the molecular 
basis of a number of disease states, especially complex multifactorial ones such as cancer.  
 
1.1 PPIs and Cancer 
A variety of genetic and epigenetic alterations induce the transformation of normal cells into cancer 
cells through the acquisition of physical and molecular characteristics that promote tumorigenesis. 
These hallmarks of cancer include sustained independent proliferation, evasion of growth 
suppressors and apoptotic signals and the ability to metastasise to distal sites.5–7 The development 
and progression of cancer is at least in part determined by a combination of alterations in the 
operation of finely-tuned PPI networks.8 It is now well established that aberrant protein-protein 
interactions, either from the loss of essential interactions, unchecked cellular signalling and 
formation and/or stabilisation of a protein complex at the wrong time or location can result in 
intracellular malfunctions, such as the uncontrolled cell growth that typifies cancer.3,4,9 Several PPI 
complexes have been implicated in the acquisition of the hallmark characteristics of cancer, the 
relay of oncogenic signals and the progression and maintenance of the malignant phenotype.10 Thus, 
over the last decade, PPI modulation has developed as an attractive molecular target for novel 
cancer therapies and as a powerful research tool in chemical biology to advance our understanding 
of the underlying mechanisms involved in carcinogenesis.11,12 
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1.2 PPI Modulators 
The major motivation driving PPI drug discovery is the potential to provide safer and more effective 
therapies for complex diseases, given the ubiquitous importance of PPIs to cellular pathology, and 
their orthogonality to conventional drug targets.1 Traditional drug development campaigns have 
primarily focused on conventional protein targets such as enzymes and transmembrane receptors, 
which have well defined active sites using a “static” protein model.12 This approach has historically 
been highly effective and profitable, but an over-reliance on similar small molecules targeting 
related protein targets has resulted in increased cases of resistance, poor selectivity and often poor 
efficacy against complex multiprotein diseases. This crisis in the pharmaceutical industry has 
highlighted the need for innovative approaches to discover novel drug leads, particularly targeting 
the increasingly prevalent diseases such as cancer and neurodegenerative disorders.1 
 
Several excellent reviews have been published which detail the challenges and successes of targeting 
PPIs,1,3,12–16 particularly towards the development of cancer therapies.2,4,8,10,11,17,18 Despite their 
pivotal role in carcinogenesis, the interest in PPIs as drug targets has historically been tempered by 
the pervasive view that the large and often noncontiguous nature of the PPI interface hampers their 
druggability. The shallow and often featureless interface surface is in sharp contrast to the well-
defined, deep pockets of conventional enzyme and receptor drug targets. Furthermore, unlike 
traditional drug targets, the majority of PPIs do not have endogenous substrate or ligands which can 
be exploited as a natural chemical starting point. Despite these challenges, major inroads into 
discovering and developing PPI modulators have been made in recent years as a result of significant 
advances in screening technologies, computational modelling techniques and in particular the 
identification of hot spots on protein interaction surfaces. Large mutational studies revealed that the 
majority of PPI interfaces contain a critical interaction site which is responsible for a 
disproportionate contribution to the binding energy of the two proteins.19,20 The binding of small 
molecule modulators to these hotspots can modulate a protein interaction which occurs over a 
much larger surface area. Additional innovative breakthroughs have demonstrated that a significant 
proportion of protein-protein interactions are driven by linear peptide motifs21 which can be 
targeted using peptides or peptidomimetics. In addition to traditional PPI interface modulation, an 
increasing number of orthosteric or allosteric modulators have been reported which alter a target 
PPI by inducing a change in the conformation or oligomeric state of one or more of the protein 
partners.11,22,23 This increasing and compelling body of evidence is dispelling the dogma that PPIs are 
intractable drug targets. This change in perception in the pharmaceutical industry is mirrored by the 
fact that there are more than 12 small molecule PPI modulators currently in clinical development as 
cancer therapeutics.11 Examples of these include, Nutlin-3 (1) an inhibitor of the p53-MDM2 PPI,24,25 
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an important complex involved in the neutralisation of tumour suppressor functions and Navitoclax 
(2) an inhibitor of the BH3-domain mediated PPIs of Bcl-2, an important regulator of apoptosis 
(Figure 1.1).26 
 
Figure 1.1. Examples of PPI modulators in clinical development as cancer therapeutics. 
 
1.3 Approaches for the Identification of PPI Modulators 
Traditional medicinal chemistry approaches which have been highly successful at addressing classical 
drug targets have proven to be less effective for the more unconventional PPI drug targets.4 
However, innovative approaches involving organic chemistry, chemical biology and computational 
modelling are valuable methods for the identification and development of novel PPI drug 
modulators. The main strategies used to discover modulators can be grouped into three inter-
related groups – namely, 1.) compound library screening, 2.) natural product-inspired PPI 
modulation and 3.) structure-based design; which are discussed in an extensive review published by 
Milroy et al.1 For the purpose of this thesis, a concise summary of these approaches will be outlined 
here and referenced to the appropriate chapter in which aspects will be described in further detail 
(Figure 1.2).   
 
High-throughput screening (HTS) of large compound libraries can be a highly effective method to 
discover new PPI modulators (Figure 1.2). Typical methods involve screening commercial libraries of 
small molecules (see Chapter 5) or fragments against a target PPI. Increasing the diversity, 
complexity and biological relevance of the screening libraries can greatly improve the likelihood of 
identifying a new drug lead. However, significant challenges can arise as a result of increasing the 
library size with regards to sample handling, assay miniaturisation and the method of hit detection. 
In silico or virtual screening can provide a useful alternative, by identifying a smaller, focused subset 
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of predicted modulators of the target PPI from a large compound library prior to in vitro assessment 
(see Chapter 2).  
 
 
Figure 1.2. Overview of the methods utilised in this research towards the identification of PPI modulators. 
 
Over the past century, natural products have provided a rich source of drug molecules due to their 
inherent biological activity, unrivalled structural complexity and the diversity of chemical space 
which they occupy (Figure 1.2). Challenges associated with accessing sufficient quantities of 
biologically active natural products and diverse analogue libraries have fostered a range of new 
techniques. These include semisynthesis (chemical modification of an advanced intermediate from 
nature), mutagenesis (reprogramming of a biosynthetic pathway or engineering an artificial cellular 
synthetic system to assemble natural products in a host organism) and biology-oriented synthesis 
(generation of a focused library of structurally diverse compounds based around validated scaffolds 
which predominate in drug molecules and natural products). However, the total synthesis of a 
complex natural product is frequently the principal approach used for structural 
elucidation/confirmation, and as a method to provide sufficient material for initial biological 
evaluation (see Chapter 3).  
 
Structure-based design approaches exploit the peptide binding epitope of one of the protein 
partners as a chemical starting point for the development of a modulator (Figure 1.2). Numerous 
examples of three-dimensional X-ray crystallographic or NMR spectroscopic structures of proteins 
complexed with their biological partners have facilitated the rational structure-based design of 
conformationally constrained peptides, peptidomimetics (see Chapter 4) and mimetics of protein 
secondary structure as novel PPI modulators.  
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These approaches provide viable methods for the identification of PPI modulators as chemical tools 
to study a protein’s role in oncogenesis or as validation of new drug targets. In this thesis (Figure 
1.2), the utilisation of a range of screening approaches to identify chemical tools to study and 
validate novel anticancer targets such as reptin (Chapter 2), PAC3 (Chapter 3) and PICK1 (Chapter 4) 
are described. Furthermore, PPI modulators identified through these approaches could be optimised 
and developed as drug leads against these novel targets, or as improved therapies for well-validated 
cancer targets such as the tumour suppressor protein, p53 (Chapter 5).  
Chapter 2: Virtual Screening 
 
6 
 
2 A Virtual Screening Approach to the Discovery of PPI Modulators 
of the AAA+ Protein Reptin 
 
2.1 Introduction 
 
2.1.1 Virtual screening 
Virtual screening (VS; also known as in silico screening) is a computer aided drug discovery (CADD) 
process which involves the fast computational screening of a library of chemical entities, in order to 
identify compounds that have the greatest potential to interact with a particular protein target27 
and, in this context modulate a specific PPI. VS can be used as a stand-alone method to identify a 
limited set of compounds for in vitro evaluation, thereby speeding up the drug discovery process and 
reducing costs. It can also be used as a prelude to high-throughput screening (HTS, see Chapter 5 for 
further discussion of HTS) to provide a more focused and selective compound collection for 
evaluation, which can reduce the cost of this process and increase hit rates.11 In silico compound 
libraries are derived from several sources, such as commercial and non-commercial supplier 
databases which can contain marketed drugs, natural products or even sets of ‘virtual’ compounds 
that arise from in silico combinatorial chemistry.28 For a VS project, the compound collection 
typically undergoes several in silico ADME/tox filtering steps in an attempt to remove compounds 
with undesirable physiochemical properties and promiscuous compounds (PAINS, Figure 2.1).29  
 
 
Figure 2.1. Virtual screening workflow. 
 
The nature of the VS approach depends on the availability of a 3D structure of the target protein or 
protein-protein complex.11 In cases where the structure has been obtained, either by X-ray 
crystallography, NMR analysis or homology modelling, potential modulators can be identified 
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through high-throughput docking strategies.14 This method involves screening an in silico library to 
identify compounds with the ability to interact with an experimentally determined druggable pocket 
or ‘hot spot’ on the protein interaction surface (Figure 2.1). Molecular docking simulations use a 
computational algorithm (DOCK, Glide, GOLD, AutoDock, Vina, etc.) to assess a compound’s ability to 
interact at the protein’s hot spot, which is in turn ranked based on a scoring function (ChemScore, X-
score, DrugScore).14 Numerous examples of modulators identified by VS that target cancer-related 
PPIs have been published, including for XIAP–caspase 9.11 X-linked inhibitor of apoptosis protein 
(XIAP) inhibits caspase mediated apoptotic cell death and is upregulated in many cancers, including 
breast, pancreas, prostate and solid tumours.10 The programme DOCK30 was used to screen a library 
comprised of 8,000 small molecules against the XIAP BIR3 domain.31 The compounds were ranked 
using X-score and 36 of the top 200 hits were assessed in a fluorescence polarisation assay (FP). Five 
of the 36 compounds showed affinity for the XIAP BIR3 domain, with one compound, Embelin (1) 
having an IC50 value of 4.1 µM (Figure 2.2). Embelin (1) inhibits prostate cancer cell (PC-3 and LNCaP) 
growth with an IC50 value of 3.7 µM and 5.7 µM respectively, and induces apoptosis in PC-3 cells via 
activation of caspase 9.31  
 
Figure 2.2. Structures of the PPI inhibitors Embelin (1)
31
 and 2
32
 identified through a VS approach. 
 
An alternative VS approach involves the identification of the binding epitope of one of the proteins 
involved in a specific interaction and the representation of this motif as a pharmacophore.11 This 
pharmacophore then enables the screening of an in silico compound library to identify compounds 
that contain the essential functional groups in the correct 3D conformation.33 Compounds are then 
ranked and selected for further bioassay evaluation based on how well they satisfy the 
pharmacophore. The pharmacophore-based approach has been used successfully in the 
identification of substituted 1,2,4-triazoles as inhibitors of the S100A10-annexin A2 PPI, which is 
implicated in the process of neo-angiogenesis and the recruitment of macrophages to tumour 
sites.34 In addition, S100A10 has recently been identified as a potential therapeutic target for the 
treatment of colorectal cancer.35 The crystal structure of the S100A10-annexin A2 complex was used 
to generate a pharmacophore model which represented the amino acid interactions present at the 
annexin A2-binding site on the S100A10 protein.32 This model was used to screen a virtual library of 
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704,000 commercially available compounds. The 586 compounds which satisfied the 
pharmacophore were subsequently docked using the programme GOLD36 into the annexin A2-
binding site. GOLD docking scores were used to select 190 compounds for further in vitro evaluation 
using a competitive FRET assay. This resulted in the identification of inhibitor 2, which had an IC50 
value of 24 µM against the S100A10-annexin A2 PPI (Figure 2.2), providing the basis for a medicinal 
chemistry optimisation programme.32  
 
The identification of modulators of PPIs, in cases where the binding interface has not been identified 
or no 3D structure of the PPI complex is available, is considerably more challenging. This is 
particularly relevant for PPIs, involving a membrane bound protein or a signalling or chaperone 
protein which forms dynamic and transient interactions.23 The identification of novel modulators in 
these cases has mainly been possible through HTS approaches.11 However, a growing area of 
research has focused on the identification of small molecules, which bind to novel allosteric ‘hot 
spot’ on the target protein and affect its PPIs through modulation of its conformation or oligomeric 
state, e.g. TNF,37 survivin,38 iNOS39.40,41 It is with this approach in mind that we undertook a virtual 
screen to identify small molecules, which bind at the ATP pocket of the AAA+ protein reptin, and 
consequently modulate its protein-protein interactome. 
 
2.1.2 The multifaceted AAA+ protein reptin  
Reptin, also known as Ruvbl2 and Tip48, is a highly conserved member of the ATPases associated 
with various cellular activities (AAA+) family of proteins. The role of reptin as an important regulator 
of key cellular functions through a range of diverse PPIs has been extensively discussed in several 
excellent reviews.42–45 Reptin is present in numerous protein and nucleoprotein complexes and is 
implicated in biological processes such as transcriptional regulation, chromatin remodelling, DNA 
damage response and ribonucleoprotein complex biogenesis (Figure 2.3). It is an integral subunit of 
several chromatin-modifying complexes, including Ino80 in yeast and animals,46,47 Tip60 in 
animals,48,49 Swr1 in yeast50 and the equivalent SRCAP in animals.51 Reptin is often coexpressed with 
pontin,52 a highly conserved ortholog of reptin. Reptin and pontin frequently share common binding 
partners and help assemble complexes containing members of the phosphatidylinositol-3 kinase–
related kinase (PIKK) family,53 which participate in many signalling pathways, including those 
involved in regulating nutrient sensing, RNA metabolism, and DNA damage response. Reptin’s 
participation in transcriptional regulatory complexes with a clear involvement in oncogenesis, such 
as those involving c-myc54 or β-catenin55,56 and its role in assembling the telomerase holoenzyme57 
will be discussed further in Section 2.1.4. Extensive research regarding the structural and oligomeric 
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organisation of reptin is likely key to understanding its diverse role in numerous biological 
processes.42  
 
 
Figure 2.3. Reptin is involved in multiple cellular pathways. Schematic representation of reptin’s involvement in 
transcription, DNA damage response, small nucleolar ribonucleotide protein (snoRNP) assembly, cellular transformation, 
cancer metastasis, apoptosis, mitosis, and development. Figure adapted from Jha et al.
43
 
 
2.1.3 Structure and oligomeric nature of reptin 
Recent X-ray crystal structures58–60 and cryo-electron microscopy structures61,62 have provided 
important details about the structure of human reptin and pontin. High-resolution X-ray crystal 
structures of hexameric pontin,58 a dodecameric complex of reptin and pontin consisting of two 
heterohexameric rings (Figure 2.4A)59 and hexameric reptin60 have been reported to date. These 
have revealed that each reptin/pontin monomer consists of three distinct structural domains (Figure 
2.4B). Domain I (DI, mainly N-terminal) and domain III (DIII, C-terminal) form the archetypical ATPase 
module of AAA+ proteins. The ATPase domain consists of two integral parts; the P-loop NTP binding 
motif (also known as the Walker A box) and the DEAD motif (also known as the Walker B box). The 
Walker A motif (consensus GxxGxK[S/T], where x is any amino acid) is involved in nucleotide binding 
and metal-ion coordination. The Walker B motif (consensus DE, where  is a hydrophobic 
amino acid) plays an important role in ATP hydrolysis and metal-ion coordination. The ATPase 
domain also contains an arginine finger which coordinates ATP hydrolysis in the hexamer and the 
sensor I and II domains. The sensor I domain distinguishes between the nucleotide diphosphate and 
triphosphate bound states whereas a highly conserved arginine residue in the sensor II binds across 
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the nucleotide binding site differentiating between the nucleotide bound and unbound states. The 
Walker A and B motifs are separated by domain II; a 170 amino-acid insert which protrudes out of 
the hexameric ring and is proposed to function as a nucleic acid binding site (Figure 2.4B).45  
 
             
Figure 2.4. Structures of the pontin monomer and the reptin-pontin dodecamer. (A) Ribbon diagram of the reptin-pontin 
dodecamer with truncated domain II [PDB 2XSZ]. Pontin monomers are shown in yellow; reptin monomers are shown in 
light blue. ATP ligands represented as spheres with grey for carbon, blue for nitrogen, red for oxygen and orange for 
phosphorus. Figure adapted from Rosenbaum et al.
42
 (B) Ribbon representation of the pontin monomer [PDB 2C90], 
showing its domain structure. Domains I-III are represented in a different colour. The Walker A and B motifs are shown in 
yellow. Figure adapted from Huen et al.
44
  
 
Members of the AAA+ family of proteins usually self-assemble into oligomers, predominantly 
hexamers, and this ability appears to be required for their biological activity.63 This is similarly the 
case for reptin, which has been observed in various oligomeric states using multiple biophysical 
techniques, including analytical ultracentrifugation, size exclusion chromatography, mass 
spectrometry and electron microscopy.45 It has been demonstrated that reptin can exist as a dimer, 
trimer, hexamer and as heterohexamers and dodecamers in conjugation with pontin. An important 
consequence of reptin oligomerisation into a hexamer is the capping of the ATPase site by a 
neighbouring monomer.64 The nucleotide binding site is completely blocked by the α5 helix of DIII, 
Arg400 of the sensor II (in reptin) and the neighbouring monomer, which makes the release of ADP 
impossible. This is consistent with the low ATPase activity experimentally observed for reptin.64,61 
Cryo-electron microscopy studies62 and molecular dynamic studies60 support the rationale that a 
nucleotide induced conformational change is required for ATPase activity. Reptin’s diverse 
repertoire of biological activities suggests that its oligomeric nature may be dependent on the 
complex or cellular process in which it is involved. The observation that adenine nucleotides alter its 
oligomeric state, promoting hexamerisation, suggests that cofactors (including DNA binding) and 
other proteins might be involved in regulating its activty.65,66 
(A)
) 
Domain I 
Walker A 
Walker B 
Domain III (B) 
Domain II 
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2.1.4 Reptin as a major player in cancer 
A growing body of evidence is highlighting reptin as a promising target for cancer therapies.67,68 This 
research has focused around reptin’s level of expression in cancer, its interactions with mediators of 
carcinogenesis and its role in cell death/viability. Reptin was shown by differential proteomic 
analysis to be overexpressed in human colorectal cancer (HCC) tumours when compared with the 
non-tumour-surrounding liver.69 Elevated expression of both reptin and pontin at both the mRNA 
and protein levels in HCC compared to the non-tumour liver was also observed.70 Reptin and/or 
pontin have since been shown to be overexpressed in a variety of human solid tumours including 
bladder, colorectal, gastric, mesothelioma, non-small cell lung cancer, as well as in several types of 
acute or chronic leukaemia, in multiple myeloma, high-grade lymphoma and Burkitt lymphoma.68 
 
The role of reptin in transcriptional regulation via its interactions with Tip60, c-myc and β-catenin, 
highlights the potential effect of its overexpression on the pathogenesis of cancer. For example, 
reptin potentiates c-myc mediated repression of the p21 gene,71 hence impeding cell cycle arrest. 
Additionally, reptin represses -catenin-dependent reporters. This suggests that reptin may 
indirectly play a role in cellular transformation, since deregulation of β-catenin signalling, due to an 
activating mutation of β-catenin or its interacting partners, has been observed in several cancers.72 
In metastatic cells, the -catenin-reptin complex is preferentially recruited to the KAI1 promoter 
where it inhibits KAI1 expression via histone deacetylation.56 As KAI1 increases cell adhesion and 
thereby inhibits metastasis, this indicates that the reptin-mediated repression of KAI1 may be 
involved in the development of metastasis. Collectively, it appears that reptin in association with -
catenin, recruits histone deacetylases to different promoters and converts the chromatin to a 
repressive state. Reptin also interacts with several other proteins with strong involvement in 
carcinogenesis such as the oncoprotein AGR265 and the telomerase components TERT and 
dyskerin.57   
 
Reptin’s role in cell death/viability has been demonstrated in several in vitro and in vivo studies. 
Decreasing reptin expression in vitro reduces tumour cell growth and increases apoptosis.73 In 
addition, doxycycline-dependent shRNA-induced in vivo silencing of reptin results in growth arrest of 
established tumours in mice xenograft experiments.74,67 These studies in combination with the loss 
of growth viability in yeast and the inactivation of several functional properties of reptin as a result 
of loss-of-function mutants of the Walker A or B motifs,43,67,68 further implicates reptin as a 
promising therapeutic target in cancer.  
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2.2 Aims of this work 
 
Reptin is a highly conserved member of the AAA+ superfamily which functions as an important 
regulator of a diverse range of cellular processes. Its presence in numerous protein and 
nucleoprotein complexes implicated in biological processes such as transcriptional regulation, 
chromatin remodelling and DNA damage response underlines its significant physiological role. In 
particular, an emerging body of evidence has implicated reptin in oncogenesis via its interactions 
with mediators of carcinogenesis and its role in cell death/viability. Despite its increasing 
prominence, no modulators of reptin’s functions or interactions have been reported to date. Herein, 
we aim to develop a chemical biology platform to discover novel small molecule regulators of 
reptin’s protein interactome, via a cross-disciplinary process in collaboration with Prof. Malcolm 
Walkinshaw and Dr Doug Houston (University of Edinburgh) and Prof. Ted Hupp (CRUK centre, 
Edinburgh).  
 
This discovery platform will involve the following stages: 
 A high-throughput virtual screen (Walkinshaw & Houston) to identify small molecules which 
are predicted to bind in the reptin ATP binding pocket 
 In vitro evaluation (Hupp group) of the allosteric effect of the top predicted hits from this 
process on reptin’s PPIs 
 Optimisation of active lead molecules through an SAR study guided by molecular modelling 
and biological evaluation 
 Investigation of the mode of action, and physiological effect of a modulator on reptin’s 
protein interactome 
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2.3 Virtual Screening and Hit Identification 
 
2.3.1 In silico screening using pontin  
As no X-ray crystal structure of reptin was available at the time these studies began, initial in silico 
screening efforts focused on the use of the X-ray crystal structure of pontin, a highly conserved 
ortholog of reptin (PDB 2C90;75 solved to a resolution of 2.3 Å). The virtual library used for this 
screen contained commercially available compound libraries from ChemBridge, Asinex, Maybridge, 
Enamine, LifeChemicals, Specs, InterBioScreen, ChemDiv and KeyOrganics. The library was filtered 
according to Oprea lead-like rules (H-bond acceptors ≤ 9; H-bond donors ≤ 5; MW ≤460; -4.6 ≤ cLogP 
≥ 4.2; cLogS ≥ -5; Number of rings ≤ 4; Number of rotatable bonds ≤ 9)76 resulting in 1,137,587 
molecules. A multiconformer version of the virtual library was produced using Multiconf-DOCK;77 an 
average of approximately 4.25 conformers per compound were generated depending on flexibility; 
this resulted in a virtual library containing a total of 4,840,093 conformers (Figure 2.5). The docking 
of this conformer virtual library of 4.8 million compounds into the ATP pocket (the Walker A motif) 
of pontin was carried out using the rigid-body docking program LIDAEUS by Dr Doug Houston.78  
 
 
Figure 2.5. Workflow diagram of the virtual screening process. Numbers of molecular entities (compounds or conformers) 
are indicated at each stage. Figure created by Dr Doug Houston.  
 
The results were ranked based on the LIDAEUS score and the top 49,971 compounds were then 
redocked using Vina. Docked poses were scored using both Vina’s internal scoring algorithm and X-
Score 1.2.79 A “rank-by-rank” consensus protocol was then used to create a ranked list. The top 
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4,974 compounds were then docked using Autodock and the binding poses predicted by Autodock 
and Vina were compared via RMSD (root-mean-square deviation is a measure of the average 
distance between the backbone atoms of the superimposed binding poses80). Predicted binding 
poses that were similar (RMSD ≤ 2.0 Å) were also scored using DrugScore 1.2.81 A final ranked list of 
the top 100 hits was prepared via a “rank-by-rank” scheme, taking the Vina, Autodock, X-Score and 
DrugScore (DSX) rank positions into account (Figure 2.5).   
 
The binding mode of the top 100 highest scoring hits from the in silico screen underwent visual 
inspection and I subsequently subdivided them into different classes based on structural similarity. 
This visual analysis resulted in the identification of 14 different structural classes. The remaining 
analogues which did not contain a common structural core were grouped separately. A limited 
number of compounds (1-3) were purchased from each representative class based on their size and 
structural diversity. A further 7 compounds were purchased from the structurally unrelated group of 
hits, resulting in a final library of 31 compounds for testing (see Appendix A). 
 
2.3.2 In vitro assessment of the top ranked in silico hits 
As the focus of this work was to identify compounds that could, in some way, regulate reptin’s 
protein-protein interactions, a previously validated PPI ELISA assay developed by the Hupp group65 
was used. In this assay, the binding of full-length reptin to a peptide (104-FVLLNLVY-111) 
representing the essential binding epitope of the reptin-binding protein AGR265 was assessed. This 
assay was initially used to demonstrate that binding of ADP to reptin modulates the reptin-AGR2 
peptide interaction. A titration of ADP revealed that low levels of the nucleotide stimulate the AGR2 
peptide binding activity of reptin, whilst higher levels of the nucleotide reduced and attenuated the 
reptin-AGR2 peptide interaction (Figure 2.6A). The biphasic effect of the nucleotide in this assay 
might be related to the stoichiometry of the nucleotide-bound hexamer or the ratio of the reptin 
monomer to hexamer at lower ADP concentrations. The 31 compounds purchased from the in silico 
screen’s top 100 highest scoring hits were then assessed using this ELISA assay. Hits were defined in 
this assay as compounds that modified (increased or decreased) significantly the signal 
corresponding to reptin binding to the AGR2 peptide compared to the DMSO control (Figure 2.6B). 
Of the 31 compounds tested at a final concentration of 100 M, 3 compounds (Figure 2.6B-C; 13, 17 
& 22) resulted in a significant response and were therefore prioritised for further study. 
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Figure 2.6. (A) The effect of ADP on the reptin-AGR2 peptide binding activity. A biotinylated version of the peptide 
binding motif from wild-type AGR2 (104-FVLLNLVY-111) was bound onto streptavidin coated wells and reptin was titrated 
followed by a primary antibody to reptin and a peroxidase linked secondary antibody to measure binding stability of reptin 
to the AGR2 peptide. The data are plotted as reptin binding activity (in RLU) as a function of reptin protein levels. Differing 
concentrations of reptin (50, 100, or 200 ng) were incubated with increasing concentrations of ADP. Low concentrations of 
ADP stimulated the AGR2-peptide binding function of reptin, in contrast with higher concentrations which attenuated its 
binding activity. (B) Evaluation of the top 31 hits from the in silico screen in the peptide binding assay at 100 µM. Data 
provided by the Hupp group. (C) Structures of primary hits 13, 17 and 22, which significantly stimulated reptin’s binding 
activity to the AGR2 peptide relative to the DMSO control. Structure of 3, an inactive analogue of hit 13.  
 
Interestingly compounds 17 and 22 appeared to be structurally related, both containing a biphenyl 
ring substituent (Figure 2.6C). In contrast, 3 which is a closely related analogue of 13 did not result in 
a significant response in the ELISA assay (Figure 2.6B). Based on these observations it was initially 
decided to focus on the class of compounds containing a biphenyl ring system, of which 17 had 
shown the most significant response (see Section 2.6 for the development of 13).  
 
(A) (B) 
(C) 
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2.3.3 Screen of the conformer library using reptin 
Analysis of the predicted binding mode of 17 in the ATP binding pocket of pontin revealed that the 
biphenyl substituent of 17 sat deep in the Walker A pocket where the adenine of ADP/ATP has been 
shown to bind (Figure 2.7A). In addition, 17 contains a pyridine-oxazolo ring system which was 
predicted to extend out of the pocket. The computational studies progressed further following the 
report of an X-ray crystal structure of reptin in an alternating heterododecameric complex with 
pontin.59 Comparison of this structure (PDB 2XSZ) with that of hexameric pontin (PDB 2C90) 
confirmed the high structural similarity between the reptin and pontin ATP-binding pockets (Figure 
2.7B).  
 
 
Figure 2.7. (A) The binding mode of 17 as predicted by Autodock is shown as black sticks. The side chains of residues that 
comprise the active site of pontin are shown as green lines and are labelled. The ADP molecule present in the pontin 
structure is coloured white and shown as sticks. The pocket is also shown as a transparent surface representation. In all 
cases nitrogen is coloured blue, oxygen red, phosphorous orange, and chlorine green. (B) Figure showing an overlay of the 
residues of the reptin and pontin ATP pockets, highlighting the difference in position of two key side chains (Arg404 and 
Gln408 in pontin and Arg400 and Gln404 in reptin). Reptin is coloured green, pontin black. The ADP molecule from the 
pontin structure is shown as sticks, the ATP from the superposed reptin structure as lines. (C) Original and optimised 
Autodock predictions of 17’s binding conformation. The predicted mode from the virtual high-throughput screen is shown 
as black lines and the hydrogen bonds it makes with Arg400 are shown as a black dashed line with its length in Å. The result 
of the docking with maximal parameters and flexible Arg400 activated is shown as grey sticks. Two hydrogen bonds shown 
in orange are predicted between the optimised 17 docking pose and the side chain. Data provided by Dr Doug Houston.  
 
However, one important difference was observed between the position of the sensor II residue 
(Arg400) in reptin compared to its position in pontin (Arg404, Figure 2.7B). In the pontin structure, 
Arg404 is folded over the ATP binding pocket whereas in the reptin monomer Arg400 was located 
such that the Walker A binding site is more open and accessible (Figure 2.7B). Rescreening of the 
conformer library using the open structure of the reptin monomer present in this complex failed to 
identify 17 as a hit. Petukhov, M. et al, previously demonstrated using molecular dynamics methods 
that Arg400 in reptin and Arg404 in pontin are highly flexible and play an essential role as a R-valve 
controlling access to the ATP-binding pocket.60 The in silico screen was then repeated for a third time 
with the side chain of Arg400 being computationally locked over the pocket. This modified screen 
predicted that 17 could bind to the Walker A site in reptin, suggesting that the correct positioning of 
(A) (B) (C) 
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the sensor II arginine is essential for the binding of 17. When 17 was docked into reptin keeping 
Arg400 flexible and using energy minimisation methods to identify the optimal interactions between 
17 and Arg400, the side chain of Arg400 was predicted to fold over the pyridine-oxazolo ring system 
in 17 (Figure 2.7C). The formation of hydrogen bonds between the side chain of Arg400 and both the 
pyridine-oxazolo ring system and the amide oxygen in 17 was predicted, suggesting that these 
interactions may be essential for the experimentally observed activity of 17. 
 
2.4 SAR Optimisation of 17 
 
2.4.1 SAR analysis of lead compound 17 
SAR studies were carried out to further dissect and enhance 17’s effect on reptin’s binding activity. 
These studies aimed i) to assess whether 17 is likely to bind in the Walker A site as predicted and ii) 
to attempt to increase the biological activity of this series of compounds. First an efficient synthesis 
of 17 was developed to provide sufficient material for further validation of this hit (Scheme 2.1). This 
was achieved through a 2-step procedure from commercially available 2-amino-3-hydroxypyridine 
(34).  
 
Scheme 2.1. Synthesis of 17. (a) (i) 3-Amino-4-chlorobenzoic acid (34), PPA, 200 C, 4 h. (ii) H2O, NaHCO3, 55%. (b) 
Biphenyl-4-carbonyl chloride, DIPEA, DCM, r.t., 24 h, 57%.  
 
Condensation of 34 and 3-amino-4-chlorobenzoic acid in polyphosphoric acid (PPA) at 200 C for 4 
hours provided the key intermediate 35a. Compound 35a was subsequently stirred with biphenyl-4-
carbonyl chloride in DCM resulting in the precipitation of the desired compound 17 from the 
reaction. 17 was purified by recrystallisation from DCM. For the purposes of the SAR study, 17 was 
viewed as comprising of 4 distinct regions (labelled A-C rings and “linker”, Scheme 2.1). 
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2.4.2 Modification of the “A” ring 
Analysis of the predicted binding pose of 17 revealed that the biphenyl moiety binds deep in the 
Walker A pocket of pontin where the adenine of ADP/ATP has previously been shown to bind (Figure 
2.7A). To probe this predicted binding mode, analogues of 17 containing modifications in the A ring 
were either purchased from Chembridge (Figure 2.8, 36-41) or synthesised in an analogous manner 
to 17 (Figure 2.8, 42 & 43).  
 
Figure 2.8. A ring analogues tested in the SAR study. Compounds 36-41 were purchased from Chembridge. Compounds 42 
& 43 were synthesised in an analogous manner to 17 (Scheme 2.1). These analogues were inactive in the reptin-AGR2 
peptide binding ELISA. 
 
Biochemical analysis of analogues 36-43 showed that significant variations in the length and width of 
the substituent in the A region were not well tolerated, as they all proved to be inactive in the ELISA 
assay. This observation was consistent with the predicted position of the A ring of 17. Interestingly, 
10% of the top 100 in silico hits from both the pontin and second reptin screens contained the 
biphenyl system present in both initial hits 17 & 22, suggesting this is an optimal functionality for the 
predicted binding. 
 
2.4.3 Modification of the “B” ring 
Analogues containing a modified B ring (44-50), which were synthesised in an analogous manner to 
17, explored two issues: i) the relative positions of the A and C rings and ii) the role of the halogen 
(Figure 2.9A). Changing the position of the amide group relative to the chlorine atom from the meta- 
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to the ortho-position (c.f. 17 vs. 44) was not tolerated as expected based on the predicted binding 
mode. Replacement of the chlorine atom in 17 with a hydrogen atom resulted in complete loss of 
activity (17 vs. 45) and this could not be rescued by the repositioning of the amide group para- to 
the pyridine-oxazolo ring (in 46). Variation of the halogen showed that an increase in atomic radius 
led to an increase in activity (47(F) < 17(Cl) < 48(Br)) with the bromine analogue 48 being the most 
active in the series (Figure 2.9B). Replacing the halogen with a methyl group (49) abolished activity.  
 
 
 
Figure 2.9. B ring analogues tested in the SAR study. (A) Compounds 44-50 were synthesised in an analogous manner to 
17 (Scheme 2.1). (B) The effects of halogen substitution in ring B on the specific binding activity of reptin. Data was 
provided by the Hupp group (n = 3). 
 
A dose titration of the halogen series confirmed a concentration dependent effect on the stimulation 
and attenuation of the specific reptin-AGR2 peptide binding activity, with as little as 1 µM of 
compound 48 showing stimulation (Figure 2.9B). The significant difference in activity between the 
(A) 
(B) 
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inactive non-halogenated analogue 45 and the most active analogue 48 (Figure 2.9B) would suggest 
that the bromine may have several roles, including van der Waals interactions, orientation of the “C” 
ring to best hydrogen bond with the Arg400 (Figure 2.7C) and a potential lowering of the barrier for 
rotation around the amide bond. 
 
2.4.4 Modification of the linker region 
Assessment of analogues 51 and 52 that contained modifications of the linker unit (Figure 2.10A) 
revealed that the activity increased with increasing linker flexibility (Figure 2.10B). Interestingly, the 
ester-containing analogue 51 was more active than the sulfonamide 52, whilst the amide 45 was 
inactive as previously mentioned (Figure 2.10B).  
 
 
 
 
Figure 2.10. Linker unit analogues tested in the SAR study. (A) Compounds 51-53 were synthesised in an analogous 
manner to 17 (Scheme 2.1). (B) The effects of linker modification on the specific binding activity of reptin. Data was 
provided by the Hupp group (n = 3). 
 
The correlation between increasing activity and increasing linker flexibility also supports the 
predicted binding mode which has 17 bound with the linker at right angles to the B ring. A lower 
energy barrier of rotation would allow the molecule to access the predicted binding conformation 
more easily, resulting in improved binding (Figure 2.7A). Incorporation of a bromine atom into the 
(A) 
(B) 
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sulfonamide analogue (53) abolished activity, suggesting the non-planar conformation of the 
sulfonamide results in a binding conformation for this analogue which does not tolerate a halogen 
atom. 
 
2.4.5 Modification of the “C” ring 
The final stage of the SAR analysis investigated the proposed binding of the C ring to R400. Docking 
studies combined with molecular dynamics revealed that potential hydrogen bonding between the C 
ring and Arg400 may play a key role in 17’s mode of action (Figure 2.7C). The first aim of this study 
was to assess if it was possible to modify or remove this region and retain activity. To this end, two 
compounds 54 and 55 were synthesised using our previously developed route (Figure 2.11).  
 
 
Figure 2.11. C ring analogues tested in the SAR study. Combination of the C ring of 22 and optimised A, B and linker 
regions of 48 resulted in compound 56 which showed an improved predicted logS value of -7.57 when compared to 48 (-
9.09). Compounds 54 and 55 were synthesised in an analogous manner to 17 (Scheme 2.1). Compounds 56 and 57 were 
synthesised by an alternative route (Scheme 2.2). These analogues were inactive in the reptin-AGR2 peptide binding ELISA. 
 
As predicted, removal of the C ring (55) abolished activity. Similarly, replacement of the pyridine 
nitrogen by a carbon (54) also abolished the activity of this compound. This suggested that it may be 
involved in a hydrogen-bonding network with R400 and neighbouring polar residues, although the 
observed inactivity could be a result of 54’s poor solubility under the assay conditions. These 
preliminary results confirmed that the C ring is essential for activity, consistent with a requirement 
for hydrogen bonding of this heterocycle to Arg400. 
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Due to the inactivity and poor solubility of initial analogues of 17 containing a modified pyridine-
oxazole ring, an alternative optimisation strategy was proposed which aimed to incorporate the C 
region of related in silico hit 22, which contains a thiophene ring linked to the B ring via an amide 
group (Figure 2.11). The heteroatoms of the C region of 22 are in a similar spatial orientation to 
those present in the heterocyclic C ring of 17, suggesting that they could form a similar hydrogen 
bonding network with R400 as predicted for 17. However, 22 contains an ester linker connecting its 
B and A rings, which is prone to hydrolytic cleavage in aqueous environments, thus potentially 
restricting 22’s utility as a chemical tool. Therefore, it was decided to combine the amide-linked 
thiophene of 22 with the optimised B ring, linker and A ring regions of 48 (Figure 2.11). This could 
potentially lead to an analogue with improved potency and pharmokinetic properties when 
compared to 22, whilst also containing a C region which may be more amenable to further 
optimisation. Furthermore, it had been observed that our initial hit 17 and our most active bromine 
derivative 48 had poor solubility which is in agreement with their predicted logS values (-8.99 & -
9.09 respectively82). The estimated logS value is a unit stripped logarithm (base 10) of the predicted 
solubility of a given compound in mole/litre. More than 80% of the drugs on the market have a logS 
value greater than -4.82 The estimated logS values of less than -9 for our analogues suggest that they 
would have poor in vivo absorption and distribution. This poor aqueous solubility is presumably due 
to the relatively flat, hydrophobic nature of these compounds, which would promote the formation 
of a strong - interaction network. The replacement of the pyridine-oxazole heterocyclic ring 
system of 48 with the amide-linked furan functionality of 22, resulted in a marked increase in the 
predicted solubility from –9.09 to –7.57 (Figure 2.11). Two analogues were selected, one which 
incorporated the amide-linked thiophene group from 22 and one which incorporated an amide-
linked furan. To access these desired analogues, an alternative synthetic route was required.  
 
The proposed synthetic route to access analogues 56 and 57 focused on a late-stage incorporation of 
the required C rings (Scheme 2.2). This versatile strategy began with the large scale synthesis of 
intermediate 59, which could be readily acylated with a range of acid chlorides to form a diverse 
library of analogues if required. The synthesis of intermediate 59 involved the coupling of 58 and 
biphenyl-4-carbonyl chloride. Subsequent transfer hydrogenation (Fe in NH4Cl) of the nitro group of 
59 provided the corresponding amine 60. Finally, 60 was acylated with 2-thiophene chloride or 2-
furoryl chloride to furnish 56 and 57 respectively (Scheme 2.2).  
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Scheme 2.2. Synthesis of C ring analogues 56 and 57. (a) Biphenyl-4-carbonyl chloride, pyridine, DCM, r.t., 18 h, 53%. (b) 
Fe, NH4Cl, MeOH, H2O, 100 C, 3 h, 90%. (c) 2-Thiophene chloride or 2-furoyl chloride, pyridine, DCM, r.t., 18 h, 56 = 85%, 
57 = 72%. 
 
Disappointingly, neither 56 nor 57 were active in the reptin-AGR2 peptide binding assay. This would 
suggest that the role played by the amide and halogen in the correct alignment of the pyridine-
oxazole ring of 48 for strong binding to Arg400 had an opposite detrimental effect on the 
corresponding amide-linked furan/thiophene ring. This is believed to result from a change in its 
spatial orientation, thereby disrupting its hydrogen bonding interactions with Arg400.  
 
In summary, an in silico screen of a 4.8 million conformer library against the ATP binding pocket of 
pontin and subsequently reptin, generated a ranked list of the top 100 predicted binders. A robust 
ELISA based protein-protein interaction assay was used to screen a selection of 31 compounds, 
which represented an overview of the chemical diversity present in the top 100 hits. 17 was 
identified from this in vitro assay to have a stimulatory/stabilisation effect on the formation of the 
reptin-AGR2 peptide interaction. 17 was modelled and subjected to SAR, guided by the ELISA based 
protein-protein interaction assay to generate a more active lead molecule 48, which we have termed 
Liddean. The SAR study also supported the predicted binding mode of 17 in the ATP pocket of reptin, 
highlighting the correct orientation of the molecule and the formation of key hydrogen bonds with 
the amide and C ring to be essential for activity. With the chemical tool Liddean (48) in hand, further 
studies were undertaken to elucidate its mode of action and its effect on reptin’s protein 
interactome. 
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2.4.6 Investigation of Liddean’s mode of action 
The investigation of Liddean (48)’s mode of action focused around two key observations. 1.) Liddean 
(48) produced a similar biphasic concentration dependent effect (Figure 2.9B) on the stimulation and 
attenuation of the specific reptin-AGR2 peptide binding as observed with ADP (Figure 2.6A). It 
stimulated the interaction at lower concentrations but attenuated it at higher concentrations. This 
would suggest that Liddean (48) has a similar physiological effect on reptin as ADP. 2.) The 
observation that the Arg400 loop needed to be closed over the ATP pocket for 17 to be identified as 
a hit from the in silico screen suggests that this could be important for its mode of action. This was 
further supported by the identification of possible hydrogen bonds with Arg400 through the use of 
molecular modelling (Figure 2.7C) and the observation that chemical modification of 17, which 
resulted in a change of its preferred conformation or hydrogen bonding network, diminished or 
abolished its activity. Arg400 is a key residue involved in the sensor II domain. On binding of 
ATP/ADP to the ATP pocket of reptin, the Arg400 closes down over the pocket; binding to the 
phosphate chain.60 This sensing of bound nucleotide could be essential for its resulting physiological 
effect.  
 
Recent research has revealed that the predominant role of nucleotide binding to reptin is through 
modulation of its protein-protein interactome and the assembly/disassembly of multiprotein 
complexes.43 This hypothesis is supported by the low levels of ATPase activity and the nucleotide 
dependent change in oligomerisation state observed for reptin.61,64 The identification of a wide 
spectrum of oligomeric states, ranging from monomer to hexamer and dodecamer including hetero-
oligomers with pontin is believed to underpin reptin’s functional diversity and broad biological 
function.45 It was therefore decided to assess whether like ADP, Liddean (48) could modify reptin’s 
ability to form homo-oligomers. Reptin was subjected to SDS denaturing (0.1%) electrophoresis in 
the presence of varying amounts of SDS (0 - 1%) in the loading buffer resulting in the observation of 
both monomeric and dimeric forms of the protein (Figure 2.12A, lanes 1, 4, 7 and 10; dimeric reptin 
is typically observed as two SDS-resistant separate bands around 130 kDa). The preincubation of 
reptin with Liddean (48) induced the formation of a stable oligomeric form of reptin that was 
approximately 250 kDa (Figure 2.12A, lane 3, 6, 9 and 12) as well as additional slower running bands, 
possibly corresponding to even higher order oligomers. The Liddean (48)-induced oligomers were 
even stable when reptin was preincubated with 1% SDS prior to electrophoresis (Figure 2.12A, lane 
12). ADP was able to induce the formation of a marginally stable oligomer (Figure 2.12A, lanes 2, 5, 
8, and 11). These data suggest that Liddean (48) is able to trap reptin in a more stable oligomeric 
state. 
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Figure 2.12. The effects of Liddean (48) on the oligomerisation of reptin. (A). Reptin (1 µg) was subjected to denaturing 
SDS (0.1%) gel electrophoresis in ADP binding buffer without or with ADP (100 µM) or Liddean (100 µM), as indicated. After 
30 minutes of incubation at room temperature, gel loading buffer was added (with the indicated SDS concentrations from 
0 to 1%), and electrophoresis was then carried out. Reptin protein was visualised by silver staining. (B). Reptin (1 µg) was 
subjected to denaturing SDS (0.1%) gel electrophoresis in ADP binding buffer with increasing concentrations of Liddean 
(48), as indicated. After 30 minutes of incubation at room temperature, gel loading buffer (0% SDS) was added and 
electrophoresis was carried out. Reptin protein was visualised by silver staining. Data provided by the Hupp group. 
 
Liddean (48) was next titrated in this gel based assay to determine if there was a correlation 
between its ability to induce reptin homo-oligomerisation and a stimulation of reptin’s binding to 
the AGR2 peptide. As little as 2 µM Liddean (48) was able to induce the formation of a stable 
oligomer (Figure 2.12B, lane 2), with maximal amounts of oligomers being induced between 64-256 
µM (Figure 2.12B, lanes 7-9). This formation of SDS-resistant oligomer correlates with the specific 
reptin-AGR2 peptide binding activity induced by Liddean (Figure 2.9B, compound 48). 
 
2.5 Liddean as a Chemical Tool 
 
2.5.1 Liddean induced modulation of reptin’s protein interactome 
Reptin can interact with a variety of signalling proteins and is often linked to oncogenesis.68 
Identifying reptin’s protein interactome is crucial to understanding its role in oncogenesis and 
identifying novel targets for drug discovery programmes. Therefore, Liddean (48) was used as a 
synthetic ADP mimetic to determine whether novel interacting proteins could be identified for 
reptin. Liddean (48) behaves in a similar manner to ADP in that it produces a concentration 
dependent stabilisation or de-stabilisation of reptin-peptide or reptin-protein interactions. 
Importantly, Liddean (48) induced a more stable oligomer than ADP, suggesting that it indeed can 
function as a useful tool to dissect the protein interactome of reptin. It is in this more stabilised 
oligomeric state of Liddean (48)-bound reptin in vitro that “consensus binding motifs” were searched 
for using next generation deep-sequencing of a combinatorial peptide-phage library in the Hupp 
group.  
(A) (B) 
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Peptide phage display is a molecular technique, whereby a gene encoding a peptide of interest is 
inserted into the genome of the capsid proteins of a bacteriophage.83–86 The encoded peptide is 
expressed or displayed in a functional form on the outer surface of the phage, creating a connection 
between the genotype (gene encoding the peptide) and the phenotype (the displayed peptide) 
within the phage particle.87 In contrast to a synthetic small molecule library, a typical peptide phage 
combinatorial library can contain as many as 1010 phage-displayed peptides88 (prey), which are 
screened simultaneously for their ability to bind to a target protein (bait) (Figure 2.13). The 
increased utilisation of this approach reflects the growing realisation that a majority of protein-
protein interactions in higher eukaryotes are driven by linear motifs. 21,89  
 
 
Figure 2.13. Peptide phage display platform. A peptide-phage library was added to immobilised reptin in the apo, ADP- or 
Liddean (48) bound forms (bait). Nonbinders were removed by extensive washing. Target-specific phage were eluted and 
amplified to provide an enriched pool. This biopanning cycle was repeated 3 times. The final target-specific, high-affinity 
phage were cloned and sequenced using next-generation deep sequencing.  
 
A drawback to most protein-protein interaction discovery platforms such as yeast two hybrid or tap-
tagging, is that they do not provide a robust opportunity for the identification of allosterically 
regulated or ligand-dependent PPIs. However, peptide phage display provides a method for 
discovering novel binding peptides for a ligand-bound target in vitro, where the bait conformation 
can be manipulated. Based on this concept, an alternative phage-based assay was developed to 
identify novel Liddean (48) induced/stabilised reptin-peptide interactions. A 12-mer peptide-phage 
combinatorial library was screened against immobilised (reptin) in its apo, ADP- or Liddean (48)-
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bound state (Figure 2.13). Phage-particles displaying peptides capable of forming an interaction with 
reptin were isolated and subjected to three rounds of biopanning, an in vitro “natural selection” 
process.83,85,86 This affinity selection procedure consists of the removal of unbound phages, the 
elution and amplification of interacting phages to create an enriched pool, which is subjected to two 
further rounds of biopanning under conditions of increasing stringency, resulting in the further 
enrichment of selective and high affinity binders.88,87 The final phage-peptide pool was subjected to 
next generation deep sequencing (a high-throughput parallel DNA sequencing method) to identify 
the peptide sequences (Figure 2.13).90–93   
 
The majority of peptides identified in the apo-reptin form (no bound ligand) were suppressed in the 
presence of ADP and Liddean (48), suggesting both ligands generally exert a similar effect on reptin’s 
peptide binding activity. However, peptides which were enriched by ligand were prioritised as we 
were primarily interested in identifying reptin PPIs which were allosterically upregulated or 
stabilised by Liddean (48). A thousand of such peptides were identified and subjected to analysis 
using MEME (Multiple EM for Motif Elicitation), a bioinformatics tool used to identify conserved 
motifs that occur repeatedly within a pool of peptides, proteins or DNA sequences (Figure 2.14A).94 
The identified consensus peptide motifs were subsequently blasted (BLAST; Basic Local Alignment 
Search Tool is a bioinformatics algorithm for comparing amino acid sequences)95 against the human 
proteome to identify known proteins which contain this particular motif.  
 
 
Figure 2.14. Identification of novel reptin binding peptides using peptide phage display linked with next-generation deep 
sequencing. (A) 1000 peptides which were enriched in the ligand bound state were processed using MEME to identify 
consensus motifs (http://meme.nbcr.net/meme/cgi-bin/meme.cgi). (B) The panel represents data from a 12-mer peptide 
screen where the core motif identified is highlighted as RER or LRER[L/G]. (C) A blast motif screen using the MEME 
derived peptide consensus sites gave rise to a peptide derived from the tumour suppressor protein p53. Data provided by 
the Hupp group. 
  
Of particular interest was the ADP and Liddean (48) induced-enrichment of a motif containing a 
RERcore (Figure 2.14B), which was identified in the tetramerisation domain of the p53 tumour 
(A) (B) (C) 
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suppressor (Figure 2.14C), an important therapeutic target for the development of anticancer 
agents.The RERmotif was also identified in the apo-reptin form suggesting it is a naturally 
occurring reptin PPI (Figure 2.14A). The interaction however, was enhanced by ADP, and to a greater 
extent by Liddean (Figure 2.14A), which is in agreement with our previously observed relative effect 
of these two different ligands on reptin. This novel reptin-p53 PPI was validated in vitro through an 
ELISA assay which demonstrated that purified p53 protein was able to bind to reptin (Figure 2.15A). 
Liddean (48) stabilised the p53-reptin complex (Figure 2.15B), which is similar to what was observed 
in the synthetic peptide-phage screen. In contrast to Liddean (48)’s stabilisation of the reptin-AGR2 
peptide complex (Figure 2.9B), Liddean (48) was found to destabilise the binding of reptin to full-
length AGR2 protein at low concentrations but stabilise it at higher concentrations (Figure 2.15B). 
This effect of Liddean (48) is similar to the effect of ADP on full-length AGR2-reptin complex 
stability.65 These data confirm that Liddean (48)-responsive peptide-binding activities of reptin can 
be translated to the corresponding interactions with the full-length target proteins, and suggest that 
the reptin oligomer (induced by Liddean) has a higher specific activity towards p53 and AGR2 
proteins. 
 
 
Figure 2.15. In vitro validation of the novel reptin-p53 PPI. (A) GST-tagged reptin and AGR2 proteins were assessed for 
their ability to bind to full length p53 using ELISA. p53 protein was absorbed onto the solid phase, and the indicated 
proteins were titrated in solution phase. The binding was detected using GST antibodies, followed by peroxidase 
conjugated secondary antibodies and processing using chemiluminescence. The data is plotted as binding activity as a 
function of protein amount (in RLU). (B). The effect of Liddean (48) on the reptin-AGR2 and reptin-p53 protein interactions 
was evaluated. Either p53 or AGR2 protein were absorbed onto the solid phase and reptin protein (200 ng) was added in 
50 µL of buffer containing increasing amounts of the indicated ligand. After 60 minutes incubation at room temperature, 
reptin protein bound to its target was detected using a reptin antibody and a peroxidase linked secondary antibody. 
Binding activity was quantified by chemiluminescence using a Fluoroskan Ascent FL Labsystems. Data provided by the Hupp 
group.  
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2.5.2 Identification of a reptin binding site on p53 
In order to fine map the reptin binding site on p53, overlapping biotinylated peptides derived from 
the open reading frame of human p53 protein (Figure 2.16A) were adsorbed onto a streptavidin 
coated solid phase and then evaluated for specific binding to the reptin protein. Two dominant 
peptides were identified which bound to reptin (Figure 2.16B). These peptide motifs overlap with 
the known MMD2 binding site (peptide 31) in the central domain of p53 and also with a motif in the 
tetramerisation domain of p53 (peptide 38).  
 
 
Figure 2.16. Fine mapping of the dominant linear peptide docking sites of reptin on p53. (A) The domain structure of p53 
including the sites bound by MDM2 (in green), proline rich motif (blue), the specific DNA-binding domain (pink); 
tetramerisation domain (yellow); and the C-terminal regulatory domain (in red). The arrows highlight the two binding sites 
mapped for reptin (in panels below). (B). An overlapping series of synthetic biotinylated peptides derived from the open 
reading frame of p53 were captured on streptavidin coated solid phase and reptin binding was detected using a reptin 
antibody and a peroxidase linked secondary antibody. Binding activity was quantified by chemiluminescence using a 
Fluoroskan Ascent FL Labsystems. Two domain regions from p53 bound to reptin and were mapped to the BOX-V domain 
(RNS…GRD) and to the tetramerisation domain (YFT…EMF). The latter peptide contains two repeats of the RER or 
LRER[L/G] motifs identified from the ligand responsive peptides using MEME (Figure 2.15). (C) Alanine scan mutagenesis of 
peptide 38 (YFTLQIRGRERFEMF) identifies key amino acid side chains that are important for reptin binding to p53; in the 
core sequence IRGRERFEMF, mutating IRGR or the overlapping RERF motif abrogates reptin binding to p53. This functional 
alanine mutagenesis is consistent with the MEME derived peptide motif obtained from the deep sequencing analysis. 
(A) 
(B) 
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Alanine scan mutagenesis of p53 peptide 38 (YFTLQIRGRERFEMF) was performed to determine 
whether a minimum binding motif could be identified (Figure 2.16C). The key amino acid contacts 
required for efficient binding of the p53 peptide to reptin forms the core RERmotif (Figure 2.16C), 
identified by the peptide-phage screen (Figure 2.15). These data further confirmed that the peptide 
combinatorial screen combined with next-generation sequencing can identify viable dominant 
docking sites for protein-protein interactions.   
 
The identification of p53 as a novel reptin interactor further enhances the knowledge surrounding 
this multifunctional AAA+ protein. Research is continuing utilising the chemical tool Liddean (48) to 
further understand the role and significance of this novel PPI. The reptin-p53 interaction has since 
been validated in vivo using knockdown and pull-down experiments, and it appears to be involved in 
regulating p53-DNA binding. The essential role, which the p53-DNA interaction plays in regulating 
apoptosis and cell cycle homeostasis, highlights the reptin-p53 PPI as a novel and promising target 
for the development of new anticancer agents. The in vivo effect of Liddean (48) on the reptin-p53 
interaction is currently being evaluated.  
 
2.6 Development of the 2nd In Silico Hit 13 
 
The power and utility of an in silico screen to identify novel small molecule PPI modulators was 
exemplified by the identification of the novel chemical tool Liddean  (48). Encouraged by the success 
of the initial discovery programme, compound 13, the 2nd hit identified from the in silico screen and 
subsequent ELISA assay was focused on (Figure 2.6). The main aim for the development of a second 
reptin modulator was towards the identification of a more water soluble lead compound to be used 
in a drug development programme. Although the development of Liddean (48) provided a useful 
chemical tool, its poor water solubility could prevent it from being a potential drug lead. In contrast, 
13 has a predicted solubility (logS) of -5.42,82 which is a good starting point for the development of a 
novel drug lead targeting reptin. 
 
2.6.1 Analysis of the predicted binding mode of 13 
Similarly to the Liddean precursor 17, 13 was not identified in the first reptin in silico screen, but was 
present in the second screen when the Arg400 loop in reptin was manually closed over the pocket. 
Analysis of the predicted binding mode of 13 (in reptin with closed Arg400 loop) revealed that it is a 
much closer mimic of ADP than Liddean (48). The benzo[1,3]dioxole ring of 13 is predicted to be 
buried deep in the ATP pocket where the adenine of ADP resides (Figure 2.17A). The amine 
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substituent of the adenine ring is thought to adopt a similar position to one of the dioxole oxygens, 
potentially forming similar hydrogen bond interactions. The core (trifluoromethyl)pyrazolo-
pyrimidine motif of 13 is predicted to be in the same position as the ribose ring of ADP (Figure 
2.17A), where interestingly the CF3 group is predicted to occupy the small hydrophobic pocket in 
which the bromine atom of Liddean (48) was predicted to bind (Figure 2.7A). In contrast to Liddean 
(48), 13 contains an amide-linked tetrahydrofuran moiety which is predicted to bind in the ATP/ADP 
phosphate channel. Most importantly, the nitrogen and oxygen atoms of the amide and the oxygen 
of the tetrahydrofuran ring overlay with oxygen atoms present in the phosphate chain of ADP 
(Figure 2.17B), suggesting the possible formation of a similar hydrogen bonding network with 
Arg400 as ADP.  
 
  
Figure 2.17. (A) The Autodock prediction of the binding mode of 13 is coloured green and shown as sticks. The ADP 
molecule present in the pontin structure is coloured black and shown as lines. The ATP pocket of reptin with the Arg400 
manually closed over the ATP pocket is shown as a transparent surface representation. In all cases nitrogen is coloured 
blue, oxygen red, phosphorous orange, and chlorine green. Figure created using Pymol. (B) Overlay of ADP and 13. Figure 
created using PyMOL. 
 
Based on the surprising discovery that related analogue 3 (Figure 2.6C) was not active in the reptin-
AGR2 peptide binding assay, the remaining members (61 and 62) of the structural class which 
contained 13 and 3 were purchased (Figure 2.18A). This would provide preliminary SAR data and 
determine whether there was scope to modify 13 without abolishing its biological activity. 
Assessment of 61 and 62 in the previously described reptin-AGR2 peptide binding ELISA revealed 
that they induced a similar stabilisation/upregulation in the interaction as 13 (Figure 2.18B). 
 
The biological activity observed for analogues of 13 containing different functionalities at the 3-
(amide-linked tetrahydrofuran) and 5-(benzo[1,3]dioxole) positions highlighted the potential to 
undertake an SAR study to optimise this lead compound. The synthesis of a diverse library of 
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analogues based around the 7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine core lends itself to a 
combinatorial chemistry approach.96,97 The development of a solution-phase synthesis of 13 which 
would be amenable to a parallel library approach would provide access to a structurally diverse 
library of analogues. A suitable synthetic route would require simple purification, display a relatively 
high substituent tolerance and provide sufficient quantities of the desired analogues in a fast and 
cost efficient manner from readily available starting materials.98 
 
 
 
Figure 2.18. (A) The structures of lead compound 13, and related analogues 3, 61 and 62. (B) The effects of analogues of 
13 on reptin-AGR2 peptide binding activity. AGR2 peptide was absorbed onto the solid phase and reptin protein was 
titrated from 0-150 ng as indicated with a fixed concentration (25 µM) of ligand (3, 13, 61, 62 and DMSO (control)).  
 
2.6.2 Development of a combinatorial approach 
The development of a suitable combinatorial approach was considerably aided by the extensive 
research undertaken to identify novel solution and solid phase combinatorial syntheses of 
heterocyclic compounds in medicinal chemistry.99,100 In particular, the pyrazolo[1,5-a]pyrimidine 
structural motif is present in a large number of pharmaceutical agents encompassing a broad range 
of biological activities, including, antiepileptic agents, anxiolytics, antidepressants, agents for the 
treatment of sleep disorders and oncolytics.101 Dalinger et al. reported a combinatorial approach to 
access a diverse library of 7-trifluoromethyl-substituted pyrazolo[1,5-a]pyrimidine analogues which 
(A) 
(B) 
Chapter 2: Virtual Screening 
 
33 
 
could potentially be adapted to provide our desired analogues.101 The general synthetic approach 
involved the treatment of trifluoromethyl-β-diketones 63 with 5-aminopyrazolecarboxylic ester 
derivatives 64 to provide the substituted pyrazolo[1,5-a]pyrimidine carboxylate core 65. These could 
be readily converted into the desired libraries of amides 66 via the corresponding acid chlorides 
(Scheme 2.3).  
 
Scheme 2.3. General scheme for the synthesis of pyrazolo[1,5-a]pyrimidine carboxylate derivatives.
101
 
 
Dalinger and coworkers accessed the required trifluoromethyl-β-diketone reagents 63 by 
trifluoroacetylation of the appropriate methyl ketones, using tBuOK in benzene.101,102 However, this 
route was deemed not suitable for the large scale synthesis of a range of trifluoromethyl-β-
diketones as it would require large quantities of toxic benzene and a column chromatographic 
purification step. Instead, a trifluoroacetylation procedure described by Danheiser et al., involving 
LiHMDS in THF (Scheme 2.4) was utilised to access the desired trifluoromethyl-β-diketone 68.103 This 
route provided 68 in quantitative yield after a simple aqueous work-up.  
 
Scheme 2.4. Synthesis of 13. (a) LiHMDS, ethyl trifluoroacetate, THF, 0 C  r.t., 3 h, quantitative. (b) (i) Ethyl 3-amino-1H-
pyrazole-4-carboxylate 64, acetic acid, reflux, 5 h, 90% (ii) NaOH, EtOH, H2O, 65 C, 4 h. (c) (i) Oxalyl chloride, DCM, DMF, 0 
C  r.t., 2 h. (ii) tetrahydrofurfurylamine, MeCN, r.t., 2 h, 72%. 
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68 was heated at reflux in the presence of commercially available ethyl 3-amino-1H-pyraxole-4-
carboxylate 64 and acetic acid to furnish the desired pyrazolo[1,5-a]pyrimidine carboxylate 69 after 
simple precipitation from ice-water. 69 was subsequently treated with solid NaOH in a H2O/EtOH 
mixture at 65 C for 4 hours. Cooling to room temperature followed by acidification yielded the 
desired acid 70 in a 4:1 ratio to unreacted ethyl carboxylate 69 which was not removed until the final 
purification (Scheme 2.4). The final step involved conversion of the acid 70 into the desired amide 13 
via the corresponding acid chloride. Dalinger et al. formed the acid chlorides by refluxing the acids 
with thionyl chloride in CCl4.
101 Optimisation of this step targeted the removal of the toxic solvent 
CCl4, which can result in adverse health effects
104 and ozone depletion.105 
 
An alternative route was developed which involved the generation of the acid chloride using oxalyl 
chloride and DMF (cat.) in DCM, followed by concentration in vacuo, dilution with MeCN and stirring 
with tetrahydrofufurylamine for 2 hours. The pure product 13 was obtained after column 
chromatography (to remove unreacted ethyl carboxylate 69) and recrystallisation from hot EtOH 
(Scheme 2.4). Further optimisation of the ester hydrolysis step is required to push it to completion 
which would remove the need for a column purification step at the end of the synthesis. The issue 
surrounding the hydrolysis of 69 appears to result from its relatively poor solubility under the 
reaction conditions. Altering the ratio of the H2O/EtOH solvent system, reaction concentration and 
time should result in the complete conversion to the desired acid 70.   
In summary, we have developed a concise synthetic route to 13 which could be used in the parallel 
synthesis of a diverse library of analogues. This four step route utilises simple aqueous work-ups or 
precipitation to access the desired intermediates and recrystallisation to provide the pure desired 
product 13. Optimisation of this route by the elimination of the column purification step in the 
synthesis of trifluoromethyl-β-diketone 68 and removal of the toxic solvents benzene and CCl4, make 
it significantly more amenable to large scale parallel synthesis. Finally, incorporating a range of 
commercially available methyl ketones or amines would provide access to a diverse library of 
analogues.  
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2.6.3 Inhibition of HCT-116 cancer cell proliferation 
As the main focus of developing this second series of compounds was towards the identification of a 
possible anticancer drug lead, 13 was assessed for its effect on the proliferation of HCT-116 cancer 
cells by the Hupp group.  
 
Figure 2.19. Effect of 13 on the proliferation of a HCT-116 +/+ cancer cell line. 13 was added after 24 hours and its effect 
monitored over 96 hours using iCELLigence (ACEA biosciences). Each data point is an average of 3 counts. Data provided by 
the Hupp group. 
 
13 was found to inhibit cell proliferation in a dose dependent manner (0-100 µM) in both a HCT-116 
(p53 +/+) cell line (Figure 2.19) and a HCT-116 (p53 -/-) cell line (data not shown). Further research is 
required to investigate if this is a cancer cell specific response and to explore if the observed 
cytotoxicity is a result of modulation of reptin’s cellular functions or an alternative off-target effect. 
However, this preliminary result validates 13 as a promising cell permeable lead molecule for a 
medicinal chemistry drug development programme. 
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2.7 Conclusions and Future Work 
 
Reptin is a central mediator of numerous cellular processes, mainly as a result of its role in the 
assembly of multiprotein complexes involved in the regulation of transcription, chromatin 
remodelling, DNA damage response and nutrient sensing. Reptin’s involvement in cellular 
regulation, signalling and pathophysiology has identified it as a promising therapeutic target, 
particularly in the area of cancer research. However, little is known about factors that control its 
multiple functions and how the relevant signalling pathways are regulated. Herein we report the 
development of a multi-disciplinary chemical biology platform to discover and optimise small 
molecule modulators of reptin’s protein interactome, thus providing chemical tools by which to 
further dissect reptin’s role in oncogenesis.  
 
This discovery platform involved the use of high-throughput virtual screening coupled to an in vitro 
PPI ELISA to identify two lead compounds, 13 and 17, from an in silico 4.8 million conformer library. 
Synthetic optimisation of 17 guided by molecular modelling and biological evaluation resulted in the 
identification of a more active analogue, Liddean (48). The SAR optimisation process also provided 
valuable insight into the binding pose, conformation and potential mode of action of 17. Future 
optimisation of Liddean (48) will focus on three areas: 1.) improved solubility 2.) optimisation of the 
C ring and 3.) generation of a tagged-derivative of Liddean (48).  
 
1.) Improving the solubility of Liddean (48) will mainly focus on disruption of the -system which 
stabilises the flat conformation of Liddean (48). Biphenyl ring systems are detrimental to solubility 
due to their planar hydrophobic nature, a larger screen of A ring derivatives could potentially lead to 
the identification a more optimal substituent. In addition, preliminary analysis of the effect of the 
pyridine-oxazole ring of Liddean (48) on its predicted solubility has highlighted this as an important 
region for optimisation.  
2.) The expanding toolbox of C-H functionalisation methodology106–108 provides an efficient and 
versatile method to access Liddean (48) analogues containing a diverse range of heterocyclic rings in 
place of the pyridine-oxazole.    
3.) Finally, modification of the pyridine-oxazole ring of Liddean (48) or incorporation of a different 
substituent at this position would provide the opportunity to tag Liddean (48) with a photoaffinity 
label or a biotin linker. These Liddean (48) derivatives could facilitate the isolation of additional 
Liddean (48)-bound reptin PPIs using affinity chromatography.  
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Reptin’s diverse range of biological functions are believed to be regulated in part, by its oligomeric 
state, which is currently known to exist from a monomer to a dodecamer. Liddean (48) was 
subsequently shown to induce the formation of higher order reptin oligomers. It is with this more 
stabilised oligomeric state of Liddean (48)-bound reptin, that peptides containing a RER motif 
were preferentially found to bind. The RER motif was subsequently validated as the core motif 
forming a reptin binding site on the tetramerisation domain of tumour suppressor protein, p53. The 
identification of this novel reptin-p53 PPI validates this platform as a valuable method for dissecting 
reptin’s protein interactome. In particular, elucidation of reptin’s role in regulating the essential 
tumour suppressor protein p53, could reveal a novel pathway involved in cancer development and 
provide a valuable new therapeutic target. Extensive research is underway to probe this interaction 
and to identify and validate further novel interacting proteins from the peptide-phage screen. In 
addition, a range of biochemical techniques are being used to analyse Liddean (48)’s effect on reptin 
and the resulting cellular responses, including, HD exchange, SEC-MALS, proximity ligation assay 
(PLA), fluorescence polarisation (FP) and cell growth assays.  
 
The second hit compound 13 obtained from the in silico – in vitro screen was developed in parallel as 
a potential drug lead, due to its superior predicted solubility when compared to the chemical tool 
Liddean (48). A preliminary SAR study containing structurally related analogues identified from the 
virtual screen revealed that it was possible to modify the substituents connected to the 
(trifluoromethyl)pyrazolo-pyrimidine core, while maintaining its biological activity. A synthetic 
approach was developed to access 13, which would in the future provide the opportunity to rapidly 
assemble a focused library of analogues containing the (trifluoromethyl)pyrazolo-pyrimidine core. 
The observed concentration dependent cytotoxicity of 13 against a HCT-116 cancer cell line 
validated it as promising cell permeable anticancer drug lead. Future work will focus on the 
development of a more potent lead compound through a combinatorial approach, and investigation 
if 13’s observed cytotoxicity is a result of modulation of reptin’s cellular functions.  
 
The utility of this in silico – in vitro approach as a method to detect novel small molecule PPI 
modulators is exemplified by the expedient and cost efficient identification of the chemical tool 
Liddean (48) and drug-lead 13 from a 4.8 million conformer library. Furthermore, this platform could 
provide a powerful approach by which to identify modulators of other therapeutically relevant 
members of the AAA+ superfamily.  
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2.8 Experimental 
 
2.8.1 General Considerations 
All chemicals and solvents were purchased from Aldrich (UK), Alfa Aesar, or Acros Organics and used 
without further purification. All reactions involving moisture sensitive reagents were performed in 
oven or flame dried glassware under a positive pressure of nitrogen. Tetrahydrofuran (THF), 
dichloromethane (DCM) and hexanes were obtained dry from a solvent purification system (MBraun, 
SPS-800). Anhydrous N,N-dimethylformamide (DMF) was purchased from Aldrich. 
 
Thin layer chromatography (TLC) analysis was performed using glass plates coated with silica gel 
(with fluorescent indicator UV254). Developed plates were air dried and analysed under a UV lamp 
(254/365 nm) or by KMnO4 dip staining. Flash chromatography was performed using silica gel (40-63 
μm, Fluorochem). 
 
Melting points were recorded in open capillaries using an Electrothermal 9100 melting point 
apparatus. Values are quoted to the nearest 1 °C and are uncorrected. 
 
Fourier Transform infra-red spectra (FT IR) were acquired on a Perkin Elmer paragon 1000 FT 
spectrophometer (KBr disc) or a Shimadzu IRAffinity-1 FT spectrophotometer with a Pike MIRacleTM 
(solid or thin film). Absorption maxima are reported in wavenumbers (cm -1). 
 
Nuclear magnetic resonance (NMR) spectra were recorded at room temperature on Bruker Avance 
500 (1H, 499.9 MHz; 13C, 125.7 MHz), Bruker Avance 400 (1H, 400.1 MHz; 13C, 100.6 MHz) and Bruker 
Avance 300 (1H, 300.1 MHz; 13C, 75.5 MHz) instruments. NMR spectra were recorded in deuterated 
solvents and internally referenced to the residual solvent peak, chloroform-d (δC 77.16, δH 7.26 
ppm), acetone-d6 (δC 29.8, δH 2.04 ppm), DMSO-d6 (δC 39.52, δH 2.50 ppm) or methanol-d4 (δC 49.0, 
δH 3.31 ppm). Chemical shifts are expressed as δ in units of ppm. 
13C NMR spectra were recorded 
using the PENDANT sequence mode. Data processing was carried out using the MestReNova 8.1.1 
NMR program (Mestrelab Research S.L.). For 1H NMR, the multiplicity used for assignment is 
indicated by the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, h 
= sextet, hept = heptet, m = multiplet, br = broad. Signals of protons and carbons were assigned, as 
far as possible, by using the following two dimensional NMR spectroscopy techniques: [1H, 1H] COSY 
(Correlation Spectroscopy), [1H, 13C] HSQC (Heteronuclear Single Quantum Coherence) and long 
range [1H, 13C] HMBC (Heteronuclear Multiple Bond Connectivity). 
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Low resolution (LR) and high resolution (HR) electrospray mass spectral (ES-MS) analyses were 
acquired by electrospray ionisation (ESI). These were acquired by the EPSRC National Mass 
Spectrometry Service or within the School of Chemistry, University of St Andrews. 
 
See Appendix B for the 1H NMR spectra of the analogues of 13 and 17 purchased from Chembridge. 
 
2.8.2 General Methods 
 
General Method A: Synthesis of the Pyridine-oxazolo core 
 
To polyphosphoric acid (20 eq.) at 120 C were added simultaneously 2-amino-3-hydroxypyridine 
34 (1 eq.) and a range of substituted benzoic acids (1 eq.). The resulting mixture was heated to 200 
C for 4 hours. After cooling slightly, ice water was added to the reaction. The solution was 
neutralised by the slow addition of a saturated sodium hydrogen carbonate solution and the 
resulting precipitate collected by filtration. Drying in a vacuum oven yielded the pure product. 
 
General Method B: N-acylation  
To a solution of the appropriate aniline (35a-j) (1 eq.) in DCM (1 mL/mmol) was added a range of 
carbonyl chlorides (2.5 eq.). The mixture was stirred for 10 minutes before the dropwise addition of 
DIPEA (1.5 eq.). The reaction was stirred at room temperature for 24-72 hours. The resulting 
precipitate was filtered and dried to yield the desired compound. Recrystallisation from DCM 
afforded the product in high purity. 
 
2.8.3 Experimental procedures 
 
2-Chloro-5-(oxazolo[4,5-b]pyridin-2-yl)aniline (35a)109 
 
Prepared from 2-amino-3-hydroxypyridine 34 (4.00 g, 36.3 mmol, 1.0 eq.) and 3-amino-4-
chlorobenzoic acid (6.23 g, 36.3 mmol, 1.0 eq.) using general method A. 35a was obtained as a white 
solid (4.90 g, 55%). mp 205-208 C; IR (solid) ν max: 3453 (NH), 3345 (NH), 1614, 1406, 1261, 781 (C-
Cl); 1H NMR (500 MHz, Chloroform-d) δ 8.57 (dd, J = 4.9, 1.5 Hz, 1H, C5’-H), 7.84 (dd, J = 8.1, 1.5 Hz, 
1H, C7’-H), 7.73 (d, J = 2.0 Hz, 1H, C6-H), 7.61 (dd, J = 8.3, 2.0 Hz, 1H, C4-H), 7.40 (d, J = 8.3 Hz, 1H, 
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C3-H), 7.29 (dd, J = 8.1, 4.9 Hz, 1H, C6’-H), 4.30 (br s, 2H, NH2); 
13C NMR (126 MHz, Chloroform-d) δ 
165.3 (C2’), 156.4 (C3’a), 146.9 (C5’), 143.6 (C1), 143.2 (C7’a), 130.2 (C3), 125.9 (C5), 123.6 (C2), 
120.3 (C6’), 118.4 (C4), 118.3 (C7’), 114.8 (C6); m/z (ES+) 246.04 ([M+H]+, 100 %); HRMS (ES+) Calcd 
for C12H9ON3Cl [M+H]
+: 246.0429, found 246.0431. Spectroscopic data are in accordance with the 
literature.109 
 
2-Bromo-5-(oxazolo[4,5-b]pyridin-2-yl)aniline (35b) 
 
Prepared from 2-amino-3-hydroxypyridine 34 (600 mg, 5.45 mmol) and 3-amino-4-bromobenzoic 
acid (1.18 g, 5.45 mmol, 1.0 eq.) using general method A. 35b was obtained as a pale brown solid 
(1.38 g, 87%). mp 211-212 C; IR (solid) ν max: 3418 (NH), 3287 (NH), 3171, 1736, 1620, 1597, 1543, 
1404; 1H NMR (300 MHz, DMSO-d6) δ 8.54 (dd, J = 4.9, 1.4 Hz, 1H, C5’-H), 8.23 (dd, J = 8.2, 1.4 Hz, 
1H, C7’-H), 7.70 (d, J = 2.1 Hz, 1H, C6-H), 7.61 (d, J = 8.2 Hz, 1H, C3-H), 7.46 (dd, J = 8.2, 4.9 Hz, 1H, 
C6’-H), 7.31 (dd, J = 8.2, 2.1 Hz, 1H, C4-H), 5.79 (br s, 2H, NH2); 
13C NMR (75 MHz, DMSO-d6) δ 164.7 
(C2’), 155.5 (C3’a), 146.7 (C1), 146.5 (C5’), 142.7 (C7’a), 133.3 (C3), 125.8 (C5), 120.7 (C6’), 119.0 
(C7’), 115.9 (C4), 113.5 (C6), 111.8 (C2); m/z (ES+) 289.99 ([79BrM+H]+, 100 %), 291.99 ([81BrM+H]+, 
100%); HRMS (ES+) Calcd for C12H9ON3Br [M+H]
+: 289.9924, found 289.9927. 
 
2-(Oxazolo[4,5-b]pyridin-2-yl)aniline (35c) 
 
Prepared from 2-amino-3-hydroxypyridine 34 (600 mg, 5.45 mmol, 1.0 eq.) and 2-amino-4-
chlorobenzoic acid (935 mg, 5.45 mmol, 1.0 eq.) using general method A. 35c was obtained as a 
white solid (690 mg, 52%). mp 256-259 C; IR (solid) ν max: 3402 (NH), 3310 (NH), 3201, 1612, 1543, 
1481, 1404, 772 (C-Cl); 1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 5.2 Hz, 1H, C5’-H), 8.19 (d, J = 8.2 
Hz, 1H, C7’-H), 7.94 (d, J = 8.3 Hz, 1H, C3-H), 7.50 – 7.35 (m, 3H, C6’-H, NH2), 7.01 (s, 1H, C6-H), 6.73 
(d, J = 8.3 Hz, 1H, C4-H); 13C NMR (126 MHz, DMSO-d6) δ 164.2 (C2’), 155.2 (C3’a), 150.3 (C1), 146.2 
(C5’), 141.1 (C7’a), 138.1 (C5), 129.9 (C3), 120.5 (C6’), 118.5 (C7’), 115.6 (C4), 115.1 (C6), 104.6 (C2); 
m/z (ES+) 246.04 ([M+H]+, 100%); HRMS (ES+) Calcd for C12H9ON3Cl [M+H]
+: 246.0429, found 
246.0430. 
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3-(Oxazolo[4,5-b]pyridin-2-yl)aniline (35d)109  
 
Prepared from 2-amino-3-hydroxypyridine 34 (300 mg, 2.70 mmol, 1.0 eq) and 3-aminobenzoic acid 
(370 mg, 2.70 mmol, 1.0 eq.) using general method A. 35d was obtained as an off-white solid (500 
mg, 88%). mp 186-189 C; 1H NMR (300 MHz, DMSO-d6) δ 8.52 (dd, J = 4.9, 1.5 Hz, 1H, C5’-H), 8.21 
(dd, J = 8.1, 1.5 Hz, 1H, C7’-H), 7.48 (app. t, J = 2.0, 1H, C2-H), 7.44 (dd, J = 8.1, 4.9 Hz, 1H, C6’-H), 
7.38 (ddd, J = 7.8, 2.0, 1.1 Hz, 1H, C4-H), 7.26 (app. t, J = 7.8 Hz, 1H, C5-H), 6.84 (ddd, J = 7.8, 2.0, 1.1 
Hz, 1H, C6-H), 5.55 (br s, 2H, NH2); 
13C NMR (75 MHz, DMSO-d6) δ 165.6 (C2’), 155.6 (C3’a), 149.5 
(C1), 146.4 (C5’), 142.6 (C7’a), 129.9 (C5), 126.3 (C3), 120.5 (C6’), 118.9 (C7’), 118.1 (C6), 114.9 (C4), 
112.3 (C2); m/z (ES+) 218.08 ([M+H]+, 100 %); HRMS (ES+) Calcd for C12H10ON3 [M+H]
+: 212.0818, 
found 212.0818. Spectroscopic data are in accordance with the literature.109 
 
4-(Oxazolo[4,5-b]pyridin-2-yl)aniline (35e)110  
 
Prepared from 2-amino-3-hydroxypyridine 34 (600 mg, 5.45 mmol, 1.0 eq.) and 4-aminobenzoic acid 
(747 mg, 5.45 mmol, 1.0 eq.) using general method A. 35e was obtained as a pale yellow solid (906 
mg, 79%). mp 257-259 C (lit. 252-254 C110); IR (solid) ν max: 3395 (NH), 3310 (NH), 3202, 1605, 1489, 
1404; 1H NMR (500 MHz, DMSO-d6) δ 8.41 (dd, J = 4.9, 1.3 Hz, 1H, C5’-H), 8.07 (dd, J = 8.1, 1.3 Hz, 
1H, C7’-H), 7.91 (d, J = 8.6 Hz, 2H, C3-H), 7.31 (dd, J = 8.1, 4.9 Hz, 1H, C6’-H), 6.71 (d, J = 8.6 Hz, 2H, 
C2-H), 6.17 (br s, 2H, NH2); 
13C NMR (126 MHz, DMSO-d6) δ 166.0 (C2’), 156.4 (C3’a), 153.4 (C1), 
145.7 (C5’), 142.3 (C7’a), 129.6 (C3), 119.3 (C6’), 117.8 (C7’), 113.5 (C2), 111.7 (C4); m/z (ES+) 212.0 
([M+H]+, 100%); HRMS (ES+) Calcd for C12H10ON3 [M+H]
+: 212.0818, found 212.0818. Spectroscopic 
data are in accordance with the literature.110  
 
2-Fluoro-5-(oxazolo[4,5-b]pyridin-2-yl)aniline (35f) 
 
Prepared from 2-amino-3-hydroxypyridine 34 (75 mg, 0.68 mmol, 1.0 eq.) and 3-amino-4-
fluorobenzoic acid (105 mg, 0.68 mmol, 1.0 eq.) using general method A. 35f was obtained as an off-
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white solid (65 mg, 50%). mp 214-216 C; IR (solid) ν max: 3464 (NH), 3318 (NH), 3194, 3039, 1613, 
1497, 1404, 1173 (C-F); 1H NMR (400 MHz, DMSO-d6) δ 8.52 (dd, J = 4.9, 1.4 Hz, 1H, C5’-H), 8.21 (dd, 
J = 8.2, 1.4 Hz, 1H, C7’-H), 7.69 (dd, J = 8.6, 2.2 Hz, 1H, C6-H), 7.51 – 7.35 (m, 2H, C6’-H, C4-H), 7.25 
(dd, J = 11.3, 8.4 Hz, 1H, C3-H), 5.65 (br s, 2H, NH2); 
13C NMR (101 MHz, DMSO-d6) δ 164.8 (C2’), 
155.6 (C3’a), 153.1 (d, J = 245.3 Hz, C2), 146.4 (C5’), 142.7 (C7’a), 137.5 (d, J = 13.8 Hz, C1), 122.4 (d, J 
= 2.7 Hz, C5), 120.53 (C6’), 118.9 (C7’), 116.0 (d, J = 19.8 Hz, C3), 115.8 (d, J = 7.4 Hz, C4), 115.0 (d, J = 
6.3 Hz, C6); m/z (ES+) 230.07 ([M+H]+, 100 %); HRMS (ES+) Calcd for C12H9ON3F [M+H]
+: 230.0724, 
found 230.0725.  
 
2-Methyl-5-(oxazolo[4,5-b]pyridin-2-yl)aniline (35g) 
 
Prepared from 2-amino-3-hydroxypyridine 34 (500 mg, 4.54 mmol, 1.0 eq.) and 3-amino-4-
methylbenzoic acid (686 mg, 4.54 mmol, 1.0 eq.) using general method A. 35g was obtained as a 
pale brown solid (716 mg, 71%). mp 171-173 C; IR (solid) ν max: 3426 (NH), 3325 (NH), 3055, 1736, 
1620, 1551, 1497, 1404, 1234, 779; 1H NMR (500 MHz, DMSO-d6) δ 8.51 (dd, J = 4.9, 1.4 Hz, 1H, C5’-
H), 8.19 (dd, J = 8.1, 1.4 Hz, 1H, C7’-H), 7.53 (d, J = 1.8 Hz, 1H, C6-H), 7.42 (dd, J = 8.1, 4.9 Hz, 1H, C6’-
H), 7.36 (dd, J = 7.6, 1.8 Hz, 1H, C4-H), 7.17 (d, J = 7.6 Hz, 1H, C3-H), 5.33 (br s, 2H, NH2), 2.15 (s, 3H, 
CH3); 
13C NMR (126 MHz, DMSO-d6) δ 165.8 (C2’), 155.8 (C3’a), 147.5 (C1), 146.3 (C5’), 142.5 (C7’a), 
130.8 (C3), 126.6 (C2), 124.0 (C5), 120.3 (C6’), 118.7 (C7’), 115.3 (C4), 112.3 (C6), 17.7 (CH3); m/z 
(ES+) 226.09 ([M+H]+, 100 %); HRMS (ES+) Calcd for C12H12ON3 [M+H]
+: 226.0975, found 226.0974. 1H 
& 13C NMR data not in accordance with literature.109 
 
4-Amino-2-(oxazolo[4,5-b]pyridin-2-yl)phenol (35h)111 
 
Prepared from 2-amino-3-hydroxypyridine 34 (600 mg, 5.45 mmol, 1.0 eq.) and 5-aminosalicylic acid 
(835 mg, 5.45 mmol, 1.0 eq.) using general method A. 35h was obtained as a dark yellow solid (690 
mg, 49%). mp 191-193 C (lit. 181-183 C111); IR (solid) ν max: 3426 (NH), 3310 (NH), 3202 (OH), 1620, 
1535, 1497, 1404, 779; 1H NMR (500 MHz, DMSO-d6) δ 10.19 (br s, 1H, OH), 8.55 (dd, J = 4.9, 1.4 Hz, 
1H, C5’-H), 8.27 (dd, J = 8.1, 1.4 Hz, 1H, C7’-H), 7.48 (dd, J = 8.1, 4.9 Hz, 1H, C6’-H), 7.27 (d, J = 2.3 Hz, 
1H, C3-H), 6.89 – 6.86 (m, 2H, C5-H, C6-H), 5.02 (br s, 2H, NH2); 
13C NMR (126 MHz, DMSO-d6) δ 
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165.2 (C2’), 153.9 (C3’a), 149.7 (C1), 146.6 (C5’), 141.8 (C4), 141.4 (C7’a), 122.3 (C5), 120.8 (C6’), 
119.0 (C7’), 117.9 (C6), 110.4 (C3), 109.5 (C2); m/z (ES+) 228.07 ([M+H]+, 100%); HRMS (ES+) Calcd for 
C12H10O2N3 [M+H]
+: 228.0768, found 228.0768. 
 
3-(Oxazolo[4,5-b]pyridin-2-yl)phenol (35i)112  
 
Prepared from 2-amino-3-hydroxypyridine 34 (55 mg, 0.5 mmol, 1.0 eq.) and 3-hydroxybenzoic acid 
(69 mg, 0.5 mmol, 1.0 eq.) using general method A. 35i was obtained as a white solid (75 mg, 71%). 
mp 198-201 C (lit. 203-204 C112); IR (solid) ν max: 3030 (OH), 2922 (OH), 2603, 1601, 1551, 1449, 
1294, 887, 781; 1H NMR (500 MHz, DMSO-d6) δ 10.06 (br s, 1H, OH), 8.54 (dd, J = 4.9, 1.4 Hz, 1H, C5’-
H), 8.24 (dd, J = 8.1, 1.4 Hz, 1H, C7’-H), 7.69 (d, J = 7.9 Hz, 1H, C4-H), 7.72 – 7.66 (m, 1H, C2-H), 7.50 – 
7.40 (m, 2H, C6’-H, C5-H), 7.07 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H, C6-H); 13C NMR (126 MHz, DMSO-d6) δ 
164.9 (C2’), 158.0 (C1), 155.5 (C3’a), 146.6 (C5’), 142.8 (C7’a), 130.7 (C5), 127.0 (C3), 120.8 (C6’), 
120.0 (C6), 119.1 (C7’), 118.5 (C4), 114.0 (C2); m/z (ES+) 213.06 ([M+H]+, 100 %); HRMS (ES+) Calcd 
for C12H9O2N2 [M+H]
+: 213.0659, found 213.0659. Spectroscopic data are in accordance with the 
literature.112 
 
5-(Benzo[d]oxazol-2-yl)-2-bromoaniline (35j) 
 
Prepared from 2-aminophenol (545 mg, 5.00 mmol, 1.0 eq.) and 3-amino-4-bromobenzoic acid (1.08 
g, 5.00 mmol, 1.0 eq.) using general method A. 35j was obtained as an off-white solid (653 mg, 45%). 
mp 198-200 C; IR (solid) ν max: 3449 (NH), 3310 (NH), 3179, 1612, 1543, 1435, 1242, 1065, 741; 
1H 
NMR (500 MHz, DMSO-d6) δ 7.81 – 7.75 (m, 2H, C4’-H, C7’-H), 7.66 (d, J = 2.1 Hz, 1H, C6-H), 7.57 (d, J 
= 8.2 Hz, 1H, C3-H), 7.46 – 7.37 (m, 2H, C5’-H, C6’-H), 7.27 (dd, J = 8.2, 2.1 Hz, 1H, C4-H), 5.75 (br s, 
2H, NH2); 
13C NMR (126 MHz, DMSO-d6) δ 162.2 (C2’), 150.1 (C3’a), 146.6 (C1), 141.5 (C7’a), 133.2 
(C3), 126.3 (C5), 125.5 (C5’), 124.9 (C6’), 119.8 (C4’), 115.7 (C4), 113.3 (C6), 111.0 (C2), 110.9 (C7’); 
m/z (ES+) 288.99 ([79BrM+H]+, 100 %), 290.99 ([81BrM+H]+, 100%); HRMS (ES+) Calcd for C13H10ON2Br 
[M+H]+: 288.9971, found 288.9975. 
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N-(2-Chloro-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (17) 
 
Prepared from 35a (300 mg, 1.42 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (769 mg, 3.55 
mmol, 2.5 eq.) using general method B. 17 was obtained after recrystallisation as a white solid (346 
mg, 57%). mp 254-256 C; IR (KBr) ν max: 3416 (NH), 3275, 3059, 3033, 1653 (C=O); 
1H NMR (400 
MHz, DMSO-d6) δ 10.39 (br s, 1H, NH), 8.61 – 8.53 (m, 2H, C5’-H, C6-H), 8.29 (dd, J = 8.2, 1.5 Hz, 1H, 
C7’-H), 8.19 – 8.11 (m, 3H, C4-H, 2  C2’’-H), 7.93 – 7.83 (m, 3H, C3-H, 2  C3’’-H), 7.82 – 7.75 (m, 2H, 
2  C6’’-H), 7.57 – 7.46 (m, 3H, C6’-H, 2  C7’’-H), 7.49 – 7.39 (m, 1H, C8’’-H); 13C NMR (101 MHz, 
DMSO-d6) δ 165.3 (CO), 163.7 (C2’), 155.4 (C3’a), 146.8 (C5’), 143.6 (C4’’), 143.0 (C7’a), 139.0 (C5’’), 
136.2 (C1), 133.4 (C2), 132.5 (C1’’), 131.0 (C3), 129.1 (2  C7’’), 128.6 (2  C2’’), 128.3 (C8’’), 127.0 (2 
 C6’’), 126.8 (2  C3’’), 126.6 (C6), 126.1 (C4), 125.2 (C5), 121.1 (C6’), 119.3 (C7’); m/z (ES-) 423.82 
([M-H]-, 100 %); HRMS (ES-) Calcd for C25H15ClN3O2 [M-H]
-: 424.0839, found 424.0853. 
 
N-(2-Bromo-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)benzamide (42) 
 
Prepared from 35b (80 mg, 0.28 mmol, 1.0 eq.) and benzoyl chloride (98 mg, 0.70 mmol, 2.5 eq.) 
using general method B. 42 was obtained after recrystallisation as a white solid (74 mg, 67%). mp 
249-251 C; IR (solid) ν max: 3271 (NH), 3055, 1651 (C=O), 1520, 1404, 1257, 779, 709, 640 (C-Br);
 1H 
NMR (400 MHz, DMSO-d6) δ 10.29 (br s, 1H, NH), 8.58 (dd, J = 4.9, 1.4 Hz, 1H, C5’-H), 8.47 (d, J = 2.0 
Hz, 1H, C6-H), 8.28 (dd, J = 8.3, 1.4 Hz, 1H, C7’-H), 8.10 – 7.98 (m, 4H, C3-H, C4-H, 2  C2’’-H), 7.69 – 
7.62 (m, 1H, C4’’-H), 7.58 (dd, J = 8.3, 6.5 Hz, 2H, 2  C3’’-H), 7.50 (dd, J = 8.3, 4.9 Hz, 1H, C6’-H); 13C 
NMR (101 MHz, DMSO-d6) δ 165.6 (CO), 163.7 (C2’), 155.3 (C3’a), 146.8 (C5’), 142.9 (C7’a), 137.6 
(C1), 134.1 (C3), 133.8 (C1’’), 132.1 (C4’’), 128.6 (2  C2’’), 127.8 (2  C3’’), 126.8 (C6), 126.4 (C4), 
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125.8 (C5), 124.9 (C2), 121.1 (C6’), 119.3 (C7’); m/z (ES+) 394.02 ([79BrM+H]+, 100 %), 396.02 
([81BrM+H]+, 100%); HRMS (ES+) Calcd for C19H13O2N3Br [M+H]
+: 394.0186, found 394.0188. 
 
N-(2-Bromo-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-2-(3-methoxyphenyl)acetamide (43) 
 
Prepared from 35b (80 mg, 0.28 mmol, 1.0 eq.) and 3-methoxyphenylacetyl chloride (129 mg, 0.70 
mmol, 2.5 eq.) using general method B. 43 was obtained after recrystallisation as a white solid (92 
mg, 75%). mp 211-213 C; IR (solid) ν max: 3271 (NH), 1667 (C=O), 1551, 1404, 1265, 1157, 802;
 1H 
NMR (400 MHz, DMSO-d6) δ 9.87 (br s, 1H, NH), 8.56 (dd, J = 4.8, 1.4 Hz, 1H, C5’-H), 8.52 (s, 1H, C6-
H), 8.27 (dd, J = 8.3, 1.4 Hz, 1H, C7’-H), 7.94 (br s, 2H, C3-H, C4-H), 7.48 (dd, J = 8.3, 4.8 Hz, 1H, C6’-
H), 7.27 (t, J = 7.8 Hz, 1H, C5’’-H), 7.02 – 6.95 (m, 2H, C2’’-H, C6’’-H), 6.85 (dd, J = 7.8, 2.3 Hz, 1H, C4’’-
H), 3.78 (s, 2H, CH2), 3.76 (s, 3H, OCH3); 
13C NMR (101 MHz, DMSO-d6) δ 169.7 (CO), 163.8 (C2’), 
159.3 (C3’’), 155.3 (C3’a), 146.8 (C5’), 142.9 (C7’a), 137.2 (C), 137.0 (C), 134.1 (C3), 129.4 (C5”), 125.6 
(C5), 125.4 (C4), 124.7 (C6), 121.6 (C2), 121.5 (C6’’), 121.1 (C6’), 119.3 (C7’), 115.0 (C2’’), 112.2 (C4’’), 
55.0 (OCH3), 42.6 (CH2);
 m/z (ES+) 438.04 ([79BrM+H]+, 100 %), 440.04 ([81BrM+H]+, 100%); HRMS 
(ES+) Calcd for C21H17O3N3Br [M+H]
+: 438.0448, found 438.0449. 
 
N-(5-Chloro-2-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (44) 
 
Prepared from 35c (550 mg, 2.60 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (1.41 g, 6.50 
mmol, 2.5 eq.) using general method B. 44 was obtained after recrystallisation as a pale yellow solid 
(185 mg, 17%). mp 254-256 °C IR (KBr) ν max: 3408 (NH), 3072, 3032, 1684 (C=O), 1590; 
1H NMR (500 
MHz, Chloroform-d) δ 12.64 (br s, 1H, NH), 9.21 (d, J = 2.0 Hz, 1H, C6-H), 8.63 (dd, J = 4.9, 1.4 Hz, 1H, 
C5’-H), 8.36 (d, J = 8.3 Hz, 2H, 2  C2’’-H), 8.20 (d, J = 8.5 Hz, 1H, C3-H), 7.92 (dd, J = 8.1, 1.4 Hz, 1H, 
C7’-H), 7.86 (d, J = 8.3 Hz, 2H, 2  C3’’-H), 7.73 – 7.66 (m, 2H, 2  C6’’-H), 7.49 (dd, J = 8.3, 6.8 Hz, 2H, 
2  C7’’-H), 7.44 – 7.39 (m, 1H, C8’’-H), 7.38 (dd, J = 8.1, 4.9 Hz, 1H, C6’-H), 7.23 (dd, J = 8.5, 2.0 Hz, 
1H, C4-H); 13C NMR (126 MHz, Chloroform-d) δ 166.1 (CO), 164.0 (C2’), 154.9 (C3’a), 147.3 (C5’), 
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145.2 (C4’’), 141.8 (C7’a), 141.0 (C5), 140.6 (C1), 140.1 (C5’’), 133.0 (C1’’), 129.4 (C3), 129.0 (2  
C7’’), 128.5 (2  C2’’), 128.2 (C8’’), 127.8 (2  C3’’), 127.4 (2  C6’’), 123.6 (C4), 121.0 (C6’), 120.9 
(C6), 118.6 (C7’), 110.8 (C2); m/z (ES+) 447.86 [M+Na]+; HRMS (ES+) Calcd for C25H16ClN3O2Na 
[M+Na]+: 448.0829, found 448.0826. 
 
N-(3-(Oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (45) 
 
Prepared from 35d (150 mg, 0.71 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (385 mg, 1.78 
mmol, 2.5 eq.) using general method B. 45 was obtained after recrystallisation as a white solid (33 
mg, 12%). mp 261-264 °C; IR (KBr) ν max: 3440 (NH), 2962, 2924, 1649 (C=O), 1527;
 1H NMR (300 
MHz, DMSO-d6) δ 10.63 (br s, 1H, NH), 8.87 (t, J = 1.9 Hz, 1H, C2-H), 8.56 (dd, J = 4.9, 1.4 Hz, 1H, C5’-
H), 8.27 (dd, J = 8.2, 1.4 Hz, 1H, C7’-H), 8.19 – 8.06 (m, 3H, C6-H, 2  C2’’-H), 8.04 – 7.93 (m, 1H, C4-
H), 7.92 – 7.82 (m, 2H, 2  C3’’-H), 7.82 – 7.72 (m, 2H, 2  C6’’-H), 7.64 (t, J = 8.0 Hz, 1H, C5-H), 7.57 – 
7.36 (m, 4H, C6’-H, C8’’-H, 2  C7’’-H); 13C NMR (75 MHz, DMSO-d6) δ 165.5 (CO), 164.8 (C2’), 155.5 
(C3’a), 146.6 (C5’), 143.4 (C4’’), 142.8 (C7’a), 140.2 (C1), 139.1 (C5’’), 133.3 (C1’’), 129.9 (C5), 129.1 
(2  C7’’), 128.5 (2  C2’’), 128.2 (C8’’), 127.0 (2  C6’’), 126.7 (2  C3’’), 126.3 (C3), 124.1 (C6), 122.8 
(C4), 120.9 (C6’), 119.1 (CH), 119.0 (CH); m/z (ES-) 389.84 ([M-H]-, 100 %); HRMS (ES-) Calcd for 
C25H16N3O2 [M-H]
-: 390.1245, found 390.1243. 
 
N-(4-(Oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (46) 
 
Prepared from 35e (300 mg, 1.42 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (769 mg, 3.55 
mmol, 2.5 eq.) using general method B. 46 was obtained after recrystallisation as an off-white solid 
(202 mg, 36%). mp 322-325 C; IR (KBr) ν max: 3358 (NH), 3067, 3056, 1672 (C=O), 1599; 
1H NMR (400 
MHz, DMSO-d6) δ 10.70 (br s, 1H, NH), 8.54 (dd, J = 4.9, 1.4 Hz, 1H, C5’-H), 8.27 (d, J = 8.8 Hz, 2H, 2  
C3-H), 8.23 (dd, J = 8.1, 1.4 Hz, 1H, C7’-H), 8.17 – 8.06 (m, 4H, 2  C2-H, 2  C2’’-H) 7.91 – 7.84 (m, 
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2H, 2  C3’’-H), 7.83 – 7.72 (m, 2H, 2  C6’’-H), 7.57 – 7.49 (m, 2H, 2  C7’’-H), 7.48 – 7.38 (m, 2H, 
C6’-H, C8’’-H); 13C NMR (101 MHz, DMSO-d6) δ 165.7 (CO), 164.8 (C2’), 155.8 (C3’a), 146.4 (C5’), 
143.5 (C), 143.4 (C), 142.7 (C7’a), 139.0 (C5’’), 133.3 (C1’’), 129.1 (2  C7’’), 128.6 (2  CH), 128.6 (2  
CH), 128.3 (C8’’), 127.0 (2  C6’’), 126.7 (2  C3’’), 120.6 (C4), 120.5 (C6’), 120.3 (2  C2), 118.8 (C7’); 
m/z (ES-) 389.91 ([M-H]-, 100 %); HRMS (ES-) Calcd for C25H16N3O2 [M-H]
-: 390.1234, found 390.1243. 
 
N-(2-Fluoro-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (47) 
 
Prepared from 35f (51 mg, 0.22 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (119 mg, 0.55 
mmol, 2.5 eq.) using general method B. 47 was obtained after recrystallisation as a white solid (75 
mg, 83%). mp 230-232 C; IR (solid) ν max: 3441 (NH), 3040, 1674 (C=O), 1520, 1404, 1250 (C-F); 
1H 
NMR (400 MHz, DMSO-d6) δ 10.47 (br s, 1H, NH), 8.65 (dd, J = 7.3, 2.3 Hz, 1H, C6-H), 8.57 (dd, J = 4.9, 
1.4 Hz, 1H, C5’-H), 8.28 (dd, J = 8.2, 1.4 Hz, 1H, C7’-H), 8.20 – 8.15 (m, 1H, C4-H), 8.13 (d, J = 8.4 Hz, 
2H, 2  C2’’-H), 7.94 – 7.83 (m, 2H, 2  C3’’-H), 7.83 – 7.74 (m, 2H, 2  C6’’-H), 7.62 (dd, J = 10.2, 8.7 
Hz, 1H, C3-H), 7.58 – 7.37 (m, 4H, C6’-H, 2  C7’’-H, C8’’-H); 13C NMR (101 MHz, DMSO-d6) δ 165.3 
(CO), 163.9 (C2’), 157.8 (d, J = 254.7 Hz, C2), 155.5 (C3’a), 146.67 (C5’), 143.6 (C4’’), 142.9 (C7’a), 
139.0 (C5’’), 132.4 (C1’’), 129.1 (2  C7’’), 128.7 (2  C2’’), 128.3 (C8’’), 127.1 (d, J = 12.6 Hz, C1), 
127.0 (2  C6’’), 126.7 (2  C3’’), 126.3 (d, J = 9.1 Hz, C4), 125.7 (C6), 122.4 (d, J = 3.0 Hz, C5), 120.9 
(C6’), 119.2 (C7’), 117.4 (d, J = 21.6 Hz, C3); m/z (ES+) 410.12 ([M+H]+, 100 %); HRMS (ES+) Calcd for 
C25H17FN3O2 [M+H]
+: 410.1299, found 410.1299. 
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N-(2-Bromo-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (48; Liddean) 
 
Prepared from 35b (300 mg, 1.04 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (563 mg, 2.60 
mmol, 2.5 eq.) using general method B. Liddean (48) was obtained after recrystallisation as a white 
solid (200 mg, 41%). mp 237-240 C; IR (KBr) ν max: 3460 (NH), 3271, 2666, 1653 (C=O), 1521;
 1H NMR 
(500 MHz, DMSO-d6) δ 10.34 (br s, 1H, NH), 8.58 (dd, J = 4.8, 1.4 Hz, 1H, C5’-H), 8.49 (d, J = 2.1 Hz, 
1H, C6-H), 8.29 (dd, J = 8.1, 1.4 Hz, 1H, C7’-H), 8.18 – 8.11 (m, 2H, 2  C2’’-H), 8.07 (dd, J = 8.4, 2.1 
Hz, 1H, C4-H), 8.03 (d, J = 8.4 Hz, 1H, C3-H), 7.93 – 7.86 (m, 2H, 2  C3’’-H), 7.79 (m, 2H, 2  C6’’-H), 
7.56 – 7.47 (m, 3H, C6’-H, 2  C7’’-H), 7.47 – 7.40 (m, 1H, C8’’-H); 13C NMR (126 MHz, DMSO-d6) δ 
165.2 (CO), 163.8 (C2’), 155.4 (C3’a), 146.9 (C5’), 143.7 (C4’’), 143.0 (C7’a), 139.1 (C5’’), 137.6 (C1), 
134.2 (C3), 132.5 (C1’’), 129.1 (2  C7’’), 128.5 (2  C2’’), 128.3 (C8’’), 127.0 (2  C6’’), 126.9 (C6), 
126.9 (2  C3’’), 126.4 (C4), 125.8 (C5), 124.9 (C2), 121.2 (C6’), 119.4 (C7’); m/z (ES-) 467.81 ([79BrM-
H]+, 100 %), 469.81 ([81BrM-H]-, 100%); HRMS (ES-) Calcd for C25H15O2N3Br [M-H]
-: 468.0348, found 
468.0351. 
 
N-(2-Methyl-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (49) 
 
Prepared from 35g (600 mg, 2.66 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (1.44 g, 6.65 
mmol, 2.5 eq.) using general method B. 49 was obtained after recrystallization as a white solid (360 
mg, 33%). mp 275-277 C; IR (solid) ν max: 3264 (NH), 1670 (C=O), 1520, 1404, 1258, 741;
 1H NMR 
(400 MHz, DMSO-d6) δ 10.17 (br s, 1H, NH), 8.55 (dd, J = 4.8, 1.4 Hz, 1H, C5’-H), 8.36 (d, J = 1.9 Hz, 
1H, C6-H), 8.26 (dd, J = 8.2, 1.4 Hz, 1H, C7’-H), 8.14 (d, J = 8.3 Hz, 2H, 2  C2’’-H), 8.06 (dd, J = 8.0, 1.9 
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Hz, 1H, C4-H), 7.88 (d, J = 8.3 Hz, 2H, 2  C3’’-H), 7.81 – 7.73 (m, 2H, 2  C6’’-H), 7.58 (d, J = 8.0 Hz, 
1H, C3-H), 7.53 (t, J = 7.5 Hz, 2H, 2  C7’’-H), 7.49 – 7.46 (m, 1H, C6’-H), 7.48 – 7.39 (m, 1H, C8’’-H), 
2.41 (s, 3H, CH3); 
13C NMR (101 MHz, DMSO-d6) δ 165.3 (CO), 164.7 (C2’), 155.6 (C3’a), 146.6 (C5’), 
143.3 (C4’’), 142.8 (C7’a), 139.1 (C5’’), 138.8 (C2), 137.4 (C1), 133.0 (C1’’), 131.6 (C3), 129.1 (2  
C7’’), 128.5 (2  C2’’), 128.2 (C8’’), 127.0 (2  C6’’), 126.7 (2  C3’’), 125.2 (C6), 124.9 (C4), 123.9 (C5), 
120.8 (C6’), 119.0 (C7’), 18.3 (CH3); m/z (ES
+) 406.15 ([M+H]+, 100 %); HRMS (ES+) Calcd for 
C26H20N3O2 [M+H]
+: 406.1550, found 406.1548. 
 
N-(4-Hydroxy-3-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide (50) 
 
Prepared from 35h (300 mg, 1.32 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (715 mg, 3.30 
mmol, 2.5 eq.) the general method B. 50 was obtained after recrystallisation as an off-white solid 
(346 mg, 64%). mp 330-332 °C; IR (KBr) ν max: 3425 (NH), 3257, 3094, 3044, 1636 (C=O), 1534; 
1H 
NMR (500 MHz, DMSO-d6) δ 10.85 (br s, 1H, OH), 10.44 (br s, 1H, NH), 8.72 (d, J = 2.7 Hz, 1H, C3-H), 
8.59 (dd, J = 4.7, 1.4 Hz, 1H, C5’-H), 8.35 (dd, J = 7.9, 1.4 Hz, 1H, C7’-H), 8.11 (d, J = 8.0 Hz, 2H, 2  
C2’’-H), 7.92 (dd, J = 8.9, 2.7 Hz, 1H, C5-H), 7.86 (d, J = 8.0 Hz, 2H, 2  C3’’-H), 7.77 (d, J = 7.3 Hz, 2H, 2 
 C6’’-H), 7.58 – 7.48 (m, 3H, C6’-H, 2  C7’’-H), 7.43 (t, J = 7.3 Hz, 1H, C8’’-H), 7.18 (d, J = 8.9 Hz, 1H, 
C6-H); 13C NMR (126 MHz, DMSO-d6) δ 165.0 (CO), 164.6 (C2’), 154.4 (C1), 153.9 (C3’a), 146.8 (C5’), 
143.2 (C4’’), 141.7 (C7’a), 139.1 (C5’’), 133.4 (C1’’), 131.8 (C4), 129.1 (2  C7’’), 128.3 (2  C2’’), 128.2 
(C8’’), 127.5 (C5), 127.0 (2  C6’’), 126.7 (2  C3’’), 121.1 (C6’), 119.3 (C7’), 119.1 (C3), 117.6 (C6), 
109.8 (C2); m/z (ES-) 405.88 ([M-H]-, 100 %); HRMS (ES-) Calcd for C25H16N3O3 [M-H]
-: 406.1185, 
found 406.1192. 
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3-(Oxazolo[4,5-b]pyridin-2-yl)phenyl [1,1'-biphenyl]-4-carboxylate (51) 
 
Prepared from 35i (85 mg, 0.40 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (212 mg, 1.00 
mmol, 2.5 eq.) using general method B. 51 was obtained after recrystallisation as a white solid (95 
mg, 61%). mp 185-187 °C; IR (solid) ν max: 3063, 1728 (C=O), 1605, 1551, 1481, 1404;
 1H NMR (500 
MHz, Chloroform-d) δ 8.61 (dd, J = 4.8, 1.5 Hz, 1H, C5’-H), 8.30 (dd, J = 8.4, 1.8 Hz, 2H, 2  C2’’-H), 
8.27 (dt, J = 7.9, 1.3 Hz, 1H, C4-H), 8.22 (t, J = 1.9 Hz, 1H, C2-H), 7.88 (dd, J = 8.2, 1.5 Hz, 1H, C7’-H), 
7.77 (dd, J = 8.4, 1.8 Hz, 2H, 2  C3’’-H), 7.68 (dt, J = 6.0, 1.4 Hz, 2H, 2  C6’’-H), 7.64 (t, J = 7.9 Hz, 1H, 
C5-H), 7.54 – 7.47 (m, 3H, C6-H, 2  C7’’-H), 7.47 – 7.40 (m, 1H, C8’’-H), 7.32 (dd, J = 8.2, 4.8 Hz, 1H, 
C6’-H); 13C NMR (126 MHz, Chloroform-d) δ 164.9 (C), 164.8 (C), 156.3 (C3’a), 151.5 (C1), 147.1 (C5’), 
146.8 (C4’’), 143.3 (C7’a), 139.9 (C5’’), 130.9 (2  C2’’), 130.4 (C5), 129.2 (2  C7’’), 128.5 (C8’’), 128.1 
(C3), 127.9 (C1’’), 127.5 (2  C6’’, 2  C3’’), 126.1 (C6), 125.8 (C4), 121.6 (C2), 120.5 (C6’), 118.5 (C7’); 
m/z (ES+) 393.12 ([M+H]+, 100 %); HRMS (ES+) Calcd for C25H17O3N2 [M+H]
+: 393.1234, found 
393.1233. 
 
N-(3-(Oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-sulfonamide (52) 
 
Prepared from 35d (85 mg, 0.40 mmol, 1.0 eq.) and biphenyl-4-sulfonyl chloride (253 mg, 1.00 
mmol, 2.5 eq.) using general method B. 52 was obtained after recrystallisation as a white solid (120 
mg, 70%). mp 193-195 °C; IR (KBr) ν max: 3067 (NH), 2893, 1551, 1404, 1337 (S=O), 1157 (S=O), 945, 
777, 762; 1H NMR (500 MHz, DMSO-d6) δ 10.82 (br s, 1H, NH), 8.55 (dd, J = 4.8, 1.4 Hz, 1H, C5’-H), 
8.26 (dd, J = 8.2, 1.4 Hz, 1H, C7’-H), 8.07 (t, J = 1.9 Hz, 1H, C2-H), 7.94 – 7.83 (m, 5H, C4-H, 2  C2’’-H, 
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2  C3’’-H), 7.71 – 7.64 (m, 2H, 2  C6’’-H), 7.54 (t, J = 8.0 Hz, 1H, C5-H), 7.49 – 7.43 (m, 4H, C6’-H, 
C6-H, 2  C7’’-H), 7.43 – 7.36 (m, 1H, C8’’-H); 13C NMR (126 MHz, DMSO-d6) δ 164.2 (C2’), 155.3 
(C7’a), 146.7 (C5’), 144.6 (C4’’), 142.8 (C3’a), 138.8 (C1), 138.1 (C), 138.0 (C), 130.6 (C5), 129.1 (2  
C7’’), 128.7 (C8’’), 127.6 (2  CH), 127.4 (2  CH), 127.1 (2  C6’’), 126.9 (C3), 123.5 (C6), 123.2 (C4), 
121.0 (C6’), 119.3 (C7’), 118.2 (C2); m/z (ES+) 428.10 ([M+H]+, 100 %); HRMS (ES+) Calcd for 
C24H18O3N3S [M+H]
+: 428.1063, found 428.1063. 
 
N-(2-Bromo-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-[1,1'-biphenyl]-4-sulfonamide (53) 
 
Prepared from 35b (80 mg, 0.28 mmol, 1.0 eq.) and biphenyl-4-sulfonyl chloride (177 mg, 0.70 
mmol, 2.5 eq.) using the general method B. 53 was obtained after recrystallisation as a white solid 
(75 mg, 53%). mp 240-242 °C; IR (solid) ν max: 3233 (NH), 1605, 1543, 1474, 1396 (S=O), 1342, 1258, 
1157 (S=O); 1H NMR (500 MHz, Chloroform-d) δ 8.66 – 8.60 (m, 2H, C5’-H, C6-H), 7.98 (dd, J = 8.4, 2.0 
Hz, 1H, C4-H), 7.96 – 7.88 (m, 3H, C7’-H, 2  C2’’-H), 7.66 (d, J = 8.4 Hz, 2H, 2  C3’’-H), 7.63 (d, J = 8.4 
Hz, 1H, C3-H), 7.60 – 7.54 (m, 2H, 2  C6’’-H), 7.44 (t, J = 7.6 Hz, 2H, 2  C7’’-H), 7.42 – 7.37 (m, 1H, 
C8’’-H), 7.36 (dd, J = 8.1, 4.9 Hz, 1H, C6’-H), 7.17 (br s, 1H, NH); 13C NMR (126 MHz, Chloroform-d) δ 
164.1 (C2’), 156.2 (C3’a), 147.3 (C5’), 146.6 (C4’’), 143.4 (C7’a), 139.0 (C5’’), 137.1 (C1’’), 135.7 (C1), 
133.7 (C3), 129.2 (2  C7’’), 128.8 (C8’’), 128.1 (2  C2’’), 127.9 (2  C3’’), 127.4 (2  C6’’), 127.3 (C5), 
125.8 (C4), 121.0 (C6), 120.8 (C6’), 120.0 (C2), 118.7 (C7’); m/z (ES+) 506.02 ([79BrM+H]+, 100 %), 
508.02 ([81BrM+H]+, 100%); HRMS (ES+) Calcd for C24H17O3N3BrS [M+H]
+: 506.0169, found 506.0160. 
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N-(5-(Benzo[d]oxazol-2-yl)-2-bromophenyl)-[1,1'-biphenyl]-4-carboxamide (54) 
 
Prepared from 35j (289 mg, 1.00 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (542 mg, 2.50 
mmol, 2.5 eq.) using general method B. 54 was obtained after recrystallisation as a white solid (250 
mg, 53%). mp 260-262 C; IR (KBr) ν max: 3269 (NH), 1653 (C=O), 1558, 1508, 1240;
 1H NMR (500 
MHz, Chloroform-d) δ 9.48 (d, J = 2.1 Hz, 1H, C6-H), 8.61 (br s, 1H, NH), 8.10 – 8.03 (m, 2H, 2  C2’’-
H), 7.96 (dd, J = 8.4, 2.1 Hz, 1H, C4-H), 7.82 – 7.73 (m, 4H, C3-H, C4’-H, 2  C3’’-H), 7.70 – 7.64 (m, 
2H, 2  C6’’-H), 7.64 – 7.60 (m, 1H, C7’-H), 7.52 – 7.46 (m, 2H, 2  C7’’-H), 7.45 – 7.40 (m, 1H, C8’’-H), 
7.39 – 7.36 (m, 2H, C5’-H, C6’-H); 13C NMR (126 MHz, Chloroform-d) δ 165.1 (CO), 162.1 (C2’), 151.0 
(C7’a), 145.5 (C4’’), 142.2 (C3’a), 139.9 (C5’’), 136.6 (C1), 133.1 (C3), 132.9 (C1’’), 129.2 (2  C7’’), 
128.4 (C8’’), 127.9 (2  C2’’, 2  C3’’), 127.4 (2  C6’’), 125.6 (CH), 124.9 (CH), 124.9 (C5), 124.3 (C4), 
120.5 (C6), 120.3 (C4’), 117.0 (C2), 111.0 (C7’); m/z (ES+) 469.05 ([79BrM+H]+, 100 %), 471.05 
([81BrM+H]+, 100%); HRMS (ES+) Calcd for C26H18O2N2Br [M+H]
+: 469.0546, found 469.0544. 
 
N-(2-Chlorophenyl)-[1,1'-biphenyl]-4-carboxamide (55) 
 
Prepared from 2-chloroaniline (128 mg, 1.00 mmol, 1.0 eq.) and biphenyl-4-carbonyl chloride (542 
mg, 2.50 mmol, 2.5 eq.) using general method B. 55 was obtained after recrystallisation as a white 
solid (250 mg, 81%). mp 144-146 C; IR (solid) ν max: 3279 (NH), 1643 (C=O), 1520, 1435, 1312, 741; 
1H NMR (500 MHz, DMSO-d6) δ 10.13 (br s, 1H, NH), 8.10 (d, J = 8.4 Hz, 2H, 2  C2’-H), 7.85 (d, J = 8.4 
Hz, 2H, 2  C3’-H), 7.80 – 7.73 (m, 2H, 2  C6’-H), 7.62 (dd, J = 7.7, 1.6 Hz, 1H, C6-H), 7.57 (dd, J = 8.1, 
1.6 Hz, 1H, C3-H), 7.55 – 7.49 (m, 2H, 2  C7’-H), 7.47 – 7.40 (m, 1H, C8’-H), 7.40 (dd, J = 7.7, 1.6 Hz, 
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1H, C5-H), 7.31 (td, J = 7.7, 1.6 Hz, 1H, C4-H); 13C NMR (126 MHz, DMSO-d6) δ 165.0 (CO), 143.4 (C4’), 
139.1 (C5’), 135.1 (C1), 132.7 (C1’), 129.6 (C3), 129.1 (C2, 2  C7’), 128.6 (C6), 128.4 (2  C2’), 128.2 
(C8’), 127.5 (C4, C5), 127.0 (2  C6’), 126.7 (2  C3’); m/z (ES+) 308.08 ([M+H]+, 100 %); HRMS (ES+) 
Calcd for C19H15ClNO [M+H]
+: 308.0837, found 308.0839. 
 
N-(2-Bromo-5-nitrophenyl)-[1,1'-biphenyl]-4-carboxamide (59) 
 
Biphenyl-4-carbonyl chloride (461 mg, 2.13 mmol, 1.0 eq.) was added to 2-bromo-5-nitroaniline 58 
(308 mg, 1.42 mmol, 1.5 eq.) in DCM (15 mL), followed by pyridine (0.17 mL, 2.13 mmol, 1.5 eq.). 
The reaction was stirred at room temperature for 18 hours. 59 was obtained after recrystallisation 
(DCM) as a white solid (300 mg, 53%). mp 203-205 C; IR (solid) ν max: 3379 (NH), 1690 (C=O), 1528 
(N-O), 1412, 1312, 741, 602 (C-Br); 1H NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H, NH), 8.51 (d, J = 1.8 
Hz, 1H, C6-H), 8.12 (d, J = 8.1 Hz, 2H, 2  C2’-H), 8.06 (br s, 2H, C3-H, C4-H), 7.89 (d, J = 8.1 Hz, 2H, 2 
 C3’-H), 7.81 – 7.75 (m, 2H, 2  C6’-H), 7.52 (t, J = 7.5 Hz, 2H, 2  C7’-H), 7.44 (t, J = 7.5 Hz, 1H, C8’-
H); 13C NMR (126 MHz, DMSO-d6) δ 165.2 (CO), 146.9 (C5), 143.8 (C4’), 139.0 (C5’), 137.8 (C1), 134.0 
(C3), 132.2 (C1’), 129.1 (2  C7’), 128.6 (2  C2’), 128.3 (C8’), 127.5 (C2), 127.0 (2  C6’), 126.8 (2  
C3’), 122.3 (C6), 121.9 (C4); m/z (ES+) 497.02 ([79BrM+Na]+, 100 %), 399.02 ([81BrM+H]+, 100%); 
HRMS (ES+) Calcd for C19H14N2O3Br [M+H]
+: 397.0182, found 397.0184. 
 
N-(5-Amino-2-bromophenyl)-[1,1'-biphenyl]-4-carboxamide (60) 
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To 59 (100 mg, 0.25 mmol, 1.0 eq.) and NH4Cl (67 mg, 1.25 mmol, 5.0 eq.) in MeOH (2 mL) and H2O 
(1 mL) at 100 C was added iron powder (70 mg, 1.25 mmol, 5.0 eq.) portionwise. After 3 hours the 
reaction was cooled to room temperature, filtered through Celite and concentrated in vacuo. The 
residue was dissolved in EtOAc (10 mL) and washed with H2O (2  5 mL), brine (5 mL), dried over 
MgSO4, filtered and concentrated to yield the desired product 60 as a white solid (83 mg, 90%). 60 
was used in the next step without further purification. 1H NMR (500 MHz, DMSO-d6) δ 9.77 (br s, 1H, 
NH), 8.11 – 7.99 (m, 2H, 2  C2’-H), 7.89 – 7.79 (m, 2H, 2  C3’-H), 7.79 – 7.73 (m, 2H, 2  C6’-H), 
7.55 – 7.46 (m, 2H, 2  C7’-H), 7.46 – 7.39 (m, 1H, C8’-H), 7.27 (d, J = 8.6 Hz, 1H, C3-H), 6.85 (d, J = 
2.7 Hz, 1H, C6-H), 6.44 (dd, J = 8.6, 2.7 Hz, 1H, C4-H), 5.39 (br s, 2H, NH2); 
13C NMR (126 MHz, DMSO-
d6) δ 164.7 (CO), 148.8 (C5), 143.2 (C4’), 139.1 (C5’), 136.4 (C1), 133.1 (C1’), 132.3 (C3), 129.1 (2  
C7’), 128.3 (2  C2’), 128.2 (C8’), 127.0 (2  C6’), 126.7 (2  C3’), 113.6 (C4, C6), 104.5 (C2). 
 
N-(3-([1,1'-Biphenyl]-4-carboxamido)-4-bromophenyl)thiophene-2-carboxamide (56) 
 
2-Thiophene carbonyl chloride (36 mg, 0.25 mmol, 3.0 eq.) was added to 60 (30 mg, 0.08 mmol, 1.0 
eq.) in DCM (1.0 mL), followed by pyridine (20 µL, 0.25 mmol, 3.0 eq.). The reaction was stirred at 
room temperature for 18 hours. The reaction was concentrated in vacuo and purified via the Biotage 
SP4 (silica-packed SNAP column 4 g; 0-40% EtOAc/hexanes) to give the title product 56 as a white 
solid (30 mg, 85%). mp 189-191 C; IR (solid) ν max: 3410 (NH), 3279 (NH), 1643 (C=O), 1589, 1515, 
1420, 1258, 1018, 802, 741, 694; 1H NMR (500 MHz, Chloroform-d) δ 8.58 – 8.47 (m, 2H, C6-H, NH), 
8.11 (br s, 1H, NH), 8.02 – 7.95 (m, 2H, 2  C2’’-H), 7.91 (dd, J = 8.8, 2.6 Hz, 1H, C2-H), 7.77 – 7.69 (m, 
2H, 2  C3’’-H), 7.68 – 7.60 (m, 3H, C5’-H, 2  C6’’-H), 7.56 (d, J = 8.8 Hz, 1H, C3-H), 7.54 (dd, J = 5.0, 
1.2 Hz, 1H, C3’-H), 7.52 – 7.46 (m, 2H, 2  C7’’-H), 7.45 – 7.39 (m, 1H, C8’’-H), 7.11 (dd, J = 5.0, 3.7 Hz, 
1H, C4’-H); 13C NMR (126 MHz, Chloroform-d) δ 165.4 (CO), 160.2 (CO), 145.4 (C4’’), 139.8 (C5’’), 
139.1 (C2’), 138.3 (C5), 136.0 (C1), 133.0 (C1’’), 132.8 (C3), 131.3 (C3’), 129.2 (2  C7’’), 128.8 (C5’), 
128.4 (C8’’), 128.1 (C4’), 127.8 (2  C2’’, 2  C3’’), 127.4 (2  C6’’), 117.5 (C2), 112.7 (C6), 108.2 (C4); 
m/z (ES+) 499.01 ([79BrM+Na]+, 100 %), 501.01 ([81BrM+H]+, 100%); HRMS (ES+) Calcd for 
C24H17N2O2BrSNa [M+Na]
+: 499.0086, found 499.0080. 
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N-(3-([1,1'-Biphenyl]-4-carboxamido)-4-bromophenyl)furan-2-carboxamide (57) 
 
2-Furoyl chloride (47 mg, 0.36 mmol, 3.0 eq.) was added to 60 (44 mg, 0.12 mmol, 1.0 eq.) in DCM 
(1.2 mL), followed by pyridine (29 µL, 0.36 mmol, 3.0 eq.). The reaction was stirred at room 
temperature for 18 hours. The reaction was concentrated in vacuo and purified via the Biotage SP4 
(silica-packed SNAP column 4 g; 0-4% MeOH/DCM) to give the title product 57 as a white solid (40 
mg, 72%). mp 210-212 C; IR (solid) ν max: 3410 (NH), 3317 (NH), 1674 (C=O), 1647 (C=O), 1508, 1260, 
750; 1H NMR (500 MHz, Chloroform-d) δ 8.58 (d, J = 2.6 Hz, 1H, C6-H), 8.57 (br s, 1H, NH), 8.24 (br s, 
1H, NH), 8.04 – 8.00 (m, 2H, 2  C2’’-H), 7.94 (dd, J = 8.8, 2.6 Hz, 1H, C2-H), 7.79 – 7.74 (m, 2H, 2  
C3’’-H), 7.69 – 7.63 (m, 2H, 2  C6’’-H), 7.58 (d, J = 8.8 Hz, 1H, C3-H), 7.54 (dd, J = 1.7, 0.9 Hz, 1H, C5’-
H), 7.53 – 7.46 (m, 2H, 2  C7’’-H), 7.45 – 7.38 (m, 1H, C8’’-H), 7.27 (dd, J = 3.5, 0.9 Hz, 1H, C3’-H), 
6.58 (dd, J = 3.5, 1.7 Hz, 1H, C4’-H); 13C NMR (126 MHz, Chloroform-d) δ 165.2 (CO), 156.2 (CO), 
147.6 (C2’), 145.4 (C4’’), 144.6 (C5’), 139.9 (C5’’), 137.9 (C5), 136.2 (C1), 133.1 (C1’’), 132.9 (C3), 
129.2 (2  C7’’), 128.4 (C8’’), 127.8 (2  C2’’, 2  C3’’), 127.4 (2  C6’), 117.0 (C2), 115.8 (C3’), 112.9 
(C4’), 112.3 (C6), 108.0 (C4); m/z (ES+) 461.05 ([79BrM+Na]+, 100 %), 463.05 ([81BrM+H]+, 100%); 
HRMS (ES+) Calcd for C24H18BrN2O3 [M+H]
+: 461.0495, found 461.0493. 
 
1-(Benzo[d][1,3]dioxol-5-yl)-4,4,4-trifluorobutane-1,3-dione (68) 
 
To 3’,4’-(methylenedioxy)acetophenone 67 (500 mg, 3.04 mmol, 1.0 eq.) in anhydrous THF (15 mL) 
at 0 C was added LiHMDS (6.08 mL, 2 eq., 1M in THF) dropwise. Ethyl trifluoroacetate (864 mg, 6.08 
mmol, 2.0 eq.) was added after 10 minutes and the reaction was stirred for a further 1 hour at 0 C 
followed by 2 hours at room temperature. The reaction was quenched by addition of a saturated 
aqueous solution of NH4Cl (10 mL) and extracted with EtOAc (3  10 mL). The organic extracts were 
combined, washed with NH4Cl (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated 
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in vacuo to give the title product 68 as a pale yellow solid (790 mg, 100%). IR (solid) ν max: 2911 (OH), 
1584 (C=O), 1489, 1437, 1260, 1126 (CF3), 887, 797; 
1H NMR (500 MHz, Chloroform-d) δ 7.58 (dd, J = 
8.3, 1.8 Hz, 1H, C6-H), 7.41 (d, J = 1.8 Hz, 1H, C4-H), 6.91 (d, J = 8.3 Hz, 1H, C7-H), 6.47 (s, 1H, C2’-H), 
6.10 (s, 2H, C2-H2); 
13C NMR (126 MHz, Chloroform-d) δ 186.3 (C1’), 175.4 (C3’), 153.1 (C7a), 148.7 
(C3a), 127.5 (C5), 124.4 (C6), 117.7 (br, CF3) 108.7 (C7), 107.5 (C4), 102.4 (C2), 92.1 (C2’). m/z (ES
-) 
259.02 ([M-H]-, 100 %); HRMS (ES-) Calcd for C11H6O4F3 [M-H]
-: 259.0218, found 259.0223. 
 
5-(Benzo[d][1,3]dioxol-5-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (70) 
 
A solution of ethyl 3-amino-1H-pyrazole-4-carboxylate 64 (194 mg, 1.25 mmol, 1.0 eq.) and 68 (325 
mg, 1.25 mmol, 1.0 eq.) in acetic acid (0.7 mL) was heated at reflux for 5 hours. After cooling to 
room temperature, the reaction mixture was poured onto ice (1.5 g). The resulting precipitate was 
filtered off, washed with water (2  5 mL), and dried to yield ethyl 5-(benzo[d][1,3]dioxol-5-yl)-7-
(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 69 (420 mg, 90%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.72 (s, 1H, C2-H), 8.30 (s, 1H, C6-H), 8.06 (dd, J = 8.3, 1.8 Hz, 1H, C6’-H), 7.96 (d, J = 1.8 
Hz, 1H, C4’-H), 7.14 (d, J = 8.3 Hz, 1H, C7’-H), 6.18 (s, 2H, C2’-H2), 4.34 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 
1.37 (t, J = 7.1 Hz, 3H, CO2CH2CH3); 
13C NMR (126 MHz, DMSO-d6) δ 161.5 (CO2Et), 157.7 (C5), 150.9 
(C7’a), 148.4 (C3’a), 147.9 (C2), 147.8 (C3a), 133.8 (d, J = 36.9 Hz, C7), 129.4 (C5’), 123.8 (C6’), 119.4 
(d, J = 275.0, CF3), 108.8 (C7’), 107.3 (C4’), 106.0 (C6), 102.8 (C3), 102.1 (C2’), 59.9 (CO2CH2CH3), 14.4 
(CO2CH2CH3). 69 was added to a mixture of NaOH (30 mg, 0.75 mmol) in EtOH/ water (1:3) (0.7 mL), 
and the reaction mixture was heated at 65 C for 4 hours. The mixture was cooled to room 
temperature and acidified with concentrated HCl until pH 1 was reached. The formed precipitate 
was filtered off, washed with water, and dried to yield a 4:1 mixture of 70 and 69 (260 mg). This 
mixture was used in the next step without further purification.  
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5-(Benzo[d][1,3]dioxol-5-yl)-N-((tetrahydrofuran-2-yl)methyl)-7-(trifluoromethyl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide (13) 
 
 
To a solution of oxalyl chloride (53 µL, 0.62 mmol, 2.0 eq.) and 70 (110 mg, 0.31 mmol, 1.0 eq., 
containing 69 (25%)) in DCM (4 mL) at 0 C was added 2 drops of DMF. The reaction was stirred at 
room temperature for 2 hours before being concentrated in vacuo. To the resulting acid chloride in 
MeCN (6 mL) was added tetrahydrofurfurylamine (70 µL, 0.62 mmol, 2.0 eq.) and the reaction was 
stirred at room temperature for 2 hours. The reaction was concentrated in vacuo and purified via 
the Biotage SP4 (silica-packed SNAP column 10 g; 0-80% EtOAc/hexanes) followed by 
recrystallisation from hot EtOH provided the title product 13 as a yellow solid (97 mg, 72%). mp 253-
255 C; IR (solid) ν max: 2918 (NH), 1663 (C=O), 1551, 1503, 1443, 1396, 1319, 1233, 1159 (CF3), 1032, 
799; 1H NMR (500 MHz, Chloroform-d) δ 8.74 (s, 1H, C2-H), 8.54 (br s, 1H, NH), 7.96 (d, J = 1.9 Hz, 
1H, C4’-H), 7.70 (dd, J = 8.2, 1.9 Hz, 1H, C6’-H), 7.67 (s, 1H, C6-H), 6.97 (d, J = 8.2 Hz, 1H, C7’-H), 6.12 
(s, 2H, C2’-H2), 4.15 (qd, J = 7.3, 3.3 Hz, 1H, C2’’-H), 4.09 – 4.00 (m, 1H, C5’’-H2), 3.98 – 3.92 (m, 1H, 
C1’’-H2), 3.94 – 3.86 (m, 1H, C5’’-H2), 3.41 (ddd, J = 13.6, 7.7, 4.2 Hz, 1H, C1’’-H2), 2.11 – 2.00 (m, 1H, 
C3’’-H2), 2.01 – 1.91 (m, 2H, C4’’-H2), 1.74 – 1.62 (m, 1H, C3’’-H2); 
13C NMR (126 MHz, Chloroform-d) 
δ 161.6 (CO), 156.7 (C5), 151.6 (C7’a), 149.4 (C3’a), 147.9 (C2), 146.7 (C3a), 135.3 (d, J = 37.3 Hz, C7), 
129.4 (C5’), 123.2 (C6’), 119.3 (d, J = 274.6 Hz, CF3), 108.8 (C7’), 107.7 (C4’), 107.0 (C3), 104.0 (d, J = 
3.9 Hz, C6), 102.3 (C2’), 78.1 (C2’’), 68.3 (C5’’), 42.8 (C1’’), 28.8 (C3’’), 26.3 (C4’’); 19F NMR (471 MHz, 
Chloroform-d) δ -68.4; m/z (ES+) 457.11 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C20H17O4N4F3Na 
[M+Na]+: 457.1100, found 457.1094. 
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3 Total Synthesis of JBIR-22, a Natural Product PPI Inhibitor of PAC3 
Homodimerisation 
 
3.1 Introduction 
 
3.1.1 Natural products 
Natural products have played a major role in the development of the pharmaceutical industry, 
providing a tremendously rich and profitable source of drug molecules.113,114 The boom in the 
pharmaceutical industry after World War II led to wide-spread screening of natural extracts in the 
hunt for pharmaceutically active agents. By the 1990s, approximately 80% of drugs were either 
natural products or related analogues, including antibiotics (e.g., penicillin, erythromycin), lipid 
control agents (e.g., lovastatin), antimalarials (e.g., quinine, artemisinin) and anticancer drugs (e.g., 
taxol, doxorubicin).115 Despite the rich source of drug leads supplied by nature, interest in natural 
product drug development waned during the past two decades as a result of the expansion in 
synthetic medicinal chemistry and combinatorial chemistry. As a result of the technical difficulties 
associated with screening natural product extracts, the often unsustainable supply from natural 
sources and the chemical complexity of natural products which frequently prohibited chemical 
synthesis of sufficient quantities for advanced biological evaluation, the proportion of new drugs 
based on natural products shrank to 50%.115 Nevertheless, natural products will continue to 
provide a rich source of drug molecules due to their biological activity, unrivalled structural 
complexity and the diversity of chemical space which they occupy.  
 
The technological advances in high-throughput screening (HTS)116 and the development in natural-
product-derived fragment libraries117 have renewed interest in natural products.118,115 This renewed 
interest has spurred research towards the identification of chemical or genetic methods of providing 
easy access to sufficient quantities of biologically active natural products and diverse analogue 
libraries of these. This has fostered a range of new techniques including semisynthesis (chemical 
modification of an advanced intermediate from nature), mutagenesis (reprogramming of a 
biosynthetic pathway or engineering an artificial cellular synthetic system to assemble natural 
products in a host organism) and biology-oriented synthesis (generation of a focused library of 
structurally diverse compounds based around validated scaffolds which predominate in drug 
molecules and natural products).1 In spite of these technological advances, the total synthesis of a 
complex natural product is frequently essential for the confirmation of its predicted structure and as 
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a method to provide sufficient material for initial biological evaluation. Furthermore, a successful 
synthetic route provides access to structural analogues for structure-activity relationship (SAR) 
studies, the opportunity for diverted total synthesis of chemical probes and the development of 
alternative semisynthetic routes. 
 
3.1.2 Natural product inspired PPI modulators 
The increasing interest in PPI modulators and the changing perception regarding the druggability of 
PPI interfaces has resulted in increased screening of natural extracts in the hunt for drug leads, 
particularly in the field of anticancer drug discovery.15 Although research into PPI modulators from 
nature is still in its infancy, there have been several promising drug leads identified such as 
thymoquinone (1), chlorofusin (2) and CGP049090 (3) (Figure 3.1).15,1  
 
Figure 3.1. PPI modulators isolated from nature. 
 
Thymoquinone (1), the bioactive constituent of the volatile oil of black seed (Nigella sativa) was 
recently reported as the first nonpeptidic inhibitor (IC50 = 1.14 µM) of the polo-box domain (PBD) of 
Polo-like kinase 1 (Plk1) binding to phosphoserine/phosphothreonine-containing peptides.119 
Inhibition of the PPI formed between the PBD and target phosphorylated peptide motifs disrupts the 
intracellular anchoring of Plk1 resulting in mitotic arrest and apoptosis in HeLa cancer cells. 
Chlorofusin (2) was isolated from a microfungus of the genus Fusarium and was shown to inhibit the 
MDM2/p53 interaction with an IC50 value of 4.6 µM.
120 MDM2 is an ubiquitin ligase involved in the 
Chapter 3: Natural Products 
 
60 
 
proteasomal degradation of the tumour suppressor protein p53. Inhibition of the MDM2/p53 PPI 
induces growth arrest and apoptosis in cancer cells (see Section 5.1.3 for further discussion). 
CGP049090 (3) was identified from a high-throughput ELISA assay of 7,000 natural compounds as an 
inhibitor of the T-cell factor 4 (Tcf4)/β-catenin PPI with an IC50 value of <10 µM.
121 Further studies 
confirmed that this fungal metabolite disrupted the Tcf4/β-catenin complex and also demonstrated 
that it inhibited proliferation of several cancer cell lines. 
 
3.1.3 JBIR-22 
An additional example which highlights the capacity to identify PPI modulators from nature was 
provided by Hashimoto et al.122 The development of a high-throughput in vitro protein fragment 
complementation assay (PCA) facilitated the screening of a 123,599-member natural product library 
containing microbial metabolites, plant extracts, and marine natural products (Figure 3.2A). The HTS 
system identified JBIR-22 (4) as a potent inhibitor of proteasome assembling chaperone 3 (PAC3) 
homodimerisation (IC50 = 0.2 µM). JBIR-22 (4) was subsequently identified by extensive NMR and MS 
analyses to be a novel tetramic acid based fungal metabolite from Verticillus sp (Figure 3.2B).123 
 
        
Figure 3.2. Identification of novel PPI inhibitor JBIR-22 (4). (A) Schematic representation of the protein fragment 
complementation assay (PCA).
122
 (Top) The target proteins fused with split monomeric Kusabira-Green protein (mKG) are 
mixed. The local effective concentration of split mKG fragments increases by the formation of a PPI between the target 
proteins A and B. The PPI can be detected by the fluorescence emitted by the reformed mKG reporter chromophore. 
(Bottom) High-throughput in vitro PPI inhibitor assay. One of the split mKG-fused target proteins (B) is incubated with the 
natural product sample. The second split mKG-fused target protein (A) is then added. No mKG fluorescence is detected if 
the natural product sample has bound to protein B and inhibited the formation of the PPI. (B) Structure of novel tetramic 
acid JBIR-22 (4) showing the assigned relative stereochemical configuration.
123
  
 
JBIR-22 (4) showed a specific inhibition of PAC3 homodimerisation (IC50 = 6 µM against both the 
TCF7/β-catenin and the PAC1/PAC2 PPIs)122, an essential chaperone involved in the assembly of the 
20S proteasome. The 20S proteasome is the catalytic core of the 26S proteasome, an enzyme 
involved in the regulation of protein expression and function by the degradation of ubiquitin-
conjugated proteins.124 The proteasomal degradation pathway is involved in many cellular processes, 
(A) (B) 
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including cell cycle control, the regulation of gene expression, and oxidative stress response, through 
the degradation of short-lived signalling proteins, and abnormal or misfolded proteins.125 The 
importance of the proteasomal degradation pathway in many essential regulatory systems and its 
higher activity in rapidly proliferating cancer cells highlighted it as a promising anticancer target. This 
approach was validated by the approval of bortezomib (5)126 as the first therapeutic proteasome 
inhibitor, which is currently in clinical use as a chemotherapeutic agent for the treatment of relapsed 
multiple myeloma and mantle-cell lymphoma. Inhibition of the proteasomal machinery by 
bortezomib (5) or the chemical tool lactacystin (6)127 (a non-peptidic natural product from 
Streptomyces bacteria) results in the effective inhibition of tumour cell growth and the induction of 
apoptosis by disruption of the controlled degradation of pro-growth cell cycle proteins (Figure 
3.3).128   
 
Figure 3.3. Current proteasome inhibitors. 
 
To further understand JBIR-22’s inhibition of PAC3’s homodimerisation, Izumikawa et al. undertook a 
docking study using the previously reported crystal structure of the PAC3 homodimer, which 
identified a potential binding site on the PPI interaction surface of the PAC3 homodimer.123 In the 
same study, JBIR-22 (4) was evaluated for its long-term cytotoxicity against the human cancer 
cervical carcinoma (HeLa) cell line due to the long half-life of the 20S proteasome in mammalian 
cells. Inhibition of PAC3’s role in the assembly of the 20S proteasome would be expected to inhibit 
proteasome generation and thereby induce a gradual decrease in proteasome activities. JBIR-22 (4) 
was shown to have an IC50 value of 68 µM after 120 hours but had no cytotoxic effect at the same 
concentration after 48 hours. The time-dependent cytotoxicity of JBIR-22 (4) is believed to support 
the in vivo inhibition of the generation of the proteasome machinery.  
  
Extensive NMR and MS analysis revealed that JBIR-22 (4) consists of a 4,4-disubstituted glutamic acid 
containing tetramic acid core, coupled to a decalin ring at its 3’-position (Figure 3.4). Izumikawa et 
al.123 were able to infer a relative configuration for both the glutamic acid side chain and the decalin 
ring of JBIR-22 (4) through the use of a range of NMR experiments (NOESY, J-resolved HMBC, DQF-
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COSY, (CT)-HMBC). NOEs and coupling constant analysis revealed that the decalin protons H6 and 
H11 were diaxial, indicating a trans-decalin ring (Figure 3.4). The NOEs between H2, H3 and H6 
proved that these protons were cofacial. The relative configuration of the glutamic acid side chain 
was determined by the J-based method129 to be either (S,S) or (R,R). These studies concluded that 
JBIR-22 (4) was one of four possible stereoisomers (Figure 3.4, 4(a-d)). Based on analysis of the 
absolute configuration of structurally related tetramic acids (e.g. harzianic acid (19), Section 3.1.7), 
the most likely diastereomer of JBIR-22 (4) contains a glutamic acid side chain with a (5’S,7’S) 
stereochemical configuration (Figure 3.4, 4a or 4b).  
 
 
 
Figure 3.4. (A) Structure and numbering of JBIR-22 diastereomer 4a. (B) Stereochemical configuration of the four 
possible stereoisomers of JBIR-22 (4). 
 
The assignment of the absolute configuration of JBIR-22 (4) is further complicated by the presence of 
a doubling of the majority of the 13C signals in the reported NMR spectrum (Figure 3.5).123 Although 
not discussed in the isolation paper, this might suggest that the natural sample contains a minor 
diastereomer, epimer or closely related compound.  
 
 
Figure 3.5. Reported 
13
C NMR spectrum of isolated tetramic acid JBIR-22 (4).
123
  
 
 
 
 
 
 
Compound 
Glutamic acid 
side chain 
Decalin ring 
4a 5’S,7’S 2S, 3S, 6R, 11S 
4b 5’S,7’S 2R, 3R, 6S, 11R 
4c 5’R,7’R 2S, 3S, 6R, 11S 
4d 5’R,7’R 2R, 3R, 6S, 11R 
(B) (A) 
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3.1.4 Tetramic acids: Structure and function 
JBIR-22 (4) is part of a diverse family of biosynthetically related natural products which contain a 
tetramic acid (pyrrolidine-2,4-dione) ring system. The tetramic acid structural motif serves as one of 
the key building blocks present in biologically active molecules isolated from natural sources ranging 
from marine organisms to fungi and terrestrial bacteria.130 Pyrrolidine-2,4-diones bearing an acyl 
substituent at the C3’ position (Figure 3.6) are the most commonly occurring tetramic acid 
derivatives in nature and have been extensively studied due to their remarkably varied and potent 
biological activities, spanning from antibiotic (reutericyclin (7), streptolydigin (8)) and antiviral 
(tenuazonic acid (9)) to anti-HIV (equisetin (10)) and anti-cancer activities (penicillenol A1 (11), 
melophlin B (12)).131 
 
Figure 3.6. Representative bioactive natural products containing the 3-acyltetramic acid structural motif. 
 
 
The diverse physiological properties of the 3-acyltetramic acids have been linked with their ability to 
strongly chelate biochemically indispensible metal ions.132 The strongly acidic 3-acyltetramic acids 
(pKa in the range 3.0-3.5130) predominately exist as the 2,4-diketo tautomer which is stabilised by an 
intramolecular hydrogen bond between the C2’-ketone and the C3’-enolic hydroxyl.133  
Chapter 3: Natural Products 
 
64 
 
 
Figure 3.7. (A) Tautomeric forms of 3-acyltetramic acids. 3-Acyltetramic acids predominantly exist in solution as a slowly 
interconverting mixture of the exo-enol tautomers B and D, with the D-tautomer prevailing. (B) 3-Acyltetramic acids form 
strong chelate complexes containing a metal ion sandwiched between the enolic oxygen of the C3’-acyl group and the 
C2’-carbonyl oxygen. M = metal; R
1
 = alkyl. 
 
3-Acyltetramic acids can exist as mixture of four possible tautomers (Figure 3.7A, A-D).132,131 The 
slowly interconverting exo-enol pair (B & D) are typically the predominant tautomeric forms in 
solution, with the D-tautomer being the prevailing form in both solution and crystalline state (Figure 
3.7A).134,135 As a consequence, 3-acyltetramic acids form strong chelate complexes containing a 
metal ion sandwiched between the enolic oxygen of the C3’-acyl group and the C2’-carbonyl oxygen 
(Figure 3.7B).132 Metal chelation by 3-acyltetramic acids of a wide range of divalent metal ions 
including Ca(II), Mg(II) and heavier metals such as Cu(II), Ni(II) and Fe(II) seems to be crucial for their 
stability and transport through biological tissues and across membranes.136 
 
The high polarity, acidity and metal-chelating ability of 3-acyltetramic acids in addition to the 
existence of multiple tautomeric forms render them difficult to handle and characterise, thus 
providing a significant synthetic challenge.137 
 
3.1.5 Biosynthesis of 3-acyltetramic acids 
In general, 3-acyltetramic acids are assembled from polyketide and α-amino acid precursors by the 
concerted actions of a polyketide synthase (PKS) - nonribosomal synthetase (NRPS) hybrid.132,138,139 
The highly reducing iterative PKS generates the polyketide which is then linked to the amino acid by 
peptide synthetases before an intramolecular cyclisation to form the pyrrolidine-2,4-dione ring 
system (Scheme 3.1). Fungal secondary metabolites containing a decalin ring at the C3’-acyl position 
(A) (B) 
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such as equisetin (10) and trichosetin (13), are products of a fungal polyketide synthase type-I (type-I 
PKS).140,141 The proposed biosynthetic pathway for the structurally related JBIR-22 (4) analogues, 
equisetin (10) and trichosetin (13), involves an asymmetric intramolecular Diels-Alder (IMDA) 
cycloaddition of heptaketide 14 before incorporation of the amino acid serine and formation of the 
tetramic acid ring (Scheme 3.1).138,140 Type I PKS can produce linear E,E-conjugated polyene and E-
enone systems which are reactive substrates for intramolecular [4+2] cycloadditions (Scheme 3.1). 
The biosynthetic Diels-Alder (DA) cycloaddition usually affords a trans-decalin adduct as a single 
diastereomer from an endo-transition state.142 The numerous examples of polyketide natural 
products containing structures which likely originated from highly diastereo- and enantioselective 
[4+2] cycloadditions supports the argument that their construction involves an enzymatically 
controlled DA reaction.143 The stereochemical outcome of asymmetric Diels-Alder reaction in the 
biosynthesis of equisetin (10) and trichosetin (13) is believed to be controlled by the polyketide 
synthetase enzyme EqiS.141 
 
 
Scheme 3.1. Proposed hybrid PKS-NRPS biosynthesis of trichosetin (13) and equisetin (10).
138,141
 Iterative PKS type-1 
synthetase EqiS generates heptaketide 14 which undergoes a [4+2] cycloaddition. NRPS mediated incorporation of (S)-
serine followed by EqiS R-domain promoted Dieckmann cyclisation releases trichosetin (13). N-methylation of trichosetin 
(13) by EqiD produces equisetin (10). Acyl-carrier protein (ACP). 
 
The Diels-Alder reaction has been proposed as a key transformation in the biosynthesis of numerous 
cyclohexene-containing secondary metabolites.142–144 However, the identification and validation of 
the enzymes implicated in this biotransformation has proven challenging. Examples of enzymatic 
systems which have demonstrated experimental evidence consistent with an enzyme catalysed DA 
reaction include solanapyrone synthase (SPS), lovastatin nonaketide synthase (LovB) and SpnF which 
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construct the core framework of the phytotoxin solanapyrone A (15), the cholesterol-lowering agent 
lovastatin (16) and the insecticide spinosyn A respectively (Figure 3.8).142–145 In addition to facilitating 
the DA reaction, these enzymes often catalyse other biosynthetic reactions, such as oxidation 
(solanapyrone synthase) and polyketide chain formation (lovastatin nonaketide synthase).142 Despite 
the extensive research undertaken in the quest to prove the existence of a Diels-Alderase, rigorous 
proof for an enzyme catalysed DA cycloaddition, mediated by transition state stabilisation has yet to 
be obtained.143 This challenge is particularly highlighted by mechanistic studies which revealed that 
the proposed natural Diels-Alderase macrophomate synthase (MPS) likely catalyses a stepwise 
Michael-aldol reaction in contrast to the predicted concerted Diels-Alders reaction.146–149 The 
concerns surrounding product inhibition of a transition state stabilised enzymatic model and the 
observation that the known putative Diels-Alderases have secondary functions have resulted in the 
widely held theory that these enzymes function as an entropy trap for the [4+2] cycloaddition. The 
enzymes convert their substrates into reactive DA precursors, which then readily undergo a 
stereoselective cycloaddition in the enzyme active site before being released.142 
 
 
Figure 3.8. Proposed “Diels-Alderase” catalysed *4+2+-cycloaddition in the biosynthesis of (A) solanapyrone A (15) and 
(B) lovastatin (16). 
 
The discovery by Janda et al.150 of an alternative non-enzymatic biosynthetic route to 3-acyltetramic 
acids from N-acylhomoserine lactones (AHLs) resulted in a renewed interest in their antibiotic 
activity.151 AHLs are a class of quorum sensing molecules produced by certain gram-negative bacteria 
(e.g. Pseudomonas aeruginosa) to control and initiate cell density dependent processes such as 
biofilm formation.152 The AHL 17 was shown to convert spontaneously into 3-acyltetramic acid 18 
under physiological conditions via an intramolecular Claisen alkylation (Scheme 3.2).150,137 This 
(A) 
(B) 
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appears to provide a competitive advantage to the AHL producing species as a result of the 
antimicrobial and siderophoric (iron-chelating) properties of the ensuing 3-acyltetramic acids.132 
Although the antimicrobial mode of action of these 3-acyltetramic acids remains to be established, it 
is believed to be linked to their ability to sequester the scarce quantities of iron in the 
environment.153 
 
 
Scheme 3.2. Spontaneous non-enzymatic intramolecular Claisen alkylation of 3-oxo-AHL 17 to generate tetramic acid 
18.
150
 
 
3.1.6 Synthesis of 3-acyltetramic acids 
The total synthesis of tetramic acid based natural products has experienced a renaissance in the past 
20 years due to their desirable biological activity and challenging structural complexity.132 This has 
resulted in a steadily increasing number of reports dealing with their isolation, biosynthesis, 
medicinal potential and the development and refinement of synthetic approaches to these natural 
products. Despite the extensive research in this area, the development of a comprehensive and 
general protocol for the synthesis of 3-acyltetramic acids is substantially less advanced due to the 
intrinsic difficulty in accessing this structural system.154 Conventional synthetic strategies have 
generally followed two main routes (Figure 3.9).130,137,154,155  
 
Figure 3.9. Conventional synthetic approaches to 3-acyltetramic acids.
154
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The first route involves the incorporation of the C3’-acyl group prior to the construction of the 
tetramic acid core (Figure 3.9, Route A). This is most commonly achieved via a Lacey-Dieckmann 
cyclisation156 of the appropriate β-ketoamide under basic conditions. However, partial racemisation 
of the C5’ stereogenic center is often observed using this protocol.157 The alternative route relies on 
the incorporation of the C3’-acyl group after the construction of the tetramic acid core. Common 
synthetic strategies to achieve this include direct C3’-acylation using an acid chloride or an O4’- to 
C3’-acyl rearrangement. Both of these methods have limited functional group tolerance due to the 
harsh conditions required in the case of the direct C3’-acylation or the poor migratory ability of α-
branched or unsaturated side chains in the O- to C-acyl rearrangement methodology. In general, 
both of these routes make use of commercially available amino acids as the source of chirality in the 
product.136 
 
The first route described is the most common strategy used for the assembly of tetramic acids 
containing more advanced C3’-acyl substituents such as a decalin ring. This synthetic strategy is 
exemplified by Ley et al.’s biomimetic synthesis of Equisetin (10) (Scheme 3.3).158,159 Their protocol 
involved an early IMDA cycloaddition of a β-ketoamide functionalised polyene chain (Scheme 3.3, 
step a) to form the decalin ring followed by incorporation of (S)-serine (Scheme 3.3, step b) and a 
Lacey-Dieckmann cyclisation (Scheme 3.3, step c) to furnish Equisetin (10).   
 
 
 
Scheme 3.3. Ley’s synthesis of Equisetin.
158,159
 Reagents and conditions: (a) BF3.Et2O, DCM, -78 C  0 C, 71%. (b) (S)-N-
methyl-O-tert-butyldimethylsilyl serine methyl ester, CF3CO2Ag, THF, Et3N, 0 C, 97%. (c) HF, CH3CN, r.t., 85% (d) MeONa, 
MeOH, r.t., quantitative.  
 
Although Ley’s synthetic strategy proved to be an excellent method to access Equisetin (10), it does 
not address the challenges associated with the synthesis of JBIR-22 (4), a member of a small sub-
family of tetramic acids containing an unnatural amino acid.  
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3.1.7 Tetramic acids containing an unnatural amino acid 
An apparent unmet challenge in the tetramic acid field appears to be the total synthesis of the 
members of a small sub-family of 3-acyltetramic acids containing an unnatural 4,4-disubstituted 
glutamic acid derivative. To date 4 members of this subfamily have been reported, although no 
synthesis has been described (Figure 3.10). Members of this sub-family display diverse biological 
activities with potential as novel therapeutic agents for the treatment of cancer (JBIR-22 (4),123 
harzianic acid (19)),160,161 HIV (Sch210972 (20))162,163 and as plant growth promoting agents (harzianic 
acid (19))164,165 and antimicrobials (zopfiellamide A (21)).166  
 
 
Figure 3.10. Sub-family of tetramic acids containing an unnatural 4,4-disubstituted glutamic acid. Absolute 
stereochemistry shown for Sch210972 (20)
162
 and harzianic acid (19)
164
; relative stereochemistry shown for JBIR-22 (4)
123
 
and zopfiellamide A (21).
166
 
 
The CCR-5 receptor is a member of the super family of seven-trans-membrane G-protein coupled 
receptors (GPCRs), which in conjugation with the CD4 glycoprotein is implicated in viral attachment 
and infection of macrophages, monocytes and T-cells in the initial stages of HIV-1 infection.167,168 The 
validation of the CCR-5 receptor as an attractive therapeutic target for the treatment of HIV 
triggered extensive research focused on the identification of selective, potent CCR-5 antagonists as 
novel anti-HIV-1 agents.169–171 A high-throughput screening campaign of a collection of extracts 
derived from bacteria, fungi and actinomycetes led to the discovery of the novel fungal secondary 
metabolite, Sch210972 (20) (Figure 3.10), produced by Chaetomium globosum, as a selective and 
potent inhibitor of the chemokine receptor, CCR-5 with an IC50 value of 79 nM.
162 Interestingly, two 
highly related isolated secondary metabolites, Sch213766 (22), the methyl ester of Sch210972 (20) 
and Sch210971 (23), the 7’-epimer of Sch210972 (20) were significantly less potent with IC50 values 
of 8.6 µM162 and 1.2 µM163 respectively (Figure 3.10). This decrease in potency strongly suggests that 
the 4,4-disubstituted glutamic acid side chain is essential for the biological activity of Sch21092 
(20).163  
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Zopfiellamide A (21) (Figure 3.10) is a secondary metabolite isolated from fermentations of the 
facultative marine fungus Zopfiella latipes.166 Zopfiellamide A (21) displayed moderate antibacterial 
activity with minimal inhibitory concentrations between 2 and 10 µg/mL against Gram-positive 
Arthrobacter citreus, Bacillus brevis, B. subtilis, B. licheniformis, Corynebacterium insidiosum, 
Micrococcus luteus, Mycobacterium phlei, Streptomyces sp. and Gram-negative Acinetobacter 
calcoaceticus. Promisingly, it proved to be selectively antimicrobial, exhibiting no cytotoxic effects 
against several mammalian cell lines at concentrations up to 100 µg/mL.166 The isolation of a second 
highly related metabolite, Zopfiellamide B (24) (Figure 3.10) which is 5-fold less potent than 
Zopfiellamide A (21), further supports the importance of the glutamic acid side chain in the biological 
activity of this family of tetramic acids. 
 
The final member of this sub-family, harzianic acid (19) (Figure 3.10), contains a polyene chain at the 
C3’-acyl position in contrast to the decalin ring moiety present in the other members (Figure 3.10). 
Harzianic acid (19) is a fungal secondary metabolite isolated from Trichoderma harzianum,172 a 
filamentous fungus which is widely used as a biopesticide and biofertiliser due to its growth 
promoting and antifungal properties.173,174 The isolated secondary metabolite harzianic acid (19) also 
demonstrates antimicrobial activity, completely inhibiting the growth of phytopathogenic agents 
P.irregulare and S.sclerotiorum in plate antifungal assays at 10 µg and R.solani at 100 µg.164,165 
Furthermore, harzianic acid (19) was identified as a plant growth promoting agent, which 
significantly increased seed germination and shoot and root growth in tomato seedlings.164,165 The 
plant growth promoting activity of harzianic acid (19) is believed to be linked to its potent 
siderophoric properties (binding affinity of 1.79  10-25 M for Fe(III)165). Microbial siderophores are 
iron-chelating agents involved in iron solubilisation which is a crucial mechanism in plant nutrient 
regulation.175–177 Harzianic acid (19) improved seedling growth even under iron-deficient conditions 
and increased the iron concentration in the plants. The antifungal and plant growth promoting 
activities of harzianic acid (19) has highlighted it as a promising bioactive compound which could be 
used as an alternative to living antagonists.165 
 
In addition, harzianic acid (19) was also identified from two fungal metabolite screens as a promising 
anticancer agent.160,161 Kawada and coworkers identified harzianic acid (19) as a selective 
serine/threonine phosphatase type 2A (PP2A) inhibitor with an IC50 value of 10 µg/mL.
160 Inhibition 
of the intracellular protein phosphatase PP2A augments natural killer cells in vivo and inhibits 
tumour metastasis. Interestingly, harzianic acid (19) was only active against PP2A when chelated to 
zinc (harzianic acid:zinc – 2:1 complex).165 This chelation dependent biological activity has been 
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observed previously for members of the tetramic acid family.132,178 Harzianic acid (19) was also 
identified in a screen of fungal metabolites as possessing low micromolar activity against three 
different cancer cell lines.161  
 
3.2 Aim of this work 
The absence of a reported synthetic route to JBIR-22 (4), the ambiguity surrounding its relative and 
absolute stereochemical configuration, the potential involvement of a “Diels-Alderase” in its 
biosynthesis and its potent activity against the promising anti-cancer PPI target PAC3, highlighted it 
as a rewarding and challenging target for total synthesis. The development of a concise and versatile 
route which could be adapted to access the other members of the sub-family of tetramic acids 
would be highly desirable. Therefore an elegant synthetic strategy would ideally fulfil the following 
requirements: 
 
 Enable a short and efficient route to furnish JBIR-22 (4) 
 Allow easy access to the stereoisomers of JBIR-22 (4) for relative and absolute 
stereochemical assignment 
 Facilitate a synthetic investigation of the possible role of a “Diels-Alderase” in the 
biosynthesis of JBIR-22 (4) 
 Provide a versatile route which could be utilised to access the other therapeutically 
promising members of this sub-family of tetramic acids 
 
3.3 Synthetic strategy 
 
3.3.1 Retrosynthetic analysis 
To achieve the main goals of our synthesis, our approach should ideally form the tetramic acid core 
of JBIR-22 (4) with the attached glutamic acid side chain early in the synthesis, as this is common to 
all members of the tetramic acid sub-family. This would be followed by incorporation of the 
divergent C3’-acyl moiety. This is in contrast to the synthetic approach most commonly used to 
access related tetramic acids such as equisetin (10), which generally form the decalin ring prior to 
formation of the tetramic acid core (Section 3.1.6). Therefore, to develop an efficient and practical 
route to this family of tetramic acids our synthetic strategy needed to address three main 
challenges: 
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1.) Access to the different members of this family containing a decalin ring at the C3’ position would 
require a late-stage Diels-Alder reaction of the appropriate polyene chain or the incorporation of a 
pre-formed decalin moiety.  
2.) Identification of a stable masked tetramic acid core onto which the polyene chain could be 
attached, thereby reducing the significant synthetic challenges associated with tetramic acids 
(Section 3.1.4).  
3.) Development of a novel, asymmetric synthesis of the required 4,4-disubstituted glutamic acids. 
 
The key step in our initial retrosynthetic strategy (Scheme 3.4) of JBIR-22 (4) was a late stage Diels-
Alder cyclisation of the appropriate polyene derivative 25. By altering the polyene side chain, a range 
of different analogues with diverse ring systems such as zopfiellamide A (21) and Sch210972 (20) 
could be accessed (Figure 3.10). A range of tetramic acids with an uncyclised polyene side chain such 
as harzianic acid (19) could also be prepared (Figure 3.10).  
 
Scheme 3.4. Retrosynthetic analysis of JBIR-22 (4). 
 
This strategy required the identification of an advanced masked tetramic acid intermediate due to 
the considerable synthetic challenges associated with handling compounds containing the tetramic 
acid motif (Section 3.1.4). Inspiration for an appropriate masked tetramic acid came from Janda et 
al.’s non-enzymatic biosynthetic route to 3-acyltetramic acids from N-acylhomoserine lactones (AHL) 
(Section 3.1.5).179 Based on this transformation it was proposed that a biomimetic synthesis using 3-
oxo-AHL derivative 26 which could undergo a late stage Lacey-Dieckmann cyclisation to reveal the 
desired tetramic acid 25 could be achieved (Scheme 3.4). It was envisioned that 26 could be 
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obtained by an N-acylation of lactone 27 with the desired polyene side chain. Intramolecular 
cyclisation of the 4,4-disubstitued glutamic acid 28 (Scheme 3.4) would furnish 27, a key 
intermediate from which a divergent approach could lead to a large and diverse collection of 
tetramic acids (Scheme 3.4). 
 
Harzianic acid (19) was identified as a being structurally related to 25, a precursor of JBIR-22 (4) in 
our retrosynthetic strategy. It was decided that it would therefore be a good initial target for 
development of this synthetic route (Scheme 3.4). The identification of a synthetic approach to 
harzianic acid (19) which could be readily adapted to access JBIR-22 (4) would provide the ideal 
validation of this approach as a general protocol for accessing the members of this tetramic acid sub-
family. Furthermore, harzianic acid (19)’s anticancer and potent siderophoric properties make it an 
attractive and rewarding synthetic target in its own right (see Section 3.1.7). 
 
3.3.2 A novel approach to 4,4-disubstituted amino acids 
The first aim in our synthetic strategy was a concise and stereoselective synthesis of the 4,4-
disubstituted glutamic acid 28. Although, there is no reported synthesis of the required 4-hydroxy-4-
isopropylglutamic acid (28), a chemical180 and an enzymatic route181,182 to the related 4-hydroxy-4-
methylglutamic acid (29) have been described. Baldwin and Long180 devised a 5-step route to 4-
hydroxy-4-methylglutamic acid (29) from Seebach’s tert butyl-substituted imidazolidinone 30183 via 
cycloadduct 32 (Scheme 3.5). Whilst this approach did provide 29 in good yield and stereoselectivity, 
it was not ideal for our synthesis due to the length of the route and the cost of reagent 30. In 
addition, it would only provide access to the (S,S) and (R,R) diastereomers of 29 as it proceeds via 
cycloadduct 32. 
 
 
Scheme 3.5. Baldwin and Long’s synthesis of 4-hydroxy-4-methylglutamic acid (29).
180
 The cycloaddition reaction 
between the homochiral-derived nitrone 31 and the appropriate alkene afforded cycloadduct 32 which after subsequent 
elaboration provided 4-hydroxy-4-methylglutamic acid (29). 
 
Instead, we focused on developing a novel synthesis of these 4,4-disubstituted amino acids. The 
simplicity and efficiency often obtained by an elegant biomimetic synthesis attracted our attention 
to a potentially biomimetic approach to these amino acids. Although the isolation of 4-hydroxy-4-
isopropylglutamic acid (28) has to the best of our knowledge not been reported, the (2S,4S) and 
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(2S,4R) isomers of 4-hydroxy-4-methylglutamic acid (29) have been isolated from Pandanus 
veitchii184 and Ledenbergia roseo-aena185 respectively, with both diastereomers occurring in Phyllitis 
scolopendrium186. It is proposed that 4-hydroxy-4-methylglutamic acid (29) derives from a homo-
aldol condensation of pyruvic acid (33), followed by transamination of the resulting 4-hydroxy-4-
methyl-2-oxoglutaric acid (34) (Scheme 3.6).187  
 
 
Scheme 3.6. Proposed biosynthesis of (2S,4R)-4-hydroxy-4-methylglutamic acid 29 from pyruvic acid 33 via an aldol 
condensation followed by a transamination.
187
 
  
Based on this biosynthetic pathway our proposed synthetic strategy to access the protected 4-
hydroxy-4-isopropylglutamic ethyl ester (35) would involve an asymmetric aldol reaction of ethyl 
pyruvate (36) and ethyl dimethylpyruvate (37) followed by a diastereoselective transamination 
(Scheme 3.7). 
 
 
Scheme 3.7. Proposed biomimetic synthesis of protected 4-hydroxy-4-isopropylglutamic ethyl ester (35). 
 
We believed that the transamination could be achieved with high selectivity using Ellman’s tert-
butanesulfinamide 38. Since its introduction by Ellman in 1997 as a chiral ammonia equivalent,188 
tert-butanesulfinamide 38 has proven to be a versatile chiral auxiliary which has found extensive use 
both in industry and academia.189 The condensation of tert-butanesulfinamide 38 with aldehydes 
and ketones yields the corresponding N-tert-butanesulfinyl aldimines and ketimines in good yield 
(Scheme 3.8). The tert-butanesulfinyl group activates these imines towards the addition of a range of 
nucleophiles and serves as a powerful chiral directing group to provide products with generally high 
diastereoselectivity.189 Subsequent removal of the tert-butanesulfinyl group under mild conditions 
cleanly provides the corresponding amines (Scheme 3.8).190  
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Scheme 3.8. General sequence for the asymmetric synthesis of amines using tert-butanesulfinamide 38.
189
  
 
In particular this method has become one of the most extensively used approaches for the 
asymmetric synthesis of amines in the development and production of drug candidates. We have 
successfully applied this methodology in the asymmetric synthesis of both enantiomers of the chiral 
amine MJ05 (see Chapter 5). Using this method, selective reduction of the imine formed by 
condensation of glutaric acid 39 and tert-butanesulfinamide 38 could provide both the (2S) or the 
(2R) diastereomers of 35 depending on the nature of the reducing agent used (Scheme 3.9). 
 
 
Scheme 3.9. Proposed diastereoselective reductive amination of 39 via the N-tert-butanesulfinyl ketimine 40. (a) 
Condensation of 39 with (RS)-38. (b) Diastereoselective reduction of the N-tert-butanesulfinyl ketimine 40. (c) Acidic 
deprotection of the tert-butanesulfinyl group. 
 
Access to the required glutaric acid 39 would require an asymmetric aldol reaction of ethyl pyruvate 
(36) and ethyl dimethylpyruvate (37). Due to the prominence of the aldol structural motif in 
numerous important natural and synthetic molecules, extensive research has been carried out to 
identify and optimise asymmetric conditions for the aldol reaction.191 This has resulted in the 
identification of numerous methods including the utilisation of chiral auxiliaries (e.g. Evan’s 
oxazolidinone192), organocatalysts (e.g. proline193) or transition metal-based catalysts such as chiral 
bisoxazoline copper(II) complexes which were used successfully by Gathergood et al.194 to catalyse a 
homo-aldol reaction of ethyl pyruvate. 
 
Unfortunately, there has been limited development of a comprehensive and general methodology 
for the asymmetric cross aldol reaction involving the use of a chiral catalyst, due to the added 
complication of a competing homo-aldol condensation and the propensity of the product to 
participate in subsequent condensation reactions. These concerns limit the options for this reaction, 
resulting in the selection of a chiral auxiliary approach. Drawbacks to this approach include the need 
for a stoichiometric quantity of an expensive chiral reagent and the added steps required for its 
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incorporation and removal. In an attempt to overcome these issues, we proposed using Ellman’s 
tert-butanesulfinamide 38 as a chiral directing group for the aldol reaction. This would then be 
followed by a diastereoselective reduction to form the desired 4,4-disubstituted amino acid 35 
(Scheme 3.10) in an analogous manner to that previously reported for the synthesis of simple 1,3-
amino alcohols.195,196 The coupling of these two steps would improve the cost and efficiency of 
accessing the required amino acid 35. 
 
Scheme 3.10. Retrosynthetic analysis of (2S,4S)-4-hydroxy-4-isopropylglutamic acid 35. Synthetic strategy would involve a 
(RS)-38 mediated asymmetric aldol condensation of 42 and 37 to furnish 40 which could then undergo a diastereoselective 
reduction to provide the desired amino acid 35. 
 
In summary, our synthetic route to 35 would involve condensing (RS)-tert-butanesulfinamide 38 with 
ethyl pyruvate (36) to provide ketimine 42 (Scheme 3.10). An asymmetric aldol reaction between 42 
and ethyl dimethylpyruvate (37) would provide the glutarate 40 which could be reduced selectively 
to form the desired 4-hydroxy-4-isopropylglutamate ethyl ester (35) after removal of the tert-
butanesulfinyl group (Scheme 3.10). 
 
3.4 Total Synthesis of Harzianic Acid  
 
3.4.1 Synthesis of the masked tetramic acid  
The synthetic route began with the condensation of (RS)-tert-butanesulfinamide 38 and ethyl 
pyruvate (36) in the presence of Ti(OEt)4 in THF at reflux for 6 hours as previously reported for this 
reaction.197 However, under these conditions only 30% of the desired tert-butanesulfinyl imine 42 
was obtained (Table 3.1). With the aid of 2D NMR and mass spectrometry the major side product 
was identified as lactone 43 which was formed in a 5:3 ratio to the desired imine 42. It was proposed 
that the formation of 43 occured via an in situ aldol reaction between initially formed imine 42 and 
remaining ethyl pyruvate (36) catalysed by Ti(OEt)4, followed by an intramolecular cyclisation and 
tautomerisation (Table 3.1). Promisingly 43 was isolated as a single diastereomer (dr >98%), 
indicating that the tert-butanesulfinyl group had a directing effect on the aldol reaction. 43 is 
tentatively assigned as the (RS,R)-diastereomer based on the later X-ray crystal structure analysis of 
related compound 46 (Scheme 3.11). 
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Table 3.1. A selection of the key results obtained from a screen of reaction conditions for the condensation of ethyl 
pyruvate (36) and (RS)-tert-butanesulfinamide 38. Reagents and conditions: (a) (RS)-tert-butanesulfinamide 38, THF. Ratio 
of 42:43 was determined by 
1
H NMR analysis of the crude reaction mixture. The proposed mechanism for synthesis of 43 
from 42 is shown, involving an asymmetric aldol reaction of 42 and ethyl pyruvate (36) to provide 44, followed by an 
intramolecular cyclisation to form 43. 
 
Entry Lewis acid 
Temperature 
(C) 
Time 
(hours) 
42 
(isolated yield) 
42:43 
(% by NMR) 
1 Ti(OEt)4 65 6 36 3:5 
2 Ti(OEt)4 r.t. 6 23 8:1 
3 MgSO4 65 6 - - 
4 ZnBr2 65 6 - - 
5 Ti(OiPr)4 65 6 22 2:5 
6 TiCl4 0  r.t. 3 - - 
7 Ti(OEt)4 40 6 29 4:1 
8 Ti(OEt)4 60 6 60 3:1 
 
Although 43 is not a synthetically useful intermediate for the synthesis of harzianic acid (19), the 
one-pot, highly diastereoselective synthesis of 43 could be used as a highly efficient first step in the 
synthesis of Sch210972 (20) (Figure 3.10). A screen of reaction conditions (a selection of which are 
shown in Table 3.1) was undertaken to improve the ratio of the desired tert-butanesulfinyl imine 42 
to the undesired lactone 43. This led to the following observations. At room temperature the aldol 
reaction to give 42 was favoured, which resulted in a higher ratio of 42:43 but in a lower overall yield 
due to a competing homo-aldol condensation of ethyl pyruvate resulting in polymerisation (entry 2). 
Changing the Lewis acid to MgSO4 or ZnBr2 resulted in no reaction whereas Ti(OiPr)4 provided a 
mixture of 42 and 43 but in a lower overall yield than Ti(OEt)4 (entries 3-5). It was found that using 
TiCl4 (entry 6) or carrying out the reaction at temperatures below 60 C with Ti(OEt)4 (entries 2 and 
7), favoured the homo-aldol reaction, promoting polymerisation of ethyl pyruvate (36) resulting in a 
significantly reduced yield of 42. Based on these observations it was proposed that in order to obtain 
both a good ratio of 42:43 and a good overall yield, ethyl pyruvate 36 would need to be added to the 
(RS)-38 and Ti(OEt)4 in THF at 60 C. This should limit the competing aldol condensation during the 
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heating of the reaction to 60 C and allow the ethyl pyruvate (36) to react quickly with 38 on 
addition. These optimised conditions resulted in the isolation of 42 in a 3:1 ratio to 43 with an 
isolated yield of 42 of 60% (entry 8). 
 
The next step involved a LDA-mediated aldol reaction between 42 and ethyl dimethylpyruvate (37) 
(Scheme 3.11). This provided the desired aldol product 45 which similarly to 44 cyclised in situ to 
form lactone 46 in a very good yield and diastereoselectivity (dr >98%). Although the source of 
diastereocontrol is unclear, Ellman and coworkers have previously proposed a Zimmerman-Traxler-
type transition state198 guided by the formation of M-O and M-N interactions for the related 
condensation of N-sulfinyl imines to simple aldehydes.196 Invoking a similar stereochemical model, in 
which the bulky isopropyl substituent of 42 is placed in the pseudo-equatorial position to reduce 1,3-
diaxial interactions would predict the formation of the (Rs,S) diastereomer of 46 (Scheme 3.11). 
Subsequently a small molecule X-ray crystal structure was obtained which confirmed that 46 was the 
expected (Rs,S) diastereomer (Scheme 3.11).  
  
Scheme 3.11. Synthesis and small molecule X-ray crystal structure of 46. The observed stereoselectivity is consistent with 
a Zimmerman-Traxler-type transition state 47 in which the bulky isopropyl group is in a pseudo-equatorial position. 
Reagents and conditions: (a) (i) i-Pr2NH, n-BuLi (2.2M in hexanes), THF, 0 C. (ii) Ethyl dimethylpyruvate (37), ZnBr2, -78 C, 
88%. X-ray crystallographic data provided by Prof. Alexandra Slawin. 
 
Although the one-pot domino aldol-cyclisation reaction removed an additional cyclisation step to 
form key intermediate 46, it introduced some significant concerns regarding the selective reduction 
of 46 to the corresponding amine 51 (Scheme 3.13). In Ellman’s proposed stereochemical model for 
the diastereoselective reduction of the β-hydroxy-N-sulfinyl imine 48 to the corresponding 1,3-
amino alcohol, the hydroxyl group plays a key role in the transition state (Scheme 3.12).196 The 
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reduction of 48 with LiBHEt3 and catecholborane has been shown to give the anti-49 and syn-50 1,3-
amino alcohols respectively, with high diastereoselectivity (Scheme 3.12).  
 
 
Scheme 3.12. Proposed stereochemical model for the diastereoselective reduction of β-hydroxy-N-sulfinyl imine 48 to 
the corresponding syn or anti 1,3-amino alcohols. 
 
It is proposed that the observed reversal in diastereofacial selectivity can be rationalised by 
considering the geometry of the N-sulfinyl imine 48 during the reduction step. Numerous X-ray 
crystal structures and NMR studies have demonstrated that the N-sulfinyl imines preferentially exist 
in the E-geometry.199,196,200 The addition of LiBHEt3 is unlikely to alter the imine geometry, resulting in 
the attack of the hydride from the opposite face to the tert-butyl substituent of (RS)-38, which would 
furnish anti-49 (Scheme 3.12). In contrast, it is believed that catecholborane can form a stable six-
membered intermediate which would promote isomerisation of 48 from the E- to Z-imine, resulting 
in the formation of syn-50 (Scheme 3.12). Due to the lactonisation step, the hydroxyl group of 46 is 
not free to chelate the metal and thus aid the formation of the transition state required for the 
selective hydride attack. In addition, 46 exists predominantly as the enamine tautomer in solution 
(the imine tautomer is not observed by 1H NMR analysis) due to the greater stability provided to the 
enamine tautomer as a result of conjugation with the lactone carbonyl. As a result of the enamine 
stability, 46 is considerably more resistant to reduction than the corresponding imine tautomer. 
 
An added complication arises due the presence of the reactive lactone and ester moieties in 46. 
Therefore, only mild reducing conditions could be utilised to prevent any unwanted reduction of 
these groups. A screen of hydride reducing agents (NaBH4, L-Selectride, NaBH3CN), transfer 
hydrogenation conditions (NH4HCO2 and Pd/C) and hydrogenation conditions (H2 and 10% Pd/C or 
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PtO2) confirmed that as predicted the enamine was stable to reduction, with either no reaction 
occurring or unselective reduction in the case of L-Selectride. Due to the added stability conferred by 
the enamine tautomer, it was decided to attempt the reduction under acidic conditions with the aim 
of forming the corresponding iminium ion, which given its increased electrophilicity would be easier 
to reduce. Initial attempts using NaBH3CN/TFA,
201 NaBH4/AcOH
202 and NaBH3CN/HCl (1.25N in 
MeOH)203 proved unsuccessful. A common method to cleave the N-tert-butanesulfinyl group is 
under acidic conditions (HCl, 4N in dioxane) which is proposed to protonate the sulfinamide 
nitrogen, activating it towards attack of Cl- at the sulfinyl group.204 With the knowledge that these 
conditions will protonate the amine, it was therefore decided to try to reduce 46 using NaBH3CN/HCl 
(4N in dioxane). Gratifyingly these conditions furnished the desired amine 51 in good yield and very 
good diastereoselectivity (dr > 95%) with concomitant deprotection of the tert-butanesulfinyl group 
(Scheme 3.13).  
 
Scheme 3.13. Diastereoselective reduction. Reagents and conditions: (a) (i) HCl (4N in dioxane), THF, 0 C, 10 minutes. (ii) 
NaBH3CN, MeOH, 1.5 hours, 0 C, 76%, dr >95%. 
 
This reaction development was undertaken using 46 which contains a free NH. However, as harzianic 
acid (19) contains a methylated amino-group, it was decided that 46 was the optimal intermediate 
to methylate. This was achieved in very high yield using iodomethane to provide 52. The tandem 
deprotection-reduction was then carried out using 52 which provided 53 with improved yield and 
diastereoselectivity (dr >98%) when compared to 51 (Scheme 3.14). 
 
 
Scheme 3.14. Synthesis of 53. Reagents and conditions: (a) LiHMDS, iodomethane (2 eq.), DMF, -15 C  r.t., 95%. (b) (i) 
HCl (4N in dioxane), THF, 0 C, 10 minutes. (ii) NaBH3CN, MeOH, 1.5 hours, 0 C, 85%, dr > 98%. 
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Initial NOE studies on crude 53 indicated that the amine and isopropyl substituents were cofacial, 
suggesting the formation of the desired (S,S)-diastereomer, which was subsequently confirmed by 
NOE analysis of the more advanced harzianic acid intermediate 55 (Section 3.4.3, Figure 3.11). Some 
further mechanistic studies were carried out to elucidate the reaction sequence in the tandem 
deprotection-reduction. The experimental procedure involved the addition of HCl (4N in dioxane) to 
52 in THF at 0 C followed by addition of NaBH3CN in methanol after 10 minutes. Work-up of the 
reaction prior to the addition of the reducing agent revealed the deprotected enamine was formed 
(Scheme 3.15). Subsequent NaBH3CN-mediated reduction of the iminium ion 54 in the presence of 
HCl (4N in dioxane) provided the desired product 53 with similar diastereoselectivity but diminished 
yield when compared to the one-pot process. As the chiral auxiliary had been cleaved prior to the 
addition of the reducing agent, the observed diastereoselectivity appears to be purely substrate 
controlled with the hydride attacking from the same side as the ester substituent (Scheme 3.15). The 
high level of diastereocontrol would suggest that it may not be purely sterically induced and could 
be a result of chelation of the reducing agent by the ester, directing the facial attack of the hydride.  
 
 
Scheme 3.15. Mechanistic studies of the deprotection-reduction reaction sequence revealed that it occurs via acid-
mediated removal of the tert-butanesulfinyl group followed by a substrate controlled diastereoselective reduction of 
the resulting iminium to provide 53. 
 
Due to the relatively high purity of the crude amine 53 isolated from the one-pot process and the 
difficulties generally associated with the purification of amines, it was decided to trap directly the 
crude amine 53 with the desired harzianic acid polyene side chain.  
 
3.4.2 Synthesis of the polyene side chain 
In the previously outlined convergent synthetic strategy, the polyene chain was introduced through 
an N-acylation of the masked tetramic acid (Scheme 3.4). A β-ketothioester was selected as the 
acylating reagent as it is often used as a biomimetic of acetyl-CoA, the acyl-transfer unit used in the 
polyketide synthase (PKS) pathway.205 Direct aminolysis of the tert-butyl thioester moiety in 56 by 53 
via a silver trifluoroacetate mediated protocol developed by the Ley group206,159 would provide the 
desired β-keto amide 55 (Scheme 3.16). As a main aim of this synthesis was the development of a 
versatile and convergent route, the β-ketothioester 56 was disconnected to provide a core fragment 
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which could be easily modified to access a range of different polyene chains. To this end, the γ,δ-
unsaturated bond of 56 was disconnected. In the forward sense this bond could ultimately be 
formed via a Horner-Wadsworth-Emmons (HWE) olefination of phosphonate 57 and aldehyde 58 
(Scheme 3.16). By utilising the phosphonate 57 as a core fragment, a range of saturated and 
unsaturated aldehydes could be incorporated to access a diverse selection of β-ketothioesters.  
 
 
Scheme 3.16. Retrosynthetic analysis of the polyene chain of harzianic acid (19). 
 
Assembly of the polyene side chain began with a PCC oxidation of commercially available trans-2-
hexen-1-ol (59) to the corresponding aldehyde 58. Whilst these conditions promoted complete 
conversion of 59 to the desired aldehyde 58, the chromium side products proved difficult to remove. 
Upon completion, the reaction was concentrated in vacuo, the residue dissolved in Et2O, filtered 
through Celite and concentrated again. For complete removal of the remaining chromium, this work-
up procedure often had to be repeated, resulting in a reduced yield of volatile 58. As a result, 
alternative oxidation protocols were explored. Manganese(IV) oxide was initially selected due to the 
simple filtration required at the end of the reaction. However, whilst this method did provide the 
desired product 58 in excellent yield, it required regular addition of manganese(IV) oxide over a 48 
hour period to push it to completion which was not optimal. We therefore tried a DDQ-mediated 
oxidation, which provided the desired aldehyde 58 quantitatively after a simple aqueous work-up 
(Scheme 3.17).  
 
 
Scheme 3.17. Oxidation of 59 to 58. Reagents and conditions: DDQ, DCM, r.t., 16 h, quantitative. 
 
With aldehyde 58 in hand we turned our attention to the synthesis of phosphonate 57. Although 57 
is a highly versatile reagent often used in the synthesis of 3-oxomacrolides,207–209 tetronic210,211 and 
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tetramic acids,212,213 its synthesis has not been optimised since it was first reported by Woodward 
and Ley in 1987.214 Their synthetic route involved the acylation of Meldrum’s acid 60 (2,2-dimethyl-
1,3-dioxane-4,6-dione) with bromoacetyl bromide to provide 61. A thermally induced pericyclic 
reaction of 61, released acetone, carbon dioxide and a highly reactive substituted ketene,215 which 
was trapped in situ by t-butylthiol to afford the 1,3-dicarbonyl containing compound 62. Treatment 
of the monosodium salt of 62 with sodium diethylphosphite afforded the desired phosphonate 57 
(Scheme 3.18, Route A). Here we report an alternative route to 57 via a direct acylation of 
Meldrum’s acid 60 with commercially available phosphonoacetic acid. Formation of 
phosphonoacetyl chloride followed by addition to Meldrum’s acid provided 63, which without 
purification was treated with t-butylthiol to give the desired phosphonate 57 in excellent yield 
(Scheme 3.18, Route B).  
 
 
Scheme 3.18. Synthesis of 57. Route A – Woodward and Ley synthesis.
214
 Reagents and conditions: (a) Bromoacetyl 
bromide, pyridine, DCM, 0 C  r.t. (b) t-Butylthiol, benzene, reflux, 73% over 2 steps. (c) (i) Na, THF, reflux. (ii) NaH, THF, -
10 C  r.t., 85% Route B – Novel synthesis. Reagents and conditions: (a) (i) Phosphonoacetic acid, SOCl2. (ii) Pyridine, 
DCM, 0 C  r.t., quantitative. (b) t-Butylthiol, MeCN, reflux, 85%. 
 
In addition to being a simpler and more efficient route it also provides access to a highly 
synthetically useful intermediate 63 (Scheme 3.18). Acyl derivatives of Meldrum’s acid are widely 
used as synthetic equivalents for the introduction of 1,3-dicarbonyl motifs in the synthesis of natural 
products.216 Using this methodology, 63 could be used to incorporate a 1,3-dicarbonyl motif into 
polyketide based-natural products bearing an attached phosphonate handle. This would facilitate 
the incorporation of a range of side chains via a HWE olefination (see Section 5.5.6 for utilisation of 
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this approach). Finally, a HWE olefination of aldehyde 58 and the dilithio-anion of 57 furnished the 
required β-ketothioester 56 (Scheme 3.19). 
 
 
Scheme 3.19. Synthesis of 56. Reagents and conditions: LiHMDS (2 eq.), THF, -78 C  0 C, 87%.  
 
3.4.3 End-game strategy: total synthesis of harzianic acid 
The end-game strategy for the synthesis of harzianic acid (19) involved coupling of the polyene side 
chain 56 to the masked tetramic acid intermediate 52, followed by cyclisation and ester hydrolysis. 
The crude amine 53 obtained from the deprotection-reduction sequence was redissolved in THF 
before the addition of CF3CO2Ag, Et3N and 56 according to Ley’s protocol (Scheme 3.20).
159 This 
afforded the desired β-ketoamide 55 in good yield. 
 
Scheme 3.20. Synthesis of harzianic acid ethyl ester 55. Reagents and conditions: (a) (i) HCl (4N in dioxane), THF, 0 C, 10 
minutes. (ii) NaBH3CN, MeOH, 1.5 hours, 0 C. (b) 56, CF3CO2Ag, Et3N, THF, 0 C  r.t., 63% over 2 steps. 
 
With the desired β-ketoamide 55 in hand an NOE study was undertaken to confirm the expected 
relative stereochemistry of the product. The NOE analysis confirmed that 55 exists as a mixture of 
keto and enol tautomers due to an observed chemical exchange (EXSY) between H1 in the two 
tautomers. In addition, it revealed that the amine and isopropyl functional groups were on the same 
face of the lactone ring (Figure 3.11). The previous assignment of the isopropyl group stereogenic 
centre as (S) by analysis of the small molecule X-ray crystal structure 46 (Scheme 3.11) enabled the 
assignment of the amine stereogenic centre as (S) also. 
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Figure 3.11. NOE analysis of 55. (a) Structure of the enol and keto tautomers of 55. Observed NOEs are highlighted. (b) (1) 
– 
1
H NMR spectra of 55 showing a (5:4) enol:keto mix of tautomers. (2) – Irradiation of H-1 (keto) reveals an EXSY with H-1’ 
(enol), which confirmed they are chemically exchangeable and thus that 55 is present as a mixture of enol:keto tautomers. 
An NOE was also observed between H-1 and H-6 and H-2a. This demonstrated that H-1 and H-2a are cofacial. COSY and 
HSQC experiments showed that H-2b is on the same carbon as H-2a (data not shown). (3) – Irradiation of H-2b revealed an 
NOE of H-2a as expected and H-6 and H-5. This demonstrated that H-2b and H-5 were cofacial and therefore on the 
opposite face to H-1 and H-2a. (4) – Irradiation of H-5 revealed an NOE with H-4 as expected and confirmed the NOE with 
H-2b. 
 
Having established the formation of the (S,S) diastereomer of 55, cyclisation of the β-ketoamide was 
then investigated. Initial attempts to cyclise the β-ketoamide 55 using tBuOK (3 eq.) in THF were 
unsuccessful, yielding a small quantity of the desired harzianic acid ethyl ester (64) with significant 
formation of unassigned side products. Optimisation of this reaction identified tBuOK (1 eq.) in THF 
as the optimal conditions, resulting in the clean conversion of 55 to 64 in 1 hour (Scheme 3.21). 
Further optimisation of this reaction focused on the observation that a small quantity (<10%) of the 
cyclised harzianic acid ethyl ester (64) formed during the silver-mediated N-acylation reaction. It was 
found that changing the solvent of this reaction from THF to MeCN resulted in the isolation of the 
 
 
 
(1) 
(2) 
(3) 
(4) 
(B) 
(A) 
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desired cyclised product 64 in very good yield (75% from lactone 52). This highly efficient tandem 
deprotection-reduction-N-acylation-cyclisation reaction sequence produced the highly advanced 
harzianic acid ethyl ester (64) in just one day from 52 (Scheme 3.21). 
 
 
Scheme 3.21. Tandem deprotection-reduction-N-acylation-cyclisation synthesis of 64. Reagents and conditions: Route A: 
(a) (i) HCl (4N in dioxane), THF, 0 C, 10 minutes. (ii) NaBH3CN, MeOH, 1.5 hours, 0 C. (b) 56, CF3CO2Ag, Et3N, THF, 0 C  
r.t., 2 h, 65% over 2 steps. (c) 
t
BuOK (1 eq.), THF, 0 C  r.t., 93%. Route B: (a) (i) HCl (4N in dioxane), THF, 0 C, 10 
minutes. (ii) NaBH3CN, MeOH, 1.5 hours, 0 C. (b) 56, CF3CO2Ag, Et3N, MeCN, 0 C  r.t., 2 h, 75% over 2 steps.  
 
A preliminary investigation of ester hydrolysis conditions was undertaken, which included refluxing 
64 in EtOH under acidic conditions (1N HCl) or basic conditions (2N NaOH). The acid hydrolysis 
conditions resulted in the recovery of the starting material 64 after 14 hours. The reaction carried 
out under basic hydrolysis conditions yielded a mixture of starting material 64, (S,S)-harzianic acid 
(19) and (R,S)-5’-epiharzianic acid (19b) after 3 hours (Scheme 3.22). The partial epimerisation at the 
C5’ stereogenic centre is a common issue observed with tetramic acids.157 While extending the 
reaction time did increase the conversion of 64 to 19, it also resulted in an increased epimerisation 
at the C5’ position, resulting in an approximate 1:1 mixture of the two diastereomers 19 and 19b 
(Scheme 3.22). Based on the observed correlation between reaction time and epimerisation, the 
focus turned towards microwave irradiation conditions which could greatly reduce the reaction time 
and hence potentially epimerisation. A screen of bases (LiOH, NaOH, KOH, Ba(OH)2), temperatures 
(80  150 C) and time revealed that the optimal conditions were NaOH (2N) in EtOH for 20 minutes 
at 110 C, providing complete conversion of 64 to 19 in an approximate 3:1 ratio to the (R,S)-
diastereomer 19b (Scheme 3.22). Harsher conditions such as the use of a stronger base (e.g., 5N 
KOH) or higher temperatures (>110 C) did reduce the reaction time, however this resulted in a 
concomitant increase in unassigned side products with no reduction in the degree of epimerisation.  
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Scheme 3.22. Microwave irradiation assisted ester hydrolysis of 64. Reagents and conditions: (a) NaOH (2N), EtOH, 110 
C, 20 minutes, 19 - 52%; 19b – 19%.  
 
Harzianic acid (19) and 5’-epiharzianic acid (19b, see Table 3.2 for spectroscopic data and Appendix 
D) were readily separable by reverse phase chromatography. An additional purification step to 
remove any chelating metals was utilised, which involved passing the samples through a plug of tosic 
acid functionalised silica. The 1H NMR, 13C NMR, HRMS, IR and the specific rotation obtained for the 
synthetic harzianic acid (19) were in excellent agreement with the data provided for the natural 
sample (Table 3.2).160,164,172  
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Table 3.2. Comparison of the physico-chemical and spectroscopic properties of isolated harzianic acid (19)
172
 and 
synthetic harzianic acid diastereomers (19) and (19b).  
(S,S)-Harzianic acid (19)172 
(reported for isolated sample) 
(S,S)-Harzianic acid (19) 
(synthesised) 
(R,S)-5’epiHarzianic acid 
(19b) 
(synthesised) 
    
   +19.6 (c 1.06, MeOH) +18.6 (c 1.06, MeOH) +118.0 (c 0.5, MeOH) 
HRMS 366.1922 [M+H]+ 366.1911 [M+H]+ 364.1757 [M-H]- 
Position 
1H NMR 
(ppm) 
13C NMR 
(ppm) 
1H NMR 
(ppm) 
13C NMR 
(ppm) 
1H NMR 
(ppm) 
13C NMR 
(ppm) 
(CD3OD, 400 MHz)
 (CD3OD, 500 MHz)
 (CD3OD, 500 MHz)
 
1 - 175.9  175.8  173.4 
2 7.09 120.4 7.09 120.3 7.11 120.6 
3 7.53 147.2 7.53 147.3 7.44 145.6 
4 6.39 131.0 6.39 131.0 6.34 131.0 
5 6.39 149.7 6.39 149.8 6.34 148.2 
6 2.23 36.4 2.24 36.4 2.23 36.3 
7 1.50 22.9 1.51 23.0 1.50 23.0 
8 0.95 14.0 0.96 14.1 0.96 14.0 
2’ - 173.9 - 173.9 - 176.4 
3’ - 100.9 - 100.9 - 102.3 
4’ - 198.9 - 198.9 - 196.3 
5’ 3.80 65.5 3.80 65.5 3.77 66.0 
6’ 1.99 36.4 1.99 36.4 2.40 37.0 
 2.33  2.34  2.47  
7’ - 79.8 - 79.8 - 78.8 
8’ 2.02 37.4 2.02 37.4 1.89 37.5 
9’ 0.97 17.5 0.98 17.9 0.95 17.6 
10’ 0.94 16.5 0.95 16.5 0.87 16.6 
11’ 2.94 27.1 2.94 27.1 2.92 28.3 
12’ - 178.6 - 178.6 - 178.2 
 
The absolute configuration of harzianic acid (19) was determined by Vinale et al. through X-ray 
diffraction studies.164 In addition, this study also revealed that in the solid state harzianic acid (19) is 
stabilised by intramolecular hydrogen bonds between O1 and O2’ and between O7’ and O4’ (Figure 
3.12A). 13C NMR analysis of 19 in MeOD (see Appendix C) revealed that the quaternary carbons (C2’-
C4’) of the tetramic acid were poorly resolved, which is in agreement with the isolation paper which 
assigned them as broad. It was found that recording the NMR spectra using deuterated chloroform 
provided very clear and well resolved signals both in 1H (Figure 3.12B) and 13C spectra (see Appendix 
C). This is presumably due to the inability of CDCl3 to participate or disrupt possible intramolecular 
and intermolecular hydrogen bonding networks in solution, thus resulting in 19 appearing as a single 
tautomer. Further analysis of the 1H NMR spectrum of 19 in CDCl3 identified the tertiary alcohol 
(O7’) at 7.25 ppm (Figure 3.12B). This is a significant downfield shift in comparison with the typically 
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observed chemical shift for alcohols between 2.0 – 5.5 ppm. The observed downfield shift is 
consistent with the deshielding of the O7’-proton via an intramolecular hydrogen bond, in 
agreement with the previously determined X-ray crystal structure.164  
 
Figure 3.12. (A) Small molecule X-ray crystal structure of (S,S)-harzianic acid (19) reported by Vinale et al. showing 
intramolecular hydrogen bonding.
164
 (B) 
1
H NMR spectrum of synthesised (S,S)-harzianic acid (19) in CDCl3 (500 MHz). 
 
In summary, a biomimetic, convergent and efficient synthesis of (S,S)-harzianic acid (19) has been 
developed. This route could be adapted for the synthesis of a range of similar tetramic acid natural 
products and analogues. The synthesis of harzianic acid (19) was achieved with a longest linear 
sequence (LLS) of 6 steps and an overall yield of 22%. Using this route we were also able to isolate 
5’-epiharzianic acid (19b) and by utilising the (S)-enantiomer of tert-butanesulfinamide 38, (R,R)-
harzianic acid (19c) and its 5’-epimer (S,R)-harzianic acid (19d) were also prepared (Table 3.3). 
 
Table 3.3. Quantities and optical rotation of all four synthesised harzianic acid diastereomers. 
Compound Quantity Synthesised 
(mg) 
Optical Rotation 
(    
  ; MeOH) 
(S,S)-Harzianic acid 19 92 +18.6 
(R,S)-5’epiHarzianic acid 19b 33 +118.0 
(R,R)-Harzianic acid 19c 81 -16.9 
(S,R)-5’epiHarzianic acid 19d 24 -121.2 
(B) 
(A) 
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3.5 Total Synthesis of JBIR-22  
 
3.5.1 Retrosynthetic analysis 
The development of a synthetic route to harzianic acid (19) provided a highly synthetically useful 
common intermediate 52 (Scheme 3.14) which could be elaborated to access JBIR-22 (4). The 
original retrosynthetic analysis of JBIR-22 (4) involved a late-stage intramolecular Diels-Alder 
cyclisation of the appropriate polyene intermediate 65 (Scheme 3.23, Route A). Incorporation of the 
polyene chain 66 could be achieved by N-acylation of the masked tetramic core 52 in an analogous 
manner to the synthesis of harzianic acid (19).  
 
Scheme 3.23. Retrosynthetic analysis of JBIR-22 (diastereomer-4a represented). Route A – Entails a late-stage IMDA of 
intermediate 65 which derives from polyene chain 66. Route B – Highlights include the incorporation of decalin moiety 
68 via an N-acylation reaction. Synthesis of 68 involves a key enantioselective Diels-Alder cyclisation of polyene 69.  
 
A key challenge in this route is the identification of a diastereoselective IMDA cyclisation of the 
complex intermediate 65. This could potentially be achieved under substrate control using an achiral 
catalyst, or through the development of a chiral catalyst-based methodology. Insight into the 
biosynthesis of JBIR-22 (4) could be provided by investigation of a possible substrate-controlled non-
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enzymatic asymmetric DA cycloaddition versus an enzymatic “Diels-Alderase” mediated reaction. 
However, a major challenge associated with this strategy is the assignment of the absolute 
configuration of the Diels-Alder product 4 in the absence of a small molecule X-ray crystal structure. 
To aid the stereochemical assignment of JBIR-22 (4), an alternative route was proposed which would 
entail an enantioselective Diels-Alder cyclisation of the trienal 69 to provide a single enantiomer of 
the decalin ring 68 prior to attaching it to 52 (Scheme 3.23, Route B). This route could provide access 
to all four predicted stereoisomers of JBIR-22 (Scheme 3.4, 4(a-d)), thus facilitating the absolute 
stereochemical assignment of JBIR-22 (4). In addition, this would also provide authentic samples of 
the diastereomers as standards for the development of a late-stage diastereoselective Diels-Alder 
cyclisation (Scheme 3.23, Route A). 
 
3.5.2 Synthesis of polyene 66 
Due to the high probability of the glutamic acid side chain existing as the (S) configuration (see 
Section 3.1.3), a large-scale synthesis of the (S)-diastereomer of the masked tetramic acid 
intermediate 52 (>5 g) was carried out. This provided a common intermediate onto which the 
appropriate polyene chain or decalin ring could be attached. With 52 in hand, the next focus was on 
the synthesis of the β-ketothioester 66, a key intermediate in Route A (Scheme 3.23).  
 
 
Scheme 3.24. Retrosynthetic analysis of 66.  
 
Chapter 3: Natural Products 
 
92 
 
It was proposed that 66 could be formed from three different fragments (Scheme 3.24). Fragment A) 
phosphonate 57 could be used to introduce the β-ketothioester functionality in an analogous 
manner to its utilisation in the synthesis of harzianic acid (19). Fragment B) the terminal diene could 
be introduced via phosphonate 70. Employing a range of different phosphonates would facilitate the 
modification of the terminal end of the chain providing access to analogues of JBIR-22 (4). Fragment 
C) the remaining core 6-carbon di-aldehyde fragment 71 could be accessed through an atom-
economical ozonolysis of cheap and readily available cyclohexene (72).  
 
Assembly of 66 began with a Schreiber ozonolysis217 of cyclohexene (72) which incorporates an in 
situ protection of one of the terminal aldehydes as an acetal to give 73, thereby differentiating 
between the terminal aldehydes (Scheme 3.25). The next step involved a HWE olefination between 
phosphonate 70 and the mono-protected aldehyde 73. Synthesis of the diene 74 from the mono-
protected aldehyde has been reported previously by Uchida et al.218 in the total synthesis of (+)-
UCS1025A (Scheme 3.25). However in contrast to our proposed synthesis, the chain elongation step 
was achieved via a Wittig reaction with 2-butenyl triphenylphosphonium bromide (76). This 
provided 74 as a mixture of isomers at the C4-C5 double bond (E/Z – 1:1) which required an 
additional isomerisation step to improve the ratio of the desired E-isomer to the unwanted Z-isomer 
(1:1  5:1). The utilisation of a HWE reaction in place of a Wittig reaction could eliminate this 
drawback, potentially providing the diene 74 in a good ratio of (E:Z) isomers (Scheme 3.25).  
 
 
Scheme 3.25. Synthesis of 73. Schreiber ozonolysis of cyclohexene (72) provides 73. Reagents and conditions: (a) (i) O3, 
DCM, MeOH, -78 C, (ii) PTSA, NaHCO3, DMS, r.t., 82%. Chain elongation of 73 to provide diene 74 has been reported 
previously via a Wittig reaction with 76.
218
 We proposed an alternative route via a HWE reaction with 70. 
 
An initial HWE test reaction using LiHMDS in THF did not yield any of the desired product 74. Further 
literature scrutiny revealed that although phosphonate 70 has been reported as a reactant/reagent 
in 53 reactions in Scifinder, its utilisation in a HWE olefination has not been reported. The most 
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common reactions of phosphonate 70 involve addition across the double bond or substitution of the 
α-position, indicating that the development of a HWE using phosphonate 70 could be difficult. 
 
An investigation of common HWE reaction conditions was conducted to identify if this 
transformation was viable (Table 3.4). This study revealed that none of the desired product 74 was 
formed when common lithium bases such as LiHMDS or nBuLi were used (entries 1 & 2), with several 
side reactions occurring. KHMDS was selected as an alternative base to investigate if the resulting 
more reactive phosphonate-stabilised carbanion would promote the desired HWE olefination. These 
conditions did promote the desired transformation, resulting in the isolation of 74 in good yield and 
moderate (E:Z) selectivity (entry 3). The higher reactivity of the phosphonate-carbanion is due to the 
comparably lower coordination ability of potassium cations compared to lithium cations.219 
However, a drawback to the lower coordination ability of potassium is a reduction in the E:Z 
selectivity of the HWE reaction. To partially overcome this issue, the solvent was changed from THF 
to DME which has been reported to improve the E-selectivity.219 This modification resulted in an 
improved E-selectivity with an E:Z ratio of 8:1 compared to 4:1 in the presence of THF, although with 
a small drop in yield (entry 4). The reaction was repeated with LiHMDS in DME which confirmed that 
the potassium base was essential as none of the desired product 74 was isolated (entry 5). 
 
Table 3.4. Optimisation of HWE reaction conditions for the formation of 74. 
 
Entry Base Solvent 
74 
(isolated yield, %) 
E:Z 
1 LiHMDS THF - - 
2 nBuLi THF - - 
3 KHMDS THF 73 4:1 
4 KHMDS DME 69 8:1 
5 LiHMDS DME - - 
 
Acid-deprotection of the acetal group of diene 74 yielded dienal 75, which after a further HWE 
olefination with 57 furnished the desired β-ketothioester polyene chain 66. Separation of the 
undesired Z-isomer was achieved by chromatographic purification to provide isomerically pure 
polyene 66.  
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Scheme 3.26. Synthesis of 66. Reagents and conditions: (a) Aq. HCl, THF, r.t., 12 h, 94%. (b) LiHMDS, 57, THF, -78 C  0 
C, 3 h, 72%. 
 
A BF3-mediated Diels-Alder cyclisation of 66 was investigated as a possible route to access a racemic 
mixture of the endo-diastereomer of the decalin ring (±)-68, which could in turn be elaborated to 
provide a mixture of JBIR-22 diastereomers 4a and 4b (Scheme 3.23, Route B). This would facilitate 
the preliminary structural validation of JBIR-22 (4) and in addition, provide a useful standard for the 
development of the asymmetric synthesis. Highly diastereoselective IMDA cyclisations have been 
reported previously in the synthesis of decalin ring containing natural products (e.g., equisetin (10), 
see Section 3.1.6). Reaction of polyene 66 with BF3.Et2O smoothly effected the desired IMDA 
cyclisation in very good yield and excellent selectivity for the racemic endo diastereomer (±)-68 
(>20:1 endo:exo). The formation of the expected endo diastereomer was confirmed by NOE analysis 
(see Appendix E). 
 
Scheme 3.27. IMDA cycloaddition of 66. Reagents and conditions: (a) BF3.Et2O, DCM, -78 C  0 C, 73%. Relative 
stereochemistry of (±)-68 is shown. 
 
Conversion of decalin (±)-68 to 4a/b proceeded smoothly via a silver-mediated N-acylation of 53, 
followed by an intramolecular Lacey-Dieckmann cyclisation to provide a mixture of JBIR-22 ethyl 
ester diastereomers 77a/b. Subsequent ester hydrolysis provided an inseparable mixture of JBIR-22 
diastereomers 4a and 4b (Scheme 3.28). Surprisingly, no epimerisation of the C5’ position was 
detected during the final hydrolysis step.  
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Scheme 3.28. End game strategy: synthesis of a diastereomeric mixture JBIR-22 diastereomers 4a and 4b. Reagents and 
conditions: (a) 53, AgCF3CO2, Et3N, THF, 0 C  r.t., 2 h, 64% over 2 steps. (b) (i) 
t
BuOK, THF, 0 C  r.t., 2 h. (ii) Aq. NaOH, 
EtOH, 110 C (MW), 20 mins, 87% over 2 steps. Relative stereochemistry of (±)-68 is shown.  
 
Comparison of the 1H and 13C NMR spectra of 4a/b with that reported for isolated JBIR-22 (4) 
showed significant discrepancies. Further investigation revealed that the final eluting step in the 
HPLC purification of the isolated JBIR-22 (4) was carried out in the presence of diethylamine.123 Due 
to the highly acidic nature of the JBIR-22 (4) carboxylic acid, the reported NMR is most likely to be 
that of the diethylamine salt of JBIR-22 (4) and not of the free acid. The NMR of the synthesised 
mixture 4a/b was repeated in the presence of diethylamine. The resulting NMR spectra were in high 
agreement with the reported NMR of JBIR-22 (4), however, with the added complication of the 
presence of more complex splitting patterns in the 1H NMR spectra and the appearance of doubling 
of the 13C NMR signals as a result of the mixture of diastereomers 4a and 4b (Figure 3.13).   
 
 
Figure 3.13. 
1
H and 
13
C NMR spectra of the diethylamine salt of JBIR-22 mixture 4a/b [Acetone-d6, 500 MHz]. 
Representative examples of the increased splitting pattern complexity (
1
H NMR) and doubling of signals (
13
C NMR) 
observed as a result of the diastereomeric mixture are magnified. See Appendix F for full spectra.  
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3.5.3 Development of an enantioselective IMDA route to JBIR-22 (4) 
As 4a and 4b could not be separated from this mixture, access to pure samples of the predicted 
stereoisomers of JBIR-22 (4a-d) would require an asymmetric synthesis of 68. The critical step in the 
synthetic strategy involved an enantioselective IMDA cyclisation of trienal 69 to provide either 
enantiomer of aldehyde 78, [(2S,3S, 6R, 7S)-78a or (2R,3R, 6S, 7R)-78b] which could be elaborated to 
furnish a single enantiomer of the desired intermediate 68 (Scheme 3.23, Route B). The trienal 69 
could be accessed via chain elongation of our previously synthesised dienal 75 (Scheme 3.29). 
 
 
Scheme 3.29. Retrosynthetic analysis of 78a. 78a could be accessed by an enantioselective IMDA cycloaddition of 69 
which would arise from a chain elongation of dienal 75. 
 
Extensive research has been carried out into the development of enantioselective IMDA routes to 78 
due to its occurrence in natural products with potent biological activities such as the 
antiproliferative agent (+)-UCS1025A (79)220 and the phytotoxic polyketide solanapyrone D (80).221 
Studies towards these and related natural products have centred around the use of either an 
organocatalytic IMDA developed by MacMillan222 or a chiral auxiliary mediated IMDA pioneered by 
Evans.223  
 
Scheme 3.30. Examples of the utilisation of the chiral auxiliary approach in the synthesis of (+)-UCS1025A (79)
218
 and 
tetrodecamycin (83).
224
  
 
Examples using the chiral auxiliary methodology include the use of (+)-camphor sultam (81) in the 
synthesis of (+)-UCS1025A (79)218 and (R)-4-benzyl-2-oxazolidinone (82) in the synthesis of the 
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decalin ring of tetrodecamycin (83) (Scheme 3.30).224 MacMillan and co-workers are pioneers in the 
field of organocatalytic IMDA reactions with the development of a range of chiral imidazolidinone 
organocatalysts which displayed excellent enantio- and diastereocontrol with good yields and 
substrate scope.225 This methodology has been used in the total synthesis of (+)-UCS1025A (79),220 
solanapyrone D (80)221 and related natural products such as amaminol A (84)226 and B227 (Scheme 
3.31).  
 
Scheme 3.31. Utilisation of imidazoline organocatalyst (R,R)-85 in the total synthesis of solananpyrone D (80)
221
 and 
amaminol A (84).
226
 Reagents and conditions: (a) 20 mol% 85.TfOH, CH3CN (2% H2O), 5 C, 48 hours, 71%. (b) 20 mol% 
85.TFA, CH3CN (2% H2O), -20 C.   
 
Based on literature precedent, an organocatalytic IMDA methodology was selected for the 
conversion of 69 to 78 (Scheme 3.29), due to the high levels of diastereo- (>20:1) and enantiocontrol 
(90% ee) reported for this transformation without the extra synthetic steps required to introduce 
and remove a chiral auxiliary.221  
 
 
Scheme 3.32. Chain elongation of 75 to 87. Reagents and conditions: (a) Diisopropyl(ethoxycarbonylmethyl) phosphonate 
(86), LiHMDS, THF, -78 C  r.t., 4 h, 88%. (b) DIBAL-H, DCM, -78 C, 30 mins, 97%.  
 
Trienal 69 was prepared using a route adapted from MacMillan’s approach in the synthesis of 
solanapyrone D (80).221 This involved an olefination of dienal 75 to furnish 87 which was 
subsequently reduced by DIBAL-H to provide alcohol 88 in excellent yield (Scheme 3.32). The final 
step in MacMillan’s route involved a catalytic tetrapropylammonium perruthenate (TPAP) oxidation 
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of alcohol 88 to the corresponding aldehyde 69 in a 59% yield. In an attempt to improve on this 
yield, a screen of oxidation conditions was carried out (Table 3.5). Conditions that removed the need 
for purification facilitating the direct use of the trienal 69 in the next step were considered highly 
valuable due to the instability of 69.  
 
Table 3.5. Optimisation of the oxidation of 88 to 78. 
 
Entry Oxidant Solvent Time 
69 
(isolated yield, %) 
1 cat. TPAP/NMO DCM 50 mins 59221 
2 DDQ DCM 12 h - 
3 PCC DCM 12 h 63 
4 PCC DCM 3 h 78 
5 Dess-Martin DCM 30 mins 100 
 
Dess-Martin periodinane was identified from the screen as the optimal oxidant for this 
transformation providing quantitative conversion to 69 in 30 minutes. In addition, a simple aqueous 
work-up furnished pure trienal 69 which could be directly used in the IMDA reaction without further 
chromatographic purification. Although this optimised route provides 69 in excellent yield (85% over 
3 steps; Scheme 3.33, Route A) from 75, it was not an ideal approach as it contained two concession 
steps.228 In an “ideal synthesis”,228–232 nonstrategic redox manipulations such as the reduction of 
ester 87 to the alcohol 88, followed by subsequent oxidation to the aldehyde 69 are regarded as 
concession steps. A strategic redox manipulation is defined as a reaction which establishes the 
correct functionality found in the target product.228 As our desired polyene 69 is in the aldehyde 
oxidation state, an ideal synthesis would transform 75 to the desired aldehyde 69 in one-step, 
without any nonstrategic redox manipulations. This was achieved by reacting 75 with the 
commercially available Wittig reagent 89, which after a simple acidic deprotection of the acetal 
provided the desired aldehyde 69 in good yield (64%) and in just one-step (Scheme 3.33, Route B).  
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Scheme 3.33. Optimised chain elongation strategy. Reagents and conditions: Route A: (a) LiHMDS, THF,  
diisopropyl(ethoxycarbonylmethyl) phosphonate (86), -78 C  r.t., 4 h, 88%. (b) DIBAL-H, DCM, -78 C, 30 mins, 97%. (c) 
Dess-Martin periodinane, DCM, H2O, r.t., 1 h, quantitative. Route B: (a) (i) (1,3-dioxolan-2-ylmethyl)triphenylphosphonium 
bromide (89), 
t
BuOK, THF, 0 C, 3.5 h. (ii) 10% aq. oxalic acid, r.t., 1 h, 64%. 
 
In contrast with our previously synthesised triene 66 (Scheme 3.26), it was not possible to remove 
the undesired minor Z-isomer of trienal 69 (C8-C9 double bond). However, this was not an issue as it 
has been shown that Z,E-dienes are uniformly inert to this catalytic IMDA, resulting in a kinetic 
purification.221,226 Trienal 69 was subjected to the catalytic IMDA conditions (20 mol% 
imidazolidinone (S,S)-85/(R,R)-85.TfOH) which afforded the desired decalins 78a and 78b 
respectively, in good yields (78a, 65%; 78b, 68%; based on consumed E,E,E-trienal) and moderate 
diastereoselectivity (dr 4:1) (Scheme 3.34). This moderate diastereoselectivity was surprising when 
compared to the selectivity reported by MacMillan and co-workers (dr >20:1). However, it was in 
agreement with the findings of Christmann et al.233 for the same transformation. This reduction in 
diastereoselectivity may be due to epimerisation of the C2 position which was also observed by 
MacMillan for similar substrates.221 The removal of the minor diastereomer was not possible until 
the final step of the synthesis. A portion of the aldehydes 78a and 78b were converted to the 
corresponding alcohols 90a and 90b via NaBH4 mediated reduction for determination of their 
enantiomeric purity (Scheme 3.34). A racemic standard was obtained by a BF3.OEt2 catalysed 
cycloaddition of 69 to provide (±)-78 as a single diastereomer, which was subsequently reduced to 
the corresponding alcohol (±)-90 (Scheme 3.34A). Enantiomeric excesses were obtained by chiral GC 
analysis using an Agilent Cyclosil-B (isotherm, 140 C, Scheme 3.34B). The determined enantiomeric 
purity of 78a (87% ee) and 78b (84% ee) are in agreement with the reported values for this reaction 
(80-90% ee).221,233,234 The enantiomeric purity could be improved if required by recrystallisation at 
the alcohol oxidation state.235 
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Scheme 3.34. (A) Synthesis of racemic decalin (±)-78 and enantiomerically enriched decalins (2S,3S, 6R, 7S)-78a and 
(2R,3R, 6S, 7R)-78b. Reagents and conditions: (a) BF3.Et2O, DCM, -78 C  0 C, 3 h, 74%. (b) 20 mol% imidazolidinone 
(S,S)-85.TfOH, MeCN (2% H2O), -5 C, 48 h, 65%, dr 4:1, 87% ee. (c) 20 mol% imidazolidinone (R,R)-85.TfOH, MeCN (2% 
H2O), -5 C, 48 h, 68%, dr 4:1, 84% ee. (d) NaBH4, EtOH, 0 C, 1 h, (±)-90 - 86%; 90a – 88%; 90b – 91%. (B) Determination of 
the enantiomeric purity of decalins 90a (middle) and 90b (bottom) via chiral GC analysis. Only section corresponding to 
the major diastereomer of 90a and 90b is shown, see Appendix G for full chromatograms. 
  
The expected relative and absolute configuration of 78a and 78b were confirmed by analysis of the 
X-ray crystallographic structures of the corresponding carboxylic acid derivatives 91a and 91b 
(Scheme 3.35). The crystalline acids 91a and 91b were obtained by rapid air oxidation (at 4 C) of 
aldehydes 78a and 78b respectively.  
(A) (B) 
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Scheme 3.35. Confirmation of the expected absolute configuration of 78a and 78b by analysis of the small molecule X-
ray crystal structures of the corresponding carboxylic acids 91a and 91b. X-ray crystallographic data provided by Dr David 
Cordes. 
 
3.5.4 Synthesis of pure samples of JBIR-22 diastereomers 4a and 4b 
Conversion of enantiomerically enriched 78a and 78b to the corresponding β-ketothioesters 68a and 
68b was required for completion of the two diastereomers of JBIR-22, 4a and 4b. This was achieved 
via a LDA-promoted aldol condensation of S-tert-butyl thioacetate (92) and the aldehydes 78a and 
78b to furnish the β-hydroxythioesters 93a and 93b respectively (Scheme 3.36). Dess-Martin 
periodinane oxidation of 93a and 93b proceeded smoothly to provide the desired β-ketothioesters 
68a and 68b respectively (Scheme 3.36).  
 
Scheme 3.36. Synthesis of β-ketothioesters (A) 68a and (B) 68b. Reagents and conditions: (a) (i) i-Pr2NH, n-BuLi (2.3M in 
hexanes), THF, 0 C, 30 mins. (ii) S-tert-butyl-thioacetate (92), THF, -78 C, 2.5 h, 93a – 66%; 93b – 69%. (b) Dess-Martin 
periodinane, DCM, r.t., 2 h, 68a – 79%; 68b – 82%. 
(A) 
(B) 
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The NMR spectroscopic data obtained for 68a and 68b were in agreement with the data previously 
obtained for (±)-68, the relative stereochemistry of which had been assigned by NOE experiments 
(see Appendix E). Conversion of the β-ketothioesters 68a and 68b to the corresponding JBIR-22 
diastereomers 4a and 4b was accomplished via a silver-mediated N-acylation of 53, followed by an 
intramolecular Lacey-Dieckmann cyclisation and ester hydrolysis, as described previously in the 
synthesis of the diastereomeric mixture 4a/b (Scheme 3.37). 4a and 4b were purified by reverse 
phase column chromatography and a portion of each was converted to the corresponding 
diethylamine salt for spectroscopic comparison with the reported JBIR-22 (4) data and the previously 
synthesised mixture of 4a/b.  
 
 
Scheme 3.37. Synthesis of JBIR-22 diastereomers (A) 4a and (B) 4b. Reagents and conditions: (a) 53, AgCF3CO2, Et3N, THF, 
0 C  r.t., 2 h, 67a – 76%; 67b – 71% over 2 steps. (b) (i) 
t
BuOK, THF, 0 C  r.t., 2 h. (ii) Aq. NaOH, EtOH, 110 C (MW), 20 
mins, 4a – 71%; 4b – 74% over 2 steps.  
 
3.5.5 Synthesis-guided configurational determination  
With pure samples of the two proposed diastereomers of JBIR-22 (4) in hand, a comparison with the 
authentic mixture of the two diastereomers 4a/b prepared previously was carried out. Both 
diastereomers have very similar 1H and 13C NMR spectra. However, comparison of the 1H NMR and 
13C NMR spectra of the two diastereomers with the 4a/b spectra, confirmed that pure samples of 
the single diastereomers had been successfully prepared and highlighted three protons (H2, H3, 
(A) 
(B) 
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H12), which had a noticeable chemical shift difference between 4a and 4b (Figure 3.14, see 
Appendix H for full spectra).  
 
 
 
   
 
Figure 3.14. 
1
H NMR analysis of synthesised JBIR-22 diastereomers 4a and 4b. (A) Structure and numbering of 4a. (B) 
Stacked spectra of the diastereomeric mixture 4a/b and the single diastereomers 4a and 4b. Characteristic proton signals 
H2, H3 and H12 are highlighted. (C) Magnification of the H2, H3 and H12 regions of the 
1
H NMR spectra of 4a/b, 4a and 4b 
and magnification of sections of the 
13
C NMR spectra of 4a/b, 4a and 4b. See Appendix H for the full 
1
H spectra of 4a and 
4b. 
 
(A) 
(B) 
 
(C) 
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Comparison of the chemical shift of protons (H2, H3, H12) with that reported for the isolated sample 
of JBIR-22 (4) revealed that the relative configuration of diastereomer 4a (Figure 3.14A) was the 
most likely structure of 4 (Table 3.6A). A detailed comparison of the 13C NMR of both diastereomers 
4a and 4b with that reported for the isolated JBIR-22 4 was undertaken to further validate the 
stereochemical assignment. This comparative study revealed that 13C chemical shifts of 4a were in 
very high agreement with that reported for 4, while 4b had some significant permutations ( ppm > 
0.1) (Table 3.6B). 
 
Table 3.6. (A) Comparison of the reported 
1
H NMR signals of H2, H3 and H12 of isolated JBIR-22 (4) and synthesised JBIR-
22 diastereomers 4a and 4b. (B) Comparison of the reported 
13
C NMR signals of isolated JBIR-22 (4) and synthesised 
JBIR-22 diastereomers 4a and 4b. JBIR-22 (4) – 
13
C (150 MHz) in Acetone-d6. 4a and 4b – 
13
C (126 MHz) in Acetone-d6. See 
Appendix H for the full 
13
C spectra of 4a and 4b. 
 
 
Compound 
number 
JBIR-22 (4)123 4a 4b 
δc (ppm)  δc (ppm)  (ppm) δc (ppm)  (ppm) 
1 196.4 196.3 -0.1 196.4 0 
2 51.0 51.0 0 51.0 0 
3 32.2 32.2 0 32.3 0.1 
4 133.6 133.6 0 133.4 -0.2 
5 131.1 131.1 0 131.2 0.1 
6 43.4 43.4 0 43.3 -0.1 
7 34.3 34.4 0.1 34.4 0.1 
8 27.6 27.6 0 27.7 0.1 
9 27.7 27.7 0 27.7 0 
10 31.0 31.1 0.1 31.0 0 
11 37.4 37.4 0 37.3 -0.1 
12 18.3 18.4 0.1 18.3 0 
2' 174.6 174.7 0.1 174.8 0.2 
3' 101.9 101.9 0 101.5 -0.4 
4' 196.1 196.1 0 195.7 -0.4 
5' 63.3 63.3 0 63.2 -0.1 
6' 37.3 37.3 0 37.1 -0.2 
7' 80 80.0 0 79.9 -0.1 
8' 36.6 36.6 0 36.6 0 
9' 18.7 18.8 0.1 18.6 -0.1 
10' 26.8 26.9 0.1 26.8 0 
11' 180.9 180.9 0 180.1 -0.8 
12' 16.8 16.9 0.1 16.8 0 
 
With the relative stereochemical configuration of JBIR-22 (4) being assigned as that of diastereomer 
4a, the final investigation involved identifying which enantiomeric series the natural product 
 
 
JBIR-22 (4) 
[ppm] 
JBIR-22 (4a) 
[ppm] 
JBIR-22 (4b) 
[ppm] 
H2 3.90 3.90 3.92 
H3 2.64 2.64 2.60 
H12 0.76 0.77 0.75 
(A) 
(B) 
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belonged in, i.e. diastereomer 4a or its enantiomer 4d. However comparison of the optical rotation 
(αD) of 4a [*α+D
20 = +71.4 (c 0.7, MeOH)] and that reported for 4 [*α+D
25 = -330.0 (c 0.7, MeOH)] 
revealed a very high discrepancy, which would not be corrected by the enantiomer 4d which should 
have an optical rotation of approximately [*α+D
20 = -71.4 (c 0.7, MeOH)]. Similarly it is significantly 
different from diastereomer 4b which has an optical rotation of [*α+D
20 = -20.5 (c 0.7, MeOH)]. This 
discrepancy could be due to many factors, including the significant differences in optical rotation 
resulting from small changes in concentration, particularly when working with small quantities of 
material isolated from natural sources. Furthermore, as previously mentioned (Figure 3.5, Section 
3.1.3), the published 13C NMR spectrum of JBIR-22 (4) contains a doubling of many signals, likely 
indicating the presence of a stereoisomer which could have a significant effect on the optical 
rotation of the sample.  
 
In an attempt to clarify this issue and provide an absolute stereochemical assignment for the 
isolated JBIR-22 (4), an authentic sample (0.9 mg) was obtained from Dr Kazuo Shin-ya.122,123 
Unfortunately, the original sample had degraded significantly (see Appendix I) and work is on-going 
to develop a suitable HPLC purification method to isolate a pure sample. This authentic sample 
would facilitate NMR doping experiments to validate 4a as having the correct relative configuration 
and comparison of the CD spectra or chiral HPLC chromatogram of the samples should provide a 
method for assigning the absolute configuration of JBIR-22 (4).   
 
In summary, the first total synthesis of JBIR-22 diastereomers 4a and 4b has been completed. This 
was achieved via a stereoselective and convergent approach, involving a longest linear sequence 
(LLS) of 10 steps and an overall yield of 6%. This synthetic approach incorporates biomimetic and 
tandem one-pot processes and has limited nonstrategic redox reactions and protecting group 
manipulations. Utilisation of this versatile approach to access 4a and 4b facilitated the validation of 
the predicted structure of isolated JBIR-22 (4) and identification that 4a contains the correct relative 
configuration. Assignment of the absolute configuration requires further comparative studies with 
an authentic isolated sample of JBIR-22 (4).  
 
Our initial synthetic strategy provided a short and stereoselective route to the desired JBIR-22 
diastereomers 4a and 4b. However, we believed an alternative synthetic strategy (Scheme 3.23, 
Route A) involving a late stage stereocontrolled IMDA cycloaddition could further optimise this 
sequence, making it more step-efficient and providing access to a diverse set of potential analogues. 
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Furthermore, exploring this route would allow additional speculation on the possible role of a “Diels-
Alderase” in the biosynthesis of JBIR-22 (4). 
 
3.5.6 Synthesis of the IMDA precursor 
The required IMDA precursor 65 was accessed by cyclisation of β-ketoamide 94, which in turn was 
generated via N-acylation of (S,S)-53 with the previously synthesised β-ketothioester polyene chain 
66 (Scheme 3.38).   
 
Scheme 3.38. Synthesis of IMDA precursor 65 via a tandem deprotection-reduction-N-acylation process followed by 
cyclisation. Reagents and conditions: (a) (i) HCl (4N in dioxane), THF, 0 C, 10 minutes. (ii) NaBH3CN, MeOH, 1.5 hours, 0 C. 
(b) 66, CF3CO2Ag, Et3N, THF, 0 C  r.t., 2 h, 67% over 2 steps. (b) 
t
BuOK, THF, 0 C  r.t., 2 h, 94%. 
 
The final optimisation of the synthetic route explored the possibility of circumventing the silver-
mediated N-acylation reaction. Drawbacks to this method include the often difficult purification of 
the strongly chelating tetramic acids, the disposal of the toxic silver salt by-products and the 
challenges associated with handling the highly pungent tert-butylthiol (odour threshold of 
<0.33 ppb236). An alternative retrosynthetic strategy was devised which involved a HWE olefination 
of phosphonate 95 and aldehyde 75 (Scheme 3.39), an approach which has been used successfully in 
the synthesis of the tirandamycins.237–239 Phosphonate 95 would arise from a base-mediated 
cyclisation of β-ketoamide 96. As the cyclisation of 96 to 95 and subsequent HWE olefination are 
both base-catalysed processes, this potentially could be carried out in a one-pot reaction. The β-
ketoamide 96 could be readily formed by a thermally induced N-acylation reaction using the novel 
Meldrum’s acid derivative 63 (Scheme 3.39), without the need for the silver-mediated coupling or 
the added steps to form the β-ketothioester 66 (Scheme 3.26).  
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Scheme 3.39. Alternative retrosynthetic analysis of 65.  
 
The tandem deprotection-reduction of 52 followed by N-acylation with 63, quickly and cleanly 
provided the desired β-ketoamide 96 (Scheme 3.40). Initial test reaction conditions for the one-pot 
domino cyclisation-HWE reaction involved the treatment of 96 with tBuOK (3 equiv.) in THF, as had 
been reported for a related process in the synthesis of streptolydigin (8).240 This method provided 
the desired product 65 in good yield (71%, Scheme 3.40). 
 
 
Scheme 3.40. Alternative synthesis of IMDA precursor 65 via a tandem deprotection-reduction-N-acylation followed by a 
one-pot cyclisation-HWE olefination. Reagents and conditions: (a) (i) HCl (4N in dioxane), THF, 0 C, 10 minutes. (ii) 
NaBH3CN, MeOH, 1.5 hours, 0 C. (b) (i) 
t
BuOK (3 eq.), THF, 0 C, 40 min. (ii) 75, THF, 0 C  r.t., 16 h, 71%. 
 
This one-pot process entails several consecutive steps, including initial cyclisation of the β-
ketoamide 96 to form 95a, the anion of 95 (which was verified by quenching of the reaction and 
isolation of 95), before addition of aldehyde 75 (Scheme 3.41).  
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Scheme 3.41. One-pot domino cyclisation-HWE olefination. Reagents and conditions: (a) (i) 
t
BuOK (1.1 eq.), THF, 0 C, 40 
min. (ii) 75, THF, 0 C  r.t., 16 h, 85%.  
 
Excess tBuOK has been used previously in related reactions to form the required enolate to undergo 
the HWE reaction. However in this case, the tertiary alkoxide 95a formed from the cyclisation step 
should abstract a proton from the methylene, α to the phosphonate, thus forming the extended 
enolate 97 required for the HWE reaction. Further optimisation of this reaction guided by these 
mechanistic insights revealed that, as predicted, only 1.1 equivalents of tBuOK was required to 
promote this one-pot process (Scheme 3.41). The desired product 65 was isolated in excellent yield 
(85%). This efficient and convergent route provided the IMDA precursor 65 in only 6 steps (LLS) from 
ethyl pyruvate (36). In addition, a simple hydrolysis of 65 could provide a novel harzianic acid (19) 
analogue. 
 
3.5.7 Investigation of the biosynthetic Diels-Alder cycloaddition 
The isolation of the natural product JBIR-22 (4) as an apparent single diastereomer123 would suggest 
that the trans-decalin ring was formed in a stereocontrolled manner, either in a non-enzymatic 
substrate-directed process or by the chiral binding site of a “Diels-Alderase”. As JBIR-22 (4) does not 
contain a stereogenic center on its polyketide chain, a non-enzyme directed biosynthetic pathway 
(Scheme 3.42, Route A) would require the incorporation of the chiral glutamic acid prior to a 
substrate-controlled IMDA cycloaddition.  
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Scheme 3.42. Proposed JBIR-22 (4) biosynthetic pathways. Route A: Substrate-controlled diastereoselective IMDA of 65. 
Route B: “Diels-Alderase” mediated asymmetric IMDA of hexaketide 98 to generate the decalin ring 99; (ACP = Acyl Carrier 
Protein).  
 
An alternative “Diels-Alderase” mediated pathway (Scheme 3.42, Route B) would involve an enzyme-
influenced asymmetric IMDA of the JBIR-22 hexaketide 98 prior to incorporation of the glutamic acid 
in an analogous manner to that proposed for the biosynthesis of lovastatin (16) and equisetin (10) 
(see Section 3.1.5). 
 
The synthesis of the IMDA precursor 65 provided a useful tool to investigate the viability of a 
substrate-controlled DA reaction in the biosynthesis of JBIR-22 (4). The experiment involved 
investigating, if 65 in the presence of an achiral Lewis acid (BF3.OEt2) could 1.) form the decalin ring 
of JBIR-22 (4) and 2.) if the glutamic acid side chain had a directing effect on the IMDA, promoting 
the formation of a single diastereomer of JBIR-22 (4). This DA reaction proceeded smoothly to form 
the trans-decalin ring; however analysis of the 1H and 13C NMR spectra of the product in comparison 
with those of the JBIR-22 ethyl ester mixture 77a/b and the single diastereomers of JBIR-22 ethyl 
ester, 77a and 77b revealed that there was no significant asymmetric induction, resulting in a 1:1 
mixture of the two diastereomers, 77a and 77b (Scheme 3.43 and Appendix J for spectra). The lack 
of stereocontrol observed in this reaction would suggest that a substrate controlled biosynthetic 
pathway is unlikely. Based on this, it is likely that JBIR-22 (4) is biosynthesised in an analogous 
manner to that proposed for lovastatin (16) and equisetin (10), i.e. it involves an asymmetric IMDA 
early in the biosynthesis where the stereochemical outcome is influenced by an enzyme involved in 
the biosynthetic pathway.   
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Scheme 3.43. Achiral Lewis acid catalysed IMDA cycloaddition of 65. Reagents and condtions: (a) BF3.Et2O, DCM, -78 C  
0 C, 6 h; 77a:77b (1:1). 
 
As no stereoinduction was observed during the formation of the decalin ring in the presence of the 
achiral Lewis acid, BF3.OEt2, the identification of a chiral catalyst which would catalyse the formation 
of a single diastereomer of JBIR-22 (4) was required.  
 
3.5.8 Development of a late-stage diastereoselective IMDA on 65 
Extensive research has resulted in the development of numerous catalytic, asymmetric 
intermolecular DA reactions.225,241,242 However, this is in stark contrast to its intramolecular 
counterpart of which there are relative few examples in the literature. In particular, the abundance 
of substrate-controlled diastereoselective IMDAs in total synthesis243 has resulted in a dearth of 
IMDA reactions for which a chiral catalyst is used to control the stereochemical outcome of the 
cycloaddition of advanced natural product intermediates. Previous research has focused nearly 
exclusively on the identification of catalytic, asymmetric conditions for the selective intramolecular 
cycloaddition of simple trienal substrates which could be elaborated to access natural products. This 
approach is epitomised by the successful application of MacMillan’s organocatalyst in the 
asymmetric synthesis of the key precursors in the total synthesis of (+)-UCS1025A (79),220 
solanapyrone D (80),221 amaminol A (84)226 and B227 and our 1st total synthesis of JBIR-22 (4a). 
Yamamoto and coworkers reported one of the first successful applications of a chiral Lewis acid to 
catalyse an asymmetric IMDA reaction.244 Treatment of trienal 100 with a single-point binding chiral 
acyloxyborane (CAB) catalyst 101 produced the [4.3.0]-bicyclic IMDA product 102 in good yields and 
high diastereo- and enantiocontrol (Scheme 3.44). However, this system was not applicable to 
trienal substrates lacking an α-substituent, resulting in significantly reduced enantiocontrol.  
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Scheme 3.44. Single-point binding acyloxyborane 101 catalysed asymmetric IMDA cycloaddition. Reagents and 
conditions: 10 mol% 101, DCM, -40 C, 84%, dr 99:1. 
 
An alternative strategy is the use of two-point catalysts which bind to bidentate dienophiles. The 
bidentate nature of the coordinating dienophile facilitates a stronger complexation with the Lewis 
acid and increased activation of the dienophile. This chelation assists the formation of a stable pre-
transition-state complex which creates a steric environment surrounding the dienophile, thus 
controlling the facial approach of the diene.  
 
 
Scheme 3.45. Asymmetric IMDA cycloadditions catalysed by two-point binding Lewis acid catalysts (A) 105 and (B) 106. 
Reagents and conditions: (a) 30 mol% 105, 4Å molecular sieves, DCM, 25 C, 10 days, 87%, dr >99:1. (b) 10 mol% 106, DCM, 
25 C, 14 hours, 97%, dr >99:1. 
 
Narasaka et al. reported the asymmetric IMDA cycloaddition of acyl oxazolidinone 103 in the 
presence of a Ti-TADDOL catalyst 105, although high catalyst loadings and extended reaction times 
were necessary (Scheme 3.45).245 Evans reported the successful application of the widely used 
intermolecular DA cationic C2-symmetric Cu(II)-tert-butyl-bis(oxazoline) catalyst 106 in the 
asymmetric IMDA cycloaddition of trienal 107 to furnish the [4.4.0]-bicyclic IMDA product 108 
(Scheme 3.45).246,247 This was subsequently applied to form a key precursor en route to the natural 
product (-)-isopulo’upone.247 
 
(A) 
(B) 
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The main and significant disadvantage of this method is the required incorporation and cleavage of 
the oxazolidinone auxiliary. However, when designing this synthetic approach we proposed that the 
1,3-dicarbonyl functionality present in the tetramic acid core of the IMDA precursor 65 could 
potentially act as a bidentate dienophile (Figure 3.15A). The inherent chelating effect of this moiety 
(Section 3.1.4) provides a synthetic advantage, potentially forming a strong coordination complex 
with the chiral catalyst. To test this hypothesis we carried out a preliminary screen of three chiral 
Lewis acid catalysts; 1.) single-point binding chiral oxazaborolidine 109, 2.) two-point binding chiral 
bisoxazoline 110, and 3.) two-point binding bis(sulfinyl)imidoamidine (siam) catalyst 111 (Figure 
3.15B). 
 
 
Figure 3.15. (A) Proposed bidentate coordination of IMDA precursor 65 to the two-point binding Lewis acid catalyst 110. 
(B) Structures of the three selected chiral Lewis acid catalysts.  
 
Corey and coworkers reported the first examples of (S)-tryptophan-derived chiral oxazaborolidine 
catalysed enantioselective intermolecular Diels-Alder reactions.248 The pre-transition-state assembly 
is proposed to be formed by one-point coordination of an enal with the boron atom in 109, 
orientating the dienophile to form a - interaction with the -electron-donating tryptophan indole 
ring, which in turn sterically shields one face of the dienophile from attack by the diene.242 Chiral 
oxazaborolidine 109 was synthesised from L-tryptophan 112 as described by Simsek et al. (Scheme 
3.46).249  
(B) (A) 
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Scheme 3.46. Synthesis of chiral oxazaborolidine 109.
249
 Reagents and conditions: (a) p-Toluenesulfonyl chloride, H2O/THF 
(9:1), Et3N, 0 C  r.t., 2.5 h, 87%. (b) Dichlorophenylborane, DCM, r.t., 1 h. 
 
Evans and coworkers pioneered the use of chiral C2-symmetric bisoxazoline-copper(II) complexes to 
catalyse enantioselective DA reactions.246,250,251 This chiral copper(II) complex has been used 
extensively to catalyse highly diastereoselective and enantioselective DA reactions, including the 
IMDA cycloaddition of 107 (Scheme 3.45), via a rigid square-planar transition state.252 Commercially 
available 2,2’-isopropylidenebis-[(4S)-4-tert-butyl-2-oxazoline] was stirred with CuCl2 and AgSbF6 in 
DCM for 12 hours to provide a dark blue solution of bis(oxazoline)-copper(II) catalyst 110.247 The C2-
symmetric bis(sulfinyl)imidoamidine (siam) ligands were developed by Ellman and coworkers as 
novel catalysts for enantioselective Diels-Alder reactions.253,254 It was envisioned that the sulfinyl 
nitrogens of the siam ligand 111 would coordinate to copper(II) in accordance with the mechanism 
proposed by the Evans group for the that Cu(II)-bisoxazoline complex 110 (Figure 3.15). However, 
although the pre-transition-state assembly has not been fully deduced, it appears the Cu(II) 
predominantly coordinates the sulfinyl oxygens of 111 in solution. The siam ligand 111 was 
synthesised by a modular route which was adapted from Ellman’s original reported synthesis 
(Scheme 3.47).253,254  
 
 
Scheme 3.47. Synthesis of siam ligand 111. Reagents and conditions: (a) Triethyl orthoformate, p-toluenesulfonic acid, 120 
C, 3 h, 97%. (b) MeNH2 (8.0M in EtOH), r.t., 16 h, 82%. (c) KHMDS, 114, THF, 0 C  r.t., 16 h, 71%. 
 
A preliminary screen of the 3 chiral catalysts involved stirring with IMDA precursor 65 in DCM at -78 
C followed by slowly warming to room temperature over 16 hours (Figure 3.16A). The reaction 
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diastereoselectivity was monitored by analysis of the chemical shift of one of the H6’ diastereotopic 
protons of the JBIR-22 ethyl ester 77 which appears as overlapping doublet of doublets in 77a/b (1:1 
mixture of 77a & 77b) compared to a single doublet of doublets in the single JBIR-22 ethyl ester 
diastereomers 77a and 77b (Figure 3.16B). As expected, the one-point binding oxazaborolidine 109 
resulted in poor conversion to the desired cycloadduct with no significant diastereoselectivity 
observed by 1H NMR (data not shown). However, both of the bidentate catalysts 110 and 111 
catalysed the IMDA cycloaddition, forming the decalin ring with excellent diastereoselectivity (endo) 
and moderate enantioselectivity, to yield a mixture which was diastereomerically enriched in 77a 
(Figure 3.16B). Furthermore, similarly to the organocatalytic cycloaddition of 69 (section 3.5.3), the 
minor E,Z,E-isomer of 65 was inert to this catalytic IMDA, resulting in kinetic purification of the IMDA 
precursor. 
             
Figure 3.16. (A) Initial test conditions for the chiral Lewis acid catalysed IMDA. Reagents and conditions: (a) Appropriate 
chiral catalyst (110/111), DCM, -78 C  r.t., 16 h. (B) Stacked magnification of the H6’ peak region in the 
1
H spectra of 
77a/b (top), the product of the siam 111 catalysed IMDA, the product of the bisoxazoline 110 catalysed IMDA and 77a 
(bottom).  
 
The siam ligand 111 catalysed the preferred formation of a the decalin ring containing the (2S, 3S, 
6R, 11S) stereochemistry, to afford diastereomer 77a as the main stereoisomer, which is in 
agreement with the expected stereochemical outcome of a DA reaction using a (SS)-
tertbutanesulfinamide 38 derived siam ligand based on the current literature.253,254 As the reaction 
had gone to completion under the initial test conditions, identification of the optimal temperature 
for this reaction could improve the observed diastereoselectivity. The reaction was repeated, 
maintaining the temperature at -78 C for 12 hours before warming the reaction to room 
temperature over 12 hours. No further significant enrichment of diastereomer 77a was observed 
(data not shown), suggesting either this is not a temperature sensitive process, or the reaction is 
(A) (B) 
77a/b 
111 
110 
77a 
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only occurring on warming to room temperature, therefore requiring further experiments at fixed 
temperatures between -78 C and room temperature to identify the optimal conditions. 
 
Analysis of the bisoxazoline-copper(II) 110 catalysed IMDA reaction highlighted two striking 
observations. It was observed that the cycloaddition had not gone to completion within the reaction 
time, indicating that this is a slower reaction and likely only occurs at temperatures higher than -78 
C. Therefore, identifying the optimal temperature for this reaction could be essential to optimising 
the diastereoselectivity. To assess this, the reaction was allowed to warm slowly from -78 C to -5 C 
over 5 hours, followed by stirring at this temperature for 16 hours. Full conversion to the desired 
cycloadduct was observed under these conditions with an apparent moderate enhancement in 
stereocontrol of the reaction as observed by 1H NMR analysis of the crude product when compared 
to the initial conditions (data not shown). However, it was difficult to quantify the level of 
improvement due to the overlapping and sloping nature of the observed signals for the H6’ proton. 
Therefore, monitoring the stereoselectivity of this IMDA reaction by 1H NMR is not optimal for 
conditions which give apparent high levels of diastereoselectivity. As a result, a chiral HPLC method 
(as no separation was achieved using standard reverse-phase HPLC methods) is currently being 
developed which will be used to analyse this IMDA reaction. As the reaction went to completion at -
5 C, a screen of temperatures between -78 C and -5 C should identify the conditions which result 
in the optimal conversion and stereoselectivity.  
 
The second and most significant observation was the isolation of diastereomer 77a as the major 
product. Based on the existing literature, the (2R, 3R, 6S, 11R)-decalin ring is the predicted 
stereochemical outcome of a (S)- bisoxazoline 110 catalysed IMDA reaction as observed in the 
cycloaddition of 107 to 108 (Scheme 3.45),255 which would result in diastereomer 77b as the major 
product. The observed switch in stereoinduction could provide key insights into the pre-transition-
state assembly of the IMDA precursor 65-catalyst 110 complex. The expected stereochemical 
outcome (2R, 3R, 6S, 11R) is based on a model involving bidentate coordination of the dienophile to 
form a distorted square planar copper center, resulting in the diene approaching from the α-Re face 
(Figure 3.17A).250 This model is supported by mechanistic investigations and X-ray and computational 
structures of the relevant models.246,255 However, the opposite sense of stereoinduction can be 
achieved by using Mg(II)- or Zn(II)- bisoxazoline complexes through the preferential formation of a 
tetrahedral pre-transition-state assembly which directs the diene to approach from the α-Si face 
(Figure 3.17B).256,251 This model would predict the formation of the (2S, 3S, 6R, 11S)-isomer of the 
decalin ring, providing diastereomer 77a as the major product, which is in agreement with the 
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experimental observation. This possible switch from a distorted square planar to a tetrahedral pre-
transition-state complex257 could be due to a steric clash between the glutamic acid side chain of 65 
and the bisoxazoline ligand 110. Although C3’-acyltetramic acids are known to coordinate 
preferentially metals between the C3’-acyl group and the C2’-amide oxygen (Section 3.1.4), this 
complex could potentially be in equilibrium in solution with a minor coordination complex involving 
the C3’-acyl group and the C4’-ketone oxygen. This alternative coordination complex would be 
particularly sterically encumbered (Figure 3.17A).  
 
 
 
Figure 3.17. (A) Distorted square-planar pre-transition-state assembly formed using a bis(oxazoline)-Cu(II) catalyst. This 
assembly favours attack of the diene from the α-Re face to preferentially form diastereomer 77b. Two possible 
coordination modes of IMDA precursor 65 to the bisoxazoline-Cu(II) catalyst 110. (B) Alternative tetrahedral pre-
transition-state assembly. This assembly may be favoured due to reduced steric interference between IMDA precursor 65 
and the bisoxazoline-Cu(II) catalyst 110. Attack of the diene would occur from the α-Si face to preferentially form 
diastereomer 77a. R = C9H15. 
 
This bisoxazoline-catalysed reaction could potentially be optimised by two alternative approaches. 
Switching from the (S)-bisoxazoline ligand 110 to its (R)-enantiomer may result in no steric 
interference, facilitating the formation of the distorted square-planer pre-transition-state, which 
would be predicted to provide the diastereomer 77a as the major product. However, an alternative 
and potentially more beneficial approach would involve optimising the reaction conditions to 
promote a tetrahedral pre-transition-state, which should improve the enantioselectivity of the 
cycloaddition by reducing any competing formation of the opposite enantiomer via the square-
planar assembly. This could be potentially achieved by changing the Lewis acid to Mg(II)242,256 or 
Zn(II)251 and/or utilising a phenyl-substituted bisoxazoline246,251 in place of the tert-butyl-substituted 
bisoxazoline 110.  
  
(A) (B) 
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3.6 Conclusions & Future Work 
Over the past century nature has provided a rich source of novel bioactive agents which have been 
developed into efficacious drugs for a multitude of disease indications. Innovative technological 
advances have provided biochemical techniques by which to screen nature’s tremendous supply of 
bioactive agents in the hunt for novel PPI modulators. Although still in its infancy, this approach has 
identified several promising therapeutic candidates, particularly in the area of cancer research.  
 
This approach is exemplified by the discovery of JBIR-22 (4), a 0.2 µM inhibitor of PAC3 
homodimerisation identified from a screen of 123,599 natural product extracts via a high-
throughput in vitro protein fragment complementation assay (PCA). JBIR-22 (4) is a novel member of 
the tetramic acid family of natural products, a ubiquitous collection of bioactive agents containing a 
pyrrolidine-2,4-dione core motif. In particular, JBIR-22 (4) forms part of a small sub-family of 
tetramic acids defined by a tetramic acid core containing an unnatural 4,4-disubstituted glutamic 
acid. The absence of a reported total synthesis targeting members of this sub-family is in sharp 
contrast to their potent activity against therapeutically relevant targets involved in HIV, cancer and 
microbial pathogenesis.  
 
3.6.1 Harzianic acid – a novel siderophoric plant growth promoting agent 
We proposed a general synthetic approach to access the members of this tetramic acid sub-family 
centred on the development of a masked tetramic acid core which could be modified by the 
attachment of the broad range of substituents to optimise diversity. A late stage manipulation would 
then reveal the synthetically challenging tetramic acid moiety. Central to this concept was the design 
of a short and stereoselective synthesis of 4,4-disubstituted glutamic acids which on cyclisation 
would provide our AHL biomimetic masked tetramic acid. This was achieved in a three step process 
involving a diastereoselective tert-butanesulfinamide 38 directed aldol cyclisation followed by an in 
situ cyclisation to furnish lactone 46. N-methylation of 46 followed by a highly diastereoselective 
substrate controlled reduction provided the free amine 53 which could be trapped by the 
appropriate β-ketothioester side chain. To validate this approach as a comprehensive and general 
protocol to access these tetramic acids we initially focused on the total synthesis of plant growth 
promoting siderophore harzianic acid (19).  
 
The polyene side chain of harzianic acid (19) was assembled from commerically available trans-
hexan-2-ol (59) via oxidation to the corresponding aldehyde 58 and subsequent incorporation of the 
β-ketothioester functionality by means of a HWE olefination. Optimisation of the silver mediated N-
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acylation protocol developed by Woodward and Ley facilitated the one-pot coupling of 53 and β-
ketothioester 56 followed by subsequent cyclisation to afford harzianic acid ethyl ester 64. 
Microwave assisted hydrolysis of 64 furnished (S,S)-harzianic acid (19) in a separable 3:1 ratio to 
(R,S)-5’-epiharzianic acid (19b). This stereoselective and convergent route facilitated the first total 
synthesis of harzianic acid (19) with a LLS of 6 steps and an overall yield of 22% (Scheme 3.48).  
 
 
Scheme 3.48. First total synthesis of harzianic acid (19). 
 
The efficacy of this synthetic approach is illustrated by the isolation of all four possible 
diastereomers of harzianic acid (19). These compounds could prove to be highly valuable tools for 
the investigation of harzianic acid’s anticancer and plant growth promoting activities. In particular, 
exploration of harzianic acid’s potent siderophoric properties could be vital to unravelling its mode 
of action. Comparison of the iron binding affinity of (R,S)-5’-epiharzianic acid (19b) and its biological 
activities, could provide a mechanism by which to explore the proposed correlation between 
harzianic acid’s iron binding properties and its antifungal and growth promoting functions. Analysis 
of the biological activity of the harzianic acid enantiomer (19c) could reveal the possibility of a 
chirally discriminating uptake mechanism or an alternative biological target by which harzianic acid 
(19) affects its physiological response.  
 
3.6.2 Identification of JBIR-22’s PAC3 binding site 
Synthesis of PPI inhibitor JBIR-22 (4) was investigated through two approaches, which were 
distinguished by the method and stage at which the IMDA cycloaddition to form the decalin ring of 
JBIR-22 (4) occurred. The first approach involved formation of the tetramic acid core with the 
attached polyene chain, prior to the IMDA cycloaddition. The second route involved an IMDA 
cycloaddition of trienal 69 to furnish the decalin ring, prior to its attachment to the masked tetramic 
acid core. As the absolute configuration of JBIR-22 (4) had not been elucidated, the second route 
was initially prioritised so the stereochemical configuration of the products could be unambiguously 
assigned.  
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Schreiber ozonolysis of cyclohexene (72), followed by a HWE olefination and acetal deprotection 
furnished trienal 75. A subsequent chiral imidazolidinone 85 catalysed IMDA cycloaddition afforded 
the enantiomerically enriched decalins 78a and 78b. Incorporation of S-tert-butyl-thioacetate  
provided the desired β-ketothioesters 68a and 68b which were coupled to 53 via the end-game 
strategy utilised in the synthesis of harzianic acid (19). Comparison of spectroscopic data of the pure 
JBIR-22 diastereomers 4a and 4b with that reported for the isolated JBIR-22 (4) revealed that 4a 
contains the correct relative stereochemical configuration. Significant discrepancies between the 
reported optical rotation value for JBIR-22 (4) and the synthesised sample 4a prevented absolute 
stereochemical assignment of the natural product. Chiral HPLC or CD analysis of a sample of natural 
JBIR-22 (4) sample in comparison with that of 4a should enable absolute stereochemical assignment. 
In summary, this expedient approach facilitated the first total synthesis of JBIR-22 diastereomers 4a 
and 4b with a LLS of 10 steps and of overall yield for 4a of 6% (Scheme 3.49). 
 
Scheme 3.49. First total synthesis of JBIR-22 (4a). 
 
The succinct and adaptable nature of the JBIR-22 (4a) synthetic route provides ample opportunity to 
explore and optimise the activity of this potent PAC3 PPI inhibitor. A particular area of interest is the 
proposed JBIR-22 binding site. A docking study reported by Izumikawa et al. identified a potential 
binding site for (2R, 3R, 6S, 11R, 5’R, 7’R)-JBIR-22 diastereomer 4d on the PAC3 homodimerisation 
interface (Figure 3.18).123 We have identified an alternative binding site on the PAC3 
homodimerisation interface using the docking software GOLD (data not shown). Analysis of the 
biological activity of the JBIR-22 diastereomers in comparison to their proposed binding site may 
reveal which site is most likely, and facilitate the optimisation of these compounds through a SAR 
study. Furthermore, it would provide a novel drug binding site for the development of future 
inhibitors of the proteasomal machinery, a validated anticancer target. 
Chapter 3: Natural Products 
 
120 
 
   
Figure 3.18. (A) The proposed JBIR-22 binding site on the PAC3 homodimerisation interface.
123
 PAC3 is shown as cartoon 
surface model with key residues shown in ball and stick model. Carbon atoms are in green. 4d is shown as ball and stick 
and carbon atoms are in cyan. In all cases, oxygen atoms are in red and nitrogen atoms in blue. (B) Structure of bound 
JBIR-22 diastereomer 4d. 
 
3.6.3 Probing JBIR-22’s biosynthetic pathway and the role of a “Diels-Alderase” 
The synthesis of the JBIR-22 diastereomers 4a and 4b provided pure standards for the development 
of the late-stage asymmetric IMDA approach. The IMDA precursor 65 was assembled by means of 
two alternative routes. The initial approach proceeded via a coupling of 53 and the appropriate β-
ketothioester 66, followed by subsequent cyclisation to afford 65. In contrast, the alternative 
approach aimed to circumvent the silver mediated N-acylation by incorporating the polyene side 
chain via a HWE olefination. This was achieved by N-acylation of amine 53 by the novel Meldrum’s 
acid derivative 63 to afford the phosphonate substituted masked tetramic acid 96. A tandem one-
pot cyclisation-HWE olefination furnished the desired IMDA precursor 65.  
 
IMDA precursor 65 proved to be a very synthetically useful chemical tool, both for the development 
of an asymmetric IMDA methodology but also as a mechanism to probe the biosynthesis of JBIR-22 
(4). JBIR-22 (4) contains a chiral decalin ring similar to that observed in lovastatin (16), equisetin (10) 
and solanapyrone A (15), which are proposed to be formed by a controversial enzyme-mediated 
enantioselective [4+2]-cycloaddition. An alternative biosynthesis of the decalin ring of JBIR-22 (4) 
could involve a non-enzymatic substrate controlled IMDA. To probe this hypothesis, an achiral Lewis 
acid catalysed cycloaddition of 65 was investigated. This resulted in the formation of the decalin ring 
as a single diastereomer but as a racemic mixture, thus forming an approximately 1:1 mixture of 
JBIR-22 ethyl ester diastereomers 77a and 77b. This would suggest that JBIR-22 (4) is formed by a 
similar biosynthetic pathway to that reported for equisetin (10), involving a “Diels-Alderase” 
mediated enantioselective IMDA.  
(A) (B) 
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3.6.4 Development of a catalytic asymmetric IMDA protocol 
Preliminary investigation of a chiral Lewis acid catalysed IMDA cycloaddition of 65, focused on 
exploiting the inherent chelating properties of the tetramic acid core. It was proposed that the 1,3-
dicarbonyl motif present in the tetramic acid core of 65 could potentially function as a bidentate 
dienophile. An initial screen identified that two-point binding Cu(II) complexes involving a 
bisoxazoline 110 or siam ligand 111 catalysed the cycloaddition in high diastereoselectivity and 
moderate enantioselectivity, affording the diastereomerically enriched 77a cycloadduct (Scheme 
3.50). Further insight into the pre-transition state assembly of the catalyst-65 complex may prove to 
be essential for optimising the diastereoselectivity. Information regarding the effect of the steric 
environment surrounding the bidentate dienophile on the stereoselectivity of the cycloaddition is 
limited due to the scarcity of reported IMDA cycloadditions of advanced natural product 
intermediates. This is compounded by the widespread use of simple oxazolidinone precursors as 
bidentate dienophiles for the development of catalytic asymmetric IMDA procedures. Therefore, the 
future optimisation of the catalytic asymmetric IMDA cycloaddition of 65, in addition to providing a 
concise and highly versatile route to JBIR-22 (4a) and related analogues, would also assist the 
development of a more general and comprehensive method for the utilisation of catalytic IMDA 
cycloadditions in the later stages of total synthesis projects.   
 
 
Scheme 3.50. Proposed late stage catalytic asymmetric IMDA cycloaddition. 
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3.7 Experimental section 
 
3.7.1 General considerations 
 
See Section 2.8.1 for general considerations. 
 
GC analyses were obtained on a Shimadzu GC consisting of a Shimadzu AOC-20i auto injector and a 
Shimadzu GC-2025 gas chromatograph. Analysis was performed using Shimadzu GCsolution v2.41 
software and separation was achieved using an Agilent Cyclosil-B column.  
 
3.7.2 Experimental procedures 
 
Ethyl (R,E)-2-((tert-butylsulfinyl)imino)propanoate (42)197 
 
Ethyl pyruvate 36 (4.3 g, 37.1 mmol, 1.5 eq.) was added to a stirred solution of (R)-(+)-2-methyl-2-
propanesulfinamide 38 (3.0 g, 24.8 mmol, 1.0 eq.) and Ti(OEt)4 (8.5 g, 37.1 mmol, 1.5 eq.) in THF 
(100 mL) at reflux. The reaction was stirred at the same temperature for 3 hours before cooling to 
room temperature. The crude reaction mixture was poured into brine (100 mL) whilst being 
vigorously stirred. The resulting suspension was filtered through Celite, and the filter cake was 
washed with EtOAc (2  30 mL). The filtrate was washed with brine (30 mL), and the brine layer was 
back extracted with EtOAc (3  30 mL). The combined organic extracts were dried over MgSO4, 
filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 180 g; 
10-50% EtOAc/hexanes) to give the title product 42 as a pale yellow oil (2.5 g, 45%) and the enamine 
tautomer as a pale yellow oil (0.8 g, 15%). 42 was isolated in a 3:1 ratio (by analysis of the crude 
NMR spectrum) to lactone 43 (1.1 g). The NMR analysis of the imine tautomer of 42 was complicated 
by the existence of rotamers. 1H NMR (500 MHz, Chloroform-d) δ(major imine-form) 4.50 – 3.96 (m, 
2H, C4-H2), 2.46 (d, J = 120.8 Hz, 3H, C1-H3), 1.37 – 1.32 (m, 3H, C5-H3), 1.27 (d, J = 27.6 Hz, 9H, 
(CH3)3); 
13C NMR (126 MHz, Chloroform-d) δ(major imine-form) 167.8 (C3), 163.6 (C2), 62.4 (d, J = 
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42.6 Hz, C4), 59.4 (C(CH3)3), 25.4 (C1), 22.8 (d, J = 37.8 Hz, (CH3)3), 18.5 (C1), 14.1 (d, J = 14.9 Hz, C5); 
1H NMR (500 MHz, Chloroform-d) δ(minor enamine-form) 5.95 (s, 1H, NH), 5.50 (t, J = 1.6 Hz, 1H, C1-
H2), 5.23 (d, J = 1.6 Hz, 1H, C1-H2), 4.28 (q, J = 7.1, 2H, C4-H2), 1.33 (t, J = 7.1 Hz, 3H, C5-H3), 1.28 (s, 
9H, (CH3)3);
 13C NMR (126 MHz, Chloroform-d) δ(minor enamine-form) 164.0 (C3), 136.2 (C2), 100.7 
(C1), 62.4 (C4), 56.7 (C(CH3)3), 22.4 (CH3)3), 14.3 (C5); m/z (ES
+) 220.10 ([M+H]+, 100 %); HRMS (ES+) 
Calcd for C9H18NO3S [M+H]
+: 220.1002, found 220.0999; * +D
2  = -121.8 (c 1.15, CHCl3). (lit. -125.8).
197 
Spectroscopic data are in accordance with the literature.197 
 
Ethyl (R)-4-(((R)-tert-butylsulfinyl)amino)-2-methyl-5-oxo-2,5-dihydrofuran-2-carboxylate (43) 
In CDCl3 at room temperature the title compound 43 exists as a mixture of rotamers. IR (KBr) ν max: 
2978 (NH), 1769 (C=O), 1748 (C=O), 1651, 1458, 1248, 1126, 1063; 1H NMR (500 MHz, Chloroform-d) 
δ 6.42 (d, J = 2.1 Hz, 1H, C3-H), 5.74 (d, J = 4.6 Hz, 1H, NH), 4.22 (qt, J = 7.1, 1.8 Hz, 2H, C3’’-H2), 1.72 
(d, J = 7.3 Hz, 3H, C1’-H3), 1.29 (s, 9H, (CH3)3), 1.30 – 1.26 (m, 3H, C4’’-H3); 
13C NMR (126 MHz, 
Chloroform-d) δ 168.5 (d, J = 15.8 Hz, CO), 168.0 (C5), 131.1 (d, J = 4.1 Hz, C4), 120.3 (d, J = 11.9 Hz, 
C3), 84.7 (d, J = 7.0 Hz, C2), 62.6 (d, J = 15.4 Hz, C3’’), 57.6 (d, J = 13.0 Hz, C(CH3)3), 22.9 (d, J = 6.6 Hz, 
C1’), 22.1 ((CH3)3), 14.0 (C4’’); m/z (ES
+) 312.09 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C12H19NO5SNa 
[M+Na]+: 312.0876, found 312.0869. * +D
2  = -52.9 (c 1.0, MeOH). 
 
Ethyl (R)-4-(((R)-tert-butylsulfinyl)amino)-2-isopropyl-5-oxo-2,5-dihydrofuran-2-carboxylate (46) 
 
To a solution of i-Pr2NH (1.68 mL, 12.0 mmol, 1.2 eq.) in THF (50 mL) was added n-BuLi (5.1 mL, 2.2 
M in hexanes, 1.1 eq.) at 0 C and the mixture was stirred for 30 minutes. The solution was then 
cooled to -78 C and 42 (2.20 g, 10.0 mmol, 1.0 eq.) was added. The reaction was stirred for a further 
30 minutes at this temperature before the addition of ZnBr2 (4.50 g, 20.0 mmol, 2.0 eq.), followed by 
ethyl dimethylpyruvate 37 (1.87 g, 13.0 mmol, 1.3 eq.). The reaction was then stirred for 3 hours at -
78 C before the addition of a saturated solution of NH4Cl (30 mL). The reaction was allowed to 
slowly warm to room temperature. The mixture was extracted with EtOAc (3  30 mL) and the 
organic layers combined and washed with brine (30 mL), dried over MgSO4, filtered, concentrated in 
vacuo and purified via the Biotage SP4 (silica-packed SNAP column 120 g; 20-60% EtOAc/hexanes) to 
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give the title product 46 as a white solid (2.80 g, 88%). mp 77-79 °C; IR (KBr) ν max: 2965 (NH), 1775 
(C=O), 1714 (C=O), 1647, 1366, 1236, 1103, 1051, 1018; 1H NMR (500 MHz, Chloroform-d) δ 6.37 (s, 
1H, C3-H), 5.71 (s, 1H, NH), 4.24 (q, J = 7.1 Hz, 2H, C3’’-H2), 2.46 (hept, J = 6.9 Hz, 1H, C1’-H), 1.34 – 
1.21 (m, 12H, (CH3)3, C4’’-H3), 1.04 (d, J = 6.9 Hz, 3H, C2’-H3), 0.89 (d, J = 6.9 Hz, 3H, C2’-H3);
 13C NMR 
(126 MHz, Chloroform-d) δ 168.5 (CO), 168.3 (C5), 131.3 (C4), 119.2 (C3), 90.7 (C2), 62.5 (C3’’), 57.6 
(C(CH3)3), 34.2 (C1’), 22.2 ((CH3)3), 17.4 (C2’), 15.8 (C2’), 14.3 (C4’’); m/z (ES
+) 318.14 ([M+H]+, 100 %); 
HRMS (ES+) Calcd for C14H24NO5S [M+H]
+: 318.1370, found 318.1366; * +D
2  = +24.1 (c 1.0, MeOH). 
 
Ethyl (R)-4-(((R)-tert-butylsulfinyl)(methyl)amino)-2-isopropyl-5-oxo-2,5-dihydrofuran-2-
carboxylate (52) 
 
To a solution of 46 (0.98 g, 3.09 mmol, 1.0 eq.) in DMF (12 mL) at -15 C was added LiHMDS (3.09 
mL, 1 M in THF, 1.0 eq.) dropwise and the reaction was stirred for 40 minutes. Iodomethane (0.38 
mL, 6.18 mmol, 2.0 eq.) was then added and the reaction was allowed to slowly warm to room 
temperature before stirring at this temperature for 2 hours. The reaction was diluted with H2O (15 
mL) before being extracted with EtOAc (3  20 mL). The organic layers were combined and washed 
with Na2S2O3 (20 mL), brine (20 mL), dried over MgSO4, filtered, concentrated in vacuo and purified 
via the Biotage SP4 (silica-packed SNAP column 40 g; 0-30% EtOAc/hexanes) to give the title product 
52 as a white solid (0.97 g, 95%). mp 70-72 °C; IR (KBr) ν max: 2970, 1763 (C=O), 1738 (C=O), 1622, 
1248, 1198, 1092, 1038, 1005; 1H NMR (500 MHz, Chloroform-d) δ 6.21 (s, 1H, C3-H), 4.31 – 4.10 (m, 
2H, C3’’-H2), 2.94 (s, 3H, NCH3), 2.45 (hept, J = 6.9 Hz, 1H, C1’-H), 1.29 (t, J = 7.1 Hz, 3H, C4’’-H3), 1.25 
(s, 9H, (CH3)3), 1.03 (d, J = 6.9 Hz, 3H, C2’-H3), 0.86 (d, J = 6.9 Hz, 3H, C2’-H3);
 13C NMR (126 MHz, 
Chloroform-d) δ 168.7 (CO), 166.9 (C5), 137.0 (C4), 122.7 (C3), 89.3 (C2), 62.5 (C3’’), 60.8 (C(CH3)3), 
34.2 (C1’), 29.3 (NCH3), 23.4 ((CH3)3), 17.3 (C2’), 15.7 (C2’), 14.3 (C4’’); m/z (ES
+) 332.15 ([M+H]+, 100 
%); HRMS (ES+) Calcd for C15H26NO5S [M+H]
+: 332.1526, found 332.1521; * +D
2  = +229.5 (c 1.0, 
MeOH). 
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(E)-Hex-2-enal (58)258 
 
trans-2-Hexen-1-ol 59 (1.0 g, 9.98 mmol, 1.0 eq.) was added to a suspension of DDQ (2.72 g, 12.0 
mmol, 1.2 eq.) in DCM (50 mL) and the reaction was stirred at room temperature for 16 h. The 
reaction was diluted with DCM (20 mL) and washed with NaHCO3 (3  30 mL), Na2S2O4 (3  30 mL) 
and brine (30 mL). The organic layer was separated and filtered through a plug of Celite. The filtrate 
was concentrated in vacuo to yield the title product 58 as a pale yellow liquid (0.97 g, 99%) which 
was used in the next step without further purification. 1H NMR (500 MHz, Chloroform-d) δ 9.50 (d, J 
= 7.9 Hz, 1H, C1-H), 6.85 (dt, J = 15.6, 6.8 Hz, 1H, C3-H), 6.11 (ddt, J = 15.6, 7.9, 1.5 Hz, 1H, C2-H), 
2.37 – 2.26 (m, 2H, C4-H2), 1.54 (h, J = 7.4 Hz, 2H, C5-H2), 0.96 (t, J = 7.4 Hz, 3H, C5-H3);
 13C NMR (126 
MHz, Chloroform-d) δ 194.3 (C1), 159.0 (C3), 133.2 (C2), 34.8 (C4), 21.3 (C5), 13.8 (C6); m/z (ES+) 
99.08 ([M+H]+, 100 %); HRMS (ES+) Calcd for C6H11O1 [M+H]
+: 99.0804, found 99.0802. Spectroscopic 
data are in accordance with the literature.258 
 
Diethyl (2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-2-hydroxyethyl)phosphonate (63) 
 
Thionyl chloride (1.11 mL, 15.3 mmol, 3.0 eq.) was added dropwise to diethylphosphoacetic acid (1.0 
g, 5.1 mmol, 1.0 eq.) and the reaction was stirred at room temperature for 3 hours. The resulting red 
solution (diethylphosphoacetyl chloride) was added dropwise to a solution of 2,2-dimethyl-1,3-
dioxane-4,6-dione 60 (0.59 g, 4.08 mmol, 0.8 eq.) and pyridine (0.82 mL, 10.2 mmol, 2 eq.) in DCM 
(25 mL) at 0 C. The reaction was stirred for 1 hour at 0 C followed by 1 hour at room temperature. 
The reaction was washed with an aqueous solution of HCl (3  10 mL), brine (10 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to yield the title product 63 as a red oil which solidified at 
4 C to yield a red amorphous solid (1.26 g, 96%). 63 was used in the next step without further 
purification. IR (KBr) ν max: 2995 (OH), 2928 (OH), 1736 (C=O), 1668 (C=O), 1578, 1396, 1248, 1196, 
1146, 1013, 920; 1H NMR (500 MHz, Chloroform-d) δ 4.18 (dq, J = 8.1, 7.1 Hz, 4H, OCH2CH3), 3.93 (d, 
J = 23.9 Hz, 2H, C1’-H2), 1.76 (s, 6H, (CH3)2), 1.33 (td, J = 7.1, 0.6 Hz, 6H, OCH2CH3);
 13C NMR (126 
MHz, Chloroform-d) δ 187.6 (C2’), 170.3 (C6), 160.6 (C4), 105.4 (C2), 93.4 (C5), 63.2 (d, J = 6.2 Hz, 
OCH2CH3), 34.5 (d, J = 126.9 Hz, C1’), 27.0 ((CH3)2), 16.5 (OCH2CH3); 
31P NMR (202 MHz, Chloroform-
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d) δ 19.0; m/z (ES+) 323.09 ([M+H]+, 100 %); HRMS (ES+) Calcd for C12H20O8P [M+H]
+: 323.0890, found 
323.0893. 
 
S-(tert-Butyl) 4-(diethoxyphosphoryl)-3-oxobutanethioate (57)207  
 
2-Methyl-2-propanethiol (4.46 mL, 39.5, 2.0 eq.) was added to a solution of 63 (6.37 g, 19.8, 1.0 eq.) 
in MeCN (120 mL) and the reaction was heated at reflux for 3 hours. The reaction was cooled to 
room temperature, concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP 
column 200 g; 0-5% MeOH/DCM) to give the title product 57 as an orange oil (5.20 g, 85%). 1H NMR 
(500 MHz, Chloroform-d) δ 4.15 (dq, J = 8.1, 7.1 Hz, 4H, OCH2CH3), 3.80 (s, 2H, C2-H2), 3.24 (d, J = 
22.7 Hz, 2H, C4-H2), 1.47 (s, 9H, (CH3)3), 1.34 (td, J = 7.1, 2.4 Hz, 6H, OCH2CH3);
 13C NMR (126 MHz, 
Chloroform-d) δ 194.3 (d, J = 6.4 Hz, C3), 192.4 (C1), 62.9 (d, J = 6.4 Hz, OCH2CH3), 58.7 (C2), 49.4 
(C(CH3)3), 42.8 (d, J = 126.6 Hz, C4), 29.8 ((CH3)2), 16.5 (d, J = 6.1 Hz, OCH2CH3); m/z (ES
+) 333.09 
([M+Na]+, 100 %); HRMS (ES+) Calcd for C12H24O5PS [M+H]
+: 311.1077, found 311.1083. Spectroscopic 
data are in accordance with the literature.207 
 
S-(tert-Butyl) (4E,6E)-3-oxodeca-4,6-dienethioate (56)212 
 
LiHMDS (7.14 mL, 1 M in THF, 2.1 eq.) was added dropwise to a solution of 57 (1.05 g, 3.40 mmol, 
1.0 eq.) in THF (34 mL) at -78 C. The reaction was stirred for 30 minutes at -78 C before the 
addition of a solution of 58 (0.40 g, 4.08 mmol, 1.2 eq.) in THF (17 mL). The reaction was stirred at -
78 C for 30 minutes before slowly warming to 0 C over 1 hour. The reaction was maintained at 0 C 
for 1 hour before quenching by addition of a saturated aqueous solution of NH4Cl (20 mL). The 
resulting mixture was extracted with EtOAc (3  20 mL). The organic extracts were combined, 
washed with brine (20 mL), dried over Na2SO4, filtered, concentrated in vacuo and purified via the 
Biotage SP4 (silica-packed SNAP column 25 g; 0-5% EtOAc/hexanes) to give the title product 56 as a 
pale yellow oil (0.75 g, 87%). In CDCl3 at room temperature the title compound exists as a (4 : 3) enol 
: keto mixture. 1H NMR (500 MHz, Chloroform-d) δ(major enol-form) 12.58 (d, J = 1.5 Hz, 1H, OH), 
7.07 (dd, J = 15.2, 10.8 Hz, 1H, C5-H), 6.19 – 6.10 (m, 1H, C6-H), 6.03 (dt, J = 14.6, 6.9 Hz, 1H, C7-H), 
5.68 (d, J = 15.2 Hz, 1H, C4-H), 5.35 (s, 1H, C2-H), 2.22 – 2.15 (m, 2H, C8-H2), 1.52 (s, 9H, (CH3)3), 1.51 
– 1.41 (m, 2H, C9-H2), 0.92 (td, J = 7.4, 5.7 Hz, 3H, C10-H3); 
13C NMR (126 MHz, Chloroform-d) 
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δ(major enol-form) 196.2 (C1), 167.1 (C3), 142.6 (C7), 139.1 (C5), 129.5 (C6), 123.0 (C4), 101.3 (C2), 
48.5 (C(CH3)3), 35.3 (C8), 30.3 ((CH3)3), 22.2 (C9), 13.9 (C10); 
1H NMR (500 MHz, Chloroform-d) 
δ(minor keto-form) 7.20 (dd, J = 15.2, 9.9 Hz, 1H, C5-H), 6.31 – 6.19 (m, 2H, C6-H, C7-H), 6.15 (dd, J = 
15.2, 10.3 Hz, 1H, C4-H), 3.71 (s, 2H, C2-H2), 2.17 – 2.09 (m, 2H, C8-H2), 1.47 (s, 9H, (CH3)3), 1.54 – 
1.38 (m, 2H, C9-H2), 0.92 (td, J = 7.4, 5.7 Hz, 3H, C10-H3); 
13C NMR (126 MHz, Chloroform-d) δ(minor 
keto-form) 193.0 (C1), 192.0 (C3), 147.4 (C7), 145.8 (C5), 129.0 (C6), 127.0 (C4), 56.7 (C2), 49.1 
(C(CH3)3), 35.4 (C8), 29.8 ((CH3)3), 22.0 (C9), 13.9 (C10); m/z (ES
+) 255.14 ([M+H]+, 100 %); HRMS (ES+) 
Calcd for C14H23O2S [M+H]
+: 255.1413, found 255.1413. Spectroscopic data are in accordance with 
the literature.212 
 
Ethyl (2S,4S)-2-isopropyl-5-oxo-4-((4E,6E)-3-oxodeca-4,6-dienamido)tetrahydrofuran-2-
carboxylate (55) 
To a solution of 52 (186 mg, 0.56 mmol, 1.0 eq.) in THF (1.5 mL) at 0 C was added HCl (0.56 mL, 4 N 
in dioxane, 4.0 eq.). The reaction was stirred for 10 minutes at this temperature before the addition 
of a solution of NaBH3CN (106 mg, 1.69 mmol, 3.0 eq.) in MeOH (3 mL). The reaction was stirred for 
a further 1 hour at 0 C before being concentrated in vacuo. The residue was partitioned between 
NaHCO3 (5 mL) and EtOAc (5 mL). The aqueous layer was extracted with EtOAc (3  10 mL) and the 
combined organic extracts were washed with brine (10 mL), dried over MgSO4, filtered, 
concentrated in vacuo to yield the crude free amine 53. 1H NMR (500 MHz, Chloroform-d) δ 4.26 (q, 
J = 7.1 Hz, 2H, C3’’’-H2), 3.56 (dd, J = 11.5, 8.4 Hz, 1H, C4-H), 2.75 (dd, J = 12.8, 8.4 Hz, 1H, C3-H2), 
2.47 (s, 3H, NCH3), 2.29 – 2.21 (m, 1H, C1’’-H), 2.06 (dd, J = 12.8, 11.5 Hz, 1H, C3-H2), 1.31 (t, J = 7.1 
Hz, 3H, C4’’’-H3), 1.03 (d, J = 6.9 Hz, 3H, C2’’-H3), 0.99 (d, J = 6.9 Hz, 3H, C2’’-H3). To a solution of 53 in 
anhydrous THF (7 mL) at 0 C was added 56 (158 mg, 0.62 mmol, 1.1 eq.) followed by Et3N (0.31 mL, 
2.26 mmol, 4.0 eq.) and CF3CO2Ag (250 mg, 1.13 mmol, 2.0 eq.). The reaction was then stirred for 1 
hour at 0 C followed by 1 hour at room temperature. The reaction was concentrated in vacuo and 
purified via the Biotage SP4 (silica-packed SNAP column 12 g; 0-40% EtOAc/hexanes) to give the title 
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product 55 as a pale yellow oil (143 mg, 65%). In CDCl3 at room temperature the title compound 
exists as a (5 : 4) enol : keto mixture. IR (thin film) ν max: 2963 (OH), 2934 (OH), 1786 (C=O), 1736 
(C=O), 1634, 1578, 1489, 1180, 997; 1H NMR (400 MHz, Chloroform-d) δ(major enol-form) 7.04 (dd, J 
= 15.2, 10.7 Hz, 1H, C5’-H), 6.21 – 6.08 (m, 1H, C6’-H), 6.06 – 5.96 (m, 1H, C7’-H), 5.81 (d, J = 15.2 Hz, 
1H, C4’-H), 5.16 (s, 1H, C2’-H), 4.96 (dd, J = 11.5, 9.0 Hz, 1H, C4-H), 4.38 – 4.14 (m, 2H, C3’’’-H2), 2.99 
(s, 3H, NCH3), 2.74 – 2.62 (m, 1H, C3-H2), 2.53 – 2.39 (m, 1H, C3-H2), 2.39 – 2.24 (m, 1H, C1’’-H), 2.16 
– 2.10 (m, 2H, C8’-H2), 1.52 – 1.39 (m, 2H, C9’-H2), 1.36 – 1.27 (m, 3H, C4’’’-H3), 1.11 – 0.98 (m, 6H, 
(C2’’-H3)2), 0.98 – 0.86 (m, 3H, C10’-H3); 
13C NMR (101 MHz, Chloroform-d) δ(major enol-form) 172.3 
(C1’), 172.1 (C5), 170.9 (C1’’’), 170.5 (C3’), 141.9 (C7’), 137.4 (C5’), 129.3 (C6’), 123.9 (C4’), 88.3 (C2’), 
86.9 (C2), 62.3 (C3’’’), 55.7 (C4), 35.1 (C8’), 34.1 (C1’’, NCH3), 31.4 (C3), 22.1 (C9’), 16.8 (C2’’), 16.3 
(C2’’), 14.2 (C4’’’), 13.7 (C10’); 1H NMR (400 MHz, Chloroform-d) δ(minor keto-form) 7.23 (dd, J = 
15.4, 10.0 Hz, 1H, C5’-H), 6.36 – 6.18 (m, 2H, C6’-H, C7’-H), 6.16 (d, J = 15.4 Hz, 1H, C4’-H), 4.80 (dd, J 
= 11.5, 9.0 Hz, 1H, C4-H), 4.37 – 4.16 (m, 2H, C3’’’-H2), 3.73 (d, J = 1.7 Hz, 2H, C2’-H2), 3.01 (s, 3H, 
NCH3), 2.74 – 2.62 (m, 1H, C3-H2), 2.53 – 2.39 (m, 1H, C3-H2), 2.39 – 2.24 (m, 1H, C1’’-H), 2.23 – 2.15 
(m, 2H, C8’-H2), 1.52 – 1.39 (m, 2H, C9’-H2), 1.36 – 1.27 (m, 3H, C4’’’-H3), 1.11 – 0.98 (m, 6H, (C2’’-
H3)2), 0.98 – 0.86 (m, 3H, C10’-H3); 
13C NMR (101 MHz, Chloroform-d) δ(minor keto-form) 193.0 (C3’), 
172.1 (C5), 170.9 (C1’’’), 167.8 (C1’), 147.7 (C7’), 145.8 (C5’), 128.8 (C4’), 126.5 (C6’), 87.1 (C2), 62.3 
(C3’’’), 56.6 (C4), 47.4 (C2’), 35.1 (C8’), 34.1 (C1’’, NCH3), 31.8 (C3), 21.8 (C9’), 16.8 (C2’’), 16.3 (C2’’), 
14.2 (C4’’’), 13.7 (C10’); m/z (ES+) 416.20 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C21H31NO6Na 
[M+Na]+: 416.2044, found 416.2037; * +D
2  = -22.0 (c 0.5, CHCl3). 
 
Harzianic acid ethyl ester (64) 
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Route A: To a solution of 55 (115 mg, 0.29 mmol, 1.0 eq.) in THF (6 mL) at 0 C was added tBuOK (36 
mg, 0.32 mmol, 1.1 eq.) and the reaction was stirred for 30 minutes. The reaction was slowly 
warmed to room temperature and stirred at this temperature for 1 hour. The reaction was 
concentrated in vacuo and the residue partitioned between DCM (10 mL) and an aqueous solution of 
HCl (10 mL, 1 N). The aqueous layer was separated and extracted with DCM (3  10 mL). The organic 
extracts were combined, washed with an aqueous solution of HCl (5 mL, 1 N), brine (5 mL), dried 
over Na2SO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP 
column 12 g; 0-60% EtOAc/hexanes) to give the title product 64 as an pale yellow oil (107 mg, 93%).  
Route B: To a solution of 52 (400 mg, 1.20 mmol, 1.0 eq.) in THF (3 mL) at 0 C was added HCl (1.20 
mL, 4 N in dioxane, 4.0 eq.). The reaction was stirred for 10 minutes at this temperature before the 
addition of a solution of NaBH3CN (228 mg, 3.62 mmol, 3.0 eq.) in MeOH (6 mL). The reaction was 
stirred for a further 1 hour at 0 C before being concentrated in vacuo. The residue was partitioned 
between a saturated aqueous solution of NaHCO3 (10 mL) and EtOAc (10 mL). The aqueous layer was 
extracted with EtOAc (3  15 mL) and the combined organic extracts were washed with brine (15 
mL), dried over MgSO4, filtered, concentrated in vacuo to yield the crude free amine 53. To a 
solution of 53 in anhydrous MeCN (24 mL) at 0 C was added 56 (305 mg, 1.20 mmol, 1.0 eq.) 
followed by Et3N (0.67 mL, 4.80 mmol, 4.0 eq.) and CF3CO2Ag (530 mg, 2.40 mmol, 2.0 eq.). The 
reaction was then stirred for 1 hour at 0 C followed by 1 hour at room temperature. The reaction 
was concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 12 g; 0-40% 
EtOAc/hexanes) to give the title product 64 as a pale yellow oil (354 mg, 75%). IR (KBr) ν max: 2965 
(OH), 2934 (OH), 1724 (C=O), 1682 (C=O), 1614, 1568, 1447, 1238, 1188, 999;  1H NMR (500 MHz, 
Chloroform-d) δ 7.49 (dd, J = 15.3, 9.9 Hz, 1H, C3-H), 7.05 (d, J = 15.3 Hz, 1H, C2-H), 6.45 – 6.17 (m, 
2H, C4-H, C5-H), 5.30 (s, 1H, OH), 4.25 (q, J = 7.1, 2H, C13’-H2), 3.68 (dd, J = 9.8, 2.2 Hz, 1H, C5’-H), 
2.98 (s, 3H, C11’-H3), 2.32 (dd, J = 14.4, 2.2 Hz, 1H, C6’-H2), 2.24 – 2.18 (m, 2H, C6-H2), 2.06 (hept, J = 
6.9 Hz, 1H, C8’-H), 1.90 (dd, J = 14.4, 9.8 Hz, 1H, C6’-H2), 1.54 – 1.43 (m, 2H, C7-H2), 1.32 (t, J = 7.1 Hz, 
3H, C14’-H3), 1.00 – 0.88 (m, 9H, C9’-H3, C10’-H3, C8-H3);
 13C NMR (126 MHz, Chloroform-d) δ 196.3 
(C4’), 175.5 (C12’), 175.5 (C1), 173.4 (C2’), 148.8 (C5), 146.5 (C3), 129.9 (C4), 119.5 (C2), 99.3 (C3’), 
78.9 (C7’), 64.5 (C5’), 61.6 (C13’), 36.8 (C8’), 35.6 (C6), 34.9 (C6’), 26.8 (C11’), 22.0 (C7), 17.5 (C9’), 
16.4 (C10’), 14.5 (C14’), 13.8 (C8); m/z (ES+) 394.22 ([M+H]+, 100 %); HRMS (ES+) Calcd for C21H32NO6 
[M+H]+: 394.2224, found 394.2223. 
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Harzianic acid (19)172 
 
To a solution of 64 (190 mg, 0.48 mmol, 1.0 eq.) in EtOH (1 mL) was added an aqueous solution of 
NaOH (1 mL, 2 N) and the reaction was heated to 110 C under microwave irradiation for 20 
minutes. The reaction was diluted with an aqueous solution of HCl (5 mL, 1N) and extracted with 
DCM (3  5 mL). The organic layers were combined, washed with brine (10 mL), dried over Na2SO4, 
filtered, concentrated in vacuo and purified via the Biotage SP4 (Reverse-phase silica-packed SNAP 
column 4 g; 20-100% H2O/(MeOH:MeCN)) to give the title product 19 (92 mg, 52%) and the 5’-
epimer 19b (33 mg, 19%) as orange solids. IR (thin film) ν max: 2963, 2934, 1717 (br), 1613, 1560, 
1449, 1408, 1261, 1042, 1003, 885; 1H NMR (500 MHz, Chloroform-d) δ 7.58 – 7.50 (m, 1H, C3-H), 
7.25 (br s, 1H, OH), 6.99 (d, J = 15.2 Hz, 1H, C2-H), 6.39 – 6.34 (m, 2H, C4-H, C5-H), 3.62 (dd, J = 10.6, 
1.3 Hz, 1H, C5’-H), 2.96 (s, 3H, C11’-H3), 2.48 (dd, J = 14.7, 1.3 Hz, 1H, C6’-H2), 2.23 (dtd, J = 7.4, 5.4, 
2.8 Hz, 1H, C6-H2), 2.01 (hept, J = 6.8 Hz, 1H, C8’-H), 1.88 (dd, J = 14.7, 10.6 Hz, 1H, C6’-H2), 1.49 (app. 
hept, J = 7.4, 2H, C7-H2), 0.98 (d, J = 6.8 Hz, 3H, C9’-H3), 0.98 (d, J = 6.8 Hz, 3H, C10’-H3), 0.94 (t, J = 
7.4 Hz, 3H, C8-H3);
 13C NMR (126 MHz, Chloroform-d) δ 197.4 (C4’), 176.8 (C1), 176.2 (C12’), 173.3 
(C2’), 150.1 (C5), 147.7 (C3), 129.8 (C4), 119.2 (C2), 98.8 (C3’), 80.0 (C7’), 64.2 (C5’), 36.1 (C8’), 35.6 
(C6), 33.9 (C6’), 26.7 (C11’), 21.9 (C7), 17.6 (C9’), 16.4 (C10’), 13.9 (C8); 1H NMR (500 MHz, 
Methanol-d4) δ 7.53 (m, 1H, C3-H), 7.09 (d, J = 15.3 Hz, 1H, C2-H), 6.39 (m, 2H, C4-H, C5-H), 3.80 (dd, 
J = 9.1, 2.5 Hz, 1H, C5’-H), 2.94 (s, 3H, C11’-H3), 2.34 (dd, J = 14.7, 2.5 Hz, 1H, C6’-H2), 2.24 (m, 2H, C6-
H2), 2.02 (m, 1H, C8’-H), 2.00 (dd, J = 14.7, 9.1 Hz, 1H, C6’-H2), 1.51 (m, 2H, C7-H2), 0.98 (d, J = 6.9 Hz, 
3H, C9’-H3), 0.96 (t, J = 7.2 Hz, 3H, C8-H3), 0.95 (d, J = 6.9 Hz, 3H, C10’-H3); 
13C NMR (126 MHz, 
Methanol-d4) δ 198.9 (C4’), 178.6 (C12’), 175.8 (C1), 173.9 (C2’) 149.8 (C5), 147.3 (C3), 131.0 (C4), 
120.3 (C2), 100.9 (C3’), 79.8 (C7’), 65.5 (C5’), 37.4 (C8’), 36.4 (C6’), 27.1 (C11’), 23.0 (C7), 17.9 (C9’), 
16.5 (C10’), 14.1 (C8); m/z (ES+) 366.19 ([M+H]+, 100 %); HRMS (ES+) Calcd for C19H28NO6 [M+H]
+: 
366.1911, found 366.1905; * +D
2  = +18.6 (c 1.06, MeOH). (lit. +19.6).172 Spectroscopic data are in 
accordance with the literature.172 
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5’-epiHarzianic acid (19b) 
 
IR (thin film) ν max: 2963, 2926, 1717 (br), 1636 (br), 1616, 1456, 1260, 1036, 804; 
1H NMR (500 MHz, 
Chloroform-d) δ 7.56 – 7.48 (m, 1H, C3-H), 7.07 (d, J = 15.3 Hz, 1H, C2-H), 6.38 – 6.32 (m, 2H, C4-H, 
C5-H), 3.87 (dd, J = 8.2, 2.8 Hz, 1H, C5’-H), 3.02 (s, 3H, C11’-H3), 2.57 (dd, J = 15.2, 2.8 Hz, 1H, C6’-H2), 
2.29 – 2.21 (m, 2H, C6-H2), 2.16 (dd, J = 15.2, 8.2 Hz, 1H, C6’-H2), 2.13 – 1.99 (m, 1H, C8’-H), 1.57 – 
1.44 (m, 2H, C7-H2), 1.05 (d, J = 6.9 Hz, 3H, C9’-H3), 1.04 (d, J = 6.9 Hz, 3H, C10’-H3), 0.96 (t, J = 7.4 Hz, 
3H, C8-H3);
 13C NMR (126 MHz, Chloroform-d) δ 196.1 (C4’), 175.6 (C12’), 175.3 (C1), 174.0 (C2’), 
149.0 (C5), 146.7 (C3), 129.9 (C4), 119.4 (C2), 99.6 (C3’), 78.3 (C7’), 63.6 (C5’), 36.0 (C8’), 35.6 (C6), 
34.7 (C6’), 27.4 (C11’), 22.0 (C7), 17.4 (C9’), 16.7 (C10’), 13.9 (C8); 1H NMR (500 MHz, Methanol-d4) δ 
7.44 (dd, J = 15.3, 10.0 Hz, 1H, C3-H), 7.11 (d, J = 15.3 Hz, 1H, C2-H), 6.41 – 6.27 (m, 2H, C4-H, C5-H), 
3.77 (br s, 1H, C5’-H), 2.92 (s, 3H, C11’-H3), 2.47 (dd, J = 15.1, 5.2 Hz, 1H, C6’-H2), 2.40 (dd, J = 15.1, 
3.2 Hz, 1H, C6’-H2), 2.23 (app. q, J = 7.0 Hz, 2H, C6-H2), 1.89 (hept, J = 6.8 Hz, 1H, C8’-H), 1.57 – 1.43 
(m, 2H, C7-H2), 0.96 (t, J = 7.3 Hz, 3H, C8-H3), 0.95 (d, J = 6.8 Hz, 3H, C9’-H3), 0.87 (d, J = 6.8 Hz, 3H, 
C10’-H3); 
13C NMR (126 MHz, Methanol-d4) δ 196.3 (C4’), 178.2 (C12’), 176.4 (C2’), 173.4 (C1), 148.2 
(C5), 145.6 (C3), 131.0 (C4), 120.6 (C2), 102.3 (C3’), 78.8 (C7’), 66.0 (C5’), 37.5 (C8’), 37.0 (C6’), 36.3 
(C6), 28.3 (C11’), 23.0 (C7), 17.6 (C9’), 16.6 (C10’), 14.0 (C8); m/z (ES+) 364.18 ([M-H]-, 100 %); HRMS 
(ES+) Calcd for C19H26NO6 [M-H]
-: 364.1766, found 364.1757; * +D
2  = +118.0 (c 0.5, MeOH). 
 
6,6-Dimethoxyhexanal (73)217 
 
A solution of cyclohexene 72 (5.06 mL, 50.0 mmol, 1.0 eq.) in dry DCM (150 mL)/MeOH (50 mL) at -
78 C was purged with O2. O3 was bubbled through the solution until it became a blue colour. The 
reaction was purged with N2 until the blue colour disappeared. PTSA (951 mg, 5.00 mmol, 0.1 eq.) 
was added and the reaction was stirred at room temperature for 1.5 hours before the addition of 
anhydrous NaHCO3 (16.8 g, 200 mmol, 4.0 eq.). Dimethyl sulfide (6.21 g, 100 mmol, 2.0 eq.) was 
added after a further 15 minutes and the reaction was stirred at room temperature for 12 hours. 
The reaction was concentrated in vacuo to approximately 40 mL. The resulting mixture was diluted 
with DCM (40 mL) and washed with H2O (3  30 mL). The aqueous extracts were combined and 
extracted with DCM (2  20 mL). The organic extracts were combined, washed with brine (30 mL), 
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dried over MgSO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed 
SNAP column 100 g; 0-40% EtOAc/hexanes) to give the title product 73 as a colourless oil (6.54 g, 
82%). 1H NMR (500 MHz, Chloroform-d) δ 9.76 (t, J = 1.7 Hz, 1H, C1-H), 4.35 (t, J = 5.7 Hz, 1H, C6-H), 
3.31 (d, J = 2.1 Hz, 6H, (OCH3)2), 2.44 (td, J = 7.3, 1.7 Hz, 2H, C2-H2), 1.80 – 1.45 (m, 4H, C3-H2, C5-H2), 
1.48 – 1.26 (m, 2H, C4-H2); 
13C NMR (126 MHz, Chloroform-d) δ 202.7 (C1), 104.4 (C6), 52.9 ((CH3)3), 
44.0 (C2), 32.4 (C5), 24.3 (C4), 22.0 (C3). Spectroscopic data are in accordance with the literature.217 
 
(2E,4E)-10,10-Dimethoxydeca-2,4-diene (74)218 
 
To a solution of diethyl 2-butenylphosphonate 70 (2.96 mL, 15.6 mmol, 1.0 eq.) in DME (60 mL) at -
78 C was added KHMDS (17.2 mmol, 1.1 eq., 1 M in THF) and the reaction was stirred for 30 
minutes. A solution of 73 in DME (30 mL) was then added and the reaction was stirred for a further 
30 minutes before stirring at 0 C for 2 hours followed by 2 hours at room temperature. The reaction 
was diluted with Et2O (30 mL)/saturated aqueous solution of NH4Cl (30 mL). The aqueous layer was 
extracted with Et2O (3  20 mL). The organic extracts were combined, washed with brine (30 mL), 
dried over MgSO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed 
SNAP column 80 g; 0-20% EtOAc/hexanes) to give the title product 74 as a colourless oil (1.76 g, 
57%, 8:1 E:Z). 1H NMR (500 MHz, Chloroform-d) δ 6.05 – 5.93 (m, 2H, C3-H, C4-H), 5.63 – 5.48 (m, 
2H, C2-H, C5-H), 4.35 (t, J = 5.7 Hz, 1H, C10-H), 3.31 (s, 6H, (OCH3)2), 2.06 (app. q, J = 7.0 Hz, 2H, C6-
H2), 1.72 (d, J = 6.1 Hz, 3H, C1-H3), 1.63 – 1.54 (m, 2H, C9-H2), 1.46 – 1.29 (m, 4H, C7-H2, C8-H2); 
13C 
NMR (126 MHz, Chloroform-d) δ 131.9 (C5), 131.8 (C3), 130.6 (C4), 127.0 (C2), 104.6 (C10), 52.7 
((OCH3)2), 32.6 (C6), 32.5 (C9), 29.4 (C7), 24.3 (C8), 18.2 (C1); m/z (ES
+) 216.20 ([M+NH4]
+, 100 %); 
HRMS (ES+) Calcd for C12H26NO2 [M+NH4]
+: 216.1958, found 216.1954. Spectroscopic data are in 
accordance with the literature.218 
 
(6E,8E)-Deca-6,8-dienal (75)259 
 
To 74 (1.74 g, 8.77 mmol, 1.0 eq.) in THF (35 mL) was added an aqueous solution of HCl (9.65 mL, 1 
N, 1.1 eq.) and the reaction was stirred at room temperature for 12 hours. The reaction was 
quenched by the addition of a saturated aqueous solution of NaHCO3 (30 mL). The mixture was 
extracted with Et2O (3  30 mL) and the organic layers were combined, washed with brine (30 mL), 
dried over MgSO4, filtered and concentrated in vacuo. Title product 75 was isolated as a pale yellow 
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liquid (1.26 g, 94%) which was used in the next step without further purification. 1H NMR (500 MHz, 
Chloroform-d) δ 9.76 (t, J = 1.8 Hz, 1H, C1-H), 6.04 – 5.92 (m, 2H, C7-H, C8-H), 5.64 – 5.45 (m, 2H, C6-
H, C9-H), 2.42 (td, J = 7.4, 1.8 Hz, 2H, C2-H2), 2.08 (app. q, J = 7.2 Hz, 2H, C5-H2), 1.72 (d, J = 6.6 Hz, 
3H, C10-H3), 1.68 – 1.55 (m, 2H, C3-H2), 1.47 – 1.37 (m, 2H, C4-H2); 
13C NMR (126 MHz, Chloroform-
d) δ 202.7 (C1), 131.5 (C8), 131.0 (C6), 130.8 (C7), 127.2 (C9), 43.8 (C2), 32.2 (C5), 28.9 (C4), 21.6 
(C3), 18.0 (C10); m/z (ES+) 153.12 ([M+H]+, 100 %); HRMS (ES+) Calcd for C10H17O [M+H]
+: 153.1274, 
found 153.1270. Spectroscopic data are in accordance with the literature.259 
 
S-(tert-Butyl) (4E,10E,12E)-3-oxotetradeca-4,10,12-trienethioate (66) 
 
To a solution of 57 (2.81 g, 9.05 mmol, 1.0 eq.) in THF (70 mL) at -78 C was added LiHMDS (18.1 mL, 
1 M in THF, 2.0 eq.) and the reaction was stirred for 30 minutes before the addition of a solution of 
75 (1.24 g, 8.15 mmol, 0.9 eq.) in THF (35 mL). The reaction was stirred for a further 30 minutes at -
78 C before slowly warming to 0 C over 2 hours. The reaction was quenched by the addition of a 
saturated aqueous solution of NH4Cl (30 mL) and extracted with EtOAc (3  30 mL). The organic 
extracts were combined, washed with brine (30 mL), dried over MgSO4, filtered and concentrated in 
vacuo and purified via the Biotage SP4 (silica-packed SNAP column 80 g; 0-10% EtOAc/hexanes) to 
give the title product 66 as a colourless oil (1.82 g, 72%). In CDCl3 at room temperature the title 
compound exists as a (2 : 3) keto : enol mixture. IR (thin film) ν max: 2924, 2859, 1653 (C=O), 1582, 
1074; 1H NMR (500 MHz, Chloroform-d) δ(major enol-form) 12.61 (br s, OH), 6.76 – 6.54 (m, 1H, C5-
H), 6.05 – 5.90 (m, 2H, C11-H, C12-H), 5.74 – 5.61 (m, 1H, C4-H), 5.61 – 5.43 (m, 2H, C10-H, C13-H), 
5.30 (s, 1H, C2-H), 2.21 – 2.14 (m, 2H, C6-H2), 2.10 – 2.01 (m, 2H, C9-H2), 1.76 – 1.68 (m, 3H, C14-H3), 
1.51 (s, 9H, (C3’’-H3)3), 1.46 – 1.36 (m, 4H, C7-H2, C8-H2); 
13C NMR (126 MHz, Chloroform-d) δ(major 
enol-form) 196.5 (C1), 166.8 (C3), 142.6 (C5), 131.6 (C10, C12), 130.7 (C11), 127.2 (C13), 124.4 (C4), 
100.5 (C2), 48.42 (C2’’), 32.7 (C6), 32.4 (C9), 30.3 ((C3’’)3), 29.0 (CH2), 28.1 (CH2), 18.2 (C14); 
1H NMR 
(500 MHz, Chloroform-d) δ(minor keto-form) 6.98 – 6.79 (m, 1H, C5-H), 6.21 – 6.08 (m, 1H, C4-H), 
6.07 – 5.93 (m, 2H, C11-H, C12-H), 5.63 – 5.46 (m, 2H, C10-H, C13-H), 3.70 (d, J = 1.0 Hz, 2H, C2-H2), 
2.29 – 2.20 (m, 2H, C6-H2), 2.10 – 2.01 (m, 2H, C9-H2), 1.76 – 1.68 (m, 3H, C14-H3), 1.46 (s, 9H, (C3’’-
H3)3), 1.47 – 1.39 (m, 4H, C7-H2, C8-H2); 
13C NMR (126 MHz, Chloroform-d) δ(minor keto-form) 192.9 
(C1), 192.0 (C3), 150.6 (C5), 131.7 (C10), 131.4 (C12), 130.9 (C11), 129.8 (C4), 127.3 (C13), 56.3 (C2), 
49.1 (C2’’), 32.6 (C6), 32.4 (C9), 29.8 ((C3’’-H3)3), 29.0 (CH2), 28.1 (CH2), 18.2 (C14); m/z (ES
+) 309.19 
([M+H]+, 100 %); HRMS (ES+) Calcd for C18H29O2S [M+H]
+: 309.1883, found 309.1883. 
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S-(tert-Butyl) 3-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-3-oxopropanethioate ((±)-
68) 
 
To a solution of 66 (815 mg, 2.64 mmol, 1.0 eq.) in DCM (80 mL) at -78 C was added BF3.Et2O (750 
mg, 5.28 mmol, 2.0 eq.) and the reaction was stirred for 1 hour before slowly warming to 0 C over 5 
hours. The reaction was diluted with H2O (40 mL) and extracted with DCM (3  40 mL).The organic 
layers were combined, washed with brine (40 mL), dried over MgSO4, filtered and concentrated in 
vacuo and purified via the Biotage SP4 (silica-packed SNAP column 25 g; 0-2% EtOAc/hexanes) to 
give the title product (±)-68 as a colourless oil (636 mg, 78%). In CDCl3 at room temperature the title 
compound exists as a (3 : 1) keto : enol mixture. IR (thin film) ν max: 2920, 2851, 1717, 1670 (C=O), 
1609, 1071; 1H NMR (500 MHz, Chloroform-d) δ(major keto-form) 5.54 (ddd, J = 10.0, 4.6, 2.6 Hz, 1H, 
C3-H), 5.39 (dd, J = 10.0, 1.8 Hz, 1H, C4-H), 3.63 – 3.42 (m, 2H, C2’-H2), 2.92 (dd, J = 11.3, 5.8 Hz, 1H, 
C1-H), 2.63 – 2.51 (m, 1H, C2-H), 1.93 – 1.83 (m, 1H, C8-H2), 1.78 – 1.69 (m, 3H, C5-H2, C6-H2, C7-H2), 
1.69 – 1.64 (m, 1H, C4a-H), 1.47 (s, 9H, (CH3)3), 1.47 – 1.44 (m, 1H, C8a-H), 1.36 – 1.21 (m, 2H, C5-H2, 
C6-H2), 1.12 – 1.01 (m, 1H, C7-H2), 0.82 (d, J = 7.1 Hz, 2H, CH3), 0.81 – 0.69 (m, 1H, C8-H2); 
13C NMR 
(126 MHz, Chloroform-d) δ(major keto-form) 203.6 (C3’), 192.3 (C1’), 131.4 (C4), 130.6 (C3), 59.4 
(C2’), 56.0 (C1), 49.2 (C), 42.2 (C4a), 36.3 (C8a), 33.2 (C5), 31.6 (C2), 29.8 ((CH3)3), 29.7 (C8), 26.8 
(C6), 26.6 (C7), 17.8 (CH3); 
1H NMR (500 MHz, Chloroform-d) δ(minor enol-form) 12.96 (d, J = 1.3 Hz, 
1H, OH), 5.57 – 5.49 (m, 1H, C3-H), 5.39 – 5.35 (m, 1H, C4-H), 5.32 (s, 1H, C2’-H), 2.40 – 2.32 (m, 1H, 
C2-H), 2.20 (ddd, J = 11.0, 5.6, 1.0 Hz, 1H, C1-H), 1.93 – 1.83 (m, 1H, C8-H2), 1.77 – 1.68 (m, 3H, C5-
H2, C6-H2, C7-H2), 1.69 – 1.64 (m, 1H, C4a-H), 1.51 (s, 9H, (CH3)3), 1.46 – 1.43 (m, 1H, C8a-H), 1.36 – 
1.21 (m, 2H, C5-H2, C6-H2), 1.13 – 1.01 (m, 1H, C7-H2), 0.99 (d, J = 7.1 Hz, 3H, CH3), 0.81 – 0.69 (m, 
1H, C8-H2);
 13C NMR (126 MHz, Chloroform-d) δ(minor enol-form) 196.10 (C1’), 178.15 (C3’), 131.62 
(C4), 130.85 (C3), 101.60 (C2’), 49.84 (C1), 48.29 (C), 43.01 (C4a), 36.40 (C8a), 35.05 (C2), 33.29 (C5), 
30.36 ((CH3)3), 30.19 (C8), 26.82 (C6), 26.70 (C7), 18.03 (CH3); m/z (ES
+) 331.17 ([M+Na]+, 100 %); 
HRMS (ES+) Calcd for C18H28O2SNa [M+Na]
+: 331.1708, found 331.1698. 
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Ethyl (3S,4S)-3-isopropyl-4-(3-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-3-
oxopropanamido)-5-oxotetrahydrofuran-3-carboxylate (67a/b) 
 
To a solution of 52 (140 mg, 0.42 mmol, 1.0 eq.) in THF (1 mL) at 0 C was added HCl (0.42 mL, 4 N in 
dioxane, 4.0 eq.). The reaction was stirred for 10 minutes at this temperature before the addition of 
a solution of NaBH3CN (80 mg, 1.27 mmol, 3.0 eq.) in MeOH (2 mL). The reaction was stirred for a 
further 1 hour at 0 C before being concentrated in vacuo. The residue was partitioned between a 
saturated aqueous solution of NaHCO3 (5 mL) and EtOAc (5 mL). The aqueous layer was extracted 
with EtOAc (3  10 mL) and the combined organic extracts were washed with brine (10 mL), dried 
over MgSO4, filtered and concentrated in vacuo to yield the crude free amine 53. To a solution of 53 
in anhydrous THF (5 mL) at 0 C was added (±)-68 (96 mg, 0.42 mmol, 1.0 eq.) followed by Et3N (0.23 
mL, 1.68 mmol, 4.0 eq.) and CF3CO2Ag (186 mg, 0.84 mmol, 2.0 eq.). The reaction was then stirred 
for 1 hour at 0 C followed by 1 hour at room temperature. The reaction was concentrated in vacuo 
and purified via the Biotage SP4 (silica-packed SNAP column 12 g; 0-40% EtOAc/hexanes) to give the 
title product 67a/b as a colourless oil (120 mg, 64%). NMR analysis is complicated by the presence of 
2 diastereomers (67a and 67b) and keto/enol tautomers of both. See 67a and 67b for the 
spectroscopic data of each diastereomer.  
 
(2S)-2-Hydroxy-2-(((2S,E)-4-(hydroxy(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-
yl)methylene)-1-methyl-3,5-dioxopyrrolidin-2-yl)methyl)-3-methylbutanoic acid (4a/b) 
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To a solution of 67a/b (100 mg, 0.22 mmol, 1.0 eq.) in THF (5 mL) at 0 C was added tBuOK (28 mg, 
0.25 mmol, 1.1 eq.) and the reaction was stirred for 1 hour. The reaction was slowly warmed to 
room temperature and stirred at this temperature for 1 hour. The reaction was concentrated in 
vacuo and the residue partitioned between DCM (5 mL) and an aqueous solution of HCl (5 mL, 1N). 
The organic layer was separated and washed with an aqueous solution of HCl (5 mL, 1N), brine (5 
mL), dried over Na2SO4, filtered and concentrated in vacuo to give JBIR-22 ethyl ester 77a/b as a 
colourless oil (100 mg, 100%), which was used in the next step without further purification. 
To a solution of 77a/b (90 mg, 0.20 mmol, 1.0 eq.) in EtOH (2 mL) was added an aqueous solution of 
NaOH (1 mL, 2N) and the reaction was heated to 110 C under microwave irradiation for 20 minutes. 
The reaction was diluted with an aqueous solution of HCl (5 mL, 1N) and extracted with DCM (3  5 
mL). The organic layers were combined, washed with brine (10 mL), dried over Na2SO4, filtered, 
concentrated in vacuo and purified via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 
g; 20-100% H2O/(MeOH:MeCN)) to give the title product 77a/b as an amorphous white solid (73 mg, 
87%). See 4a and 4b for the spectroscopic data of each diastereomer.  
 
Ethyl (2E,8E,10E)-dodeca-2,8,10-trienoate (87)260 
 
To a solution of diisopropyl(ethoxycarbonylmethyl) phosphonate 86 (5.86 mL, 24.6 mmol, 1.0 eq.) in 
THF (250 mL) at -78 C was added LiHMDS (25.9 mmol, 1.05 eq., 1 M in THF) and the reaction was 
stirred for 30 minutes. A solution of 75 (3.75 g, 24.6 mmol, 1.0 eq.) in THF (40 mL) was then added 
and the reaction was stirred for a further 1.5 hours at -78 C before stirring at 0 C for 1.5 hours 
followed by 30 minutes at room temperature. The reaction was quenched by addition of a saturated 
aqueous solution of NH4Cl (100 mL). The reaction was extracted with EtOAc (3  100 mL). The 
organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, filtered, 
concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 300 g; 0-10% 
EtOAc/hexanes) to give the title product 87 as a colourless oil (4.83 g, 88%). 1H NMR (500 MHz, 
Chloroform-d) δ 6.95 (dt, J = 15.6, 7.0 Hz, 1H, C3-H), 6.08 – 5.90 (m, 2H, C9-H, C10-H), 5.80 (dt, J = 
15.6, 1.6 Hz, 1H, C2-H), 5.63 – 5.46 (m, 2H, C8-H, C11-H), 4.18 (q, J = 7.1 Hz, 2H, OCH2CH3), 2.26 – 
2.14 (m, 2H, C4-H2), 2.06 (dt, J = 7.0, 7.0 Hz, 2H, C7-H2), 1.72 (d, J = 6.3 Hz, 3H, C12-H3), 1.54 – 1.36 
(m, 4H, C5-H2, C6-H2), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3); 
13C NMR (126 MHz, Chloroform-d) δ 166.9 
(C1), 149.3 (C3), 131.7 (C8), 131.5 (C10), 130.8 (C9), 127.2 (C11), 121.5 (C2), 60.3 (OCH2CH3), 32.4 
(C7), 32.2 (C4), 29.0 (C6), 27.6 (C5), 18.2 (C12), 14.4 (OCH2CH3); m/z (ES
+) 245.13 ([M+Na]+, 100 %). 
Spectroscopic data are in accordance with the literature.260 
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 (2E,8E,10E)-Dodeca-2,8,10-trien-1-ol (88)221 
 
To a solution of 87 (4.83 g, 21.7 mmol, 1.0 eq.) in DCM (210 mL) at -78 C was added DIBAL-H (54.3 
mmol, 2.5 eq., 1.1 M in cyclohexane) and the reaction was stirred for 30 minutes before being 
quenched by addition of MeOH (24 mL). Upon warming to room temperature, a saturated solution 
of sodium potassium tartrate (200 mL) was added and the mixture was stirred vigorously for 12 
hours. The mixture was extracted with DCM (3  100 mL). The organic extracts were combined, 
washed with brine (100 mL), dried over Na2SO4, filtered, concentrated in vacuo and purified via the 
Biotage SP4 (silica-packed SNAP column 300 g; 0-20% EtOAc/hexanes) to give the title product 88 as 
a colourless oil (3.80 g, 97%). 1H NMR (500 MHz, Chloroform-d) δ 6.07 – 5.93 (m, 2H, C9-H, C10-H), 
5.70 – 5.63 (m, 2H, C2-H, C3-H), 5.63 – 5.48 (m, 2H, C8-H, C11-H), 4.08 (d, J = 5.4 Hz, 2H, C1-H2), 2.13 
– 1.96 (m, 4H, C4-H2, C7-H2), 1.72 (d, J = 6.3 Hz, 3H, C12-H3), 1.46 – 1.33 (m, 4H, C5-H2, C6-H2); 
13C 
NMR (126 MHz, Chloroform-d) δ 133.5 (C3), 132.0 (C8), 131.8 (C10), 130.5 (C9), 129.1 (C2), 127.0 
(C11), 64.0 (C1), 32.5 (C7), 32.2 (C4), 29.1 (C6), 28.8 (C5), 18.2 (C12). Spectroscopic data are in 
accordance with the literature.221 
 
(2E,8E,10E)-Dodeca-2,8,10-trienal (69)221 
 
Route A: To a solution of 88 (1.19 g, 6.57 mmol, 1.0 eq.) in DCM (40 mL) at room temperature was 
added Dess-Martin Periodinane (4.18 g, 9.86 mmol, 1.5 eq.). After stirring for 30 minutes, H2O (0.18 
mL, 9.86 mmol, 1.5 eq.) was added and the reaction stirred for a further 30 minutes. The reaction 
was concentrated in vacuo, diluted with EtOAc (80 mL) and a 1:1 (v:v) 10% sodium thiosulfate: 
saturated sodium bicarbonate solution (40 mL). After stirring for 30 minutes, the organic layer was 
separated and the aqueous layer was extracted with EtOAc (3  40 mL). The organic layers were 
combined, washed with a saturated aqueous solution of NaHCO3 (3  40 mL), brine (40 mL), dried 
over Na2SO4, filtered and concentrated in vacuo to give the title product 69 as a colourless oil which 
was used directly in the next step without further purification (1.17 g, 100%). 
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Route B: To a solution of (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide 89 (368 mg, 0.85 
mmol, 1.3 eq.), in anhydrous THF (2 mL) at 0 C was added tBuOK (1.05 mL, 1.6 eq., 1 M in THF) 
dropwise. The mixture was stirred for 30 minutes before the addition of a solution of 75 (100 mg, 
0.66 mmol, 1.0 eq.) in anhydrous THF (2.5 mL). The reaction was stirred at 0 C for 3 hours. A 10% 
aqueous solution of oxalic acid (5 mL) was added and the reaction was stirred at room temperature 
for a further 1 hour. The mixture was extracted with Et2O (4  10 mL) and the combined organic 
layers were washed with a saturated aqueous solution of NaHCO3 (10 mL), brine (10 mL), dried over 
Na2SO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 
4 g; 0-2% EtOAc/hexanes) to give the title product 69 as a colourless oil (75 mg, 64%). 1H NMR (500 
MHz, Chloroform-d) δ 9.50 (d, J = 7.9 Hz, 1H, C1-H), 6.84 (dt, J = 15.5, 6.8 Hz, 1H, C3-H), 6.11 (ddt, J = 
15.5, 7.9, 1.5 Hz, 1H, C2-H), 6.04 – 5.95 (m, 2H, C9-H, C10-H), 5.63 – 5.55 (m, 1H, C11-H), 5.56 – 5.47 
(m, 1H, C8-H), 2.39 – 2.29 (m, 2H, C4-H2), 2.08 (td, J = 7.1, 7.1 Hz, 2H, C7-H2), 1.73 (d, J = 6.2 Hz, 3H, 
C12-H3), 1.58 – 1.47 (m, 2H, C5-H2), 1.49 – 1.39 (m, 2H, C6-H2); 
13C NMR (126 MHz, Chloroform-d) δ 
194.3 (C1), 158.9 (C3), 133.2 (C2), 131.6 (C8), 131.2 (C10), 130.9 (C9), 127.4 (C11), 32.7 (C7), 32.3 
(C4), 29.0 (C6), 27.4 (C5), 18.2 (C12). Spectroscopic data are in accordance with the literature.221 
 
2-Methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbaldehyde (78)221,233 
  
To 69 (78a, 1.25 g, 7.01 mmol, 1.0 eq.; 78b, 1.45 g, 8.13 mmol, 1.0 eq.; 85% E,E-diene geometry) in a 
2% v/v solution of H2O/MeCN (3.3 mL/mmol) at -5 C was added a solution of (2S,5S)-5-benzyl-2-
tertbutyl-3-methylimidazolidin-4-one trifluoromethanesulfonic acid salt (1.4 mL, 0.2 eq., 1M in 
MeCN) for 78a, or (2R,5R)-5-benzyl-2-tertbutyl-3-methylimidazolidin-4-one trifluoromethanesulfonic 
acid salt (1.63 mL, 0.2 eq., 1M in MeCN) for 78b. The reaction was stirred at -5 C for 48 hours before 
being concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 4 g; 0-2% 
EtOAc/hexanes) to give 78a (0.69 g, 65%,1 dr 4:1,2 87% ee3) and 78b (0.84 g, 68%,1 dr 4:1,2 84% ee3) 
as colourless oils. 1Yields reported based on the conversion of the E,E-diene substrate to IMDA 
product. 2Diastereomeric ratios were determined by 1H NMR analysis. 3Enantiomeric purity was 
determined by chiral GC analysis of the corresponding alcohols (90a & 90b). 1H NMR (500 MHz, 
Chloroform-d) δ 9.75 (d, J = 4.3 Hz, 1H, C1’-H), 5.54 (ddd, J = 9.9, 4.5, 2.6 Hz, 1H, C3-H), 5.42 (d, J = 
9.9 Hz, 1H, C4-H), 2.66 – 2.51 (m, 1H, C2-H), 2.38 (ddd, J = 11.4, 6.0, 4.3 Hz, 1H, C1-H), 1.85 – 1.71 (m, 
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4H, C5-H2, C6-H2, C7-H2, C8-H2), 1.74 – 1.64 (m, 1H, C4a-H), 1.67 – 1.58 (m, 1H, C8a-H), 1.39 – 1.29 
(m, 2H, C6-H2, C7-H2), 1.17 – 1.07 (m, 1H, C5-H2), 1.04 (d, J = 7.1 Hz, 3H, CH3), 1.02 – 0.93 (m, 1H, C8-
H2);
 13C NMR (126 MHz, Chloroform-d) δ 207.2 (C1’), 131.4 (C4), 131.1 (C3), 55.6 (C1), 42.2 (C4a), 
35.7 (C8a), 33.1 (C5), 31.9 (C2), 30.3 (C8), 26.7 (CH2), 26.6 (CH2), 17.1 (CH3). Spectroscopic data are in 
accordance with the literature.221,233 
 
2-Methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methanol (90)233 
 
NaBH4 (1.5 eq.) was added slowly to a solution of 78a (40 mg, 0.22 mmol, 1.0 eq.) or 78b (83 mg, 
0.47 mmol, 1.0 eq.) in EtOH (5 mL/mmol) at 0 C, and the reaction was stirred for 1 hour. The 
reaction was quenched by addition of a saturated aqueous solution of NH4Cl and extracted with 
Et2O. The organic layers were combined, washed with H2O, brine, dried over Na2SO4, filtered, 
concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column; 0-10% 
EtOAc/hexanes) to give 90a (35 mg, 88%, dr 4:1) and 90b (77 mg, 91%, dr 4:1) as white solids. 90a - 
Chiral GC analysis Agilent Cyclosil-B (length: 30 m, thickness: 0.250 mm, film thickness: 0.25 μm), 
carrier gas: He, linear velocity: 40 cm/sec, temperature: 140 °C, tR minor (1R, 2R, 4aS, 8aR) 23.0 min, 
tR major (1S, 2S, 4aR, 8aS) 23.6 min, 87% ee; 90b - Chiral GC analysis Agilent Cyclosil-B (length: 30 m, 
thickness: 0.250 mm, film thickness: 0.25 μm), carrier gas: He, linear velocity: 40 cm/sec, 
temperature: 140 °C, tR major (1R, 2R, 4aS, 8aR) 23.0 min, tR minor (1S, 2S, 4aR, 8aS) 23.8 min, 84% 
ee; 1H NMR (400 MHz, Chloroform-d) δ 5.59 (ddd, J = 9.9, 4.8, 2.6 Hz, 1H, C3-H), 5.36 (d, J = 9.9 Hz, 
1H, C4-H), 3.83 (dd, J = 10.7, 5.4 Hz, 1H, C1’-H2), 3.53 (dd, J = 10.7, 9.3 Hz, 1H, C1’-H2), 2.49 – 2.33 (m, 
1H, C2-H), 1.81 – 1.64 (m, 6H, C1-H, C4a-H, C5-H2, C6-H2, C7-H2, C8-H2), 1.36 – 1.18 (m, 2H, C6-H2, C7-
H2), 1.16 – 1.06 (m, 1H, C8a-H), 1.06 – 0.95 (m, 2H, C5-H2, C8-H2), 0.92 (d, J = 7.0 Hz, 3H, CH3); 
13C 
NMR (101 MHz, Chloroform-d) δ 132.4 (C3), 131.4 (C4), 63.2 (C1’), 44.3 (C1), 43.7 (C4a), 37.8 (C8a), 
33.4 (C5), 31.6 (C2), 29.4 (C8), 26.9 (CH2), 26.7 (CH2), 15.6 (CH3). Spectroscopic data is in accordance 
with the literature.233 
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S-(tert-Butyl) 3-hydroxy-3-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)propanethioate 
(93) 
 
To a solution of i-Pr2NH (1.3 eq.) in anhydrous THF (4 mL/mmol) was added n-BuLi (1.2 eq., 2.3 M in 
hexanes) at 0 C and the mixture was stirred for 30 minutes. The solution was then cooled to -78 C 
and a solution of S-tert-butyl-thioacetate 92 (1.5 eq.) in anhydrous THF (2 mL/mmol) was added. 
After a further 30 minutes at -78 C, a solution of 78a (0.34 g, 1.9 mmol, 1.0 eq.) or 78b (0.5 g, 2.8 
mmol, 1.0 eq.) in anhydrous THF (2 mL/mmol) was added, and the reaction was stirred for 2 hours. 
The reaction was quenched by the addition of a saturated aqueous solution of NH4Cl, warmed to 
room temperature and extracted with EtOAc. The organic layers were combined, washed with H2O, 
brine, dried over Na2SO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-
packed SNAP column; 0-5% EtOAc/hexanes) to give 93a (0.38 g, 66%) and 93b (0.60 g, 69%) as 
colourless oils. 93a and 93b were obtained as an inconsequential 7:3 mixture of diastereomers. IR 
(thin film) ν max: 2920, 2851, 1680, 1670, 1456, 1364, 1030; 
1H NMR (400 MHz, Chloroform-d) 
δ(major diastereomer) 5.53 (ddd, J = 9.9, 4.9, 2.5 Hz, 1H, C3-H), 5.33 (d, J = 9.9 Hz, 1H, C4-H), 4.25 – 
4.11 (m, 1H, C3’-H), 2.79 (dd, J = 15.8, 9.3 Hz, 1H, C2’-H2), 2.70 (dd, J = 15.8, 2.9 Hz, 1H, C2’-H2), 2.52 
(d, J = 3.8 Hz, 1H, OH), 2.33 – 2.22 (m, 1H, C2-H), 2.08 – 1.97 (m, 1H, C8-H2), 1.85 – 1.67 (m, 4H, C4a-
H, C5-H2, C6-H2, C7-H2), 1.66 – 1.58 (m, 1H, C1-H), 1.47 (s, 9H, (CH3)3), 1.34 – 1.23 (m, 3H, C8a-H, C6-
H2, C7-H2), 1.18 – 1.03 (m, 2H, C5-H2, C8-H2), 0.99 (d, J = 7.0 Hz, 3H, CH3); 
13C NMR (101 MHz, 
Chloroform-d) δ(major diastereomer) 201.1 (C1’), 132.4 (C3), 131.5 (C4), 70.7 (C3’), 50.4 (C2’), 46.9 
(C1), 44.5 (C4a), 38.4 (C8a), 33.9 (C2), 33.7 (C5), 31.3 (C8), 29.9 ((CH3)3), 27.2 (CH2), 26.7 (CH2), 17.0 
(CH3); 
1H NMR (400 MHz, Chloroform-d) δ(minor diastereomer) 5.51 (ddd, J = 9.9, 5.0, 2.6 Hz, 1H, C3-
H), 5.32 (d, J = 9.9 Hz, 1H, C4-H), 4.46 – 4.33 (m, 1H, C3’-H), 2.81 (dd, J = 15.7, 10.0 Hz, 1H, C2’-H2), 
2.59 (dd, J = 15.7, 2.5 Hz, 1H, C2’-H2), 2.39 (d, J = 3.2 Hz, 1H, OH), 2.36 – 2.25 (m, 1H, C2-H), 2.09 – 
1.99 (m, 1H, C8-H2), 1.87 – 1.64 (m, 4H, C4a-H, C5-H2, C6-H2, C7-H2), 1.47 (s, 9H, (CH3)3), 1.45 – 1.41 
(m, 1H, C1-H), 1.42 – 1.34 (m, 1H, C8a-H), 1.34 – 1.21 (m, 2H, C6-H2, C7-H2), 1.14 – 1.02 (m, 1H, C5-
H2), 1.07 (d, J = 7.0 Hz, 3H, CH3), 1.04 – 0.94 (m, 1H, C8-H2);
 13C NMR (101 MHz, Chloroform-d) 
δ(minor diastereomer) 201.2 (C1’), 132.8 (C3), 130.9 (C4), 68.1 (C3’), 49.3 (C2’), 46.4 (C1), 44.6 (C4a), 
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36.9 (C8a), 33.5 (C5), 31.6 (C2), 29.9 ((CH3)3), 29.3 (C8), 26.9 (CH2), 26.8 (CH2), 18.3 (CH3); m/z (ES
+) 
333.19 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C18H30O2SNa [M+Na]
+: 333.1864, found 333.1855. 
 
S-(tert-Butyl) 3-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-3-oxopropanethioate (68) 
 
To a solution of 93a (0.29 g, 0.93 mmol, 1.0 eq.) or 93b (0.58 g, 1.88 mmol, 1.0 eq.) in DCM (10 
mL/mmol) at room temperature was added Dess-Martin Periodinane (1.2 eq.). The reaction was 
stirred for 2 hours before being quenched by addition of a 1:1 (v:v) saturated sodium thiosulfate: 
saturated sodium bicarbonate solution (10 mL/mmol). The mixture was extracted with DCM. The 
organic extracts were combined, washed with brine, dried over Na2SO4, filtered, concentrated in 
vacuo and purified via the Biotage SP4 (silica-packed SNAP column; 0-1% EtOAc/hexanes) to give 68a 
(0.23 g, 79%, dr 4:1) and 68b (0.48 g, 82%, dr 4:1). Spectroscopic data for the major diastereomer 
was in accordance with that obtained for 68a/b. 
 
Ethyl (2S,4S)-2-isopropyl-4-(N-methyl-3-((1S,2S,4aR,8aS)-2-methyl-1,2,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl)-3-oxopropanamido)-5-oxotetrahydrofuran-2-carboxylate (67a) 
To a solution of 52 (0.32 g, 0.97 mmol, 1.0 eq.) in THF (2.5 mL) at 0 C was added HCl (0.97 mL, 4 eq., 
4 N in dioxane). The reaction was stirred for 10 minutes at this temperature before the addition of a 
solution of NaBH3CN (0.18 g, 2.92 mmol, 3.0 eq.) in MeOH (5 mL). The reaction was stirred for a 
further 1 hour at 0 C before being concentrated in vacuo. The residue was partitioned between a 
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saturated aqueous solution of NaHCO3 (5 mL) and EtOAc (5 mL). The aqueous layer was extracted 
with EtOAc (3  5 mL) and the combined organic extracts were washed with brine (10 mL), dried 
over Na2SO4, filtered and concentrated in vacuo to yield the crude free amine 53. To a solution of 53 
in anhydrous THF (12 mL) at 0 C was added 68a (0.27 g, 0.88 mmol, 0.9 eq.) followed by Et3N (0.54 
mL, 3.89 mmol, 4.0 eq.) and CF3CO2Ag (0.43 g, 1.95 mmol, 2.0 eq.). The reaction was then stirred for 
1 hour at 0 C followed by 1 hour at room temperature. The reaction was concentrated in vacuo and 
purified via the Biotage SP4 (silica-packed SNAP column 12 g; 0-40% EtOAc/hexanes) to give 67a as a 
pale yellow oil (0.30 g, 76%). IR (thin film) ν max: 2963, 2922, 2853, 1786, 1734 (C=O), 1717, 1647 
(C=O), 1260, 1022; 1H NMR (500 MHz, Chloroform-d) δ 5.55 (ddd, J = 9.9, 4.7, 2.6 Hz, 1H, C3-H), 5.39 
(d, J = 9.9 Hz, 1H, C4-H), 4.76 (dd, J = 11.5, 9.1 Hz, 1H, C4’’-H), 4.33 – 4.19 (m, 2H, CO2CH2CH3), 3.60 
(d, J = 15.1 Hz, 1H, C2’-H2), 3.53 (d, J = 15.1 Hz, 1H, C2’-H2), 3.02 (s, 3H, NCH3), 3.00 – 2.93 (m, 1H, C1-
H), 2.68 (dd, J = 12.8, 9.1 Hz, 1H, C3’’-H2), 2.65 – 2.57 (m, 1H, C2-H), 2.48 (dd, J = 12.8, 11.5 Hz, 1H, 
C3’’-H2), 2.39 – 2.30 (m, 1H, C1’’’-H), 1.93 – 1.82 (m, 1H, C8-H2), 1.79 – 1.66 (m, 4H, C4a-H, C5-H2, C6-
H2, C7-H2), 1.52 – 1.42 (m, 1H, C8a-H), 1.37 – 1.27 (m, 2H, C6-H2, C7-H2), 1.32 (t, J = 7.2 Hz, 3H, 
CO2CH2CH3), 1.31 – 1.22 (m, 1H, C8-H2), 1.09 – 0.99 (m, 1H, C5-H2), 1.05 (d, J = 7.1 Hz, 3H, C2’’’-H3), 
1.03 (d, J = 6.8 Hz, 3H, C2’’’-H3), 0.83 (d, J = 7.1 Hz, 3H, CH3); 
13C NMR (126 MHz, Chloroform-d) δ 
205.7 (C3’), 172.1 (C1’’), 171.0 (CO2Et), 167.2 (C1’), 131.4 (C4), 130.5 (C3), 87.2 (C2’’), 62.4 
(CO2CH2CH3), 56.8 (C4’’), 55.8 (C1), 50.3 (C2’), 42.1 (C4a), 36.3 (C8a), 35.6 (NCH3), 34.2 (C1’’’), 33.2 
(C5), 31.7 (C2), 31.4 (C3’’), 29.6 (C8), 26.7 (CH2), 26.6 (CH2), 17.8 (CH3), 17.0 (C2’’’), 16.5 (C2’’’), 14.3 
(CO2CH2CH3); m/z (ES
+) 470.25 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C25H37O6NNa [M+Na]
+: 
470.2513, found 470.2507. 
 
Ethyl (2S,4S)-2-isopropyl-4-(N-methyl-3-((1R,2R,4aS,8aR)-2-methyl-1,2,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl)-3-oxopropanamido)-5-oxotetrahydrofuran-2-carboxylate (67b) 
To a solution of 52 (0.31 g, 0.95 mmol, 1.0 eq.) in THF (2.5 mL) at 0 C was added HCl (0.95 mL, 4 eq., 
4 N in dioxane). The reaction was stirred for 10 minutes at this temperature before the addition of a 
solution of NaBH3CN (0.18 g, 2.85 mmol, 3.0 eq.) in MeOH (5 mL). The reaction was stirred for a 
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further 1 hour at 0 C before being concentrated in vacuo. The residue was partitioned between a 
saturated aqueous solution of NaHCO3 (5 mL) and EtOAc (5 mL). The aqueous layer was extracted 
with EtOAc (3  5 mL) and the combined organic extracts were washed with brine (10 mL), dried 
over Na2SO4, filtered and concentrated in vacuo to yield the crude free amine 53. To a solution of 53 
in anhydrous THF (12 mL) at 0 C was added 68b (0.26 g, 0.86 mmol, 0.9 eq.) followed by Et3N (0.53 
mL, 3.82 mmol, 4.0 eq.) and CF3CO2Ag (0.42 g, 1.91 mmol, 2.0 eq.). The reaction was then stirred for 
1 hour at 0 C followed by 1 hour at room temperature. The reaction was concentrated in vacuo and 
purified via the Biotage SP4 (silica-packed SNAP column 12 g; 0-40% EtOAc/hexanes) to give 77b as a 
pale yellow oil (0.27 g, 71%). IR (thin film) ν max: 2924, 2853, 1790, 1734 (C=O), 1717, 1647 (C=O), 
1624, 1261, 1022; 1H NMR (500 MHz, Chloroform-d) δ 5.55 (ddd, J = 9.9, 4.7, 2.6 Hz, 1H, C3-H), 5.39 
(d, J = 9.9 Hz, 1H, C4-H), 5.01 (dd, J = 11.6, 9.1 Hz, 1H, C4’’-H), 4.33 – 4.20 (m, 2H, CO2CH2CH3), 3.59 
(s, 2H, C2’-H2), 2.99 (s, 3H, NCH3), 2.97 – 2.91 (m, 1H, C1-H), 2.71 (dd, J = 12.9, 9.1 Hz, 1H, C3’’-H2), 
2.66 – 2.57 (m, 1H, C2-H), 2.42 (dd, J = 12.9, 11.6 Hz, 1H, C3’’-H2), 2.38 – 2.30 (m, 1H, C1’’’-H), 1.90 – 
1.81 (m, 1H, C8-H2), 1.79 – 1.65 (m, 4H, C4a-H, C5-H2, C6-H2, C7-H2), 1.53 – 1.42 (m, 1H, C8a-H), 1.32 
(t, J = 7.1 Hz, 3H, CO2CH2CH3), 1.37 – 1.27 (m, 3H, C6-H2, C7-H2, C8-H2), 1.05 (d, J = 6.9 Hz, 3H, C2’’’-
H3), 1.09 – 0.99 (m, 1H, C5-H2), 1.03 (d, J = 6.8 Hz, 3H, C2’’’-H3), 0.84 (d, J = 7.1 Hz, 3H, CH3); 
13C NMR 
(126 MHz, Chloroform-d) δ 205.7 (C3’), 172.3 (C1’’), 170.9 (CO2Et), 167.4 (C1’), 131.4 (C4), 130.5 (C3), 
87.1 (C2’’), 62.4 (CO2CH2CH3), 55.9 (C4’’, C1), 50.4 (C2’), 42.2 (C4a), 36.4 (C8a), 34.7 (NCH3), 34.3 
(C1’’’), 33.2 (C5), 31.7 (C2), 31.5 (C3’’), 29.7 (C8), 26.8 (CH2), 26.6 (CH2), 17.8 (CH3), 17.0 (C2’’’), 16.4 
(C2’’’), 14.3 (CO2CH2CH3); m/z (ES
+) 470.25 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C25H37O6NNa 
[M+Na]+: 470.2513, found 470.2506. 
 
(1S,2S,4aR,8aS,5’S,7’S) – JBIR-22 (4a) 
 
To a solution of 67a (226 mg, 0.50 mmol, 1.0 eq.) in THF (10 mL) at 0 C was added tBuOK (62 mg, 
0.56 mmol, 1.1 eq.) and the reaction was stirred for 1 hour. The reaction was slowly warmed to 
room temperature and stirred at this temperature for 1 hour. The reaction was concentrated in 
vacuo and the residue partitioned between DCM (10 mL) and an aqueous solution of HCl (10 mL, 
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1N). The aqueous layer was separated and extracted with DCM (3  10 mL). The organic extracts 
were combined, washed with an aqueous solution of HCl (5 mL, 1 N), brine (5 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to give JBIR-22 ethyl ester 77a as a colourless oil (226 mg, 
100%), which was used in the next step without further purification. To a solution of 77a (215 mg, 
0.48 mmol, 1.0 eq.) in EtOH (4 mL) was added an aqueous solution of NaOH (3 mL, 2N) and the 
reaction was heated to 110 C under microwave irradiation for 20 minutes. The reaction was diluted 
with an aqueous solution of HCl (5 mL, 1N) and extracted with DCM (3  5 mL). The organic extracts 
were combined, washed with brine (10 mL), dried over Na2SO4, filtered, concentrated in vacuo and 
purified via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 g; 20-100% 
H2O/(MeOH:MeCN)) to give the title product 4a as an orange solid (143 mg, 71%). A portion of 4a 
was treated with Et2N to form the salt. Spectroscopic data was obtained for the JBIR-22 4a-Et2N salt. 
* +D
2 = +71.4 (c 0.7, MeOH); IR (thin film) ν max: 2920, 2849, 1645, 1616, 1570, 1447, 1387, 1233, 
1032, 999, 891, 779; 1H NMR (500 MHz, Acetone-d6) δ 5.54 (ddd, J = 9.8, 4.5, 2.5 Hz, 1H, C4-H), 5.30 
(d, J = 9.8 Hz, 1H, C5-H), 3.90 (dd, J = 11.5, 5.8 Hz, 1H, C2-H), 3.41 (dd, J = 10.0, 1.3 Hz, 1H, C5’-H), 
2.73 (s, 3H, C10’-H3), 2.70 – 2.59 (m, 1H, C3-H), 2.31 (dd, J = 13.7, 1.3 Hz, 1H, C6’-H2), 2.04 – 1.97 (m, 
1H, C8’-H), 2.00 – 1.91 (m, 1H, C10-H2), 1.73 – 1.70 (m, 1H, C7-H2), 1.70 – 1.67 (m, 1H, C6-H), 1.67 – 
1.65 (m, 2H, C8-H2, C9-H2), 1.62 (dd, J = 13.7, 10.0 Hz, 1H, C6’-H2), 1.52 – 1.38 (m, 1H, C11-H), 1.30 – 
1.28 (m, 2H, C8-H2, C9-H2), 1.09 – 0.97 (m, 1H, C7-H2), 0.91 (d, J = 6.6 Hz, 3H, C9’-H3), 0.90 (d, J = 6.6 
Hz, 3H, C12’-H3), 0.77 (d, J = 7.2 Hz, 3H, C12-H3), 0.75 – 0.63 (m, 1H, C10-H2); 
13C NMR (126 MHz, 
Acetone-d6) δ 196.3 (C1), 196.1 (C4’), 180.9 (C11’), 174.7 (C2’), 133.6 (C4), 131.1 (C5), 101.9 (C3’), 
80.0 (C7’), 63.3 (C5’), 51.0 (C2), 43.4 (C6), 37.4 (C11), 37.3 (C6’), 36.6 (C8’), 34.4 (C7), 32.2 (C3), 31.1 
(C10), 27.7 (C9), 27.6 (C8), 26.9 (C10’), 18.8 (C9’), 18.4 (C12), 16.9 (C12’). m/z (ES-) 418.22 ([M-H]-, 
100 %); HRMS (ES-) Calcd for C23H32O6N [M-H]
-: 418.2235, found 418.2226. 
 
(1R,2R,4aS,8aR,5’S,7’S) – JBIR-22 (4b) 
 
To a solution of 67b (121 mg, 0.27 mmol, 1.0 eq.) in THF (5 mL) at 0 C was added tBuOK (34 mg, 
0.30 mmol, 1.1 eq.) and the reaction was stirred for 1 hour. The reaction was slowly warmed to 
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room temperature and stirred at this temperature for 1 hour. The reaction was concentrated and 
the residue partitioned between DCM (5 mL) and an aqueous solution of HCl (5 mL, 1N). The 
aqueous layer was separated and extracted with DCM (3  10 mL). The organic extracts were 
combined, washed with HCl (5 mL, 1 N), brine (5 mL), dried over Na2SO4, filtered and concentrated in 
vacuo to give JBIR-22 ethyl ester 77b as a colourless oil (121 mg, 100%), which was used in the next 
step without further purification. To a solution of 77b (110 mg, 0.25 mmol, 1.0 eq.) in EtOH (3 mL) 
was added an aqueous solution of NaOH (2 mL, 2N) and the reaction was heated to 110 C under 
microwave irradiation for 20 minutes. The reaction was diluted with an aqueous solution of HCl (5 
mL, 1N) and extracted with DCM (3  5 mL). The organic layers were combined, washed with brine 
(10 mL), dried over Na2SO4, filtered, concentrated in vacuo and purified via the Biotage SP4 
(Reverse-phase silica-packed SNAP column 4 g; 20-100% H2O/(MeOH:MeCN)) to give the title 
product 4b as an orange solid (78 mg, 74%). A portion of 4b was treated with Et2N to form the salt. 
Spectroscopic data was obtained for the JBIR-22 4b-Et2N salt. * +D
2 = -20.5 (c 0.7, MeOH); IR (thin 
film) ν max: 2916, 2849, 1647, 1560, 1437, 1387, 1234, 1065, 1032, 997, 891, 781; 
1H NMR (500 MHz, 
Acetone-d6) δ 5.52 (ddd, J = 9.8, 4.5, 2.5 Hz, 1H, C4-H), 5.30 (d, J = 9.8 Hz, 1H, C5-H), 3.92 (dd, J = 
11.5, 5.8 Hz, 1H, C2-H), 3.36 (dd, J = 10.0, 1.2 Hz, 1H, C5’-H), 2.72 (s, 3H, C10’-H3), 2.65 – 2.55 (m, 1H, 
C3-H), 2.31 (dd, J = 13.7, 1.2 Hz, 1H, C6’-H), 2.02 – 1.97 (m, 2H, C8’-H, C10-H2), 1.74 – 1.70 (m, 1H, 
C7-H2), 1.70 – 1.68 (m, 3H, C6-H, C8-H2, C9-H2), 1.64 (dd, J = 13.7, 10.0 Hz, 1H, C6’-H2), 1.51 – 1.40 
(m, 1H, C11-H), 1.29 – 1.27 (m, 2H, C8-H2, C9-H2), 1.09 – 0.98 (m, 1H, C7-H2), 0.91 (d, J = 6.6 Hz, 3H, 
C9’-H3), 0.91 (d, J = 6.6 Hz, 3H, C12’-H3), 0.75 (d, J = 7.3 Hz, 3H, C12-H3), 0.73 – 0.68 (m, 1H, C10-H2); 
13C NMR (126 MHz, Acetone-d6) δ 196.4 (C1), 195.7 (C4’), 180.1 (C11’), 174.8 (C2’), 133.4 (C4), 131.2 
(C5), 101.5 (C3’), 79.9 (C7’), 63.2 (C5’), 51.0 (C2), 43.3 (C6), 37.3 (C11), 37.1 (C6’), 36.6 (C8’), 34.4 
(C7), 32.3 (C3), 31.0 (C10), 27.7 (C9, C8), 26.8 (C10’), 18.6 (C9’), 18.3 (C12), 16.8 (C12’); m/z (ES-) 
418.22 ([M-H]-, 100 %); HRMS (ES-) Calcd for C23H32O6N [M-H]
-: 418.2235, found 418.2226. 
 
Isopropyl (2S,4S)-4-(4-(diethoxyphosphoryl)-N-methyl-3-oxobutanamido)-2-isopropyl-5-
oxotetrahydrofuran-2-carboxylate (96) 
To a solution of 52 (205 mg, 0.62 mmol, 1.0 eq.) in THF (1.5 mL) at 0 C was added HCl (0.62 mL, 4 
eq., 4 N in dioxane). The reaction was stirred for 10 minutes at this temperature before the addition 
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of a solution of NaBH3CN (117 mg, 1.86 mmol, 3.0 eq.) in MeOH (3 mL). The reaction was stirred for 
a further 1 hour at 0 C before being concentrated in vacuo. The residue was partitioned between a 
saturated aqueous solution of NaHCO3 (5 mL) and EtOAc (5 mL). The aqueous layer was extracted 
with EtOAc (3  5 mL) and the combined organic extracts were washed with brine (10 mL), dried 
over Na2SO4, filtered and concentrated in vacuo to yield the crude free amine 53. To a solution of 53 
in anhydrous MeCN (6 mL) was added a solution of 63 in anhydrous MeCN (3 mL), and the reaction 
was heated at reflux for 2.5 hours. The reaction was concentrated in vacuo and purified via the 
Biotage SP4 (silica-packed SNAP column 12 g; 0-8% MeOH/DCM) to give the title product 96 as an 
orange oil (220 mg, 79%). In CDCl3 at room temperature the title compound 96 exists as a (7 : 3) enol 
: keto mixture. The NMR signals are reported for the major keto tautomer. 1H and 13C spectra are 
complicated by 31P splitting. IR (thin film) ν max: 2978, 2936, 1784, 1734 (C=O), 1636 (C=O), 1236, 
1184, 1022; 1H NMR (500 MHz, Chloroform-d) δ 4.83 – 4.71 (m, 1H, C4-H), 4.33 – 4.21 (m, 2H, C3’’-
H2), 4.21 – 4.07 (m, 4H, (C7’-H2)2), 3.81 (s, 2H, C2’-H2), 3.25 (dd, J = 22.6, 4.4 Hz, 2H, C4’-H2), 3.01 (s, 
3H, NCH3), 2.68 (dd, J = 12.8, 9.1 Hz, 1H, C3-H2), 2.47 (dd, J = 12.8, 11.4 Hz, 1H, C3-H2), 2.38 – 2.29 
(m, 1H, C1’’’-H), 1.37 – 1.28 (m, 9H, C4’’-H3, (C8’-H3)2), 1.05 (d, J = 6.9 Hz, 3H, C2’’’-H3), 1.02 (d, J = 6.9 
Hz, 3H, C2’’’-H3); 
13C NMR (126 MHz, Chloroform-d) δ 195.7 (C3’), 172.1 (C5), 171.0 (C1’’), 167.3 
(C1’), 87.2 (C2), 63.0 (d, J = 6.5 Hz, C7’), 62.4 (C3’’), 56.7 (C4), 49.7 (C2’), 42.5 (d, J = 125.9 Hz, C4’), 
35.3 (NCH3), 34.2 (C1’’’), 31.5 (C3), 17.0 (C2’’’), 16.5 (C2’’’), 16.4 (C8’), 14.3 (C4’’). 
31P NMR (202 MHz, 
Chloroform-d) δ 19.2. m/z (ES+) 472.17 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C19H32O9NPNa 
[M+Na]+: 472.1707, found 472.1696; * +D
2  = -9.2 (c 1.0, MeOH). 
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Ethyl (2S,4S)-2-isopropyl-4-((4E,10E,12E)-N-methyl-3-oxotetradeca-4,10,12-trienamido)-5-
oxotetrahydrofuran-2-carboxylate (94) 
 
To a solution of 52 (0.53 g, 1.59 mmol, 1.0 eq.) in THF (4 mL) at 0 C was added HCl (1.59 mL, 4 eq., 4 
N in dioxane). The reaction was stirred for 10 minutes at this temperature before the addition of a 
solution NaBH3CN (0.30 g, 4.77 mmol, 3.0 eq.) in MeOH (8 mL). The reaction was stirred for a further 
1 hour at 0 C before being concentrated in vacuo. The residue was partitioned between a saturated 
aqueous solution of NaHCO3 (10 mL) and EtOAc (10 mL). The aqueous layer was extracted with 
EtOAc (3  10 mL) and the combined organic extracts were washed with brine (10 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to yield the crude free amine 53. To a solution of 53 in 
anhydrous THF (19 mL) at 0 C was added a solution of 66 (0.39 g, 1.27 mmol, 0.8 eq.) in anhydrous 
THF (13 mL), followed by Et3N (0.89 mL, 6.36 mmol, 4.0 eq.) and CF3CO2Ag (0.70 g, 3.18 mmol, 2.0 
eq.). The reaction was then stirred for 1 hour at 0 C followed by 1 hour at room temperature. The 
reaction was concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 12 
g; 0-40% EtOAc/hexanes) to give 94 as a pale yellow oil (0.38 g, 67%). In CDCl3 at room temperature 
the title compound 94 exists as a (5 : 4) enol : keto mixture. IR (thin film) ν max: 2970, 2936, 1790, 
1734 (C=O), 1647 (C=O), 1184; 1H NMR (500 MHz, Chloroform-d) δ(major enol-form) 6.65 (ddd, J = 
15.0, 8.9, 5.3 Hz, 1H, C5’-H), 6.05 – 5.93 (m, 2H, C11’-H, C12’-H), 5.85 – 5.75 (m, 1H, C4’-H), 5.63 – 
5.46 (m, 2H, C10’-H, C13’-H), 5.12 (s, 1H, C2’-H), 4.99 – 4.92 (m, 1H, C4-H), 4.33 – 4.21 (m, 2H, C3’’-
H2), 2.99 (s, 3H, NCH3), 2.74 – 2.61 (m, 1H, C3-H2), 2.52 – 2.39 (m, 1H, C3-H2), 2.38 – 2.28 (m, 1H, 
C1’’’-H), 2.22 – 2.14 (m, 2H, C6’-H2), 2.10 – 2.02 (m, 2H, C9’-H2), 1.72 (d, J = 6.7 Hz, 3H, C14’-H3), 1.54 
– 1.37 (m, 4H, C7’-H2, C8’-H2), 1.36 – 1.26 (m, 3H, C4’’-H3), 1.09 – 0.99 (m, 6H, (C2’’’-H3)2); 
13C NMR 
Chapter 3: Natural Products 
 
148 
 
(126 MHz, Chloroform-d) δ(major enol-form) 172.6 (C1’), 172.2 (C5), 171.0 (C1’’), 170.4 (C3’), 140.8 
(C5’), 131.7 (C10’), 131.6 (C12’), 130.7 (C11’), 127.1 (C13’), 125.3 (C4’), 87.6 (C2’), 87.2 (C2), 62.4 
(C3’’), 55.8 (C4), 34.3 (C1’’’), 34.2 (NCH3), 32.6 (CH2), 32.3 (CH2), 31.5 (C3), 29.1 (CH2), 28.1 (CH2), 18.2 
(C14’), 17.0 (C2’’’), 16.5 (C2’’’), 14.3 (C4’’); 1H NMR (500 MHz, Chloroform-d) δ(minor keto-form) 7.00 
– 6.89 (m, 1H, C5’-H), 6.17 (d, J = 16.3 Hz, 1H, C4’-H), 6.08 – 5.88 (m, 2H, C11’-H, C12’-H), 5.64 – 5.49 
(m, 2H, C10’-H, C13’-H), 4.79 (dd, J = 11.5, 9.0 Hz, 1H, C4-H), 4.36 – 4.18 (m, 2H, C3’’-H2), 3.71 (d, J = 
2.9 Hz, 2H, C2’-H2), 3.00 (s, 3H, NCH3), 2.73 – 2.62 (m, 1H, C3-H2), 2.52 – 2.39 (m, 1H, C3-H2), 2.40 – 
2.29 (m, 1H, C1’’’-H), 2.30 – 2.20 (m, 2H, C6’-H2), 2.10 – 2.02 (m, 2H, C9’-H2), 1.72 (d, J = 6.7 Hz, 3H, 
C14’-H3), 1.54 – 1.44 (m, 4H, C7’-H2, C8’-H2), 1.36 – 1.28 (m, 3H, C4’’-H3), 1.09 – 0.99 (m, 6H, (C2’’’-
H3)2); 
13C NMR (126 MHz, Chloroform-d) δ(minor keto-form) 193.1 (C3’), 172.2 (C5), 171.0 (C1’’), 
167.7 (C1’), 150.8 (C5’), 131.7 (C10’), 131.4 (C12’), 130.9 (C11’), 129.5 (C4’), 127.3 (C13’), 87.1 (C2), 
62.4 (C3’’), 56.7 (C4), 47.2 (C2’), 34.3 (C1’’’), 35.4 (NCH3), 32.6 (CH2), 32.5 (CH2), 32.0 (C3), 29.1 (CH2), 
27.5 (CH2), 18.2 (C14’), 17.0 (C2’’’), 16.5 (C2’’’), 14.3 (C4’’);
 m/z (ES+) 448.27 ([M+H]+, 100 %); HRMS 
(ES+) Calcd for C25H38O6N [M+H]
+: 448.2694, found 448.2691; * +D
2  = +16.5 (c 1.0, MeOH). 
 
Ethyl (S)-2-hydroxy-2-(((S,E)-4-((2E,8E,10E)-1-hydroxydodeca-2,8,10-trien-1-ylidene)-1-methyl-3,5-
dioxopyrrolidin-2-yl)methyl)-3-methylbutanoate (65) 
 
Route A: To a solution of 94 (170 mg, 0.38 mmol, 1.0 eq.) in THF (8 mL) at 0 C was added tBuOK (47 
mg, 0.42 mmol, 1.1 eq.) and the reaction was stirred for 1 hour. The reaction was slowly warmed to 
room temperature and stirred for a further 1 hour. The reaction was concentrated and the residue 
partitioned between DCM (10 mL) and an aqueous solution of HCl (10 mL, 1N). The aqueous layer 
was separated and extracted with DCM (3  10 mL). The organic extracts were combined, washed 
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with an aqueous solution of HCl (5 mL), brine (5 mL), dried over Na2SO4, filtered, concentrated in 
vacuo and purified via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 g; 20-100% 
H2O/(MeOH:MeCN)) to give the title product 65 as an yellow oil (159 mg, 94%). 
Route B: To a solution of 96 (100, 0.22 mmol, 1.0 eq.) in THF (2.5 mL) at 0 C was added tBuOK (0.24 
mL, 1.1 eq., 1M in THF) and the reaction was stirred for 40 minutes. To the mixture was added a 
solution of 75 (102 mg, 0.67 mmol, 3.0 eq.) in THF (1 mL) and the reaction was stirred for a further 
15 minutes before being warmed to room temperature and stirred for 16 hours. The reaction was 
quenched by the addition of an aqueous solution of HCl (3 mL, 1N) and extracted with DCM (3  10 
mL). The organic extracts were combined, washed with brine (10 mL), dried over Na2SO4, filtered, 
concentrated in vacuo and purified via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 
g; 20-100% H2O/(MeOH:MeCN)) to give the title product 65 as an yellow oil (83 mg, 85%). IR (thin 
film) ν max: 2964, 2931, 1717 (C=O), 1690 (C=O), 1645 (C=O), 1586, 1449, 1242, 989; 
1H NMR (500 
MHz, Chloroform-d) δ 7.24 – 7.13 (m, 1H, C3’-H), 7.08 – 7.03 (m, 1H, C2’-H), 6.04 – 5.90 (m, 2H, C9’-
H, C10’-H), 5.62 – 5.45 (m, 2H, C8’-H, C11’-H), 4.24 (q, J = 7.1 Hz, 2H, C3’’’-H2), 3.67 (dd, J = 9.6, 2.2 
Hz, 1H, C2-H), 2.97 (s, 3H, NCH3), 2.37 – 2.29 (m, 2H, C4’-H2), 2.30 – 2.28 (m, 1H, C1’’-H2), 2.10 – 2.00 
(m, 3H, C3’’-H, C7’-H2), 1.90 (dd, J = 14.5, 9.6 Hz, 1H, C1’’-H2), 1.71 (d, J = 6.4 Hz, 3H, C12’-H3), 1.57 – 
1.45 (m, 2H, C5’-H2), 1.46 – 1.37 (m, 2H, C6’-H2), 1.31 (t, J = 7.1 Hz, 3H, C4’’’-H3), 0.94 (d, J = 7.3 Hz, 
3H, C4’’-H3), 0.93 (d, 7.3 Hz, 3H, C4’’-H3); 
13C NMR (126 MHz, Chloroform-d) δ 196.3 (C3), 175.5 
(C1’’’), 175.1 (C1’), 173.4 (C5), 151.8 (C3’), 131.6 (C10’), 131.4 (C8’), 130.8 (C9’), 127.2 (C11’), 121.6 
(C2’), 98.9 (C4), 78.8 (C2’’), 64.5 (C2), 61.6 (C3’’’), 36.8 (C3’’), 34.9 (C1’’), 33.3 (C4’), 32.4 (C7’), 29.1 
(C6’), 27.7 (C5’), 26.8 (NCH3), 18.1 (C12’), 17.5 (C4’’), 16.4 (C4’’), 14.5 (C4’’’); m/z (ES
-) 446.25 ([M-H]-, 
100 %); HRMS (ES-) Calcd for C25H36O6N [M-H]
-: 446.2548, found 446.2549. 
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4 Design and Development of Peptidomimetic Inhibitors of PICK1 
PDZ mediated PPIs 
 
4.1 Introduction 
 
4.1.1 Peptidomimetics 
The direct application of native proteins/peptides as pharmacologically active compounds is a widely 
exploited starting point in the development of PPI modulators.261 However, the low bioavailability, 
poor proteolytic stability and off-target effects of the conformationally flexible polypeptides has 
limited the clinical application of peptide-based drug discovery (PBDD).262 One way to overcome the 
drawbacks associated with native peptides is the development of peptidomimetics.261,263,264 These 
are small molecules which are designed to mimic the biological activity of peptides but with 
improved pharmacodynamic and pharmacokinetic profiles. Numerous examples of three-
dimensional X-ray crystallographic or NMR spectroscopic structures of proteins complexed with their 
biological partners have facilitated the rational structure-based design of peptidomimetic PPI 
inhibitors through modification of novel scaffolds or the optimisation of native peptide 
ligands.261,264,1  
 
Peptidomimetics are classified as structural mimetics (Type-I), functional mimetics (Type-II) or 
topographical mimetics (Type-III).262,263 Type-I peptidomimetics or pseudopeptides typically contain a 
structurally similar peptide backbone bearing the required functionalities to mimic the side-chains of 
the native amino acids. Several successful examples of type-I peptidomimetics have been reported, 
including the recently developed inhibitors of the MLL1-WDR5 PPI (Figure 4.1).265 Mixed lineage 
leukemia 1 (MLL1) is a histone-lysine-methyltransferase (HMT) responsible for the methylation of 
histones. Disruption of the MLL1-WDR5 PPI through point mutations at WDR5 caused dissociation of 
the protein complex and loss of MLL1 HMT activity.266 This makes small molecule inhibition of the 
MLL1-WDR5 PPI a highly promising strategy for the treatment of certain forms of leukemia. Previous 
studies had identified tripeptide Ac-ARA-NH2 1, the minimum binding epitope of MLL1, to be a 
potent binder of WDR5 (Ki = 120 nM). Systematic evaluation of the binding of 1 to WDR5 through the 
incorporation of natural and unnatural amino acids resulted in MM-101 2, which had a 100-fold 
increase in binding affinity (Ki = <1 nM) (Figure 4.1). Most importantly, 2 was effective at inhibiting 
cell growth and inducing apoptosis in MLL1 mediated leukemia without general toxicity to normal 
bone marrow cells or non-MLL cells.267  
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Figure 4.1. Development of a novel MLL1-WDR5 PPI inhibitor 2 from tripeptide 1.
1
 
 
Type-II peptidomimetics are small non-peptide molecules which do not mimic the structure of the 
parent peptide but can bind to the peptide receptor and modulate the associated PPI. Initially, type 
II mimetics were considered to be direct structural analogues of the natural peptide, but further 
studies indicate that a large number of these antagonists bind to receptor subsites different than 
those used by the parent peptide. Despite this uncertainty, the approach has been successful in 
producing a number of potential drug lead structures; in particular the identification of several G-
protein coupled receptor (GPCR) antagonists.263  
 
Type-III peptidomimetics represent the ideal concept for mimetics and are characterised by novel 
non-peptide scaffolds, containing the required functional groups in a well-defined spatial orientation 
to form a strong interaction with the biological target.262,263 Structure-based design coupled with 
structure-activity relationship studies are first used to define the minimum binding epitope and the 
main pharmacophoric elements involved in binding. A novel scaffold is then designed which aligns 
the critical structural features, in a 3D arrangement, to facilitate strong binding to the biological 
target. The resulting peptidomimetic is expected to produce a similar physiological response to that 
observed with the native peptide, but with enhanced properties such as higher proteolytic stability, 
increased bioavailability and improved potency and selectivity.261 Type-III peptidomimetics have 
been used successfully to target a range of PPIs involved in cancer progression. By combining 
chemical synthesis with X-ray crystallography and conformational analysis, Rew et al. discovered 
novel inhibitors of the p53-MDM2 PPI,268 an important negative regulator of the tumour suppressor 
protein p53269 (see Chapter 5 for further discussion on the biological significance of the p53-MDM2 
PPI). This structure-based design approach identified AM-8553 (3), a highly potent (IC50 = 2.2 nM), 
selective and orally bioavailable inhibitor of the p53-MDM2 PPI.268 In addition, type-III 
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peptidomimetics have proven to be a rich source of potent, cell permeable inhibitors of PDZ domain 
mediated PPIs.270–275  
 
 
Figure 4.2. The structure of p53-MDM2 PPI inhibitor AM-8553 (3).
268
 
 
4.1.2 PDZ Domains 
PSD-95/Discs-large/ZO-1 homology (PDZ) domains are among the most common protein domains in 
the human genome, playing important roles in several therapeutically relevant protein–protein 
interactions, like those involved in protein trafficking and the formation of multiprotein signalling 
complexes.276 The role of PDZ domains in the clustering and localisation of proteins at the plasma 
membrane has important biological implications, e.g. in signalling, mediating the adhesive properties 
of specific cells, ion transport and formation of the paracellular barriers (tight junctions).276,277 
 
Of all canonical PPIs, PDZ domains are the most similar to traditional ligand–receptor interactions, as 
the interaction interface is comprised of a groove on the PDZ domain, binding to the terminal (3–5) 
amino-acid residues of the C-terminus of its interacting partner (Figure 4.3).278 The structure of the 
PDZ domain comprises of six β-strands (βA-βF) and two -helices (A and B), which fold into a six-
stranded β-sandwich domain (Figure 4.3). Peptide ligands bind in an extended groove between 
strand βB and helix B, thus serving as an additional antiparallel β-strand within the PDZ domain. As 
only three residues of the PDZ binding motif contribute to the majority of the energetics of the 
interaction with the PDZ domain (the ‘hotspot’), the development of a predictive pharmacophore 
model leading to the identification of a nonpeptide small-molecule inhibitor is thought possible.279  
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Figure 4.3. A ribbon representation of the structure of PSD-95 PDZ2. The canonical fold contains six β-sheets and two  -
helices. A peptide ligand (orange) is shown bound to the PDZ between the βB strand and  B helix.
280
  
 
Recent evidence has supported the idea that PDZ domains might be valuable drug targets. 
Membrane-permeable peptides that block the PDZ interaction between PSD-95 and the NMDA 
glutamate receptor result in the selective inhibition of neuronal nitric oxide synthase (nNOS) 
activation.281 This effect is believed to reduce ischemic brain injury during stroke. Other recent 
findings suggest that blocking the PDZ domains of the NHERF-1,274 AF-6,282 or dishevelled283 proteins 
which are involved in cell signalling and cell differentiation might provide potential therapeutic 
approaches towards the treatment of cancer.284 Furthermore, the PDZ domain of the PICK1 protein, 
which binds to the C-terminus of ionotropic glutamate receptors, has recently been recognised as a 
valid therapeutic target for the treatment of brain ischemia, pain and cocaine addiction.285  
 
4.1.3 Protein Interacting with C Kinase (PICK1) 
Protein interacting with C kinase (PICK1) is a scaffolding protein containing a single N-terminal PDZ 
domain that interacts with the PDZ motifs of several proteins, which have roles in neuronal cell 
morphology, mitochondrial-dependent apoptosis and synaptic plasticity.286 PICK1 regulates the 
synaptic clustering, trafficking and recycling of its interacting partners, by facilitating their PKC 
(protein kinase C)-mediated phosphorylation.287,276  
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4.1.4 PICK1 in the brain 
PICK1 has been studied extensively due to its role in regulating several important neuronal proteins 
and its interactions with a number of disease-associated proteins implicated in cancer,288 
schizophrenia289 and pain.278 At the synapse, PICK1 has been shown to have an important role in 
neurotransmission, plasticity, neurotransmitter vesicle docking and receptor cycling.290 PICK1 
interacts with the C-terminal tail of AMPAR subunits GluR2 and GluR3.291 It was reported to change 
the subcellular localisation of GluR2, regulating the removal and insertion of AMPARs from the 
plasma membrane, a process that plays an important role in regulating long-term depression (LTD) 
and long-term potentiation (LTP).290 These processes have recently received a lot of attention due to 
their proposed role in learning and memory.290 Hence, specific small-molecule inhibitors of the PICK1 
PDZ domain could facilitate the exploration of a variety of physiological processes and provide leads 
for potential novel therapeutics targeted towards a number of neurological disorders, including 
stroke, neurodegeneration, pain, depression, anxiety, epilepsy and schizophrenia. 
 
4.1.5 PICK1 and cancer 
PICK1 also interacts with proteins that are involved in governing processes such as cellular 
morphology, cellular polarity and migration. For instance, PICK1 interacts with the ephrin family of 
receptor tyrosine kinases (RTKs) and the neuregulin (NRG) ErbB receptor tyrosine kinases.278 The 
ErbB-Rs are overexpressed in a number of breast, lung and kidney cancers.292 These receptors 
consist of four members named epidermal growth factor (EGF), ErbB2/HER2, ErbB3/HER3 and 
ErbB4/HER4. The C-terminus located PDZ motif of ErbB2/HER2 binds the PDZ domain of PICK1, 
which regulates its surface expression, clustering and activation.279 The ErbB2/HER2 receptor is 
overexpressed in about 30% of human breast cancers and is also frequently altered in carcinoma of 
lungs and kidneys.292 The important role of the ErB2/HER2 in human breast cancer development has 
being highlighted by its utilisation as a novel target for the monoclonal antibody Herceptin in breast 
cancer therapy.293 Furthermore, PICK1 has been shown to be overexpressed in a range of human 
cancers, including, breast, lung, gastric, colorectal and ovarian. Zhang et al. demonstrated that siRNA 
mediated silencing of PICK1 expression in breast cancer cells led to significant inhibition of cell 
proliferation and cell cycle arrest in the S phase in vitro and inhibited xenograft tumour growth in 
nude mice.288  
 
In the same study, high levels of PICK1 in cancer were found to correlate with ErbB2/HER2 protein 
expression, suggesting this specific protein-protein interaction as a potential novel therapeutic 
target for the treatment of breast cancer. A small molecule inhibitor of the PICK1 PDZ domain would 
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allow further investigation of PICK1’s greatly understudied role in cancer and potentially provide 
new leads for targeted breast cancer therapies.  
 
4.1.6 Small molecule PICK1 Inhibitors 
Thorsen et al. reported the first small-molecule inhibitor (FSC231 4) of the PICK1 PDZ domain, 
identified from a screen of ~44,000 compounds in a fluorescent polarisation assay (Figure 4.4).285 
The inhibitor bound the PICK1 PDZ domain with a Ki value of 9.6 μM, which is comparable to that 
observed for the endogenous C-terminal peptide ligands. FSC231 (4) was shown to inhibit the role of 
PICK1 in GluR2 trafficking and block both LTD and LTP expression in hippocampal CA1 neurons.285 
However, further SAR studies revealed that modifications of this core structure decreased activity in 
all cases, except for compound 5 which showed a marginal increase in activity with a Ki value of 7.2 
μM (Figure 4.4).294 The inability to modify successfully this structure has prevented its use as a lead 
compound for the identification of a nanomolar inhibitor of the PICK1 PDZ domain. In addition, poor 
solubility and cell permeability has limited its use as a biological tool to study these important 
physiological processes.  
 
 
Figure 4.4. Structures of known PICK1 PDZ domain inhibitors FSC231 (4) and 5. 
 
4.1.7 Small molecule PDZ Inhibitors 
In 2003, Fujii et al. developed the first cell permeable small molecule PDZ inhibitor (Figure 4.5, 
compound 6), which targeted MAGI3, an important regulator of tissue organisation and 
differentiation.295 This selective peptidomimetic inhibitor was rationally designed to bind the second 
PDZ domain of MAGI3 and docking studies revealed that the indole overlaps with the C-terminal 
tetrapeptide of the known MAGI3 PDZ ligand PTEN. This designed indole scaffold has since been 
modified by Fujii and others to target a range of PDZ domains such as that of dishevelled,270,273 
NHERF1274,296 and PSD-95.297,271 This scaffold therefore provides the opportunity for the design and 
development of a small focused library of cell permeable small molecules to target the PICK1 PDZ 
domain.  
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Figure 4.5. Structure of the first small molecule inhibitor of the MAGI3 PDZ domain. 
 
4.2 Aims of this work 
Our interest in PICK1 arose from its significant role in excitatory neurotransmission and synaptic 
function via its interaction with the GluR2 subunit of the glutamate receptor family and its 
interaction with ErbB2 which is involved in governing processes such as cellular morphology, cellular 
polarity and migration. The PICK1 PDZ domain binds the C-terminal 3-5 amino acids of its binding 
partner, resulting in a more traditional ligand–receptor interaction. This small, well-defined binding 
pocket should facilitate the design of small molecule inhibitors of PICK1’s PPIs providing a useful 
biological tool for the study of the important physiological processes in which PICK1 plays a key role. 
It could also potentially provide a lead compound for the development of a novel therapeutic agent.  
 
The design of PICK1 PDZ inhibitors is greatly aided by the identification of a core indole scaffold 
which has been used successfully to target a wide range of PDZ domains (Section 4.1.7). Extensive 
PICK1 PDZ domain mapping and the availability of crystal structures of the PDZ domain and co-
crystal structures with bound ligand should facilitate the design of a series of PICK1 inhibitors.  
 
The main aims of this project were to: 
1. Utilise the modelling software GOLD to design a series of small molecule PICK1 
inhibitors based on an indole scaffold. 
2. Develop a high-yielding and versatile route to the desired compounds. 
3. Synthesise all designed compounds for biological testing.  
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4.3 Analysis of the PICK1 PDZ Domain 
An important step in the rational design of small molecules that occlude crucial binding sites 
(“hotspots”) on protein-protein interaction interfaces is the use of site-directed mutagenesis and in-
depth molecular modelling to map the interaction site. The therapeutic interest in PICK1’s PDZ 
interactions and the availability of X-ray crystal structures of the PICK1 PDZ domain and co-crystal 
structures with bound peptide partners has resulted in comprehensive domain-mapping studies of 
the PICK1 PDZ domain.286,298,299 These studies have helped to refine the binding site more precisely, 
which should facilitate the design of selective small molecule inhibitors.279  
 
PDZ domains bind three different C-terminal consensus sequences, which are referred to as class I, 
class II and class III interactions. These motifs are identified by the consensus sequence of the 
terminal three amino acids of the interacting ligand; type I terminates with (S/T)ХФ, type II with 
ФХФ, and type III with (D/E) ХФ, where Х is any amino acid and Ф is any hydrophobic amino 
acid.276 The PDZ domain of PICK1 does not fully conform to this classification, since it binds both type 
I ligands (e.g. PKC) and type II ligands (e.g. GluR2). However, it has been shown to bind a 
prototypical class II sequence (-WLKV) with 10-fold greater affinity that the class I sequence of PKC 
(-QSAV).299  
 
To aid our design of small molecules targeting the PICK1 PDZ domain we focused on PICK1’s 
interaction with class II ligands, since these include the two protein interactions of interest (GluR2 
and ErbB2). Furthermore, PICK1’s interaction with class II ligands has been shown to be more 
biologically relevant due to their stronger binding affinity and the much greater number of class II 
than class I interactions.286  
 
The binding between the PICK1 PDZ domain and the GluR2 peptide (VKI) has been extensively 
studied using site-directed mutagenesis and analysis of the available X-ray crystal (PDB code: 
3HPK300) and solution NMR (PDB code: 2PK2277) structures. This has resulted in the identification of 
binding pockets for P-2 to P0 residues of the GluR2 peptide (where P0 corresponds to the terminal 
amino acid). In the GluR2 peptide (-VKI), the residues P-2 (Val) and P0 (Ile) made the major binding 
contributions, while the side chain of P-1 (Lys) makes minimal contact with the PDZ domain (Figure 
4.6). The role of the P-1 residue in binding is thought to be insignificant due to the highly diverse 
selection of amino acid residues present at this position in PICK1 PDZ-binding peptides.277,301 
However, a key cation-π interaction between the lysine residue and the Phe53 of the PICK1 PDZ 
domain may have been overlooked (Figure 4.6). A cation-π interaction is the electrostatic attraction 
between a cation and an negative electrostatic potential associated with the face of a simple π 
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system.302 Studies have shown that this specific interaction is energetically comparable or stronger 
than a typical hydrogen bond. Cation-π interactions make a significant contribution to the overall 
stability of most proteins;303 with on average one such interaction occurring per 77 amino acid 
residues.304 They also contribute significantly to intermolecular contacts and interactions at protein-
protein interfaces305 as well as between proteins and endogenous ligands and drug molecules.306 The 
existence of a cation-π interaction in this case is strongly supported by the localisation of the P-1 
lysine directly above Phe53 (4.3 Å) within the 6.0 Å distance required for the interaction to occur.307 
This interaction may be important for the strength of the binding interaction and selectivity. 
 
 
Figure 4.6. Representation of the crystal structure of the GluR2 peptide VKI bound into the PICK1 PDZ domain (PDB: 
3HPK). Important residues are highlighted. The PDZ domain is shown as a transparent surface (electrostatic). Carbons are 
shown in grey, nitrogens in blue and oxygens in red. Figure created using Accelrys Discovery Studio Visualiser 4.1. 
 
The P0 pocket consists of a small hydrophobic pocket that accommodates the Ile(0) side chain and a 
carboxylate binding domain (CBD), which binds the carboxyl-terminus of the peptide. The pocket is 
formed by the residues Lys27 and Asp28 (KD motif), Ile37 and Ile90 which make important hydrophobic 
interactions with the P0 and P-2 residues and the CBD which contains the PDZ domain GLGF motif, 
which in PICK1 consists of the residues Leu32-Ile33-Gly34-Ile35 (LIGI motif) (Figure 4.6).286 The size of 
the P-2 pocket is influenced by the conformation of the Ile37 residue, which is set by the amino acid 
side chain of the P0 residue.298 The Lys83 residue in the P-2 pocket creates a hydrophobic interaction 
with the Val(-2) residue which is essential for the class II binding motif. The side chain of the P-2 
residue is sandwiched between the Lys83 and Ala87 residues on the β helix (Figure 4.6).277  
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The extensive domain mapping undertaken for the PICK1 PDZ domain has identified key 
hydrophobic interactions in the P0 and P-2 pockets and hydrogen bonding interactions with the CBD 
required by peptides and hence small molecules to bind strongly to the PDZ domain. The variability 
at the P-1 position should facilitate the incorporation of a range of side chains to potentially identify 
substituents with added bonding interactions, improved selectivity between class II PDZ domains 
and improved pharmokinetic properties.  
 
4.4 Series 1 Inhibitors 
 
4.4.1 Design of series 1 inhibitors 
The first aim of this project was to use an indole scaffold based on Fujii’s MAGI3 PDZ inhibitor 6295 
(Figure 4.5) to design a PICK1 PDZ domain inhibitor. To achieve this aim, it was necessary to compare 
the binding of Fujii’s indole 6 with that of an endogenous PICK1 ligand to identify the regions of the 
indole scaffold that could be utilised to mimic the peptide binding (Figure 4.7). This revealed that 
substitution at the 1- and 3-positions of the indole ring could be used to mimic the P-1 and P-2 
amino acid side chains respectively. Further modelling showed that the incorporation of an amide 
group at the 3-position of the indole could potentially mimic the 2nd amide group of the GluR2 
peptide backbone. This analysis resulted in the indole scaffold 7 being designed to target the PICK1 
PDZ domain, where substituents R1, R2 and R3 should bind in the P0, P-1 and P-2 pockets respectively 
(Figure 4.7). 
 
 
  
Figure 4.7. Comparison of binding of indole scaffold 7 with GluRu peptide (VKI). 
 
Analysis of the size, shape and possible interactions in the binding pockets led to the identification of 
a series of substituents which were predicted to bind well in these pockets. Further analysis of the 
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amino acid side chains of known PICK1 peptide ligands, especially those with high binding 
affinities,286 provided a second set of potential substituents for our lead compound. These two sets 
of potential substituents were combined in all possible permutations and docked in both available 
crystal structures using the modelling software GOLD.308 These results were then analysed to identify 
analogues that adopted a similar binding pose to the GluR2 peptide (VKI) and ranked using the 
GoldScore algorithm (see Appendix K for selection of the docking results).309  
 
 
Figure 4.8. A designed indole based inhibitor of the PICK1 PDZ domain. 
 
The two substituents selected for the R1 position to bind in the P0 pocket were a methyl and an 
isopropyl group (Figure 4.10). Valine is the most common P0 residue of all PICK1 ligands and has 
been shown to be accommodated by the P0 hydrophobic pocket with little effect on the size and 
shape of the P-2 pocket.299,298 The methyl group was selected since all previously reported PDZ 
inhibitors based on Fujii’s indole scaffold contain a methyl group at this position, and the modelling 
study predicted that it should also fit in the P0 pocket.  
 
Three hydrophobic substituents were selected for the R3 substituent (Figure 4.10). A benzyl group 
was chosen as three of the four peptides with the strongest binding affinities for PICK1 contain a 
residue with an aromatic based side chain at the P-2 position (e.g., Ephrin B1 (Tyr), Parkin (Phe)).286 
Analysis of a series of different length and branched aliphatic chains identified an ethyl and an 
isobutyl (leucine mimic) group at the R3 position as forming the strongest hydrophobic interactions 
with the P-2 pocket.  
 
The final step was the identification of substituents for the highly variable P-1 position. Due to this 
variability, the selection of substituents based on known PICK1 ligands was not feasible. Our focus 
instead concentrated on substituents that may be able to provide additional interactions not 
exploited by the endogenous ligands, thus, potentially increasing the binding affinity of these 
designed ligands. Analysis of the crystal structure of PICK1 revealed that the base of the P-1 pocket is 
Chapter 4: Peptidomimetics 
 
161 
 
formed by the aromatic side chain of Phe53 (Figure 4.6). This highlighted several potential 
interactions that could be targeted such as π-π stacking, hydrophobic and cation-π interactions.307  
 
   
Figure 4.9. Comparison of the GOLD binding mode of a designed indole ligand 8 (Figure 4.8) (left) versus the crystal 
structure (PDB: 3HPK) of the PICK1 PDZ domain with the GluR2 peptide (VKI) bound (right). The solvent accessible 
surface of the protein is shown, with positively charged regions in blue and negatively charged regions in red. Ligands are 
shown as sticks with carbon atoms in green, nitrogen atoms in blue and oxygen atoms in red. Figure created using Pymol. 
 
Docking studies showed that an ethylbenzene substituent at the R2 position would place the 
aromatic ring above the Phe53 within the 3.4-3.6 Å distance required for a π-π interaction (Figure 
4.9).307 This also resulted in a high predicted GoldScore (see Appendix K). PICK1 ligands contain a 
range of short aliphatic side chains at this particular position; docking studies predicted that an 
isopentane group in the R2 position would form the strongest hydrophobic interactions in the P-1 
pocket.  
 
The cation-π interaction was the final interaction selected as a possible target binding interaction in 
the P-1 pocket. A di-alkylated amine was selected as the desired cation source based on a recent 
study conducted by the Diederich group on factor Xa inhibitors, which demonstrated that stepwise 
methylation of an ammonium substituent binding in an aromatic pocket increased the binding 
affinity by 3 orders of magnitude.310 Dennis Dougherty proposed that the correlation between 
increasing activity and increasing amine methylation resulted from the dispersion of the cationic 
charge onto the methyl groups due to the inherent electronegativity of the nitrogen atom, which 
ultimately resulted in a larger interaction area. The reduction of the desolvation cost of the 
hydrogens in the ammonium NH groups with stepwise methylation was also implicated in the 
observed increase in affinity.311 Modelling studies identified that an N-dimethylethanamine 
substituent in the R2 position would place the di-alkylated amine directly over Phe53.  
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Figure 4.10. Selected R
1
, R
2
 & R
3
 substituents for the core indole scaffold. 
  
Further analysis of this substituted indole scaffold as a good peptidomimetic of the GluR2 peptide 
was carried out using Accelrys Discovery Studio. Overlay of the designed inhibitor 8 (Figure 4.8) and 
the GluR2 peptide (VKI) revealed that the R1, R2 and R3 substituents were placed in the same 
proximity as the desired peptide residue side-chains (Figure 4.11A).The carboxylic acid group and the 
amide also aligned well with the analogous groups on the peptide. Analysis of the bonding 
interactions of 8 with the PICK1 PDZ domain demonstrated that the inhibitor could be forming all the 
key interactions required for binding of a class II peptide to the PICK1 PDZ domain (Figure 4.11B). 8 
was predicted to form hydrogen bonds to Ile33, Gly34 and Ile35 within the LIGI motif of the carboxylic 
acid binding domain (CBD), hydrophobic interactions with Ile90 and Lys83 and the added π-π 
interaction with Phe53. 
 
 
Figure 4.11. (A) Overlay of the GluR2 peptide ligand for the PICK1 PDZ and the designed small molecule inhibitor 8. 
Carbons are shown as grey (8) or green (VKI), nitrogen as blue and oxygen as red. (B) Predicted binding interactions of 8 
with the PICK1 PDZ domain. Hydrophobic interactions are highlighted by green disks, electrostatic interactions by pink 
disks and dotted lines show specific hydrogen bonds and π-π interactions. 
 
(A) (B) 
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4.4.2 Synthesis of series 1 inhibitors 
The designed indole-3-amide scaffold would allow generation of a small, focused chemical library 
with varying substituents at the R1, R2 and R3 positions (Figure 4.10). A synthetic route was 
developed that would set the R1 position at the beginning of the synthesis and provide an 
opportunity to modify the R2 and R3 positions towards the end of the process, thus facilitating 
simpler analogue synthesis (Scheme 4.1). 
 
 
Scheme 4.1. Proposed synthetic route to the series 1 inhibitors. (a) Esterification. (b) Cross-coupling. (c) Indole formation. 
(d) N-alkylation. (e) Nitration and reductive acylation. (f) Saponifaction. 
 
It was decided to first synthesise the series of analogues containing a methyl group at the R1 position 
as the required starting material 9 (Scheme 4.2) was commercially available. This eliminated the 
potentially difficult cross-coupling step needed to incorporate the isopropyl group in place of the 
methyl group.  
 
The preparation of the key indole intermediate 13 proceeded smoothly from commercially available 
9 (Scheme 4.2). Esterification of 9 and ortho-iodination using iodine monochloride gave 11. 
Sonogashira cross-coupling of 11 with ethynyltrimethylsilane provided alkynylaniline 12, which 
afforded in turn the desired indole 13 via a CuI-mediated heteroannulation (Scheme 4.2).312 The use 
of CuI in the heteroannulation step instead of palladium resulted in the simultaneous removal of the 
trimethylsilyl group, consequently removing the need for a further synthetic step to cleave it.  
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Scheme 4.2. Synthetic route to key indole intermediate 13. Reagents & conditions: (a) SOCl2, MeOH, 12 h, r.t., 94%. (b) ICl, 
MeOH, H2O, CaCO3, 0 °C, 4 h, 56%. (c) Ethynyltrimethylsilane, Pd(PPh3)2Cl2, CuI, Et3N, r.t., 87%. (d) CuI, DMF, 100 °C, 74%. 
 
The relatively low yield obtained for the ortho-iodination step resulted from the formation of the 
competing ortho-iodinated regioisomer. Fujii et al.295 reported a 34% yield when using iodine 
monochloride at room temperature. However, dropwise addition of ICl at 0 °C, improved the yield of 
11 to 56% (Scheme 4.2, step b). Starting material 10 can be recovered by hydrogenation of the 
carbon-iodine bond of the unwanted isomer using H2 and Pd/C if required.  
 
The alkylation of 13 with a range of alkyl halides provided the desired N-substituted indoles (14a-c), 
which could be readily nitrated under mild conditions using in situ formed acetyl nitrate to furnish 
the corresponding 3-nitroindoles (15a-c, Scheme 4.3).313 The nitro group provided a useful synthetic 
handle for the incorporation of the selected R3 side chains through a one-pot reductive acylation 
(Scheme 4.4). 
 
 
Scheme 4.3. N-alkylation and nitration. Reagents & conditions: (a) 14a - (Bromoethyl)benzene, NaH, DMF, r.t., 8 h, 46%, 
14b - 1-bromo-2-methylpropane, NaH, DMF, r.t., 8 h, 63%, 14c - 2-chloro-N,N-dimethylethylamine hydrochloride, NaH, 
DMF, r.t., 8 h, 68% (b) HNO3, Ac2O, 0 °C, 2 h, 15a - 70%, 15b - 44%, 15c - 42%.  
 
The reductive acylation was achieved via a Pd/C catalysed hydrogenation of the 3-nitroindole 15 to 
the corresponding amine, followed by in situ trapping of the reactive amine by an anhydride 
(Scheme 4.4).314 In addition to the benefit of reducing a two-step process to a one-pot procedure, 
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this method also bypassed possible difficulties associated with purifying and handling reactive 3-
aminoindoles. Ester hydrolysis gave the desired final compounds 16(a-f), which were isolated as the 
sodium salts, to improve their water solubility for biological testing.  
 
 
Compound R2 R3 
Yield 
(%, over 2 steps) 
16a ethylbenzene ethyl 61 
16b ethylbenzene isobutyl 47 
16c isobutyl ethyl 76 
16d isobutyl isobutyl 82 
16e isobutyl ethylbenzene 39 
16f N,N-dimethylethane ethyl 42 
 
Scheme 4.4. Reagents & conditions: (a) (i) Propionic anhydride, isovaleric anhydride or 2-phenylacetic anhydride, MeOH, 
10% Pd/C, H2, 40 °C, 1 h. (ii) MeOH, NaOH, reflux, 4 h. See table for yields. 
 
4.4.3 Development of an alkyl-aryl cross coupling reaction 
With a synthetic route developed to the series of compounds containing a methyl group at the R1 
position, an additional step was required to enable the incorporation of an isopropyl group at the 
same position. The initial strategy involved the use of a Suzuki cross-coupling.  
 
 
Scheme 4.5. Attempted Suzuki-Miyuara cross-coupling. Selected examples of the conditions screened – (1) 19a, Pd(PPh3)4, 
Na2CO3 (H2O), Toluene, Ethanol, reflux. (2) 19a, Pd(PPh3)4, K3PO4, dioxane, 90 °C. (3) 19b, Pd(PPh3)4, Cs2CO3, 
dimethoxyethane, H2O, 125 °C, MW. (4) 19b, Pd(PPh3)4, K2CO3, Toluene, Ethanol, H2O, reflux. (5) 19a, Pd(dppf)Cl2, Na2CO3 
(H2O), DMF, 70 °C.   
 
This was attempted by reacting methyl 5-amino-2-bromobenzoate (17) with both isopropylboronic 
acid (19a) or its pinacol ester 19b under a wide variety of base, solvent and temperature conditions 
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(Scheme 4.5). However, this route proved to be unsuccessful under the reaction conditions 
investigated. 
 
Further literature research revealed, that although transition metal-catalysed cross-coupling has 
seen significant advances in the coupling of sp2-hybridised carbon nucleophiles with aryl or vinyl 
halides, only a handful of studies have been published concerning the analogous cross-coupling of 
secondary sp3-hybridised carbon nucleophiles with aryl halides.315 The major difficulties with this 
transformation are associated with two key steps in the mechanistic cycle: the transmetalation step, 
which is more difficult for secondary alkyl groups than other organic moieties, and the reductive 
elimination process, which competes with facile β-hydride elimination leading to isomerised 
coupling products (Figure 4.12).316 The development of a successful catalytic method requires the 
identification of ligands that enhance the rate of reductive elimination relative to β-hydride 
elimination, thus suppressing product isomerisation.  
 
 
Figure 4.12. Proposed catalytic cycle for the cross-coupling of i-PrM and an aryl halide.
316
 
 
Pioneering work carried out by Kumada/Tamao (1972)317 and Hayashi (1984)318 demonstrated that 
secondary alkyl Grignard reagents could be coupled with a limited range of aryl and vinyl halides 
using dichloro[1,3-bis(diphenylphosphino)-propane] nickel(II) (NiCl2(dppp)) and dichloro*1,1′-
bis(diphenylphosphino) ferrocene] palladium(II) (PdCl2(dppf)). A test reaction using PdCl2(dppf) and 
isopropyl zinc bromide resulted in the isolation of only the n-propyl product 20 that results from β-
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hydride elimination (Figure 4.12), thus indicating that this catalytic method was not suitable for our 
substrate (Scheme 4.6). 
 
 
Scheme 4.6. Attempted cross-coupling using PdCl2(dppf) and isopropyl zinc bromide yielded the undesired isomerised 
product 20. Reagents & conditions: (a) Isopropylzinc bromide, Pd(dppf)Cl2, THF, 70 °C, 4 h. 
 
Additional research in this area includes Molander’s comprehensive study of the Pd-catalysed 
Suzuki-Miyaura coupling of secondary alkyltrifluoroborates with aryl halides in the presence of 
nBuPAd2.
319 They reported the formation of the desired secondary product in a good ratio to the 
isomerised primary alkyl coupling product in a number of examples. However, poor product ratios 
and yields were obtained when electron-deficient and/or ortho-substituted aryl halide substrates 
were used, and limited functional group tolerance was observed. In other work Joshi-Pangu et al. 
reported a general Ni-catalysed Negishi process for the cross-coupling of secondary alkylzinc halides 
and aryl iodides.320 They postulated that a Ni-based catalytic system could overcome the inherent 
problems associated with the Pd-catalysed systems based upon the success of nickel catalysis in 
cross-couplings involving an alkyl moiety. This process solved the β-hydride elimination problem, 
with selectivity up to 300:1 in favour of the secondary alkyl product over the primary product. 
However, the authors reported that this method did not work well with ortho-substituted aryl 
halides, in accordance with previous reports. This would limit the use of this method for our 
substrate 17 as it contains an ortho electron-withdrawing ester group. Hence unsurprisingly, no 
reaction occurred with our substrate under their reported conditions at 40 °C, or at higher 
temperatures of 60 °C, reflux or microwave irradiation at 120 °C, with starting material 17 being 
recovered in all cases. 
 
A more recent investigation for a general Pd-catalysed procedure which facilitates the coupling of 
secondary nucleophiles and aryl halides was carried out by Han and Buchwald.316 The published 
report detailed the Pd-catalysed coupling of secondary alkylzinc halides with aryl bromides using 
sterically-bulky phosphine ligands (Figure 4.13). They carried out a screen of phosphine ligands, 
which resulted in the identification of a new ligand CPhos (21a), which gave a high ratio of branched 
(i-Pr) to linear (n-Pr) products in excellent yields. Furthermore, they demonstrated that this method 
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was compatible with electron-deficient and/or ortho-substituted aryl halide substrates with only a 
small decrease in selectivity and yield reported in these particular cases.  
 
 
Figure 4.13. The structures of the CPhos (21a) and RuPhos ligands (21b). 
 
As CPhos (21a) was not commercially available, a test reaction using this method with the 
commercially available phosphine ligand RuPhos (21b) was attempted. Buchwald obtained a 3:1 
ratio of the branched (i-Pr)-24 to linear (n-Pr)-25 product with an overall yield of 78% when 21b was 
used in the presence of an ortho-ether substituted aryl bromide 22. In contrast, a 27:1 ratio of 
products with an overall yield of 97% was obtained when CPhos (21a) was used with the same 
substrate 22 (Scheme 4.7).316  
 
 
Scheme 4.7. Ligand effects in the coupling of 22 and 23. (a) Pd(OAc)2 (1 mol%), ligand (21a/21b) (2 mol%), THF, 0 C  r.t., 
30 minutes. 21a – 24:25 (27:1), 97%; 21b – 24:25 (3:1), 78%.
316
 
 
We therefore postulated that if a similar selectivity and yield could be achieved with our substrate 
using RuPhos (21b), this would validate this approach and CPhos (21a) would be synthesised for 
testing with our substrate.  
 
Scheme 4.8. Synthesis of the CPhos (21a) ligand. Reagents & conditions: (a) (i) n-BuLi, hexane, reflux. (ii) 2-
Bromochlorobenzene, hexane, reflux, 84% (b) (i) n-BuLi, THF, -78 °C. (ii) ClPCy2, -78 °C → r.t., 72%. 
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The utilisation of Buchwald’s Pd-catalysis system and the RuPhos ligand provided an inseparable 6:1 
mixture of the desired branched (i-Pr) product 18 to the unwanted linear (n-Pr) product 20, with an 
overall yield of 85% (Figure 4.14). The increase in selectivity and yield when compared to Buchwald’s 
system presumably resulted from the electron-donating effect of the amine reducing the electron-
deficiency of the aryl bromide. Encouraged by this very promising result, the synthesis of the CPhos 
ligand (21a) was carried out via a 3-step process starting from commercially available N1,N1,N3,N3-
tetramethylbenzene-1,3-diamine 26 (Scheme 4.8).316 Ortho-lithiation of 26 and subsequent reaction 
with 2-bromochlorobenzene yielded 27. Lithium-halogen exchange of the aryl bromide of 27 
followed by reaction with chlorodicyclohexylphosphine furnished the desired CPhos (21a) ligand 
(Scheme 4.8). 
 
 
Figure 4.14. Aryl-alkyl cross-coupling reaction in the presence of the RuPhos (21b) or CPhos (21a) ligand. Reagents & 
conditions: (a) Pd(OAc)2, Isopropylzinc bromide (0.5 M in THF), toluene, r.t., 30 minutes. 
1
H NMR spectra – magnification of 
the alkyl region. (Top) RuPhos – 85%, 18:20 (6:1). (Bottom) CPhos – 93%, 18:20 (>30:1). 
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With the CPhos ligand 21a in hand, the cross-coupling reaction between aryl halide 17 and isopropyl 
zinc bromide (23) was repeated. In the presence of 21a, the cross-coupling reaction occurred with 
very high selectivity (>30:1) for the branched (i-Pr) product 18 to the linear (n-Pr) product 20 with an 
excellent overall yield of 93% (Figure 4.14). Han and Buchwald provided evidence in their report that 
the improved ratio of branched to linear products in the presence of the CPhos ligand was due to the 
slow relative rates of β-hydride elimination-reinsertion versus reductive elimination (Figure 4.12).316  
 
This mild and highly selective cross-coupling reaction provides an easy, high-yielding route to the 
required starting material 18. This methodology will facilitate the future synthesis of a range of 
analogues with an isopropyl group at the R1 position. The future selection of substituents for the R2 
and R3 positions will be guided by biological data acquired for analogues 16(a-f), which contain a 
methyl group at the R1 position. 
 
4.5 Series 2 Inhibitors 
 
4.5.1 Design of series 2 inhibitors 
While carrying out the docking studies on the first series of potential PICK1 PDZ inhibitors, it was 
observed that in certain cases, the compound docked in the pocket in a flipped orientation placing 
the indole 2’-position pointing into the pocket instead of out of it. As a result, it was decided to 
modify the indole scaffold to exploit this potential new binding mode and ultimately identify a 
second series of PICK1 PDZ inhibitors. This led to the design of indole scaffold 28 (Figure 4.15). 
 
    
Figure 4.15. (A) Core indole scaffold 28 of the series 2 inhibitors with the predicted binding mode highlighted. (B) 
Predicted GOLD binding mode of a designed series 2 inhibitor in the PICK1 PDZ domain. The solvent accessible surface of 
the protein is shown, with positively charged regions in blue and negatively charged regions in red. Ligand is shown as 
sticks, carbons in green, nitrogens in blue and oxygens in red.  
 
(A) (B) 
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This alternative binding mode has since be identified by Ducki and co-workers for a related indole 
peptidomimetic designed to competitively inhibit the interaction between the C-terminal domain of 
the 5-HT2A serotonin receptor and the PDZ1 domain of PSD-95.
271 The design, synthesis and 
biological evaluation of a series of substituted indoles identified compound 29 which inhibited the 5-
HT2A/PSD-95 PPI with an IC50 value of 190 µM. Subsequent determination of the three-dimensional 
structure of the protein/ligand complex through 1H−15N HSQC NMR analysis of the PSD-95 PDZ 
domain in the absence or presence of 29 coupled with intermolecular nuclear Overhauser effect 
(NOE) restraints and high ambiguity driven protein-protein DOCKing (HADDOCK) provided an insight 
into the binding mode of 29. The NMR solution structure revealed that the indole-2’-COOH of 29 
interacted with the backbone of the carboxyl binding domain (GLGF), in agreement with the 
predicted binding of both 29 and in our case 28. 
 
 
 
Figure 4.16. (A) The structure of 5-HT2A/PSD-95 PPI inhibitor 29. (B) NMR solution structure of the PSD-95 PDZ1/ligand 29 
complex.
271
 Protein is shown as a surface representation (Coulombic charges). Ligand 29 is shown in sticks with carbon 
atoms in orange, oxygen atoms in red, and nitrogen atoms in blue.  
  
Similarly to the series 1 inhibitors, the analysis of known PICK1 peptide ligands and an extensive 
modelling study led to the selection of a range of substituents on the indole scaffold 29, which 
should facilitate strong binding to the PICK1 PDZ domain (Figure 4.17). The predicted binding score 
(GoldScore) for series 2 was shown to be comparable with the first series. Furthermore, it was 
proposed that access to the desired analogues in this series should be less challenging synthetically 
than series 1. 
 
Figure 4.17. Selected R
1
, R
2
 & R
3
 substituents for series 2 small molecule inhibitors. 
(A) (B) 
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4.5.2 Synthesis of series 2 inhibitors 
The route to the second series of peptidomimetics was greatly simplified by the removal of the 
carboxylic acid at the 6-position of the indole ring. This resulted in a symmetrical starting material 
which did not require pre-functionalisation in order to control the indole formation, as only one 
isomer was possible. To take advantage of this, a modified version of the robust Fischer indole 
synthesis was chosen as the key step in this route.321 Furthermore, given the large number of 
commercially available hydrazine compounds, it was possible to introduce the isopropyl substituent 
at the 5-position without the need for the troublesome cross-coupling reaction required for the 
previous series of compounds.  
 
The proposed synthesis of the desired compounds involved a 3-step procedure starting with a 
Fischer indole synthesis, followed by N-alkylation and ester hydrolysis to give the free acid. The 
route began with condensation of the substituted hydrazine hydrochloride with an -ketoacid ester 
in an acetic acid catalysed Fischer indole cyclisation.321 The -ketoacid esters 30b and 30c required 
for the Fischer indole step were prepared from their corresponding -ketoacid (Scheme 4.9B) or by 
a Grignard reaction in the case of methyl 2-oxo-5-phenylpentanoate 30a (Scheme 4.9A). 
 
 
Scheme 4.9. Synthesis of the -ketoacid esters 30(a-c). Reagents & conditions: Route A (a) Mg, THF, reflux, 1 h. (b) 
Dimethyl oxalate, Et2O, -78 °C → 0 °C, 69%. Route B (a) H2SO4, EtOH, reflux, 6 h, quantitative. 
 
The condensation of substituted hydrazine hydrochlorides 31a and 31b with -ketoacid ester 30a 
provided the desired indole esters 32a and 32b as an inseparable mixture of the methyl and ethyl 
esters, resulting from a transesterfication reaction between the ethanol solvent that was used and 
the -ketoacid methyl ester 30a (Scheme 4.10). This transesterification reaction did not prove to be 
too troublesome as the ester group was hydrolysed in the final step to give the corresponding acid. 
(A) 
(B) 
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Scheme 4.10. Synthesis of compounds 32(a-b). (a) AcOH, EtOH, reflux, 4-6 h. R = methyl/ethyl. 
 
In the case of 32(c-f), the required -ketoacid was protected as the -ketoacid ethyl ester 30(b-c) to 
avoid the formation of the mixture of methyl and ethyl esters observed with 32a and 32b (Scheme 
4.9). A significantly reduced yield was obtained for the Fisher indole reaction when γ-branched -
ketoacid esters were used, as demonstrated by 32d and 32f (Scheme 4.11).  
 
 
 
Scheme 4.11. Synthesis of compounds 32(c-f). (a) AcOH, EtOH, reflux, 4-6 h. For yield see table.  
 
The final steps to convert the indoles 32 to the desired compounds 33 involved N-alkylation of the 
indole nitrogen followed by ester hydrolysis. This was achieved using sodium hydride in DMF in the 
presence of the appropriate alkyl bromide, followed by sodium hydroxide mediated ester hydrolysis. 
This method was used successfully to synthesise 33b and 33c (Scheme 4.12). 
 
 
Compound R1 R2 
Yield 
(%) 
32c Isopropyl Methyl 67 
32d Isopropyl Isopropyl 38 
32e Methyl Methyl 67 
32f Methyl Isopropyl 28 
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Scheme 4.12. Synthesis of final compounds 33(a-j). Reagents & conditions: (a) Appropriate alkyl bromide, NaH (4 eq.), 
DMF, 100 °C, 5 h. [a] Final compounds 33b & 33c were synthesised via an alternative two-step procedure. Reagents & 
conditions: (a)(i) Appropriate alkyl bromide, NaH (2 eq.), DMF, 100 °C, 4 h. (ii) NaOH (2N), EtOH, reflux, 4 h. 
 
The N-alkylation of the indole ring did not go to completion when attempting to N-alkylate 32a with 
(bromoethyl)benzene. In an attempt to push the reaction to completion, a further 2 equivalents of 
sodium hydride were added to the reaction mixture. This resulted in complete N-alkylation of 32a 
with concurrent hydrolysis of the ester to provide the desired acid product 33a in one step. This was 
thought to have occurred due to the reaction of NaH with H2O during the addition of the extra 
equivalents of NaH, to form NaOH. The NaOH would have subsequently hydrolysed the ester. This 
method was observed to be reproducible with the other intermediates and proceeded in reasonable 
yields in all cases. This route was therefore chosen as a one-pot procedure for the synthesis of the 
desired compounds (Scheme 4.12).  
 
Compound R1 R2 R3 
Yield 
(%) 
33a Methyl Ethylbenzene Ethylbenzene 50 
[a]33b Isopropyl Ethylbenzene n-butyl 68 
[a]33c Isopropyl Methyl n-butyl 57 
33d Isopropyl Methyl Ethylbenzene 38 
33e Isopropyl Isopropyl Ethylbenzene 41 
33f Isopropyl Ethylbenzene Ethylbenzene 53 
33g Isopropyl Isopropyl n-butyl 81 
33h Methyl Methyl Ethylbenzene 56 
33i Methyl Isopropyl n-butyl 73 
33j Methyl Isopropyl Ethylbenzene 41 
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4.6 Biological Assessment 
The series 1 and series 2 compounds were investigated for their ability to bind the PICK1 PDZ 
domain in a fluorescence polarisation (FP) assay by the Gether group (University of Copenhagen, 
Denmark). In this FP competition binding experiment, fixed concentrations of PICK1 protein and a 
fluorescently labelled peptide were titrated with an increasing amount of ligand. Competitive 
binding of the ligand results in a decrease in FP signal. An Oregon Green-fluorescently labelled 
peptide (OG-DATC13) corresponding to the 13C-terminal residues of the dopamine transporter 
(DAT), a potent PICK1 PDZ domain ligand was used in the assay. This assay identified 5 compounds 
with promising PICK1 PDZ binding activity, series 1 compound 16a, and series 2 compounds 33c, 33e, 
33g and 33j.  
 
The series 2 compounds could be grouped into two pairs based on their relative binding affinities 
and chemical structure. The first pair 33e and 33j, displayed moderate binding affinities with Ki 
values of 63.9 and 23.8 µM respectively (Figure 4.18). Analysis of the predicted binding modes of 
these compounds in comparison with their binding affinities revealed insights into important factors 
for binding.  
  
 
Figure 4.18. 33e and 33j dose-dependently inhibit peptide binding to the PICK1 PDZ domain (A) Chemical structure of 33e 
and 33j. (B) FP competition curves for 33e and 33j using a fixed concentration of Oregon Green-labelled DAT peptide (OG-
DAT C13,~30 nM) and incubation (1 hour) together with purified PICK1 and indicated compounds before FP measurements. 
The control is a 5% DMSO/buffer solution. Data are shown as bound relative to maximum bound OG-DAT C13 (means of 
triplicates ± SE) and representative of n = 2. Data provided by the Gether group. 
(A) (B) 
33e 
33j 
Control 
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Both compounds contain an isopropyl group which is predicted to reside in the P0 pocket of the 
PICK1 PDZ domain. This is in agreement with the preference for a valine in this position of the 
endogenous peptides. Similarly, both compounds contain an ethylbenzene substituent which is 
predicted to bind in the variable P-1 pocket. This would suggest that the phenyl group is positioned 
correctly to form the proposed - stacking interaction with the Phe53 present in the PICK1 PDZ 
domain. Finally, an approximate 3-fold increase in binding affinity was observed for 33j, which 
contains a methyl group in the P-2 position in contrast to the isopropyl group present at the same 
position on 33e. Previous studies undertaken with the endogenous peptides revealed that the size of 
the P-2 pocket is influenced by the conformation of the Ile37 residue, which is set by the amino acid 
side chain of the P0 residue. It was observed that the presence of a bulky residue (i.e. valine) in the 
P0 pocket induced a conformational change which reduced the size of the P-2 pocket, thereby 
increasing the preference for smaller substituents at this position. This is in agreement with the 
increased binding affinity observed on replacing the isopropyl of 33e for the smaller methyl of 33j 
(Figure 4.18). 
 
The second pair of series 2 inhibitors displayed an order of magnitude increase in binding affinity for 
the PICK1 PDZ domain with low µM affinities [Ki = 5.8 µM (33g), 2.0 µM (33c)]. The large increase in 
binding affinity appears to be largely due to the presence of an n-butyl group in the P-1 position of 
33g and 33c, in place of the ethylbenzene present in 33e and 33j (Figure 4.19). 
 
  
Figure 4.19. 33g and 33c dose-dependently inhibit peptide binding to the PICK1 PDZ domain (A) Chemical structure of 
33g and 33c. (B) FP competition curves for 33g and 33c. Data provided by the Gether group. 
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The n-butyl substituent was selected as a mimic for the hydrophobic backbone of the lysine residue 
of the GluR2 peptide (VKI). This suggests that optimal binding is achieved with substituents which 
attempt to mimic the residues present on the endogenous peptides. The n-butyl substituent appears 
to result in a preference for a bulkier isopropyl group in the P-2 position. However, the placement of 
a bulkier group in the P-2 pocket results in a conformational change of Ile37, thereby reducing the 
size of the P0 pocket. This is in agreement by the approximate 3-fold increase in affinity observed for 
33c which contains a smaller methyl group in the P0 pocket when compared to 33g which contains 
an isopropyl. 
 
One compound, 16a from the series 1 inhibitors displayed a promising binding affinity with a Ki value 
of 8.7 µM. Similarly, to 33e and 33j, 16a contains an ethylbenzene substituent which is predicted to 
form a - interaction in the P-1 pocket. All of the series 1 inhibitors contain a methyl group in the 
P0 position, and it appears this induces a preference for an ethyl substituent at the P-2 position. 
 
  
Figure 4.20. 16a dose-dependently inhibits peptide binding to the PICK1 PDZ domain (A) Chemical structure of 16a. (B) FP 
competition curves for 16a. Data provided by the Gether group. 
 
In the above cases the error on the data points is higher than normally observed for peptides 
screened in this FP assay. This is believed to be due to the kinetics of binding of these molecules 
which appear to have slower binding rates than peptides. Further control experiments are currently 
being carried out to rule out other possibilities such as compound precipitation. 
 
   
competition 1mM TBS
-8 -7 -6 -5 -4 -3
0
20
40
60
80
100
AH-D1
CTL
Log[compound] in M
m
P
(A) (B) 
16a 
Control 
Chapter 4: Peptidomimetics 
 
178 
 
4.7 Conclusions & Future Work 
  
PICK1 contains a single N-terminal PDZ domain that interacts with the PDZ motifs of several proteins, 
which have roles in neuronal cell morphology, mitochondrial-dependent apoptosis and synaptic 
plasticity. Herein we reported the design and synthesis of two series of small molecule 
peptidomimetic inhibitors of the PICK1 PDZ domain. A docking study based on Fujii’s previously 
reported PDZ domain inhibitor 6 led to the identification of two indole scaffolds 7 and 29, which 
were subsequently used as core fragments for two series of compounds designed to inhibit PICK1 
PDZ domain mediated PPIs. Molecular modelling and analysis of known endogenous PICK1 peptide 
ligands guided the selection of a range of substituents for the indole scaffolds, with the aim of 
identifying selective high affinity binders.  
 
The development of an 8-step synthetic route to the series 1 inhibitors involving late stage 
functionalisation of indole intermediate 13 provided access to 6 diverse analogues. These analogues 
contain a methyl group in the R1 position originating from the indole intermediate 13, however, the 
design process had identified an isopropyl group as the optimum R1-substituent for binding in the P0 
pocket. The lack of a general and comprehensive method to introduce diversity at this position is 
presumably a contributing factor to the exclusive use of a methyl group at this position in the 
previously reported indole-based peptidomimetic PDZ inhibitors.271,273,274,295–297 
 
 
Scheme 4.13. Summary of the synthetic route utilised to access the series 1 inhibitors. 
 
The most efficient method for the introduction of diversity at the R1 position is a cross coupling 
reaction. However, few studies have been reported which address the issues associated with the 
challenging cross-coupling reaction of secondary sp3-hybridised carbon nucleophiles with aryl 
halides. Further investigation led to the identification of a recent method reported by the Buchwald 
group,316 which utilised a Pd(II)-CPhos (21a) catalyst system to promote the sp3-sp2 cross coupling 
reaction. This method was subsequently employed to access the required isopropyl starting material 
18 in high yield and selectivity for the desired product over the linear (n-Pr) product 20. This method 
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not only addressed the issues we encountered but also could provide a general method by which to 
incorporate an isopropyl or similar branched alkyl substituent at this position of related indole 
peptidomimetics.   
 
 
Scheme 4.14. A Pd(II)-CPos (21a) catalysed sp
3
-sp
2
 cross coupling reaction provided isopropyl derivative 18 which could 
be utilised to provide series 1 inhibitors with an isopropyl substituent at the R
1
 position. 
 
Biological assessment of these analogues in a FP binding assay revealed that 16a displayed high 
affinity for the PICK1 PDZ domain with a Ki value of 8.2 µM. Optimisation of this promising lead 
compound will explore the modification of the R1 and R2 positions. In particular, the development of 
the Pd(II)-CPhos (21a) cross coupling reaction to access to the isopropyl reagent 18 will facilitate the 
synthesis of the isopropyl derivative 34. The second optimisation approach will be guided by the 
observed order of magnitude increase in binding affinity observed in the series 2 inhibitors on 
exchanging the ethylbenzene substituent binding in the P-1 pocket for an n-butyl substituent. A 
similar modification of 16a could greatly improve its binding affinity. Biological assessments of these 
analogues 34 and 35 will guide additional optimisation studies. 
 
 
Scheme 4.15. Proposed optimised series 1 analogues. 
 
An expedient and versatile 2-step synthesis was developed to access the novel series 2 inhibitors. A 
Fischer indole synthesis was utilised to provide the indole ring containing the desired substituents at 
the R1 and R2 positions. A subsequent one-pot domino alkylation-hydrolysis incorporated the R3 
substituents and hydrolysed the ester to form the desired acid products. This concise route was used 
to synthesis 10 analogues which were assessed in a FP binding assay. Two of the analogues 33g and 
33c displayed potent binding affinity for the PICK1 PDZ domain with Ki values of 5.8 and 2.0 µM 
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respectively. Noteworthy observations from the preliminary SAR study revealed that an alkyl 
substituent is optimal at the R3 position, and that cross-talk between the P0 and P-2 pockets of the 
PICK1 PDZ domain is an important regulator of ligand binding affinity. Future optimisation studies 
will attempt to identify the optimal alkyl substituent at the R3 position and the best combination of 
substituents at the R1 and R2 positions for high affinity binding.  
 
 
Scheme 4.16. Summary of the synthetic route utilised to access the series 1 inhibitors. 
 
In conclusion, two series of novel peptidomimetic PICK1 PDZ domain inhibitors were developed. 
Three of these compounds displayed <10 µM binding affinity for the PICK1 PDZ domain, which are 
among the most active inhibitors of a PDZ domain reported to date. Interestingly, the series 2 
inhibitors which were designed to exploit a potentially novel binding mode resulted in a higher 
percentage of active binders with higher binding affinities for the PICK1 PDZ domain than the series 
1 inhibitors. The high affinity binders from both series will be utilised as chemical tools for the 
investigation of PICK1’s role in disease states such as schizophrenia, depression and particularly to 
investigate its role in activation and surface expression of the dominant breast cancer drug target 
HER2. Future optimisation of these compounds will aim to identify a nanomolar inhibitor of a PDZ 
domain as a part of a PICK1 PPI inhibition drug discovery programme.   
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4.8 Experimental 
 
4.8.1 General Considerations 
 
See Section 2.8.1 for general considerations. 
4.8.2 General Methods 
 
General Method A: Indole N-alkylation 
To a stirred suspension of sodium hydride (2.0 eq., 60% in mineral oil) in anhydrous DMF (3 
mL/mmol) at 0 °C was added a solution of the appropriate indole (1.0 eq.) in anhydrous DMF (2 
mL/mmol) dropwise. The mixture was stirred at 0 °C for 30 minutes followed by the slow addition of 
the appropriate alkyl bromide (1.5 – 3.0 eq.). The mixture was stirred at room temperature for 8 
hours. The mixture was poured onto crushed ice (10 g/mmol) and extracted with ether (3). The 
combined organics were washed with water, brine, dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified via the Biotage SP4 (silica-packed SNAP column). 
 
General Method B: Nitration 
 
Preformed acetyl nitrate was generated by the dropwise addition of neat 70% HNO3 (3.0 eq.) to 
acetic anhydride (2 mL/mmol) at 0 °C, followed by standing at room temperature for 10 minutes. To 
a stirred solution of the appropriate indole (1.0 eq.) in acetic anhydride (5 mL/mmol) at -78 °C was 
added dropwise the solution of freshly prepared acetyl nitrate. The mixture was allowed to warm to 
0 °C and maintained at this temperature for 2 hours. The mixture was poured into ice (10 g/mmol) 
and stirred for 1 hour. The aqueous solution was extracted with EtOAc (3). The combined organic 
extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was purified via the Biotage SP4 (silica-packed SNAP column). 
 
General Method C: Reductive acylation  
 
To a solution of the nitro indole (1.0 eq.) and the appropriate anhydride (3.0-8.0 eq.) in anhydrous 
methanol (14 mL/mmol) was added 10% palladium on carbon (0.4 eq.). The reaction mixture was 
heated at 40 °C under a hydrogen atmosphere (hydrogen filled balloon) for 1 hour. The catalyst was 
removed by filtration through Celite and the mixture was concentrated in vacuo.  
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General Method D: Ester hydrolysis  
 
The crude ester was treated with an aqueous sodium hydroxide solution (2N, 0.1 mL) in methanol (1 
mL) and heated at reflux for 16 hours. The reaction was concentrated in vacuo and the crude 
product was purified via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 g; 0-8% 
MeOH/H2O). 
 
General Method E: Fischer Indole Synthesis 
 
A mixture of the appropriate hydrazine monochloride (1.0 eq.), corresponding -ketoacid ester (1.6 
eq.) and glacial acetic acid (0.2 eq.) in anhydrous ethanol (2 mL/mmol) was heated at reflux for 4-6 
hours, cooled to room temperature and concentrated in vacuo. The crude product was purified via 
the Biotage SP4 (silica-packed SNAP column; EtOAc/hexanes). 
 
General Method F: One-pot indole N-alkylation and ester hydrolysis 
 
Anhydrous DMF (3 mL/mmol) was added to sodium hydride (2.0 eq., 60% in mineral oil) in an oven-
dried round bottom flask. The solution was cooled to 0 °C and the appropriate indole (1.0 eq.) in 
anhydrous DMF (1 mL/mmol) was added. The mixture was stirred at room temperature for 30 
minutes followed by the addition of the alkyl bromide (1.5 eq.). The reaction was heated at 100 °C 
for 4 hours. A second portion of sodium hydride (2.0 eq., 60% in mineral oil) was added and the 
reaction stirred at 100 °C for 1 hour. The reaction was then cooled to room temperature, poured 
into ice water and extracted with Et2O (x3). The combined organic extracts were washed with brine, 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified via the 
Biotage SP4 (silica-packed SNAP column; EtOAc/hexanes). 
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4.8.3 Experimental procedures (Series 1) 
 
Methyl 5-amino-2-methylbenzoate (10) 
 
Thionyl chloride (2.4 mL, 33.0 mmol, 10.0 eq.) was added to a solution of 5-amino-2-methylbenzoic 
acid 9 (0.5 g, 3.3 mmol, 1.0 eq.) in anhydrous methanol (10 mL/mmol) at 0 °C. The reaction was then 
stirred at room temperature for 12 hours. The solvent was removed under reduced pressure and the 
resulting white solid was dissolved by the slow addition of a saturated aqueous solution of NaHCO3 
(20 mL). The mixture was extracted with EtOAc (3  20 mL) and the combined organic extracts were 
washed with brine (20 mL), dried over MgSO4, filtered and concentrated. The title product 10 was 
obtained as a colourless oil (0.51 g, 94%), which did not require further purification. 1H NMR (400 
MHz, Chloroform-d) δ 7.25 (d, J = 2.7 Hz, 1H, C6-H), 7.02 (d, J = 8.1 Hz, 1H, C3-H), 6.75 (dd, J = 8.1, 
2.7 Hz, 1H, C4-H), 3.87 (s, 3H, OCH3), 2.46 (s, 3H, ArCH3);
 13C NMR (101 MHz, Chloroform-d) δ 168.3 
(CO2Me), 144.1 (C), 132.6 (C3), 130.2 (C), 130.1 (C), 119.1 (C4), 117.1 (C6), 51.9 (OCH3), 20.9 (ArCH3); 
m/z (ES+) 166.07 ([M+H]+, 100 %). Spectroscopic data are in accordance with the literature.322  
 
Methyl 5-amino-4-iodo-2-methylbenzoate (11) 
 
A solution of iodine monochloride dichloromethane(53.4 mL, 1M, 1.5 eq.) was added dropwise to a 
mixture of methyl 5-amino-2-methylbenzoate 10 (5.87 g, 35.6 mmol, 1.0 eq.), methanol (75 mL), 
water (7.5 mL), and calcium carbonate (10.7 g, 107 mmol, 3.0 eq.) at 0 °C and stirred for 4 hours. A 
solution of sodium sulfite (5.3 g) in water (20 mL) was added to the reaction and the resulting 
mixture was stirred at room temperature for 1 hour, filtered and concentrated in vacuo. The residue 
was diluted with EtOAc (30 mL) and washed with water (2  30 mL) followed by brine (30 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified via the Biotage SP4 
(silica-packed SNAP column 100 g; 0-3% EtOAc/hexanes) to give the title product 11 as a pale yellow 
solid (5.83 g, 56%). mp 73-75 °C (lit. 77 C295); 1H NMR (400 MHz, Chloroform-d) δ 7.55 (s, 1H, C3-H), 
7.29 (s, 1H, C6-H), 3.86 (s, 3H, OCH3), 2.42 (s, 3H, ArCH3);
 13C NMR (101 MHz, Chloroform-d) δ 167.8 
(CO2Me), 144.9 (C4), 141.8 (C3), 131.1 (C1), 130.5 (C2), 116.3 (C6), 89.3 (C5), 52.0 (OCH3), 20.4 
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(ArCH3); m/z (ES
+) 291.91 ([M+H]+, 100 %). Spectroscopic data are in accordance with the 
literature.295  
 
Methyl 5-amino-2-methyl-4-((trimethylsilyl)ethynyl)benzoate (12) 
 
Methyl 5-amino-4-iodo-2-methylbenzoate 11 (4.79 g, 16.5 mmol, 1.0 eq.), Pd(PPh3)2Cl2 (0.58 g, 0.83 
mmol, 0.05 eq.), and CuI (0.16 g, 0.83 mmol, 0.05 eq.) were added to an oven-dried flask under a N2 
atmosphere. Dry Et3N (5 mL/mmol) was added, and the resulting suspension was cooled to 0 °C. 
Ethynyltrimethylsilane (2.6 mL, 18.2 mmol, 1.1 eq.) was added dropwise, followed by stirring at 
room temperature for 3 hours. The Et3N was removed in vacuo, and ether (20 mL) was added to the 
resulting residue. After filtration through Celite, the organic extract was washed with brine (20 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified via the 
Biotage SP4 (silica-packed SNAP column 100 g; 0-30% EtOAc/hexanes) to give the title product 12 as 
a pale yellow solid (3.71 g, 87%). mp 61-63 °C; IR (KBr) ν max: 3469 (NH2), 3371 (NH2), 2947, 2144 (-
C≡C-), 1694 (C=O), 1625 (C=C), 1248 (C-O); 1H NMR (300 MHz, Chloroform-d) δ 7.28 (s, 1H, C6-H), 
7.17 (s, 1H, C3-H), 3.86 (s, 3H, OCH3), 2.42 (s, 3H, ArCH3), 0.26 (s, 9H, Si(CH3)3);
 13C NMR (126 MHz, 
Chloroform-d) δ 167.8 (CO2Me), 145.8 (C4), 135.1 (C3), 130.4 (C1), 129.0 (C2), 116.4 (C6), 111.8 (C5), 
102.2 (C2’), 101.0 (C1’), 52.0 (OCH3), 20.7 (ArCH3), 0.17 (Si(CH3)3); m/z (ES
+) 262.10 ([M+H]+, 100 %). 
HRMS (ES-) Calcd for C14H19NO2SiNa [M+Na]
+: 284.1083, found 284.1073. 
 
Methyl 5-methyl-1H-indole-6-carboxylate (13) 
 
To methyl 5-amino-2-methyl-4-((trimethylsilyl)ethynyl)benzoate 12 (1.8 g, 6.9 mmol, 1.0 eq.) and CuI 
(2.63 g, 13.8 mmol, 2.0 eq.) was added DMF (4 mL/mmol). The mixture was heated at 100 °C for 2 
hours before being cooled to room temperature. The reaction was diluted with Et2O (60 mL), filtered 
over Celite, washed with brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was purified via the Biotage SP4 (silica-packed SNAP column 50 g; 0-20% 
EtOAc/hexanes) to give the title product 13 as a pale yellow solid (0.95 g, 74%). mp 63-65 °C; IR (KBr) 
ν max: 3322 (NH), 2926, 1695 (C=O), 1444 (C=C), 1314, 1262 (C-O);
 1H NMR (500 MHz, Chloroform-d) δ 
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8.30 (br s, 1H, NH), 8.09 (s, H, C7-H), 7.48 (s, 1H, C4-H), 7.33 (d, J = 2.6 Hz, 1H, C3-H), 6.50 (d, J = 2.6 
Hz, 1H, C2-H), 3.91 (s, 3H, OCH3), 2.69 (s, 3H, ArCH3);
 13C NMR (126 MHz, Chloroform-d) δ 169.0 
(CO2Me), 133.8 (C3a), 131.2 (C), 131.2 (C), 127.7 (C3), 123.5 (C6), 122.8 (C4), 114.5 (C7), 102.4 (C2), 
51.8 (OCH3), 22.4 (ArCH3); m/z (ES
-) 187.90 ([M-H]-, 100 %); HRMS (ES-) Calcd for C11H10NO2 [M-H]
-: 
188.0712, found 188.0710. 
 
Methyl 5-methyl-1-phenethyl-1H-indole-6-carboxylate (14a) 
 
14a was prepared from methyl 5-methyl-1H-indole-6-carboxylate 13 (0.20 g, 1.06 mmol, 1.0 eq.) and 
(bromoethyl)benzene (0.22 mL, 1.59 mmol, 1.5 eq.) using general method A. The crude product was 
purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-20% EtOAc/hexanes) to give a 
mixture of the starting material methyl 5-methyl-1H-indole-6-carboxylate 13 (80 mg), and the title 
product 14a as a yellow oil (0.14 g, 46%, 76% based on recovered 13). IR (KBr) ν max: 2951, 1710 
(C=O), 1442 (C=C), 1240 (C-O), 1649 (C=O); 1H NMR (500 MHz, Chloroform-d) δ 8.01 (s, 1H, C7-H), 
7.44 (s, 1H, C4-H), 7.32 – 7.18 (m, 3H, 3  ArH), 7.08 – 7.04 (m, 2H, 2  ArH), 6.97 (d, J = 3.0, 1H, C2-
H), 6.35 (d, J = 3.0, 1H, C3-H), 4.38 (t, J = 7.2 Hz, 2H, C1’-H2), 3.93 (s, 3H, OCH3), 3.12 (t, J = 7.2 Hz, 2H, 
C2’-H2), 2.69 (s, 1H, ArCH3); 
13C NMR (126 MHz, Chloroform-d) δ 169.1 (CO2Me), 138.5 (C3’), 133.8 
(C7a), 132.0 (C3a), 131.5 (C2), 130.7 (C5), 128.9 (2  ArCH), 128.8 (2  ArCH), 126.9 (C6’), 123.1 (C4), 
122.9 (C6), 112.8 (C7), 100.6 (C3), 51.8 (OCH3), 48.4 (C1’), 36.9 (C2’), 22.5 (ArCH3); m/z (ES
+) 315.94 
([M+Na]+, 100 %); HRMS (ES+) Calcd for C19H19NO2Na [M+Na]
+: 316.1313, found 316.1320. 
 
Methyl 1-isobutyl-5-methyl-1H-indole-6-carboxylate (14b) 
 
14b was prepared from methyl 5-methyl-1H-indole-6-carboxylate 13 (0.35 g, 1.85 mmol, 1.0 eq.) and 
1-bromo-2-methylpropane (0.40 mL, 3.70 mmol, 2.0 eq.) using general method A. The crude product 
was purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-20% EtOAc/hexanes) to give the 
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title product 14b as a pale yellow oil (0.29 g, 63%). IR (thin film) ν max: 2957, 2361, 1717 (C=O), 1437, 
1236 (C-O); 1H NMR (500 MHz, Chloroform-d) δ 8.00 (s, 1H, C7-H), 7.45 (s, 1H, C4-H), 7.18 (d, J = 3.0 
Hz, 1H, C2-H), 6.41 (d, J = 3.0, 1H, C3-H), 3.93 (m, 5H, OCH3, C1’-H2), 2.68 (s, 3H, ArCH3), 2.31 – 2.09 
(m, 1H, C2’-H), 0.92 (d, J = 6.7 Hz, 6H, 2  C3’-H3); 
13C NMR (126 MHz, Chloroform-d) δ 169.1 
(CO2Me), 134.4 (C7a), 131.9 (C2), 131.8 (C3a), 130.5 (C5), 123.0 (C4), 122.8 (C6), 113.1 (C7), 100.4 
(C3), 54.4 (C1’), 51.8 (OCH3), 29.7 (C2’), 22.5 (ArCH3), 20.4 (C3’); m/z (ES
+) 246.15 ([M+H]+, 100 %); 
HRMS (ES+) Calcd for C15H19NO2Na [M+Na]
+: 268.1313, found 268.1302. 
 
Methyl 1-(2-(dimethylamino)ethyl)-5-methyl-1H-indole-6-carboxylate (14c) 
 
14c was prepared from methyl 5-methyl-1H-indole-6-carboxylate 13 (0.20 g, 1.06 mmol, 1.0 eq.) and 
2-chloro-N,N-dimethylethylamine hydrochloride (0.46 g, 3.18 mmol, 3.0 eq.) using general method 
A. The crude product was purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-5% 
MeOH/DCM) to give the title product 14c as a yellow oil (0.19 g, 68%). IR (thin film) ν max: 2947, 2361, 
1713 (C=O), 1694, 1437, 1234 (C-O), 1045; 1H NMR (400 MHz, Chloroform-d) δ 8.03 (s, 1H, C7-H), 
7.44 (s, 1H, C4-H), 7.27 (d, J = 3.1 Hz, 1H, C2-H), 6.42 (d, J = 3.1, 1H, C3-H), 4.26 (t, J = 7.0 Hz, 2H, C1’-
H2), 3.92 (s, 3H, OCH3), 2.71 (t, J = 7.0 Hz, 2H, C2’-H2), 2.68 (s, 3H, ArCH3), 2.30 (s, 6H, 2  C3’-H3); 
13C 
NMR (101 MHz, Chloroform-d) δ 169.0 (CO2Me), 134.1 (C7a), 131.8 (C3a), 131.6 (C2), 130.7 (C5), 
123.1 (C4), 122.9 (C6), 112.7 (C7), 101.0 (C3), 59.2 (C2’), 51.8 (OCH3), 45.9 (C3’), 44.9 (C1’), 22.4 
(ArCH3); m/z (ES
+) 261.16 ([M+H]+, 100 %); HRMS (ES+) Calcd for C15H21N2O2 [M+H]
+: 261.1603, found 
261.1594. 
 
Methyl 5-methyl-3-nitro-1-phenethyl-1H-indole-6-carboxylate (15a) 
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15a was prepared from methyl 5-methyl-1-phenethyl-1H-indole-6-carboxylate 14a (0.28 g, 0.95 
mmol, 1.0 eq.) using general method B. The crude product was purified via the Biotage SP4 (silica-
packed SNAP column 10 g; 0-20% EtOAc/hexanes) to give the title product 15a as a yellow solid (0.22 
g, 70%). mp 119-121 °C; IR (KBr) ν max: 1708 (C=O), 1516 (N-O), 1380 (N-O) 1243 (C-O);
 1H NMR (500 
MHz, Chloroform-d) δ 8.14 (s, 1H, C4-H), 8.00 (s, 1H, C7-H), 7.83 (s, 1H, C2-H), 7.32 – 7.19 (m, 3H, 3  
ArH), 7.06 – 6.98 (m, 2H, 2  ArH), 4.45 (t, J = 6.9 Hz, 2H, C1’-H2), 3.95 (s, 3H, OCH3), 3.18 (t, J = 6.9 
Hz, 2H, C2’-H2), 2.74 (s, 3H, ArCH3);
 13C NMR (126 MHz, Chloroform-d) δ 168.0 (CO2Me), 136.8 (C3’), 
136.1 (C5), 133.0 (C7a), 132.8 (C2), 129.2 (2  ArCH), 128.7 (2  ArCH), 128.1 (C3), 127.6 (C6’), 126.2 
(C6), 123.7 (C3a), 123.2 (C4), 113.8 (C7), 52.2 (OCH3), 49.5 (C1’), 36.3 (C2’), 22.5 (ArCH3); m/z (ES
+) 
339.13 ([M+H]+, 100 %); HRMS (ES+) Calcd for C19H19N2O4 [M+H]
+: 339.1339, found 339.1345. 
 
Methyl 1-isobutyl-5-methyl-3-nitro-1H-indole-6-carboxylate (15b) 
 
15b was prepared from methyl 1-isobutyl-5-methyl-1H-indole-6-carboxylate 14b (0.29 g, 1.17 mmol, 
1.0 eq.) using general method B. The crude product was purified via the Biotage SP4 (silica-packed 
SNAP column 10 g; 0-10% EtOAc/hexanes) to give the title product 15b as a yellow amorphous solid 
(0.15 g, 44%). IR (neat) ν max: 3125, 2959, 1703 (C=O), 1522 (N-O), 1373 (N-O), 1236 (C-O), 1076, 781;
 
1H NMR (400 MHz, Chloroform-d) δ 8.16 (s, 1H, C4-H), 8.14 (s, 1H, C2-H), 8.02 (s, 1H, C7-H), 4.01 (d, J 
= 7.5 Hz, 2H, C1’-H2), 3.95 (s, 3H, OCH3), 2.74 (s, 3H, ArCH3), 2.34 – 2.19 (m, 1H, C2’-H), 0.98 (d, J = 6.7 
Hz, 6H, 2  C3’-H3);
 13C NMR (101 MHz, Chloroform-d) δ 168.1 (CO2Me), 136.0 (C5), 133.5 (C7a), 
133.1 (C2), 128.2 (C3), 126.3 (C6), 123.6 (C3a), 123.1 (C4), 114.0 (C7), 55.4 (C1’), 52.3 (OCH3), 29.3 
(C2’), 22.5 (ArCH3), 20.2 (C3’); m/z (ES
+) 313.12 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C15H18N2O4Na 
[M+Na]+: 313.1164, found 313.1151. 
 
Methyl 1-(2-(dimethylamino)ethyl)-5-methyl-3-nitro-1H-indole-6-carboxylate (15c) 
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15c was prepared from methyl 1-(2-(dimethylamino)ethyl)-5-methyl-1H-indole-6-carboxylate 14c 
(0.28 g, 1.08 mmol, 1.0 eq.) using general method B. The crude product was purified via the Biotage 
SP4 (silica-packed SNAP column 10 g; 0-5% MeOH/DCM) to give the title product 15c as a yellow 
solid (0.14 g, 42%). mp 138-140 °C; IR (neat) ν max: 3113, 2951, 2771, 1703 (C=O), 1520 (N-O), 1454, 
1369 (N-O) 1240 (C-O), 1078; 1H NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H, C2-H), 8.12 (s, 1H, C4-
H), 8.03 (s, 1H, C7-H), 4.27 (t, J = 6.3 Hz, 2H, C1’-H2), 3.94 (s, 3H, OCH3), 2.77 (t, J = 6.3 Hz, 2H, C2’-H2), 
2.72 (s, 3H, ArCH3), 2.30 (s, 6H, 2  C3’-H3);
 13C NMR (101 MHz, Chloroform-d) δ 168.0 (CO2Me), 
136.0 (C5), 133.6 (C2), 133.3 (C7a), 128.3 (C3), 126.1 (C6), 123.6 (C3a), 123.1 (C4), 113.6 (C7), 58.2 
(C2’), 52.2 (OCH3), 45.5 (C3’), 45.2 (C1’), 22.4 (ArCH3); m/z (ES
+) 306.14 ([M+H]+, 100 %); HRMS (ES+) 
Calcd for C15H20N3O4 [M+H]
+: 306.1454, found 306.1441. 
 
Sodium 5-methyl-1-phenethyl-3-propionamido-1H-indole-6-carboxylate (16a) 
 
Methyl 5-methyl-1-phenethyl-3-propionamido-1H-indole-6-carboxylate was prepared from methyl 
5-methyl-3-nitro-1-phenethyl-1H-indole-6-carboxylate 15a (40 mg, 0.12 mmol, 1.0 eq.) and 
propionic anhydride (50 μL, 0.36 mmol, 3.0 eq.) using general method C. The crude product was 
used in the next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ 7.91 (s, 1H, 
C7-H), 7.82 (s, 1H, C2-H), 7.31 – 7.24 (m, 3H, 2  ArCH, C4-H), 7.24 – 7.19 (m, 1H, C6’-H), 7.16 – 7.08 
(m, 2H, 2  ArCH), 4.32 (t, J = 7.6 Hz, 2H, C1’-H2), 3.92 (s, 3H, OCH3), 3.13 – 3.08 (m, 2H, C2’-H2), 2.68 
(s, 3H, ArCH3), 2.47 (q, J = 7.6 Hz, 2H, C2’’-H2), 1.30 (t, J = 7.6 Hz, 3H, C3’’-H3);
 13C NMR (101 MHz, 
Chloroform-d) δ 171.3 (C1’’), 168.8 (CO2Me), 138.3 (C3’), 131.7 (C7a), 130.3 (C5), 128.8 (4  ArCH), 
126.9 (C6’), 123.5 (C3a), 123.4 (C6), 122.6 (C2), 118.7 (C4), 113.6 (C3), 113.2 (C7), 51.9 (OCH3), 48.3 
(C1’), 37.1 (C2’), 30.2 (C2’’), 22.5 (ArCH3), 10.1 (C3’’). The crude methyl 5-methyl-1-phenethyl-3-
propionamido-1H-indole-6-carboxylate was hydrolysed according to general method D. The crude 
product was purified via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 g; 0-20% 
MeOH/DCM) to give the title product 16a as a white solid (27 mg, 61% over 2 steps). IR (neat) ν max: 
3262 (NH), 2922, 1684 (C=O), 1645, 1558, 1281, 1246, 1072, 880; 1H NMR (500 MHz, Methanol-d4) δ 
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7.92 (s, 1H, C7-H), 7.65 (s, 1H, C2-H), 7.51 (s, 1H, C4-H), 7.23 – 7.18 (m, 2H, C5’-H), 7.17 – 7.12 (m, 
1H, C6’-H), 7.11 – 7.06 (m, 2H, C4’-H), 4.38 (t, J = 7.1 Hz, 2H, C1’-H2), 3.09 (t, J = 7.1 Hz, 2H, C2’-H2), 
2.64 (s, 3H, ArCH3), 2.46 (q, J = 7.6 Hz, 2H, C2’’-H2), 1.24 (t, J = 7.6 Hz, 3H, C3’’-H3);
 13C NMR (126 
MHz, Methanol-d4) δ 174.7 (C1’’), 172.7* (CO2Na), 139.9 (C3’), 133.1 (C7a), 130.7 (C5), 129.8 (C4’), 
129.5 (C5’), 127.5 (C6’), 125.3 (C3a, C6), 124.1 (C2), 120.8 (C4), 115.0 (C3), 113.9 (C7), 48.8* (C1’), 
37.9 (C2’), 30.1 (C2’’), 22.5 (ArCH3), 10.7 (C3’’); m/z (ES
+) 349.15 ([M-H]-, 100 %); HRMS (ES-) Calcd 
for C21H21N2O3 [M-H]
-: 349.1558, found 349.1549. *denotes that the carbon was identified via HMBC. 
 
Sodium 5-methyl-3-(3-methylbutanamido)-1-phenethyl-1H-indole-6-carboxylate (16b) 
 
Methyl 5-methyl-3-(3-methylbutanamido)-1-phenethyl-1H-indole-6-carboxylate was prepared from 
methyl 5-methyl-3-nitro-1-phenethyl-1H-indole-6-carboxylate 15a (40 mg, 0.12 mmol, 1.0 eq.) and 
isovaleric anhydride (72 μL, 0.36 mmol, 3.0 eq.) using general method C. The crude product was used 
in the next step without further purification. 1H NMR (500 MHz, Chloroform-d) δ 7.92 (s, 1H, C7-H), 
7.82 (s, 1H, C2-H), 7.30 – 7.26 (m, 3H, 2  ArCH, C4-H), 7.24 – 7.20 (m, 1H, C6’-H), 7.13 (dd, J = 6.9, 
1.7 Hz, 2H, 2  ArCH), 4.32 (dd, J = 8.4, 6.8 Hz, 2H, C1’-H2), 3.92 (s, 3H, OCH3), 3.15 – 3.06 (m, 2H, C2’-
H2), 2.69 (s, 3H, ArCH3), 2.34 – 2.21 (m, 3H, C2’’-H2, C3’’-H), 1.05 (d, J = 6.3 Hz, 6H, 2  C4’’-H3); 
13C 
NMR (126 MHz, Chloroform-d) δ 170.1 (C1’’), 168.8 (CO2Me), 138.3 (C3’), 131.6 (C7a), 130.4 (C5), 
128.8 (4  ArCH), 126.9 (C6’), 123.5 (C3a), 123.5 (C6), 122.7 (C2), 118.7 (C4), 113.5 (C3), 113.2 (C7), 
51.9 (OCH3), 48.3 (C1’), 46.5 (C2’’), 37.1 (C2’), 26.6 (C3’’), 22.7 (C4’’), 22.6 (ArCH3). The crude methyl 
5-methyl-3-(3-methylbutanamido)-1-phenethyl-1H-indole-6-carboxylate was hydrolysed according 
to general method D. The crude product was purified via the Biotage SP4 (Reverse-phase silica-
packed SNAP column 4 g; 0-20% MeOH/DCM) to give the title product 16b as a white solid (23 mg, 
47% over 2 steps). mp 233-235 °C; IR (neat) ν max: 3281 (NH), 2953, 1681 (C=O), 1641, 1558, 1406, 
1283, 1248, 881; 1H NMR (500 MHz, Methanol-d4) δ 7.93 (s, 1H, C7-H), 7.64 (s, 1H, C2-H), 7.51 (s, 1H, 
C4-H), 7.23 – 7.18 (m, 2H, C5’-H), 7.18 – 7.10 (m, 1H, C6’-H), 7.10 – 7.07 (m, 2H, C4’-H), 4.38 (t, J = 
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7.1 Hz, 2H, C1’-H2), 3.09 (t, J = 7.1 Hz, 2H, C2’-H2), 2.65 (s, 3H, ArCH3), 2.31 (d, J = 7.3 Hz, 2H, C2’’-H2), 
2.24 – 2.12 (m, 1H, C3’’-H), 1.03 (d, J = 6.6 Hz, 6H, 2  C4’’-H3); 
13C NMR (126 MHz, Methanol-d4) δ 
173.4 (C1’’), 172.3* (CO2Na), 139.9 (C3’), 133.1 (C7a), 130.8 (C5), 129.8 (C4’), 129.5 (C5’), 127.5 (C6’), 
125.5 (C3a, C6), 124.4 (C2), 120.8 (C4), 114.8 (C3), 114.0 (C7), 49.1* (C1’), 46.2 (C2’’), 37.9 (C2’), 27.7 
(C3’’), 22.8 (C4’’), 22.6 (ArCH3);
 m/z (ES+) 401.18 ([M+H]+, 100 %); HRMS (ES+) Calcd for C23H26N2O3Na 
[M+H]+: 401.1833, found 401.1836. *denotes that the carbon was identified via HMBC. 
 
Sodium 1-isobutyl-5-methyl-3-propionamido-1H-indole-6-carboxylate (16c) 
 
Methyl 1-isobutyl-5-methyl-3-propionamido-1H-indole-6-carboxylate was prepared from methyl 1-
isobutyl-5-methyl-3-nitro-1H-indole-6-carboxylate 15b (45 mg, 0.16 mmol, 1.0 eq.) and propionic 
anhydride (0.1 mL, 0.8 mmol, 5.0 eq.) using general method C. The crude product was used in the 
next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ 7.97 (s, 1H, C7-H), 7.87 (s, 
1H, C2-H), 7.86 (br s, 1H, NH), 7.30 (s, 1H, C4-H), 3.92 (s, 3H, OCH3), 3.88 (d, J = 7.4 Hz, 2H, C1’-H2), 
2.67 (s, 3H, ArCH3), 2.48 (q, J = 7.6 Hz, 2H, C2’’-H2), 2.25 – 2.10 (m, 1H, C2’-H), 1.30 (t, J = 7.6 Hz, 3H, 
C3’’-H3), 0.90 (d, J = 6.7 Hz, 6H, 2  C3’-H3); 
13C NMR (101 MHz, Chloroform-d) δ 171.3 (C1’’), 168.9 
(CO2Me), 132.0 (C7a), 130.1 (C5), 123.4 (C), 123.3 (C), 123.2 (C2), 118.7 (C4), 113.4 (C7), 113.3 (C3), 
54.2 (C1’), 51.9 (OCH3), 30.1 (C2’’), 29.8 (C2’), 22.5 (ArCH3), 20.4 (C3’), 10.1 (C3’’). The crude methyl 
1-isobutyl-5-methyl-3-propionamido-1H-indole-6-carboxylate was hydrolysed according to general 
method D. The crude product was purified via the Biotage SP4 (Reverse-phase silica-packed SNAP 
column 4 g; 0-10% MeOH/DCM) to give the title product 16c as a white solid (39 mg, 76% over 2 
steps). mp 243-245 °C; IR (neat) ν max: 3260, 2961, 1676, 1650, 1560, 1406, 1381, 1275, 1240, 880;
 1H 
NMR (500 MHz, Methanol-d4) δ 8.00 (s, 1H, C7-H), 7.77 (s, 1H, C2-H), 7.54 (s, 1H, C4-H), 3.96 (d, J = 
7.4 Hz, 2H, C1’-H2), 2.66 (s, 3H, ArCH3), 2.48 (q, J = 7.6 Hz, 2H, C2’’-H2), 2.18 (dt, J = 12.9, 6.4 Hz, 1H, 
C2’-H), 1.25 (t, J = 7.6 Hz, 3H, C3’’-H3), 0.92 (d, J = 6.6 Hz, 6H, 2  C3’-H3);
 13C NMR (126 MHz, 
Methanol-d4) δ 174.7 (C1’’), 172.5* (CO2Na), 133.5 (C7a), 130.7 (C5), 125.2 (C3a, C6), 124.5 (C2), 
120.8 (C4), 114.9 (C3), 114.1 (C7), 54.8 (C1’), 31.0 (C2’), 30.1 (C2’’), 22.6 (ArCH3), 20.5 (C3’), 10.7 
(C3’’); m/z (ES+) 325.15 ([M+H]+, 100 %); HRMS (ES+) Calcd for C17H22N2O3Na [M+H]
+: 325.1523, 
found 325.1522. *denotes that the carbon was identified via HMBC. 
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Sodium 1-isobutyl-5-methyl-3-(3-methylbutanamido)-1H-indole-6-carboxylate (16d) 
 
Methyl 1-isobutyl-5-methyl-3-(3-methylbutanamido)-1H-indole-6-carboxylate was prepared from 
methyl 1-isobutyl-5-methyl-3-nitro-1H-indole-6-carboxylate 15b (50 mg, 0.17 mmol, 1.0 eq.) and 
isovaleric anhydride (0.27 mL, 1.36 mmol, 8.0 eq.) using general method C. The crude product was 
used in the next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ 7.97 (s, 1H, 
C7-H), 7.87 (s, 1H, C2-H), 7.29 (s, 1H, C4-H), 3.92 (s, 3H, OCH3), 3.88 (d, J = 7.4 Hz, 2H, C1’-H2), 2.68 (s, 
3H, ArCH3), 2.34 – 2.13 (m, 4H, C2’-H, C2’’-H2, C3’’-H), 1.04 (d, J = 6.3 Hz, 6H, 2  C4’’-H3), 0.91 (d, J = 
6.6 Hz, 6H, 2  C3’-H3); 
13C NMR (101 MHz, Chloroform-d) δ 170.1 (C1’’), 168.9 (CO2Me), 132.0 (C7a), 
130.1 (C5), 123.4 (C3a, C6), 123.3 (C2), 118.7 (C4), 113.4 (C7), 113.3 (C3), 54.2 (C1’), 51.9 (OCH3), 
46.5 (C2’’), 29.8 (C2’), 26.5 (C3’’), 22.7 (C4’’), 22.6 (ArCH3), 20.4 (C3’). The crude methyl 1-isobutyl-5-
methyl-3-(3-methylbutanamido)-1H-indole-6-carboxylate was hydrolysed according to general 
method D. The crude product was purified via the Biotage SP4 (Reverse-phase silica-packed SNAP 
column 4 g; 0-15% MeOH/DCM) to give the title product 16d as a white solid (49 mg, 82% over 2 
steps). mp 244-246 °C; IR (neat) ν max: 3281 (NH), 2953, 2932, 1682 (C=O), 1651, 1558, 1279, 1246, 
883; 1H NMR (400 MHz, Methanol-d4) δ 7.92 (s, 1H, C7-H), 7.74 (s, 1H, C2-H), 7.53 (s, 1H, C4-H), 3.94 
(d, J = 7.3 Hz, 2H, C1’-H2), 2.64 (s, ArCH3), 2.38 – 2.28 (m, 2H, C2’’-H2), 2.25 – 2.14 (m, 2H, C2’-H, C3’’-
H), 1.04 (d, J = 6.6 Hz, 6H, 2  C4’’-H3), 0.92 (d, J = 6.6 Hz, 6H, 2  C3’-H3); 
13C NMR (101 MHz, 
Methanol-d4) δ 173.8 (CO2Na), 173.4 (C1’’), 133.5 (C7a), 130.0 (C5), 127.5 (C6), 124.8 (C3a), 124.2 
(C2), 120.6 (C4), 114.7 (C3), 113.3 (C7), 54.8 (C1’), 46.2 (C2’’), 31.0 (C2’), 27.7 (C3’’), 22.8 (C4’’), 22.3 
(ArCH3), 20.5 (C3’); m/z (ES
+) 353.18 ([M+H]+, 100 %); HRMS (ES+) Calcd for C19H26N2O3Na [M+H]
+: 
353.1836, found 353.1840. 
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Sodium 1-isobutyl-5-methyl-3-(2-phenylacetamido)-1H-indole-6-carboxylate (16e) 
 
Methyl 1-isobutyl-5-methyl-3-(2-phenylacetamido)-1H-indole-6-carboxylate was prepared from 
methyl 1-isobutyl-5-methyl-3-nitro-1H-indole-6-carboxylate 15b (35 mg, 0.12 mmol, 1.0 eq.) and 2-
phenylacetic anhydride (0.18 g, 0.72 mmol, 6.0 eq.) using general method C. The crude product was 
used in the next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ 7.95 (s, 1H, 
C7-H), 7.82 (d, J = 0.5 Hz, 1H, C2-H), 7.48 – 7.38 (m, 5H, C4’’-H, C5’’-H, C6’’-H), 6.95 (s, 1H, C4-H), 3.91 
(s, 3H, OCH3), 3.87 (d, J = 7.4 Hz, 2H, C1’-H2), 3.82 (s, 2H, C2’’-H2), 2.62 (s, 3H, ArCH3), 2.25 – 2.10 (m, 
1H, C2’-H), 0.90 (d, J = 6.7 Hz, 6H, 2  C3’-H3); 
13C NMR (126 MHz, Chloroform-d) δ 168.8 (CO2Me), 
168.4 (C1’’), 134.8 (C3’’), 132.0 (C7a), 130.2 (C5), 129.8 (2  ArCH), 129.4 (2  ArCH), 127.9 (C6’’), 
123.5 (C), 123.2 (C), 123.1 (C2), 118.4 (C4), 113.4 (C7), 113.0 (C3), 54.2 (C1’), 51.9 (OCH3), 44.2 (C2’’), 
29.8 (C2’), 22.6 (ArCH3), 20.4 (C3’). The crude methyl 1-isobutyl-5-methyl-3-(2-phenylacetamido)-1H-
indole-6-carboxylate was hydrolysed according to general method D. The crude product was purified 
via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 g; 0-10% MeOH/DCM) to give the 
title product 16e as a white solid (18 mg, 39% over 2 steps). mp 236 -238 °C; IR (neat) ν max: 3279, 
2957, 1672 (C=O), 1647, 1557, 1389, 1277, 1244, 878; 1H NMR (500 MHz, Methanol-d4) δ 7.79 (s, 1H, 
C7-H), 7.69 (s, 1H, C2-H), 7.50 (s, 1H, C4-H), 7.42 – 7.37 (m, 2H, C4’’-H), 7.33 (dd, J = 8.5, 6.8 Hz, 2H, 
C5’’-H), 7.27 – 7.23 (m, 1H, C6’’-H), 3.92 (d, J = 7.4 Hz, 2H, C1’-H2), 3.77 (s, 2H, C2’’-H2), 2.62 (s, 3H, 
ArCH3), 2.24 – 2.05 (m, 1H, C2’-H), 0.90 (d, J = 6.7 Hz, 6H, 2  C3’-H3); 
13C NMR (126 MHz, Methanol-
d4) δ 175.7 (CO2Na), 171.5 (C1’’), 137.2 (C3’’), 133.6 (C7a), 130.1 (C6, C4’’), 129.6 (C5’’), 129.2 (C5), 
127.9 (C6’’), 124.1 (C3a), 123.5 (C2), 120.2 (C4), 114.6 (C3), 112.3 (C7), 54.8 (C1’), 43.7 (C2’’), 30.9 
(C2’), 22.0 (ArCH3), 20.4 (C3’); m/z (ES
+) 387.17 ([M+H]+, 100 %); HRMS (ES+) Calcd for C22H24N2O3Na 
[M+H]+: 387.1679, found 387.1678. 
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Sodium 1-(2-(dimethylamino)ethyl)-5-methyl-3-propionamido-1H-indole-6-carboxylate (16f) 
 
Methyl 1-(2-(dimethylamino)ethyl)-5-methyl-3-propionamido-1H-indole-6-carboxylate was prepared 
from methyl 1-(2-(dimethylamino)ethyl)-5-methyl-3-nitro-1H-indole-6-carboxylate 15c (35 mg, 0.11 
mmol, 1.0 eq.) and propionic anhydride (73 µL, 0.57 mmol, 5.0 eq.) using general method C. The 
crude product was used in the next step without further purification. 1H NMR (400 MHz, 
Chloroform-d) δ 8.00 (s, 1H, C7-H), 7.89 (s, 1H, C2-H), 7.36 (br s, 1H, NH), 7.29 (s, 1H, C4-H), 4.21 (t, J 
= 7.1 Hz, 2H, C1’-H2), 3.91 (s, 3H, OCH3), 2.70 (t, J = 7.1 Hz, 2H, C2’-H2), 2.67 (s, 3H, ArCH3), 2.47 (q, J = 
7.6 Hz, 2H, C2’’-H2), 2.29 (s, 6H, 2  C3’-H3), 1.29 (t, J = 7.6 Hz, 3H, C3’’-H3); 
13C NMR (101 MHz, 
Chloroform-d) δ 171.4 (C1’’), 168.8 (CO2Me), 131.8 (C7a), 130.4 (C5), 123.5 (C3a, C6), 122.9 (C2), 
118.8 (C4), 113.7 (C3), 113.0 (C7), 59.1 (C2’), 51.9 (OCH3), 45.8 (C3’), 44.7 (C1’), 30.1 (C2’’), 22.5 
(ArCH3), 10.1 (C3’’). The crude methyl 1-(2-(dimethylamino)ethyl)-5-methyl-3-propionamido-1H-
indole-6-carboxylate was hydrolysed according to general method D. The crude product was purified 
via the Biotage SP4 (Reverse-phase silica-packed SNAP column 4 g; 0-20% H2O/MeOH) to give the 
title product 16f as an amorphous yellow solid (16 mg, 42% over 2 steps). 1H NMR (500 MHz, 
Methanol-d4) δ 7.69 (s, 1H, C2-H), 7.62 (s, 1H, C7-H), 7.47 (s, 1H, C4-H), 4.31 (t, J = 7.1 Hz, 2H, C1’-H2), 
2.89 (t, J = 7.1 Hz, 2H, C2’-H2), 2.58 (s, 3H, ArCH3), 2.47 (q, J = 7.6 Hz, 2H, C2’’-H2), 2.39 (s, 6H, 2  C3’-
H3), 1.24 (t, J = 7.6 Hz, 3H, C3’’-H3); 
13C NMR (126 MHz, Methanol-d4) δ 178.5* (CO2Na), 174.7 (C1’’), 
135.3* (C6), 133.3 (C7a), 128.2* (C5), 123.3 (C3a), 121.9 (C2), 119.8 (C4), 115.3 (C3), 110.1 (C7), 59.3 
(C2’), 45.4 (C3’), 44.7 (C1’), 30.1 (C2’’), 21.3 (ArCH3), 10.7 (C3’’); m/z (ES
+) 340.16 ([M+H]+, 100 %); 
HRMS (ES+) Calcd for C17H23N2O3Na [M+H]
+: 340.1632, found 340.1632. *denotes that the carbon 
was identified via HMBC. 
 
2'-Bromo-N2,N2,N6,N6-tetramethylbiphenyl-2,6-diamine (27) 
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To N,N,N,N-tetramethylbenzene-1,3-diamine 26 (0.2 g, 1.22 mmol, 1.0 eq.) in anhydrous hexanes 
(2.5 mL) under a N2 atmosphere was added n-butyllithium (0.6 mL, 1.2 eq., 2.5M in THF). The 
reaction mixture was heated at reflux for 1 hour before cooling to room temperature. 2-
Bromochlorobenzene (0.16 mL, 1.34 mmol, 1.1 eq.) was then added dropwise over 15 minutes with 
vigorous stirring. The reaction mixture was heated at reflux for a further 2 hours. The reaction was 
quenched at room temperature by the slow addition of water (2.5 mL). The aqueous layer was 
extracted with ether (3  2.5 mL). The combined organic layers were dried over MgSO4, filtered, 
concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-5% 
EtOAc/hexanes) to give the title product 27 as a white solid (0.33 g, 84%). 1H NMR (400 MHz, 
Chloroform-d) δ 7.65 (ddd, J = 8.0, 1.2, 0.5 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.14 (ddd, J = 8.0, 6.6, 2.5 Hz, 
1H), 6.88 (d, J = 8.0 Hz, 2H), 2.44 (s, 12H, 2  NCH3); 
13C NMR (101 MHz, Chloroform-d) δ 153.4 (C), 
140.3 (C), 133.4 (ArCH), 132.8 (ArCH), 130.4 (C), 129.0 (ArCH), 127.7 (ArCH), 127.0 (ArCH), 126.4 (C), 
114.0 (2  ArCH), 44.1 (NCH3)2). m/z (ES
+) 319.05 ([M+H]+, 100 %); Spectroscopic data are in 
accordance with the literature.316  
 
2'-(Dicyclohexylphosphino)-N2,N2,N6,N6-tetramethylbiphenyl-2,6-diamine (CPhos (21a)) 
 
n-Butylithium (0.38 mL, 1.2 eq., 2.5M in THF) was added dropwise to a solution of 27 (0.25 g, 0.78 
mmol, 1.0 eq.) in THF (3.2 mL) at -78 C and the resulting mixture was maintained at this 
temperature for 30 minutes. Chlorodicyclohexylphosphine (0.20 mL, 0.94 mmol, 1.2 eq.) was then 
added dropwise via syringe over 15 min. The reaction mixture was stirred at -78 C for 1 hour and 
then allowed to slowly warm to room temperature. The reaction mixture was quenched by the slow 
addition of MeOH (5 mL) and filtered through a plug of silica gel topped with Celite, eluting with 
EtOAc (12 mL). The filtrate was concentrated in vacuo and purified using preparative TLC (10% 
EtOAc/hexanes) to give the title product CPhos (21a) as a white solid (0.26 g, 72%). 1H NMR (500 
MHz, Chloroform-d) δ 7.69 (d, J = 7.4 Hz, 1H), 7.43 – 7.30 (m, 4H), 6.91 (d, J = 8.0 Hz, 2H), 2.48 (s, 
12H, 2  NCH3), 2.01 – 1.54 (m, 12H), 1.36 – 1.01 (m, 10H); 
13C NMR (126 MHz, Chloroform-d) δ 
153.5, 146.3 (d, J = 31.2 Hz), 136.9 (d, J = 17.0 Hz), 133.2 (d, J = 6.5 Hz), 132.7 (d, J = 3.2 Hz), 132.2, 
128.6, 127.5, 125.8, 114.0, 44.9, 35.2 (d, J = 15.2 Hz), 31.3 (d, J = 16.4 Hz), 29.6 (d, J = 12.2 Hz), 28.0 
(d, J = 11.3 Hz), 27.7 (d, J = 8.6 Hz), 26.7 (observed complexity due to P-C splitting); 31P NMR (202 
Chapter 4: Peptidomimetics 
 
195 
 
MHz, Chloroform-d) δ -9.01. m/z (ES+) 437.25 ([M+H]+, 100 %); Spectroscopic data are in accordance 
with the literature.316 
  
Methyl 5-amino-2-isopropylbenzoate (18) 
 
To an oven-dried microwave vial charged with CPhos (21a) (61 mg, 0.14, 0.04 eq.) and Pd(OAc)2 (16 
mg, 0.07 mmol, 0.02 eq.) was added a solution of methyl 5-amino-2-bromobenzoate 17 (0.80 g, 3.48 
mmol, 1.0 eq.) in toluene (5.6 mL). The reaction mixture was cooled to 0 C before the slow addition 
of isopropylzinc bromide (8.4 mL, 1.2 eq., 0.5M in THF). The reaction was allowed to warm to room 
temperature and stirred for 30 minutes. The reaction mixture was then quenched by the addition of 
aqueous hydrochloric acid (10 mL, 1N) and extracted with ethyl acetate (3  10 mL).The organic 
layers were combined, dried over MgSO4, filtered, concentrated in vacuo and purified via the 
Biotage SP4 (silica-packed SNAP column 25 g; 0-10% EtOAc/hexanes) to give the title product 18 as a 
yellow oil (0.63 g, 93%). IR (thin film) ν max: 3372 (NH), 2957, 1713 (C=O), 1624, 1503, 1443, 1315;
 1H 
NMR (500 MHz, Chloroform-d) δ 7.19 (d, J = 8.4 Hz, 1H, C3-H), 7.04 (d, J = 2.7 Hz, 1H, C6-H), 6.79 (dd, 
J = 8.4, 2.7 Hz, 1H, C4-H), 3.87 (s, 3H, OCH3), 3.56 (hept, J = 6.9 Hz, 1H, C1’-H), 1.20 (d, J = 6.9 Hz, 6H, 
2  C2’-H3); 
13C NMR (126 MHz, Chloroform-d) δ 169.1 (CO), 143.8 (C5), 139.7 (C2), 130.5 (C1), 127.3 
(C3), 118.9 (C4), 116.0 (C6), 52.1 (OCH3), 29.0 (C1’), 24.3 (C2’); m/z (ES
+) 194.12 ([M+H]+, 100 %); 
HRMS (ES+) Calcd for C11H16NO2 [M+H]
+: 194.1103, found 194.1174. 
 
4.8.4 Experimental procedures (Series 2) 
 
Methyl 2-oxo-5-phenylpentanoate (30a)274 
 
Magnesium turnings (0.32 g, 13.1 mmol, 1.3 eq.) were activated by vigorous stirring overnight under 
a nitrogen atmosphere and then suspended in anhydrous THF (20 mL). 1-Bromo-3-phenylpropane 
(1.53 mL, 10.1 mmol, 1.0 eq.) was added dropwise under a gentle reflux. The stirring was continued 
for 30 minutes to give a solution of (3-phenylpropyl)magnesium bromide. In a separate flask, 
dimethyl oxalate (3.56 g, 30.3 mmol, 3.0 eq.) in dry Et2O (20 mL) was cooled to -78 C before 
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dropwise addition of the (3-phenylpropyl)magnesium bromide solution. The mixture was stirred at 0 
°C for 3 hours, diluted with aqueous 1M hydrochloric acid (20 mL), and extracted with EtOAc (3  20 
mL). The combined organic extracts were washed with a saturated aqueous solution of NaHCO3 (30 
mL), brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-20% EtOAc/hexanes) to give the title 
product 30a as a colourless liquid (1.42 g, 69%). 1H NMR (300 MHz, Chloroform-d) δ 7.34 – 7.25 (m, 
2H, 2  ArH), 7.24 – 7.14 (m, 3H, 3  ArH), 3.85 (s, 3H, C1’-H), 2.86 (t, J = 7.3 Hz, 2H, C3-H2), 2.67 (t, J 
= 7.6 Hz, 2H, C5-H2), 2.10 – 1.88 (m, 2H, C4-H2);
 13C NMR (75 MHz, Chloroform-d) δ 194.0 (C2), 161.5 
(C1), 141.1 (C6), 128.5 (4  ArCH), 126.2 (C9), 52.9 (C1’), 38.6 (C3), 34.8 (C5), 24.5 (C4); m/z (ES+) 
206.09 ([M+Na]+, 100 %). Spectroscopic data are in agreement with the literature.274  
 
Ethyl 2-oxobutanoate (30b)323 
 
To solution of 2-ketobutyric acid (0.75 g, 7.4 mmol, 1.0 eq.) in EtOH (7 mL) was added H2SO4 (0.08 
mL, 1.5 mmol, 0.2 eq.) dropwise. The mixture was heated at reflux for 6 hours. The mixture was 
cooled to room temperature and concentrated in vacuo. The residue was diluted with EtOAc (20 
mL), washed with a saturated aqueous solution of NaHCO3 (10 mL), water (10 mL), brine (10 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The title product 30b was obtained as a 
colourless liquid (0.95 g, quant.), which did not require further purification. 1H NMR (400 MHz, 
Chloroform-d) δ 4.31 (q, J = 7.1 Hz, 2H, C1’-H2), 2.87 (q, J = 7.2 Hz, 1H, C3-H2), 1.36 (t, J = 7.1 Hz, 3H, 
C2’-H3), 1.13 (t, J = 7.2 Hz, 3H, C4-H3). Spectroscopic data are in agreement with the literature.
323  
 
Ethyl 4-methyl-2-oxopentanoate (30c)324 
 
To solution of 2-ketobutyric acid (0.5 g, 3.8 mmol, 1 eq.) in EtOH (4 mL) was added H2SO4 (0.04 mL, 
0.8 mmol, 0.2 eq.) dropwise. The mixture was heated at reflux for 6 hours. The mixture was cooled 
to room temperature and concentrated in vacuo. The residue was diluted with EtOAc (20 mL), 
washed with a saturated aqueous solution of NaHCO3 (10 mL), water (10 mL), brine (10 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The title product 30c was obtained as a colourless 
liquid (0.60 g, quantitative), which did not require further purification. 1H NMR (300 MHz, 
Chloroform-d) δ 4.31 (q, J = 7.1 Hz, 2H, C1’-H2), 2.71 (d, J = 6.8 Hz, 2H, C3-H2), 2.19 (m, 1H, C4-H), 
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1.36 (t, J = 7.1 Hz, 3H, C2’-H3), 0.96 (d, J = 6.7 Hz, 6H, 2  C5-H3);
 13C NMR (75 MHz, Chloroform-d) δ 
194.6 (C2), 161.6 (C1), 62.5 (C1’), 48.0 (C3), 24.3 (C4), 22.6 (2  C5), 14.2 (C2’); m/z (ES+) 144.98 
([M+H]+, 100 %). Spectroscopic data are in agreement with the literature.324 
 
Methyl/ethyl 5-methyl-3-phenethyl-1H-indole-2-carboxylate (32a) 
 
32a was prepared from p-tolylhydrazine hydrochloride 31a (200 mg, 1.26 mmol) and methyl 2-oxo-
5-phenylpentanoate 30a (417 mg, 2.02 mmol) using general method A. The crude mixture was 
purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-8% EtOAc/hexanes) to give the title 
product 32a as an inseparable mixture of the methyl and ethyl ester (10:1). The mixture was isolated 
as a pale yellow solid (322 mg). The ratio of products was determined by analysis of the integration 
of the methyl-CH3 (major product) compared to the ethyl-CH3 (minor product). All other signals are 
as they appear in the spectra and represent the mixture of esters. 1H NMR (400 MHz, Chloroform-d) 
δ 8.63 (br s, 1.1H, NH), 7.40 (s, 1.1H, C4-H), 7.34 – 7.07 (m, 7.7H, 7  ArH), 4.41 (q, J = 7.1 Hz, 0.2H, 
CO2CH2CH3) 3.91 (s, 3H, CO2CH3), 3.41 – 3.32 (m, 2.2H, C1’-H2), 2.98 – 2.89 (m, 2.2H, C2’-H2), 2.46 (s, 
3.3H, C1’’-H3), 1.42 (t, J = 7.1 Hz, 0.3H, CO2CH2CH3); 
13C NMR (101 MHz, Chloroform-d) δ 162.8 
(CO2R), 142.3 (C3’), 134.3 (C7a), 129.4 (C5), 128.6 (2  ArCH), 128.3 (2  ArCH), 128.0 (C3a), 127.6 
(C6), 125.9 (C6’), 123.8 (C3), 123.1 (C2), 120.0 (C4), 111.5 (C7), 60.8 (CO2CH2CH3), 51.7 (CO2CH3), 37.4 
(C2’), 27.2 (C1’), 21.5 (C1’’), 13.4 (CO2CH2CH3). 
 
Methyl/ethyl 5-isopropyl-3-phenethyl-1H-indole-2-carboxylate (32b) 
 
32b was prepared from 4-isopropylphenylhydrazine hydrochloride 31b (200 mg, 1.07 mmol) and 
methyl 2-oxo-5-phenylpentanoate 30a (353 mg, 1.71 mmol) using general method A. The crude 
mixture was purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-8% EtOAc/hexanes) to 
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give the title product 32b as an inseparable mixture of the methyl and ethyl esters (3:1.2). The 
mixture was isolated as a pale yellow solid (255 mg). The ratio of products was determined by 
analysis of the integration of the methyl-CH3 (major product) compared to the ethyl-CH3 (minor 
product). All other signals are as they appear in the spectra and represent the mixture of esters. 1H 
NMR (400 MHz, Chloroform-d) δ 8.64 (br s, 1.4H, NH), 7.38 (s, 1.4H, C4-H), 7.35 – 7.15 (m, 9.8H, 7  
ArH), 4.40 (q, J = 7.1 Hz, 0.8H, CO2CH2CH3), 3.92 (s, 3H, CO2CH3), 3.40 – 3.36 (m, 2.8H, C1’-H2), 3.07 – 
2.91 (m, 4.2H, C2’-H2, C1’’-H), 1.43 (t, J = 7.1 Hz, 1.2H, CO2CH2CH3), 1.30 (d, J = 6.9 Hz, 8.4H, 2  C2’’-
H3);
 13C NMR (101 MHz, Chloroform-d) δ 162.9 (CO2R), 142.4 (C3’), 140.9 (C5), 134.7 (C7a), 128.7 (2  
ArCH), 128.4 (2 ArCH), 128.0 (C3a), 126.0 (C6), 125.4 (C6’), 124.3 (C2), 123.2 (C3), 117.4 (C4), 111.7 
(C7), 60.8 (CO2CH2CH3), 51.8 (CO2CH3), 37.5 (C2’), 34.4 (C1’’), 27.2 (C1’), 24.6 (2  C2’’), 13.4 
(CO2CH2CH3). 
 
Ethyl 5-isopropyl-3-methyl-1H-indole-2-carboxylate (32c) 
 
32c was prepared from 4-isopropylphenylhydrazine hydrochloride 31b (250 mg, 1.34 mmol) and 
ethyl 2-oxobutanoate 30b (450 mg, 5.0 mmol) using general method E. The crude product was 
purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-10% EtOAc/hexanes) to give the title 
product 32c as a crystalline white solid (222 mg, 67%). mp 129-131 °C; IR (KBr) ν max: 3330 (NH), 
2927, 1674 (C=O), 1463 (C=C), 1264 (C-O); 1H NMR (500 MHz, CDCl3) δ 8.61 (br s, 1H, NH), 7.47 (d, J = 
1.6 Hz, 1H, C4-H), 7.30 (d, J = 8.5 Hz, 1H, C7-H), 7.23 (dd, J = 8.5, 1.6 Hz, 1H, C6-H), 4.41 (q, J = 7.1 Hz, 
2H, CO2CH2CH3), 3.03 (hept, J = 6.8 Hz, 1H, C1’’-H), 2.61 (s, 3H, C1’-H3), 1.43 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.32 (d, J = 6.8 Hz, 6H, 2  C2’’-H3);
 13C NMR (126 MHz, CDCl3) δ 162.8 (CO2CH2CH3), 
140.7 (C5), 134.6 (C7a), 128.7 (C3a), 125.4 (C6), 123.7 (C2), 120.1 (C3), 117.4 (C4), 111.6 (C7), 60.7 
(CO2CH2CH3), 34.4 (C1’’), 24.7 (2  C2’’), 14.6 (CO2CH2CH3), 10.1 (C1’); m/z (ES
+) 246.13 ([M+H]+, 100 
%); HRMS (ES+) Calcd for C15H20NO2 [M+H]
+: 246.1494, found 246.1487. 
 
Ethyl 3,5-diisopropyl-1H-indole-2-carboxylate (32d) 
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32d was prepared from 4-isopropylphenylhydrazine hydrochloride 31b (222 mg, 1.19 mmol) and 
ethyl 4-methyl-2-oxopentanoate 30c (300 mg, 1.9 mmol) using general method E. The crude product 
was purified via the Biotage SP4 (silica-packed SNAP column 10 g; 0-10% EtOAc/hexanes) to give the 
title product 32d as a yellow solid (122 mg, 38%). mp 64-66 °C; IR (KBr) ν max: 3320 (NH), 2961, 1688 
(C=O), 1467 (C=C), 1255 (C-O); 1H NMR (400 MHz, CDCl3) δ 8.58 (br s, 1H, NH), 7.68 (dd, J = 1.7, 0.7 
Hz, 1H, C4-H), 7.31 (dd, J = 8.5, 0.7 Hz, 1H, C7-H), 7.21 (ddd, J = 8.5, 1.7, 0.7 Hz, 1H, C6-H), 4.40 (q, J = 
7.1 Hz, 2H, CO2CH2CH3), 4.08 (hept, J = 7.1 Hz, 1H, C1’-H), 3.01 (hept, J = 6.9 Hz, 1H, C1’’-H), 1.48 (d, J 
= 7.1 Hz, 6H, 2  C2’-H3), 1.42 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 1.32 (d, J = 6.9 Hz, 6H, 2  C2’’-H3);
 13C 
NMR (101 MHz, CDCl3) δ 162.5 (CO2CH2CH3), 140.3 (C5), 135.0 (C7a), 131.0 (C3), 126.7 (C3a), 124.8 
(C6), 122.1 (C2), 119.4 (C4), 111.9 (C7), 60.7 (CO2CH2CH3), 34.4 (C1’’), 25.8 (C1’), 24.7 (2  C2’’), 22.9 
(2  C2’), 14.6 (CO2CH2CH3); m/z (ES
+) 296.01 ([M+Na]+, 100 %); HRMS (ES-) Calcd for C17H22NO2 [M-
H]-: 272.1651, found 272.1657. 
 
Ethyl 3,5-dimethyl-1H-indole-2-carboxylate (32e) 
 
32e was prepared from p-tolylhydrazine hydrochloride 31a (444 mg, 2.8 mmol) and ethyl 2-
oxobutanoate 30b (650 mg, 5.0 mmol) using general method E. The crude product was purified via 
the Biotage SP4 (silica-packed SNAP column 10 g; 0-10% EtOAc/hexanes) to give the title product 
32e as a white solid (409 mg, 67%). mp 133-135 °C; IR (KBr) ν max: 3307 (NH), 2931, 1680 (C=O), 1473 
(C=C), 1264 (C-O); 1H NMR (500 MHz, CDCl3) δ 8.60 (br s, 1H, NH), 7.46-7.42 (m, 1H, C4-H), 7.26 (d, J 
= 8.4 Hz, 1H, C7-H), 7.15 (dd, J = 8.4, 1.6 Hz, 1H, C6-H), 4.41 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 2.59 (s, 
3H, C1’-H3), 2.46 (s, 3H, ArCH3), 1.43 (t, J = 7.1 Hz, 3H, CO2CH2CH3);
 13C NMR (126 MHz, CDCl3) δ 162.8 
(CO2CH2CH3), 134.4 (C7a), 129.3 (C5), 128.9 (C3a), 127.6 (C6), 123.6 (C2), 120.2 (C4), 119.8 (C3), 
111.4 (C7), 60.7 (CO2CH2CH3), 21.6 (ArCH3), 14.6 (CO2CH2CH3), 10.1 (C1’); m/z (ES
+) 240.04 ([M+Na]+, 
100 %); HRMS (ES+) Calcd for C13H15NO2Na [M+Na]
+: 240.1000, found 240.0992. 
 
Ethyl 3-isopropyl-5-methyl-1H-indole-2-carboxylate (32f) 
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32f was prepared from p-tolylhydrazine hydrochloride 31a (189 mg, 1.19 mmol) and ethyl 4-methyl-
2-oxopentanoate 30c (300 mg, 1.9 mmol) using general method E. The crude product was purified 
via the Biotage SP4 (silica-packed SNAP column 10 g; 0-8% EtOAc/hexanes) to give the title product 
32f as a yellow solid (82 mg, 28%). mp 103-105 °C; IR (KBr) ν max: 3347 (NH), 2975, 1675 (C=O), 1433 
(C=C), 1253 (C-O); 1H NMR (300 MHz, CDCl3) δ 8.66 (br s, 1H, NH), 7.68 – 7.64 (m, 1H, C4-H), 7.27 (d, J 
= 8.4 Hz, 1H, C7-H) 7.13 (dd, J = 8.4, 1.6 Hz, 1H, C6-H), 4.41 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.11 (hept, 
J = 7.1 Hz, 1H, C1’-H), 2.46 (s, 3H, ArCH3), 1.48 (d, J = 7.1 Hz, 6H, 2  C2’-H3), 1.43 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3);
 13C NMR (75 MHz, CDCl3) δ 162.5 (CO2CH2CH3), 134.7 (C7a), 130.7 (C3), 128.8 (C5), 127.2 
(C6), 126.8 (C3a), 122.1 (C4), 122.1 (C2), 111.7 (C7), 60.7 (CO2CH2CH3), 25.8 (C1’), 22.9 (2  C2’), 21.8 
(ArCH3), 14.6 (CO2CH2CH3); m/z (ES
-) 268.00 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C15H20NO2 
[M+H]+: 246.1494, found 246.1482. 
 
5-Methyl-1,3-diphenethyl-1H-indole-2-carboxylic acid (33a) 
 
33a was prepared from 32a (100 mg, 0.34 mmol) and (bromoethyl)benzene (0.09 mL, 0.68 mmol) 
using general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 10 g; 0-10% EtOAc/hexanes) to give the title product 33a as a white solid (65 mg, 50%). mp 
202-204 °C; IR (KBr) ν max: 3436 (OH), 2925, 1666 (C=O), 1456 (C=C), 1287 (C-O);
 1H NMR (500 MHz, 
CDCl3) δ 7.46 (s, 1H, C4-H), 7.37 – 7.20 (m, 12H, 12  ArH), 4.81 – 4.73 (m, 2H, C1’’’-H2), 3.50 – 3.43 
(m, 2H, C1’-H2), 3.15 – 3.07 (m, 2H, C2’’’-H2), 3.04 – 2.97 (m, 2H, C2’-H2), 2.49 (s, 3H, C1’’-H3);
 13C 
NMR (126 MHz, CDCl3) δ 167.8 (CO2H), 142.6 (C3’), 138.9 (C3’’’), 137.3 (C7a), 129.7 (C5), 129.1 (2  
ArCH), 128.7 (2  ArCH), 128.7 (2  ArCH), 128.5 (2  ArCH), 128.3 (C6), 127.5 (C3), 126.9 (C3a), 
126.7 (ArCH), 126.0 (ArCH), 122.9 (C2), 120.3 (C4), 110.2 (C7), 47.0 (C1’’’), 37.7 (C2’), 37.3 (C2’’’), 
28.2 (C1’), 21.6 (C1’’); m/z (ES-) 381.91 ([M-H]-, 100 %); HRMS (ES-) Calcd for C26H24NO2 [M-H]
-: 
382.1807, found 382.1803. 
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1-Butyl-5-isopropyl-3-phenethyl-1H-indole-2-carboxylic acid (33b) 
 
To a suspension of sodium hydride (22 mg, 0.54 mmol, 2.0 eq., 60% in mineral oil) in anhydrous DMF 
(1.0 mL) at 0 C was added 32b (88 mg, 0.27 mmol, 1.0 eq.) in anhydrous DMF (0.3 mL). The mixture 
was stirred at room temperature for 30 minutes before the addition of 1-bromobutane (0.09 mL, 
0.81 mmol, 3.0 eq.). The reaction was then heated at 100 C for 4 hours before being cooled to room 
temperature and poured into ice water (10 mL). The mixture was extracted with Et2O (3  10 mL) 
and the organic layers were combined, washed with brine (10 mL), dried over MgSO4, filtered and 
concentrated in vacuo. To a solution of the crude ester in ethanol (5 mL) was added an aqueous 
solution of NaOH (1.5 mL, 2N) and the resulting mixture was heated at reflux for 4 hours. The 
reaction was then cooled to room temperature, diluted with brine (10 mL), acidified to pH 6 with HCl 
(1 N) and extracted with Et2O (3  10 mL). The combined organic extracts were washed with a 
saturated solution of NaHCO3 (10 mL), brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified via the Biotage SP4 (silica-packed SNAP column 4 g; 0-8% 
EtOAc/hexanes) to give the title product 33b as a crystalline white solid (65 mg, 68% over 2 steps). 
mp 122-124 °C; IR (KBr) ν max: 3445 (OH), 2957, 1666 (C=O), 1454 (C=C), 1265 (C-O);
 1H NMR (500 
MHz, CDCl3) δ 7.42 (s, 1H, C4-H), 7.34 (d, J = 8.6 Hz, 1H, C7-H), 7.29 (m, 5H, C6-H, 2  C4’-H, 2  
C5’H), 7.23 – 7.19 (m, 1H, C6’-H), 4.56 (t, J = 7.4 Hz, 2H, C1’’’-H2), 3.49 – 3.42 (m, 2H, C1’-H2), 3.01 (m, 
3H, C1’’-H, C2’-H2), 1.81 (p, J = 7.4 Hz, 2H, C2’’’-H2), 1.41 (h, J = 7.4 Hz, 2H, C3’’’-H2), 1.31 (d, J = 6.9 
Hz, 6H, 2  C2’’-H3), 0.98 (t, J = 7.4 Hz, 3H, C4’’’-H3);
 13C NMR (126 MHz, CDCl3) δ 167.6 (CO2H), 142.6 
(C3’), 140.8 (C5), 137.8 (C7a), 128.7 (2  ArCH), 128.4 (2  ArCH), 127.6 (C3), 126.6 (C3a), 126.0 (C6’), 
125.7 (C6), 123.0 (C2), 117.4 (C4), 110.6 (C7), 45.1 (C1’’’), 37.7 (C2’), 34.3 (C1’’), 33.0 (C2’’’), 28.1 
(C1’), 24.6 (2  C2’’), 20.4 (C3’’’), 14.1 (C4’’’); m/z (ES-) 361.93 ([M-H]-, 100 %); HRMS (ES-) Calcd for 
C24H28NO2 [M-H]
-: 362.2120, found 362.2123. 
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1-Butyl-5-isopropyl-3-methyl-1H-indole-2-carboxylic acid (33c) 
 
To a suspension of sodium hydride (25 mg, 0.62 mmol, 2.0 eq., 60% in mineral oil) in anhydrous DMF 
(1.0 mL) at 0 C was added a solution of 32c (71 mg, 0.31 mmol, 1.0 eq.) in anhydrous DMF (0.3 mL). 
The mixture was stirred at room temperature for 30 minutes before the addition of 1-bromobutane 
(0.05 mL, 0.43 mmol, 1.4 eq.). The reaction was then heated at 100 C for 4 hours before being 
cooled to room temperature and poured into ice water (10 mL). The mixture was extracted with 
Et2O (3  10 mL) and the organic layers were combined, washed with brine (10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. To a solution of the crude ester in ethanol (5 mL) was 
added an aqueous solution of NaOH (1.5 mL, 2N) and the resulting mixture was heated at reflux for 4 
hours. The reaction was then cooled to room temperature, diluted with brine (10 mL), acidified to 
pH 6 with HCl (1 N) and extracted with Et2O (3  10 mL). The combined organic extracts were 
washed with a saturated solution of NaHCO3 (10 mL), brine (10 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 4 g; 0-8% EtOAc/hexanes) to give the title product 33c as a white solid (67 mg, 57% over 2 
steps). mp 152-154 °C; IR (KBr) ν max: 3444 (OH), 2959, 1666 (C=O), 1455 (C=C), 1269 (C-O);
 1H NMR 
(500 MHz, CDCl3) δ 7.51 (s, 1H, C4-H), 7.30 (m, 2H, C6-H, C7-H), 4.53 (t, J = 7.5 Hz, 2H, C1’’’-H2), 3.04 
(hept, J = 6.9 Hz, 1H, C1’’-H), 2.67 (s, 3H, C1’-H3), 1.77 (p, J = 7.5 Hz, 2H, C2’’’-H2), 1.38 (h, J = 7.5 Hz, 
2H, C3’’’-H2), 1.33 (d, J = 6.9 Hz, 6H, 2  C2’’-H3), 0.95 (t, J = 7.5 Hz, 3H, C4’’’-H3); 
13C NMR (126 MHz, 
CDCl3) δ 168.0 (CO2H), 140.6 (C5), 137.8 (C7a), 127.2 (C3a), 125.7 (C6), 123.7 (C3), 123.3 (C2), 117.6 
(C4), 110.5 (C7), 45.0 (C1’’’), 34.3 (C1’’), 33.1 (C2’’’), 24.6 (2  C2’’), 20.4 (C3’’’), 14.0 (c4’’’), 11.3 (C1’); 
m/z (ES-) 272.11 ([M-H]-, 100 %); HRMS (ES-) Calcd for C17H22NO2 [M-H]
-: 272.1651, found 272.1652. 
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5-Isopropyl-3-methyl-1-phenethyl-1H-indole-2-carboxylic acid (33d) 
 
33d was prepared from 32c (100 mg, 0.41 mmol) and (bromoethyl)benzene (0.29 mL, 1.64 mmol) 
using general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 10 g; 0-10% EtOAc/hexanes) to give the title product 33d as a white solid (50 mg, 38%). mp 
177-179 °C; IR (KBr) ν max: 3445 (OH), 2956, 1666 (C=O), 1455 (C=C), 1268 (C-O);
 1H NMR (500 MHz, 
CDCl3) δ 7.53 (s, 1H, C4-H), 7.27 (m, 7H, 7  ArH), 4.76 – 4.72 (m, C1’’’-H2), 3.07 (m, 3H, C1’’-H, C2’’’-
H2), 2.71 (s, 3H, C1’-H3), 1.34 (d, J = 6.8 Hz, 6H, 2  C2’’-H3);
 13C NMR (126 MHz, CDCl3) δ 167.9 
(CO2H), 140.8 (C5), 139.0 (C3’’’), 137.6 (C7a), 129.1 (2  ArCH), 128.7 (2  ArCH), 127.3 (C3a), 126.6 
(C6’’’), 126.0 (C6), 124.0 (C3), 123.1 (C2), 117.7 (C4), 110.2 (C7), 47.0 (C1’’’), 37.4 (C2’’’), 34.3 (C1’’), 
24.6 (2  C2’’), 11.3 (C1’); m/z (ES-) 320.16 ([M-H]-, 100 %); HRMS (ES-) Calcd for C21H22NO2 [M-H]
-: 
320.1656, found 320.1653. 
 
3,5-Diisopropyl-1-phenethyl-1H-indole-2-carboxylic acid (33e) 
 
33e was prepared from 32d (40 mg, 0.18 mmol) and (bromoethyl)benzene (0.07 mL, 0.54 mmol) 
using general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 4 g; 0-10% EtOAc/hexanes) to give the title product 33e as a white solid (26 mg, 41%). mp 
152-154 °C; IR (KBr) ν max: 3429 (OH), 2959, 1658 (C=O), 1459 (C=C), 1262 (C-O);
 1H NMR (300 MHz, 
CDCl3) δ 7.68 (s, 1H, C4-H), 7.32 – 7.09 (m, 7H, 7  ArH), 4.67 – 4.55 (m, 2H, C1’’’-H2), 4.10 (hept, J = 
7.1 Hz, 1H, C1’-H), 3.08 – 2.89 (m, 3H, C1’’-H, C2’’’-H2), 1.46 (d, J = 7.1 Hz, 6H, 2  C2’-H3), 1.27 (d, J = 
6.9 Hz, 6H, 2  C2’’-H3); 
13C NMR (126 MHz, CDCl3) δ 167.8 (CO2H), 140.3 (C5), 139.0 (C3’’’), 137.9 
(C7a), 133.6 (C3), 129.0 (2  ArCH), 128.7 (2  ArCH), 126.7 (C6’’’), 125.4 (C3a), 125.1 (C6), 122.3 
Chapter 4: Peptidomimetics 
 
204 
 
(C2), 120.0 (C4), 110.6 (C7), 47.0 (C1’’’), 37.2 (C2’’’), 34.4 (C1’’), 26.4 (C1’), 24.7 (2  C2’’), 23.2 (2  
C2’); m/z (ES-) 347.93 ([M-H]-, 100 %); HRMS (ES-) Calcd for C23H26NO2 [M-H]
-: 348.1964, found 
348.1970. 
 
5-Isopropyl-1,3-diphenethyl-1H-indole-2-carboxylic acid (33f) 
 
33f was prepared from 32b (50 mg, 0.16 mmol) and (bromoethyl)benzene (0.04 mL, 0.32 mmol) 
using general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 4 g; 0-10% EtOAc/hexanes) to give the title product 33f as a white solid (35 mg, 53%). mp 
175-177 °C; IR (KBr) ν max: 3424 (OH), 2958, 1663 (C=O), 1456 (C=C), 1261;
 1H NMR (400 MHz, CDCl3) 
δ 7.42 (s, 1H, C4-H), 7.36 – 7.19 (m, 12H, ArH), 4.81 – 4.72 (m, 2H, C1’’’-H2), 3.53 – 3.44 (m, 2H, C1’-
H2), 3.15 – 3.08 (m, 2H, C2’’’-H2), 3.08 – 2.96 (m, 3H, C1’’-H, C2’-H2), 1.32 (d, J = 6.9 Hz, 6H, 2  C2’’-
H3);
 13C NMR (101 MHz, CDCl3) δ 167.5 (CO2H), 142.6 (C3’), 141.0 (C5), 139.0 (C3’’’), 137.6 (C7a), 
129.1 (2  ArCH), 128.8 (2  ArCH), 128.7 (2  ArCH), 128.5 (2  ArCH), 127.9 (C3), 126.8 (C3a), 126.7 
(C6’’’), 126.0 (C6’), 125.9 (C6), 122.9 (C2), 117.6 (C4), 110.3 (C7), 47.0 (C1’’’), 37.7 (C2’), 37.4 (C2’’’), 
34.3 (C1’’), 28.1 (C1’), 24.6 (2  C2’’); m/z (ES-) 409.91 ([M-H]-, 100 %); HRMS (ES-) Calcd for 
C28H28NO2 [M-H]
-: 410.2120, found 410.2115. 
 
1-Butyl-3,5-diisopropyl-1H-indole-2-carboxylic acid (33g) 
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33g was prepared from 32d (62 mg, 0.23 mmol) and 1-bromobutane (0.08 mL, 0.69 mmol) using 
general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP column 4 
g; 0-10% EtOAc/hexanes) to give the title product 33g as a white solid (56 mg, 81%). mp 155-157 °C; 
IR (KBr) ν max: 3438 (OH), 2961, 1666 (C=O), 1457 (C=C), 1259 (C-O);
 1H NMR (500 MHz, CDCl3) δ 7.73 
(d, J = 1.5 Hz, 1H, C4-H), 7.33 (d, J = 8.7 Hz, 1H, C7-H), 7.26 (dd, J = 8.7, 1.5 Hz, 1H, C6-H), 4.46 (t, J = 
7.4 Hz, 2H, C1’’’-H2), 4.16 (hept, J = 7.3 Hz, 1H, C1’-H), 3.02 (hept, J = 7.0 Hz, 1H, C1’’-H), 1.77 (p, J = 
7.4 Hz, 2H, C2’’’-H2), 1.51 (d, J = 7.3 Hz, 6H, 2  C2’-H3), 1.39 (h, J = 7.4 Hz, 2H, C3’’’-CH2), 1.33 (d, J = 
7.0 Hz, 6H, 2  C2’’-H3), 0.96 (t, J = 7.4 Hz, 3H, C4’’’-H3); 
13C NMR (126 MHz, CDCl3) δ 168.1 (CO2H), 
140.0 (C5), 138.1 (C7a), 133.3 (C3), 125.2 (C3a), 124.9 (C6), 122.4 (C2), 119.8 (C4), 110.8 (C7), 45.1 
(C1’’’), 34.4 (C1’’), 32.9 (C2’’’), 26.4 (C1’), 24.6 (2  C2’’), 23.2 (2  C2’), 20.4 (C3’’’), 14.0 (C4’’’); m/z 
(ES-) 389.84 ([M-H]-, 100 %); HRMS (ES-) Calcd for C25H16N3O2 [M-H]
-: 390.1245, found 390.1243. 
 
3,5-Dimethyl-1-phenethyl-1H-indole-2-carboxylic acid (33h) 
 
33h was prepared from 32e (100 mg, 0.46 mmol) and (bromoethyl)benzene (0.25 mL, 1.84 mmol) 
using general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 10 g; 0-10% EtOAc/hexanes) to give the title product 33h as a white solid (75 mg, 56%). mp 
201-203 °C; IR (KBr) ν max: 3442 (OH), 2929, 1666 (C=O), 1454 (C=C), 1267 (C-O);
 1H NMR (500 MHz, 
CDCl3) δ 7.49 (s, 1H, C4-H), 7.33 – 7.18 (m, 7H, 7  ArH), 4.76 – 7.42 (m, 2H, C1’’’-H2), 3.10 – 3.06 (m, 
2H, C2’’’-H2), 2.69 (s, 3H, C1’-H3), 2.48 (s, 3H, C1’’-H3);
 13C NMR (126 MHz, CDCl3) δ 168.0 (CO2H), 
139.0 (C3’’’), 137.3 (C7a), 129.4 (C5), 129.1 (2  ArCH), 128.7 (2  ArCH), 128.2 (C6), 127.5 (C3a), 
126.6 (C6’’’), 123.7 (C3), 123.1 (C2), 120.5 (C4), 110.1 (C7), 46.9 (C1’’’), 37.3 (C2’’’), 21.6 (C1’’), 11.3 
(C1’); m/z (ES-) 292.07 ([M-H]-, 100 %); HRMS (ES-) Calcd for C19H18NO2 [M-H]
-: 292.1338, found 
292.1328. 
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1-Butyl-3-isopropyl-5-methyl-1H-indole-2-carboxylic acid (33i) 
 
33i was prepared from 32f (40 mg, 0.16 mmol) and 1-bromopropane (0.05 mL, 0.48 mmol) using 
general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP column 4 
g; 0-10% EtOAc/hexanes) to give the title product 33i as a white solid (32 mg, 73%). mp 162-164 °C; 
IR (KBr) ν max: 3424 (OH), 2932, 1663 (C=O), 1440 (C=C), 1269 (C-O); 
1H NMR (500 MHz, CDCl3) δ 7.70 
(s, 1H, C4-H), 7.29 (d, J = 8.6 Hz, 1H, C7-H), 7.18 (d, J = 8.6 Hz, 1H, C6-H), 4.47 (t, J = 7.5 Hz, 2H, C1’’’-
H2), 4.15 (hept, J = 7.4 Hz, 1H, C1’-H), 2.47 (s, 3H, C1’’-H3), 1.76 (p, J = 7.5 Hz, 2H, C2’’’-H2), 1.50 (d, J = 
7.4 Hz, 6H, 2  C2’-H3), 1.36 (h, J = 7.5 Hz, 2H, C3’’’-H2), 0.95 (t, J = 7.5 Hz, 3H, C4’’’-H3); 
13C NMR (126 
MHz, CDCl3) δ 168.1 (CO2H), 137.9 (C7a), 133.1 (C3), 128.7 (C5), 127.3 (C6), 125.4 (C3a), 122.5 (C4), 
122.4 (C2), 110.7 (C7), 45.1 (C1’’’), 32.8 (C2’’’), 26.4 (C1’), 23.2 (2  C2’), 21.7 (C1’’), 20.4 (C3’’’), 14.0 
(C4’’’); m/z (ES+) 274.18 ([M+H]+, 100 %); HRMS (ES+) Calcd for C17H24NO2 [M+H]
+: 274.1802, found 
274.1804. 
 
3-Isopropyl-5-methyl-1-phenethyl-1H-indole-2-carboxylic acid (33j) 
 
33j was prepared from 32f (40 mg, 0.16 mmol) and (bromoethyl)benzene (0.07 mL, 0.48 mmol) 
using general method F. The crude product was purified via the Biotage SP4 (silica-packed SNAP 
column 4 g; 0-10% EtOAc/hexanes) to give the title product 33j as a white solid (21 mg, 41%). mp 
170-172 °C; IR (KBr) ν max: 3443 (OH), 2961, 1661 (C=O), 1460 (C=C), 1263 (C-O);
 1H NMR (500 MHz, 
CDCl3) δ 7.72 (s, 1H, C4-H), 7.32 – 7.17 (m, 7H, 7  ArH), 4.69 (t, J = 7.9 Hz, 2H, C1’’’-H2), 4.16 (hept, J 
= 7.3 Hz, 1H, C1’-H), 3.08 (t, J = 7.9 Hz, 2H, C2’’’-H2), 2.48 (s, 3H, C1’’-H3), 1.52 (d, J = 7.3 Hz, 6H, 2  
C2’-H3);
 13C NMR (126 MHz, CDCl3) δ 168.0 (CO2H), 138.9 (C3’’’), 137.7 (C7a), 133.3 (C3), 129.0 (2  
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ArCH), 128.9 (C5), 128.7 (2  ArCH), 127.6 (C6), 126.7 (C6’’’), 125.5 (C3a), 122.6 (C4), 122.4 (C2), 
110.5 (C7), 46.9 (C1’’’), 37.1 (C2’’’), 26.4 (C1’), 23.1 (2  C2’), 21.8 (C1’’); m/z (ES+) 322.18 ([M+H]+, 
100 %); HRMS (ES+) Calcd for C21H24NO2 [M+H]
+: 322.1802, found 322.1808. 
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5 High-Throughput Screening as a Method for the Discovery of p53 
Activators 
 
5.1 Introduction 
 
5.1.1 High-throughput screening 
High-throughput Screening (HTS) is a well-established drug discovery process that has been used for 
several decades both in academia and the pharmaceutical industry to assess quickly the biological or 
biochemical activity of a library of drug-like compounds.325,326 Technological advances in robotic 
automation, data handling and miniaturisation of assay methods has facilitated the rapid, efficient 
and increasingly cost effective screening of large libraries of small molecules in order to identify 
modulators of a target protein’s activity.327 HTS of large compound libraries can be a highly effective 
method to discover novel PPI modulators.328,329 In particular, it can provide the opportunity to 
serendipitously discover modulators with novel modes of action, such as modulation of a PPI 
through binding to unknown hot spots or clefts, or through novel mechanisms such as alteration of a 
protein partner’s oligomeric or conformational status. For new or less well-defined PPIs, which lack 
structural information, or endogenous lead compounds, HTS is arguably the only reliable method to 
discover modulators.1  
 
However, despite many impressive success stories in classical drug discovery, HTS has had mixed 
results in identifying new PPI modulators, partly owing to the difficulties associated with developing 
reliable in vitro high-throughput PPI assays.11 This issue often occurs as a result of the inability to 
recreate the target PPI in an in vitro setting, rather than the availability of a suitable assay method, 
as numerous robust examples have been developed which primarily monitor a change in 
fluorescence or absorption on formation of the PPI, i.e., fluorescence resonance energy transfer 
(FRET), enzyme-linked immunosorbent assay (ELISA) and fluorescence polarisation (FP). The 
development of an appropriate in vitro HTS assay is usually hampered by the difficulties associated 
with the isolation of the pure, functional protein partners due to complexities such as the 
requirement for membrane stabilisation, essential cofactors or additional adapter proteins to form a 
multiprotein complex. Often, a peptide or domain fragment is used in place of one or both of the 
protein partners, and inhibition of this PPI in vitro may not be transferable to the corresponding PPI 
between the full-length proteins.11  
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The dynamic, transient and heterogeneous behaviour of many therapeutically interesting PPIs 
makes them significantly more challenging drug targets, particularly in an in vitro setting.1 Forward 
chemical genetic screens provide a solution to many of these issues by monitoring changes in 
phenotype on a cellular level as a result of modulation of a protein’s signalling pathway or 
interactome.330 This approach can provide a mechanism by which to identify PPI modulators of 
intractable transient or multiprotein interactions.  
 
5.1.2 Non-genotoxic p53 activators 
The forward chemical genetic (FCG) approach (Figure 5.1) utilises cell-based assays to search for 
small molecules that promote a specific phenotype.330–332 This approach to drug discovery has many 
advantages over the more classical methods based on biochemical screens but also provides a 
significant challenge in elucidating a hit compound’s precise mechanism of action in cells. Although 
the FCG approach can result in the identification of modulators of complex PPIs, this is purely 
serendipitous as it monitors primarily a particular phenotypic change without any preconception of 
the molecular target. Therefore the observed phenotypic response could be as a result of numerous 
pathways including modulation of a PPI, or a classical enzyme target. Identification of the biological 
target is often the most significant challenge associated with this approach.333,334  
  
 
Figure 5.1. The forward chemical genetic (FCG) approach to drug discovery.
335
  
 
In the case of high-throughput screens carried out using a mammalian cell based assay, one clear 
advantage is that hit compounds show activity in cells at a concentration required for further 
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preclinical development. In addition, cell-based assays that require the expression of a reporter 
protein, select for compounds that are not general cytotoxics due to the fact that a synthetic event 
must occur in their presence.335 Therefore this approach can be particularly valuable for the 
identification of selective, non-toxic anticancer drug leads. In particular, the FCG approach is 
increasingly being applied to the discovery of compounds that activate the tumour suppressor 
protein p53.335–337    
 
5.1.3 p53 & cancer 
Carcinogenesis is a multistep process involving dynamic changes in the genome. The transformation 
of a normal cell to a cancer cell generally involves the activation of oncogenes and the inactivation of 
tumour suppressor genes and pro-apoptotic genes.5 A major advance in this area was the discovery 
of the tumour suppressor gene p53 in 1979.338,339 This gene encodes for a homotetrameric 
transcription factor that regulates the expression of a variety of genes involved in cell cycle 
progression, apoptosis, DNA repair, cell-cycle arrest, nitric oxide production and angiogenesis.340 p53 
accumulates in the nucleus in response to genotoxic and nongenotoxic cellular stresses, including 
DNA damage and oncogene activation. This triggers transcriptional activation of p53 target genes 
such as those involved in DNA repair, cell cycle arrest, senescence and/or apoptosis.341,342 
 
In the absence of a genotoxic stress, p53 undergoes a rapid turnover which keeps it at a low level. 
The levels of p53 are mainly regulated by ubiquitin ligases, such as MDM2, MDM4, Pirh2 and Cop1. 
MDM2 and MDM4 (or MDMX) are key regulators of p53 whose amplification or overexpression are 
frequently observed in human tumours.343 MDM2 is an E3 ubiquitin ligase that catalyses 
ubiquitination of p53, an event that results in subsequent degradation of p53 by the 
proteasome.344,345 MDM4 also contributes to the E3 ligase activity of MDM2 and MDM2/MDM4 
heterodimers have greater E3 ligase activity towards p53 than MDM2 alone. There are now a variety 
of known small molecules that impair the interaction of p53 with MDM2346–349 including Nutlin-3 (2, 
Figure 5.2).350  
 
The central role played by p53 in preventing tumour development is clear. More than 50% of adult 
human cancers are characterised by inactivating mutations or deletions in the p53 gene.351,352 In 
addition to these, there are several other tumour types in which p53 is wild-type but errors in the 
control mechanisms that lead to p53 activation occur.353 Therefore, it is widely accepted that new 
non-genotoxic small molecule activators of wild-type p53 may play a crucial role in providing novel 
therapeutic treatments for cancer.336 The challenge resides in the activation of p53 transcription 
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without the DNA damaging mutagenic effects of classical chemotherapeutic and radiotherapy 
treatments.  
 
5.1.4 Identification of a new p53 activator (±)-MJ05 
In collaboration with the Lain group at the Karolinski Institute in Sweden, a FCG screen of 20,000 
drug-like molecules was carried out using an ARN8 human cancer cell line. This cell line derives from 
A375 human melanoma cells which bear wild type p53, and contain a reporter gene (β-
galactosidase) placed under the control of a p53-dependent promoter. This initial screen identified 
77 compounds, which activated p53 transcription greater than 2-fold. These hits were then 
rescreened in a secondary MTT assay, to determine their cytotoxicity on ARN8 cells. 11 compounds 
were found to reduce cell viability at less than 10 μM, thus identifying them as potential lead 
compounds.  
 
The second focus of this screening process was the identification of lead compounds which displayed 
promising therapeutic windows (therapeutic index). The therapeutic window is the concentration 
range between the ED50 (effective dose for 50% of the population) and TD50 (toxic dose for 50% of 
the population).354 The greater the concentration range of this therapeutic window, the less toxicity 
is observed at the concentration of drug required for its therapeutic effect. For many drugs, the 
optimum dose required for effective and safe therapy varies significantly from patient to patient.355 
A wide therapeutic window allows for the alteration of an individual’s drug dose to better fulfil their 
requirements without adverse effects, and also to reduce the risk of serious toxicity from poor 
patient compliance. The majority of current cancer chemotherapies are plagued by very narrow 
therapeutic windows, which results in significant adverse side effects and the inability to increase 
drug concentration for resistant cases due to a potentially severe toxic response. This highlights the 
need to identify new potent anti-cancer agents with wide therapeutic windows. 
  
In the case of this screening program, all hit compounds were analysed based on their effect on cell 
viability of the ARN8 cancer cell line and on human normal dermal fibroblasts (HNDFs). Their 
therapeutic window was determined by the difference in IC50 values across the two cell lines. The 
larger the concentration range between the two IC50 values the less risk of toxic side effects due to 
unselective targeting of normal cells. The 11 compounds were rescreened in the MTT assay against 
the HNDF cell line. This identified one compound, named (±)-MJ05 (1), which was shown to have 
minimal effect on the cell viability or proliferation of HNDFs, whilst displaying significant activity 
against ARN8 cells with an IC50 value <10 µM (Figure 5.2). (±)-MJ05 (1) was also shown to have an 
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IC50 value against the HNDF cells, which was greater than 5-fold the IC50 value observed against the 
cancer cell line. This was a very promising therapeutic window when compared to Nutlin-3 (2),350 a 
Roche PPI inhibitor of MDM2 mediated degradation of p53 which is currently in clinical trials (Figure 
5.2). Nutlin-3 (2) was shown to have a similar IC50 against both the HNDF and the ARN8 cell lines, 
which could potentially lead to significant toxicity and selectivity issues in clinical use.  
 
 
 
Figure 5.2. (A) Structures of (±)-MJ05 (1) and Nutlin-3 (2). (B) Therapeutic window of (±)-MJ05 (1) and Nutlin-3 (2). Data 
provided by the Lain group. 
 
Having identified (±)-MJ05 (1) as an interesting compound, the challenging process of target 
identification was considered. A chemoinformatic search revealed that (±)-MJ05 (1) had been 
previously shown to inhibit the MDM2/MDM4 interaction in a cell based screen (NCBI database; 
deposited by the Sanford-Burnham Centre for Chemical Genomics), an event that according to the 
current literature could lead to the activation of p53.346,348 According to the Sandord-Burnham 
screen, (±)-MJ05 (1) inhibited the MDM2/MDM4 interaction by 72% at a concentration of 8 μM.  
 
 
 
(A) 
(B) 
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5.2 Aims of this work 
 
In collaboration with the Lain group at the Karolinski Institute in Sweden, a forward chemical 
genetics approach was used to screen 20,000 drug-like molecules using an ARN8 human tumour cell 
line. This led to the identification of (±)-MJ05 (1), which was shown to be a p53 activator with 
cytotoxicity against ARN8s cells. Further analysis revealed that (±)-MJ05 (1) had a very promising 
therapeutic window, with an IC50 value >30 μM against human normal dermal fibroblasts (HNDFs). 
Literature research revealed that (±)-MJ05 (1) had been previously identified as an MDM2/MDM4 
protein-protein interaction inhibitor, suggesting a novel route to modulate p53 activity. (±)-MJ05 (1) 
was selected as a promising lead compound for further biological and chemical development as a 
novel non-genotoxic small molecule p53 activator based on its biological activity, promising 
therapeutic window but most relevant in the context of this thesis, its potential mechanism of p53 
activation. 
 
The first aim of this project was to devise an efficient method to synthesise an authentic sample of 
(±)-MJ05 (1) to validate its previously observed biological activity. The synthetic route should allow 
for easy modification of (±)-MJ05 (1) for structure-activity relationships (SAR) studies and facilitate a 
large scale synthesis of (±)-MJ05 (1) for further exploration of its biological effects, for example, 
xenograft experiments in mice. 
 
The second aim of this work was the development of an asymmetric synthesis to access 
enantiomerically pure samples of (+)- and (-)-MJ05 (1). Thus providing a mechanism by which to 
determine if MJ05 (1)'s activity is as a result of modulation of a chirally discriminating biological 
target (i.e. only one enantiomer would be expected to produce the observed activity), in contrast to 
unselective cytotoxicity. This could potentially facilitate a reduction in dosage, provide a valuable 
control molecule (the inactive enantiomer) and decrease off-target toxic effects. 
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5.3 Synthesis and Biological Assessment of (±)-MJ05 
 
5.3.1 Synthesis of target compound (±)-MJ05 
A 4-step synthesis of (±)-MJ05 (1) was developed, starting from commercially available 1,3-
cyclohexanedione (3) (Scheme 5.1). 1,3-Cyclohexanedione (3) was treated with dimethylformamide- 
dimethylacetal (DMF-DMA) to provide the enamine-substituted cyclohexanedione 4,356 which was 
subjected to AcOH-catalysed cyclocondensation with 4-fluorophenylhydrazine hydrochloride to 
afford pyrazole 5.357 Subsequent reductive amination of 5 gave the 4-aminotetrahydroindazole 6. 
Finally, the target compound (±)-MJ05 (1) was readily prepared by an N-acylation of crude 6 with 2-
picolinic acid 
 
Scheme 5.1. Synthetic route to target compound (±)-MJ05 (1). Reagents & conditions: (a) DMF-DMA, reflux, 2 h, 71%. (b) 
(i) 4-Fluorophenylhydrazine hydrochloride, MeOH, H2O, NaOH, reflux, 2 h. (ii) AcOH, H2O, 110 °C, 1.5 h, 77%. (c) NH4Ac, 
NaBH3CN, 2-propanol, 4 Å molecular sieves, 70 °C, 12 h. (d) 2-Picolinic acid, EDC.HCl, Et3N, HOBt, DMAP, DCM, r.t., 
overnight, 65% over 2 steps. 
 
This synthetic route provided a short, high-yielding approach to the desired compound (±)-MJ05 (1). 
Furthermore, the incorporation of a range of hydrazines in the cyclocondensation step (Scheme 5.1, 
step b) and carboxylic acids in the N-acylation step (Scheme 5.1, step d) would enable a relatively 
simple and thorough future exploration of the SAR of (±)-MJ05 (1). The structure of (±)-MJ05 (1) was 
validated and characterised by 1H NMR, 13C NMR, 2D NMR and ESI-MS and a sample was sent to the 
Lain group at the Karolinski Institute in Sweden for testing in the previously described p53 activation 
and cell death assays (Figure 5.3). 
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Figure 5.3. Comparison of the biological activity of the “original” (±)-MJ05 (1) sample with the “new” synthesised 
sample. (A) p53 transcriptional activation in the β-galactosidase assay as a result of increasing concentrations of “original” 
or “new” (±)-MJ05 (1) sample and known p53 activator Tenovin-6. (B) Percentage cell viability as measured in the MTT 
assay in the presence of increasing concentrations of “original” and “new” (±)-MJ05 (1) sample. Data provided by the Lain 
group. 
 
The authentic synthesised sample of (±)-MJ05 (1) elicited a similar p53 transcriptional activation 
response and cytotoxicity as the original sample obtained from the commercial supplier for the HTS 
(Figure 5.3). This confirmed the authenticity of the “original” sample and highlighted 1 as a 
promising compound for future development.  
 
5.3.2 Mouse xenograft studies  
The previously described synthesis (Scheme 5.1) was repeated to provide a greater quantity of (±)-
MJ05 (1) (~2 g) for mouse xenograft studies. In this study, mice were implanted with ARN8 
(melanoma cell line) derived tumours onto their backs, and the tumour size/volume was monitored 
over 15 days. The increase in tumour size was then compared between mice which were treated 
with (±)-MJ05 (1) (150 mg/Kg) and the control mice which were treated with the vector (DMSO) 
control (Figure 5.4). 
 
 
Figure 5.4. Effect of (±)-MJ05 (1) (150 mg/Kg) on tumour volume over 15 days. Each data point represents the average of 
10 mice. Data provided by the Lain group. 
(A) (B) 
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The mouse xenograft study showed a significant difference in tumour size between the mice treated 
with (±)-MJ05 (1) compared with the untreated mice after 15 days. (±)-MJ05 (1) impaired tumour 
growth over this time period resulting in significantly smaller tumours compared with the control 
mice (Figure 5.4). It should be noted, however that tumour growth was not stopped and the tumour 
was not cleared at this dose of (±)-MJ05 (1). Promisingly, (±)-MJ05 (1) did not appear to have any 
toxic effect on the mice at concentrations up to 150 mg/Kg. Encouraged by this result, it was decided 
to synthesise both enantiomers of (±)-MJ05 (1) and assess whether there was a difference in activity 
between the two enantiomers. 
 
5.4 Synthesis and Biological Assessment of (+)-MJ05 and (-)-MJ05 
 
5.4.1 Synthesis of MJ05 enantiomers 
To achieve this aim, an asymmetric variant of the reductive amination step described in the previous 
synthesis (Scheme 5.1, step c) would be required to access either enantiomer of 4-amino- 
tetrahydroindazole 6. Methods based upon the chiral amine reagent tert-butanesulfinamide 7 
(Scheme 5.2) have become some of the most extensively used synthetic approaches for asymmetric 
amine synthesis for both the discovery and production of drug candidates.190,204 From a practical 
standpoint, either enantiomer of 7 was commercially available and also relatively inexpensive to 
synthesise on a large scale if required in the future.358 More importantly, the synthetic steps used to 
prepare amines from 7 are typically robust and broad in scope, providing a straightforward route to 
both enantiomers of (±)-MJ05 (1).  
 
A previous study by the Ellman group identified that NaBH4 reduction of tert-butanesulfinyl imines 
occurred with high levels of diastereofacial control (Scheme 5.2).359 (RS)-tert-Butanesulfinamide 7 
was condensed with a variety of ketones prior to in situ NaBH4 mediated reduction, to yield 
predominantly the (RS,R) diastereomer 8 of the sulfinamide product.  
 
 
Scheme 5.2. Condensation of (RS)-tert-butanesulfinamide 7 with a variety of ketones followed by in situ reduction with 
NaBH4 or L-Selectride to yield the (RS,R)-8 and (RS,S)-9 diastereomers respectively.
358
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In subsequent research it was observed that the alternative reducing agent L-Selectride gave the 
opposite sense of asymmetric induction to provide predominantly the (RS,S) diastereomer 9.
358 The 
complementary sense of induction provided by these two reducing reagents would allow for the 
preparation of both amine stereoisomeric precursors of (±)-MJ05 (1) from a single enantiomer of 7. 
Coyler et al.199 proposed a cyclic versus acyclic transition state model to explain the origin of the 
reversal in diastereofacial selectivity observed upon switching the reducing agent. 1H NMR analysis 
revealed that the sulfinyl imines formed during the condensation step existed solely as the (E)-
isomers. They proposed that in the case of NaBH4 reduction, the (RS,E)-sulfinyl imine was reduced via 
a closed transition state, wherein the sulfinyl oxygen participates in the delivery of the hydride which 
would result in the observed (RS,R)-sulfinamide product 10 (Scheme 5.3A).  
 
 
Scheme 5.3. Coyler et al.’s mechanistic proposal to rationalise the stereoselectivity of the sulfinyl imine reduction.
17
 
 
However, in the case of poorly coordinating metal hydrides such as L-Selectride (due to its bulky sec-
butyl groups), the hydride would attack the electrophilic imine carbon atom in a sterically controlled 
fashion via an open transition state. As a result, hydride delivery would occur from the same face as 
the sulfur lone pair to furnish the observed (RS,S)-sulfinamide product 11 as predicted by the Felkin-
Ahn model (Scheme 5.3B). 
 
Sulfinyl imine 12 was prepared by condensation of ketone 5 and (RS)-7 in the presence of Ti(OEt)4, 
which acted both as a desiccant and as a Lewis acid. In situ reduction of the sulfinyl imine 12 with 
either L-Selectride or NaBH4 in THF at -48 °C yielded two diastereomers, which were predicted to be 
the (RS,S)-13 and (RS,R)-14 diastereomers (Scheme 5.4) of the sulfinamide product respectively based 
on the previously discussed transition state models (Scheme 5.3).  
(A) 
(B) 
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Scheme 5.4. Diastereoselective reductive amination. Reagents & conditions: (a) (RS)-7, Ti(OEt)4, THF, 75 °C. (b) L-
Selectride, THF, -48 °C, 2 h (c) NaBH4, THF, -48 °C  0 C, 16 h. (d) HCl, MeOH, r.t. 
 
Purification by flash chromatography resulted in both diastereomers (13 and 14) being isolated in 
high yield and purity.  
 
Figure 5.5. 
1
H NMR analysis of the diastereomers (RS,S)-13 and (RS,R)-14. 
(RS,S)-13 
(RS,R)-14 
Chapter 5: High-Throughput Screening 
 
219 
 
The 1H NMR spectra of 13 and 14 showed two diagnostic peaks that were used to distinguish 
between the two diastereomers (Figure 5.5). The proton at the stereogenic centre has a small 
chemical shift and splitting pattern difference between the two diastereomers, and the pyrazole 
protons are also distinguishable by a significant change in chemical shift (from 7.65 ppm in 13 to 
7.80 ppm in 14). 
 
The tert-butanesulfinyl group of 13 and 14 was cleaved under acidic conditions to obtain both the S-
(15) and R-(16) amine stereoisomers respectively (Scheme 5.4). 15 and 16 were subsequently 
subjected to the previously described N-acylation step with 2-picolinic acid to provide 
enantiomerically pure (-)-MJ05 (1) and (+)-MJ05 (1) (Scheme 5.5). Based on the predicted 
diastereofacial control in the reduction, these enantiomers were assigned as the (S)-1 and (R)-1 
enantiomers of MJ05. 
 
 
Scheme 5.5. (A) N-acylation of amines 15 and 16 with 2-picolinic acid to form (-)-MJ05 (1) and (+)-MJ05 (1). Reagents & 
conditions: (a) 2-Picolinic acid, EDC.HCl, Et3N, HOBt, DMAP, DCM, r.t., overnight; (-)-MJ05 (1) – 88%, >99% ee, *α+D
20= -71.8 
(c 0.1, CHCl3); (+)-MJ05 (1) – 93%, 98% ee, *α+D
20= +72.4 (c 0.1, CHCl3). (B) Chiral HPLC analysis of (±)-MJ05, (-)-MJ05 and 
(+)-MJ05. Chiralpak AD-H (5% IPA/hexanes, 1 mL min
-1
, 254 nm, 30 C). 
 
 
 
(±)-MJ05 (B) (A) 
(-)-MJ05 
(+)-MJ05 
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The two enantiomers were isolated in high enantiomeric purity which was determined by chiral 
HPLC analysis using a Chiralpack AD-H column (Scheme 5.5B) and shown to induce an approximately 
equal and opposite optical rotation. The two enantiomers were subsequently tested by the Lain 
group for their effect on p53 activation and cell viability to determine if they were modulating a 
biological target capable of discriminating between the two enantiomers. 
 
5.4.2 Biological analysis of the MJ05 enantiomers 
Interestingly, the biological assessment of (-)-MJ05 (1) revealed that it does not activate p53 
transcription and similarly had no effect on the viability of the ARN8 cancer cell line at 
concentrations up to 10 µM (Figure 5.6). In contrast, (+)-MJ05 (1) was shown to activate p53 
transcription to a greater extent than (±) MJ05 (1) and also appeared to be nearly twice as potent 
(IC50 value of 2.2 µM) as (±)-MJ05 (1) at killing the ARN8 cells (IC50 value of 4.0 µM)(Figure 5.6). 
This promising result identified (-)-MJ05 (1) as a highly valuable control compound for further 
biological assays, and suggested that (+)-MJ05 (1) was targeting an enzyme or protein that is capable 
of discriminating between the two enantiomers. Most importantly these results identified (+)-MJ05 
(1) as a more potent and promising lead for future biological testing and chemical development.  
 
 
Figure 5.6. Effect of (+)- and (-)-MJ05 (1) on (A) p53 transcriptional activation and (B) cell viability (ARN8 cells). Data 
provided by the Lain group. 
 
5.4.3 Large scale synthesis of (+)-MJ05 (1) 
As a result of the very promising biological data collected for (+)-MJ05 (1), it was necessary to carry 
out a larger scale synthesis of (+)-1 to enable further biological investigation and also verify if (+)-
MJ05 (1) was the predicted (R)-enantiomer. To achieve this goal it was decided to use the opposite 
enantiomer of the chiral auxiliary 7, (SS)-tert-butanesulfinamide, as this would facilitate the use of L-
Selectride as the reducing agent to furnish the desired (SS,R)-sulfinamide product. The use of L-
Selectride rather than NaBH4 simplifies the reaction procedure, as it is added drop-wise directly to 
the sulfinyl-imine solution without the need to cannula the sulfinyl-imine solution onto a pre-formed 
(A) (B) 
(±)-MJ05 
(+)-MJ05 
(-)-MJ05 
(±)-MJ05 
(+)-MJ05 
(-)-MJ05 
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suspension of the reducing agent, as is the case with NaBH4. Furthermore, in the original synthesis of 
(+)- and (-)-MJ05 (1) (Scheme 5.4), the L-Selectride reduction resulted in a small increase in 
diastereoselectivity and yield when compared to the NaBH4 reduction, possible due to the slow 
addition of the reducing agent and the removal of the imine transfer step in addition to any inherent 
increase in selectivity associated with the change in transition state (Scheme 5.4). This increase in 
yield and selectivity would have a more significant impact on the large scale synthesis of (+)-MJ05 
(1). 
 
The synthesis was carried out from ketone 5 using the previously described procedures (Scheme 
5.6). The 1H NMR spectrum of the isolated (SS,R)-sulfinamide diastereomer 17 was identical to that 
of the previously isolated (RS,S)-sulfinamide diastereomer 13 as would be expected. Subsequent 
cleavage of the sulfinamide 17 yielded the 4-aminotetrahydroindazole 16, which on coupling with 2-
picolinic acid provided (+)-MJ05 (1). This was shown to have an equivalent positive optical rotation 
and chiral HPLC trace to that obtained for the previously synthesised sample of (+)-MJ05 (1).  
 
Scheme 5.6. Diastereoselective reductive amination. Reagents & conditions: (a) (i) (SS)-7, Ti(OEt)4, THF, 75 °C. (ii) L-
Selectride, THF, -48 °C, 73%, dr 94:6 (b) HCl, MeOH, r.t., 90% (c) 2-picolinic acid, EDC.HCl, Et3N, HOBt, DMAP, DCM, r.t., 
overnight, 91%, >98% ee, *α+D
20= +72.1 (c 0.1, CHCl3). 
 
The diastereofacial control observed by Ellman et al. was confirmed for our substrate by X-ray 
crystallographic analysis of the isolated sulfinamide diastereomer 17 obtained by L-Selectride 
reduction of the (SS)-tert-butanesulfinyl imine 7. The X-ray structure of 17 confirmed the formation 
of the expected (SS,R) diastereomer (Figure 5.7). This result confirms that (+)-MJ05 (1) was the 
predicted (R)-enantiomer. 
 
Chapter 5: High-Throughput Screening 
 
222 
 
   
Figure 5.7. Two different views of the X-ray crystal structure of (SS,R)-sulfinamide diastereomer 17. Hydrogens added 
after refinement for clarity. X-ray crystallographic data provided by Prof. Alexandra Slawin. 
 
The large scale sample of (R)-(+)-MJ05 (1) was shown to have identical biological activity to the 
original (R)-(+)-MJ05 (1) sample and provided sufficient material (5 g) for further comprehensive 
biological assessment and target identification.  
 
5.4.4 (R)-MJ05 mediated induction of pro-apoptotic activity 
The potential of (R)-MJ05 (1) as a novel selective anticancer agent is currently being extensively 
explored by a collaborative team involving the Lain group (Karolinska Institutet , Sweden), Bathia 
group (City of Hope National Medical Center, USA) and the McCormack group (Haukeland University 
Hospital, Norway). A summary of the main results to date are outlined below.  
 
A greater than additive increase in toxicity was observed for (R)-MJ05 (1) in combination with p53-
MDM2 inhibitor nutlin-3 (2) against the ARN8 melanoma cell line. This increase in cytotoxicity did 
not occur when (R)-MJ05 (1) was combined with other p53 activators such as tenovin-6 (18, Figure 
5.8). Interestingly, (R)-MJ05 (1) did not have any effect on the viability of nutlin-3 (2) treated normal 
cells (HNDFs), highlighting this as a potential adjuvant therapy with reduced cytotoxicity against 
normal cells. It was observed that (R)-MJ05 (1) elicited physiological responses which are similar to 
those attributed to p14ARF, a tumour suppressor with both p53 dependent and independent 
effects.360 The ability of (R)-MJ05 (1) to mimic p14ARF function is an interesting feature of this 
molecule, as it has been observed that p14ARF gene expression is inactivated in a high proportion of 
tumours that retain wild type p53, including chronic myelogenous leukaemia (CML).361,362  
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Figure 5.8. The chemical structures of Tenovin-6 (18) and Nilotinib (19).  
 
Tyrosine kinase inhibitors (TKI) are the mainstay of CML treatment, but fail to eliminate leukaemia 
stem cells (LSC), leading to high risk of disease recurrence when treatment is stopped. There is 
considerable interest in the development of new strategies to target CML LSC. (R)-MJ05 (1)’s effect 
on primary normal cord blood (CB) or CML cells by itself, and in combination with TKI inhibitor 
Nilotinib (19, Figure 5.8) was assessed. Treatment with (R)-MJ05 (1) (5 and 10 μM) selectively 
induced expression of p53 target genes in CML but not normal CB cells as a single agent, or when 
combined with Nilotinib (19). (R)-MJ05 (1) (5 and 10μM) increased apoptosis and inhibited 
proliferation of CML cells without affecting normal CB cells. Combination of (R)-MJ05 (1) with 
Nilotinib (19) (1μM) resulted in a significant selective increase in apoptosis of CML cells. 
 
In summary, (R)-MJ05 (1) shares the therapeutically relevant effects of p53 and p14ARF tumour 
suppressors. Treatment of (R)-MJ05 (1) in combination with nutlin-3 (2) resulted in a selective and 
significant increase in cytotoxicity against an ARN8 cancer cell line. In addition, studies indicate that 
(R)-MJ05 (1) is effective in selectively inducing apoptosis and inhibiting growth of primitive CML 
stem cells by itself and to an even greater extent in combination with Nilotinib (19), with significantly 
reduced effects on normal stem cells. Although the majority of (R)-MJ05 (1)’s physiological effects 
have been elucidated, its principal biological target has not yet been identified.  
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5.5 Conclusions and Future Work 
 
(±)-MJ05 (1) was identified from a phenotypic screen of 20,000 drug-like molecules as a selective 
p53 activator with potent cytotoxic activity against an ARN8 cancer cell line. Further analysis showed 
that its cytotoxicity was highly selective for the cancer cell line over a human normal dermal 
fibroblast (HNDF) cell line. The promising therapeutic window obtained for 1 is a highly desirable 
property for new cancer chemotherapeutics. (±)-MJ05 (1) had also been previously identified as an 
inhibitor of the MDM2/MDM4 protein-protein interaction, which is central to cellular degradation of 
p53.  
 
A versatile and high-yielding 4-step synthesis was developed to (±)-MJ05 (1), which facilitated the 
large-scale synthesis of 1 for biological assessment. Testing of (±)-MJ05 (1) in a mouse xenograft 
model showed that it significantly impaired tumour growth over a 15 day period. Based on this in 
vivo activity, a tert-butanesulfinamide diastereoselective reductive amination was utilised to access 
both enantiomers of (±)-MJ05 (1). The (+)-MJ05 (1) enantiomer proved to be more active than the 
original racemic (±)-MJ05 towards p53 transcriptional activation and had increased cytotoxicity, 
whilst (-)-MJ05 was inactive under the same conditions. This also identified (-)-MJ05 as a valuable 
control molecule, and revealed that (+)-MJ05’s activity is likely as a result of modulation of a chirally 
discriminating biological target. 
 
A large scale synthesis of (+)-MJ05 was then undertaken to provide material for further biological 
assessment. X-ray crystal structure analysis of the isolated diastereomer 17 revealed that it was the 
predicted (SS,R) sulfinamide diastereomer, thus confirming that (+)-MJ05 was in fact (R)-(+)-MJ05. 
 
Comprehensive biological assessment of (R)-MJ05 has revealed that it is a promising candidate for 
use in adjuvant therapy in the treatment of cancer. (R)-MJ05 resulted in a greater than additive 
cytotoxic effect against ARN8 cells in combination with nutlin-3 (2), with no concomitant increase in 
cytotoxicity against normal (HNDF) cells. Furthermore, an ex-vivo xenograft study using CML cells 
revealed that (R)-MJ05 selectively induced p53 target genes, increased apoptosis and inhibited 
proliferation of CML cells without affecting normal (CB) cells.  
 
Current research is focused on the development of (R)-MJ05 as a preclinical drug lead. Assessment 
of (R)-MJ05’s off-target effects revealed that it is highly selective, showing no activity against a panel 
of 146 purified kinases, 16 lipid kinases as well as 16 cyclin-dependent kinases. Preliminary in vitro 
pharmokinetic studies revealed that (R)-MJ05 has adequate chemical and metabolic stability. Future 
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synthetic optimisation of (R)-MJ05 will focus on improving its in vitro and in vivo pharmokinetic and 
pharmodynamic properties. Although, much of (R)-MJ05’s physiological effects have been identified, 
its primary biological target has not been elucidated. The attachment of a photoaffinity tag 
containing a radioactive, fluorescent, or immunoreactive constituent or a biotin-linker to (R)-MJ05 
(1) could provide a powerful chemical tool for target identification studies. 
 
5.6 Experimental 
 
5.6.1 General considerations 
 
See Section 2.8.1 for general considerations. 
 
HPLC analyses were obtained on a Gilson HPLC consisting of a Gilson 305 pump, Gilson 306 pump, 
Gilson 811C dynamic mixer, Gilson 805 manometric module, Gilson 401C dilutor, Gilson 213XL 
sample injector and sample detection was performed with a Gilson 118 UV/vis detector. Separation 
was achieved using a Chiralpak AD-H column.  
 
5.6.2 General Methods 
 
General Method A: N-acylation 
To a solution of 2–picolinic acid (2 eq.), HOBt (1.5 eq.), EDC.HCl (1.5 eq.) and Et3N (1.5 eq.) in DCM 
(20 mL/mmol) were added the appropriate 4-aminotetrahydroindazole (1 eq.) and DMAP (0.1 eq.). 
The resulting solution was stirred at room temperature for 16 hours. The solution was concentrated 
in vacuo; the residue was diluted with EtOAc and with a saturated aqueous solution of NaHCO3 (3), 
brine, dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified via the 
Biotage SP4 (silica-packed SNAP; EtOAc/hexanes). 
 
General Method B: tert-Butanesulfinyl cleavage 
To a solution of the appropriate sulfinamide (1 eq.) in anhydrous methanol (10 mL/mmol) was added 
concentrated HCl (1 mL/mmol) dropwise. The solution was then stirred at room temperature for 4 
hours. The reaction was quenched by addition of a saturated aqueous solution of NaHCO3, and 
diluted with DCM and water. The organic layer was separated, washed with a saturated aqueous 
solution of NaHCO3, brine, dried with MgSO4, filtered and concentrated in vacuo. The obtained 
product did not require further purification. 
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5.6.3 Experimental Procedures 
 
2-((Dimethylamino)methylene)cyclohexane-1,3-dione (4)356 
 
A solution of 1,3-cyclohexanedione 3 (5.0 g, 44.6 mmol, 1.0 eq.) in N,N-dimethylformamide dimethyl 
acetal (8.9 mL, 66.9 mmol, 1.5 eq.) was heated at reflux for 2 hours. Upon cooling, an orange solid 
precipitated, which was stirred in Et2O (40 mL) and collected by filtration to give the title product 4 
as an orange powder (5.3 g, 71%), which did not require further purification. mp 101-103 °C (lit. 117-
119 °C);356 1H NMR (300 MHz, Chloroform-d) δ 8.04 (s, 1H, C1’-H), 3.38 (s, 3H, CH3), 3.16 (s, 3H, CH3), 
2.46 (dd, J = 8.6, 4.3 Hz, 4H, C4-H2, C6-H2), 2.00 – 1.87 (m, 2H, C5-H2); 
13C NMR (75 MHz, Chloroform-
d) δ 195.2 (C1, C3), 161.2 (C1’), 108.4 (C2), 47.5 (CH3), 43.7 (CH3), 37.2 (C4, C6), 18.6 (C5); m/z (ES
+) 
168.04 ([M+H]+, 100 %); Spectroscopic data are in agreement with the literature.356  
 
1-(2-Fluorophenyl)-6,7-dihydro-1H-indazol-4(5H)-one (5)357 
 
To a solution of 2-((dimethylamino)methylene)cyclohexane-1,3-dione 4 (1.67 g, 10.0 mmol, 1.0 eq.) 
in methanol (60 mL) and water (10 mL) were added 4-fluorophenylhydrazine hydrochloride (1.63 g, 
10.0 mmol, 1.0 eq.) and sodium hydroxide (0.40 g, 10.0 mmol, 1.0 eq.). The resulting mixture was 
heated at reflux for 2 hours and concentrated in vacuo. To the residue were added AcOH (60 mL) 
and water (30 mL) and the corresponding mixture was heated at 110 °C for 2 hours. On completion 
of the reaction, the solution was concentrated in vacuo. The residue was diluted with EtOAc (100 
mL) and washed with a saturated aqueous solution of NaHCO3 (3  50 mL), brine (50 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified via the Biotage SP4 
(silica-packed SNAP 50 g; 25-50% EtOAc/hexanes) to provide the title product 5 as a yellow solid 
(1.77 g, 77%). mp 104-106 °C (lit. 100-103 °C);357 IR (KBr) ν max: 2957, 1663 (C=O), 1508, 1408, 1226;
 
1H NMR (400 MHz, Chloroform-d) δ 8.10 (s, 1H, C3-H), 7.54 (td, J = 7.6, 1.7 Hz, 1H, C5’-H), 7.47 
(dddd, J = 8.3, 7.6, 4.9, 1.8 Hz, 1H, C4’-H), 7.34 – 7.29 (m, 1H, C6’-H), 7.29 – 7.24 (m, 1H, C3’-H), 2.80 
(td, J = 6.2, 1.5 Hz, 2H, C7-H2), 2.57 – 2.53 (m, 2H, C5-H2), 2.20 – 2.10 (m, 2H, C6-H2); 
13C NMR (101 
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MHz, Chloroform-d) δ 193.3 (C4), 156.1 (d, J = 252.0 Hz, C2’), 151.7 (C7a), 139.2 (C3), 131.0 (d, J = 7.7 
Hz, C4’), 128.5 (C5’), 126.6 (br, C7’), 125.2 (d, J = 3.9 Hz, C6’), 120.3 (C3a), 116.9 (d, J = 19.7 Hz, C3’), 
38.1 (C5), 23.5 (C6), 22.1 (d, J = 5.0 Hz, C7); m/z (ES+) 252.89 ([M+Na]+, 100 %); HRMS (ES+) Calcd for 
C13H11N2OFNa [M+Na]
+: 253.0753, found 253.0757. 
 
1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-amine (6) 
 
A solution of 1-(2-fluorophenyl)-6,7-dihydro-1H-indazol-4(5H)-one 5 (1.0 g, 4.3 mmol, 1.0 eq.) in 2-
propanol (80 mL) was treated, under vigorous stirring, with ammonium acetate (3.3 g, 43.4 mmol, 
10.0 eq.). After complete dissolution, molecular sieves (4 Å, 1.5 g) and NaBH3CN (1.3 g, 21.7 mmol, 
5.0 eq.) were added and the reaction mixture was stirred for 12 hours at 70 °C. The solution was 
concentrated in vacuo. The residue was diluted with EtOAc (200 mL) and washed thoroughly with a 2 
M aqueous solution of NaOH (20 mL) and brine (20 mL), dried over MgSO4, filtered and concentrated 
in vacuo. Without further purification, the crude compound 6 was directly used in the next step. See 
15 and 16 for the spectroscopic data for each enantiomer. 
 
N-(1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)picolinamide; (±)-MJ05 (1) 
 
Prepared from 1-(2-fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-amine 6 (0.90 g, 3.9 mmol, 1.0 
eq.) and 2–picolinic acid (0.48 g, 3.9 mmol, 1.0 eq.) using general method A. Purified via the Biotage 
SP4 (silica-packed SNAP column 10 g; 20-50% EtOAc/hexanes) to give the title product (±)-1 as a 
white solid (0.92 g, 65% over 2 steps). mp 96-98 °C; IR (KBr) ν max: 3288 (NH), 2945, 1661 (C=O), 
1516; 1H NMR (500 MHz, Chloroform-d) δ 8.47 (dd, J = 4.7, 0.6 Hz, 1H, C6’’-H), 8.19 (m, 2H, NH, C3’’-
H), 7.82 (td, J = 7.7, 1.6 Hz, 1H, C4’’-H), 7.62 (s, 1H, C3-H), 7.45 – 7.27 (m, 3H, C5’-H, C4’-H, C5’’-H), 
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7.29 – 7.16 (m, 2H, C6’-H, C3’-H), 5.37 – 5.25 (m, 1H, C4-H), 2.63 – 2.45 (m, 2H, C7-H2), 2.18 – 2.03 
(m, 1H, C5-H), 1.97 – 1.71 (m, 3H, C5-H, C6-H2);
 13C NMR (126 MHz, Chloroform-d) δ 163.7 (CO), 
156.3 (d, J = 251.5 Hz, C2’), 149.9 (C2’’), 148.1 (C6’’), 141.8 (C7a), 139.4 (C3), 137.4 (C4’’), 130.0 (d, J 
= 7.7 Hz, C4’), 128.6 (C5’), 127.4 (d, J = 11.8 Hz, C1’), 126.2 (C5’’), 124.8 (d, J = 3.9 Hz, C6’), 122.3 
(C3’’), 118.0 (C3a), 116.7 (d, J = 20.1 Hz, C3’), 42.4 (C4), 30.1 (C5), 21.6 (C7), 20.1 (C6); m/z (ES+) 
358.86 ([M+Na]+, 100 %); HRMS (ES+) Calcd for C19H17N4OFNa [M+Na]
+: 359.1284, found 359.1283. 
 
(R)-N-((S)-1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)-2-methylpropane-2-sulfinamide 
(13) 
 
1-(2-Fluorophenyl)-6,7-dihydro-1H-indazol-4(5H)-one 5 (0.30 g, 1.30 mmol, 1.0 eq.) was added to a 
solution of (RS)-2-methyl-2-propanesulfinamide 7 (189 mg, 1.56 mmol, 1.20 eq.) and Ti(OEt)4 (0.55 
mL, 2.6 mmol, 2.0 eq.) in THF (2.5 mL) at room temperature. The mixture was heated at 75 °C for 12 
hours. The mixture was cooled to -48 °C and L-Selectride (3.9 mL, 1 M in THF, 3 eq.) was added 
dropwise. After 2 hours, the reaction was warmed to 0 °C and MeOH was added dropwise until gas 
evolution was no longer observed. The crude reaction mixture was poured into an equal volume of 
brine while being vigorously stirred. The resulting suspension was filtered through a plug of Celite, 
and the filter cake was washed with EtOAc. The filtrate was washed with brine (20 mL), and the 
brine layer was extracted with EtOAc (3  10 mL). The combined organic extracts were dried over 
MgSO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 
10 g; 20-70% EtOAc/hexanes) to give the title product 13 as a white solid (366 mg, 84%). * +D
2 = -
30.0 (c 0.1, CHCl3); mp 94-96 °C; IR (KBr) ν max: 3418 (NH), 3220, 2921, 1667, 1460, 1194;
 1H NMR 
(500 MHz, Chloroform-d) δ 7.65 (s, 1H, C3-H), 7.48 – 7.42 (m, 1H, C5’-H), 7.41 – 7.36 (m, 1H, C4’-H), 
7.27 – 7.22 (m, 1H, C6’-H), 7.24 – 7.18 (m, 1H, C3’-H), 4.53 – 4.50 (m, 1H, C4-H), 3.37 (d, J = 9.4 Hz, 
1H, NH), 2.59 – 2.44 (m, 1H, C7-H2), 2.32 – 2.23 (m, 1H, C5-H2), 2.00 – 1.91 (m, 1H, C6-H2), 1.89 – 
1.78 (m, 2H, C5-H2, C6-H2), 1.27 (s, 9H, (CH3)3); 
13C NMR (101 MHz, Chloroform-d) δ 156.4 (d, J = 
251.5 Hz, C2’), 141.5 (C7a), 139.4 (C3), 130.1 (d, J = 7.8 Hz, C4’), 128.7 (C5’), 127.4 (d, J = 11.7 Hz, 
C1’), 124.9 (d, J = 4.0 Hz, C6’), 119.2 (C3a), 116.8 (d, J = 19.9 Hz, C3’), 56.3 (C(CH3)3)), 50.8 (C4), 33.3 
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(C5), 22.9 ((CH3)3), 21.6 (d, J = 4.5 Hz, C7), 20.3 (C6); m/z (ES
+) 358.04 ([M+Na]+, 100 %); HRMS (ES+) 
Calcd for C17H22N3OSFNa [M+Na]
+: 358.1365, found 358.1367.  
  
(R)-N-((R)-1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)-2-methylpropane-2-sulfinamide 
(14) 
 
1-(2-Fluorophenyl)-6,7-dihydro-1H-indazol-4(5H)-one 5 (0.60 g, 2.60 mmol, 1.0 eq.) was added to a 
solution of (RS)-2-methyl-2-propanesulfinamide 7 (0.38 g, 3.12, 1.2 eq.) and Ti(OEt)4 (1.1 mL, 5.2 
mmol, 2.0 eq.) in THF (5 mL) at room temperature. The mixture was heated at 75 °C for 12 hours. 
The mixture was cooled to -48 °C and then added dropwise via cannula to a -48 °C suspension of 
NaBH4 (0.39 g, 10.4 mmol, 4.0 eq.) in a minimum amount of THF. The reaction mixture was warmed 
to 0 °C and stirred for 16 hours before the dropwise addition of MeOH until gas evolution was no 
longer observed. The crude reaction mixture was poured into an equal volume of brine while being 
rapidly stirred. The resulting suspension was filtered through a plug of Celite, and the filter cake was 
washed with EtOAc. The filtrate was washed with brine (20 mL), and the brine layer was extracted 
with EtOAc (3  10 mL). The combined organic extracts were dried over MgSO4, filtered, 
concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 10 g; 20-70% 
EtOAc/hexanes) to give the title product 14 as a white solid (0.7 g, 80%). * +D
2 = +0.50 (c 0.42, 
CHCl3); mp 106-108 °C; IR (KBr) ν max: 3433 (NH), 3205, 2954, 1514, 1041;
 1H NMR (300 MHz, 
Chloroform-d) δ 7.80 (s, 1H, C3-H), 7.46 (td, J = 7.9, 1.8 Hz, 1H, C5’-H), 7.43 – 7.35 (m, 1H, C4’-H), 
7.28 – 7.24 (m, 1H, C6’-H), 7.24 – 7.18 (m, 1H, C3’-H), 4.58 (dd, J = 9.6, 4.9 Hz, 1H, C4-H), 3.32 (d, J = 
4.9 Hz, 1H, NH), 2.66 – 2.39 (m, 2H, C7-H2), 2.04 – 1.73 (m, 4H, C5-H2, C6-H2), 1.24 (s, 9H, (CH3)3); 
13C 
NMR (75 MHz, Chloroform-d) δ 156.7 (d, J = 251.5 Hz, C2’), 142.1 (C7a), 140.1 (C3), 130.4 (d, J = 7.8 
Hz, C4’), 129.0 (C5’), 127.5 (br, C1’), 125.2 (d, J = 3.9 Hz, C6’), 119.2 (C3a), 117.0 (d, J = 20.1 Hz, C3’), 
56.0 (C(CH3)3)), 48.6 (C4), 31.8 (C5), 23.1 ((CH3)3), 21.9 (d, J = 4.7 Hz, C7), 19.7 (C6); m/z (ES
+) 357.90 
([M+Na]+, 100 %); HRMS (ES+) Calcd for C17H22N3OSFNa [M+Na]
+: 358.1365, found 358.1358. 
 
 
 
Chapter 5: High-Throughput Screening 
 
230 
 
(S)-1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-amine (15) 
 
Prepared from (R)-N-((S)-1-(2-fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)-2-methylpropane-2-
sulfinamide 13 (1.06 g, 3.16 mmol, 1.0 eq.) using general method B. The title product 15 was 
obtained as a pale yellow oil (0.66 g, 91%), which did not require further purification. 1H NMR (400 
MHz, Chloroform-d) δ 7.72 (s, 1H, C3-H), 7.45 (td, J = 7.6, 1.7 Hz, 1H, C5’-H), 7.42 – 7.34 (m, 1H, C4’-
H), 7.27 – 7.18 (m, 2H, C6’-H, C3’-H), 4.09 – 4.02 (m, 1H, C4-H), 2.61 – 2.42 (m, 2H, C7-H2), 2.12 – 
1.99 (m, 1H, C5-H2), 2.03 – 1.90 (m, 1H, C6-H2), 1.81 – 1.68 (m, 1H, C6-H2), 1.61 – 1.47 (m, 1H, C5-H2);
 
13C NMR (101 MHz, Chloroform-d) δ 156.5 (d, J = 251.4 Hz, C1’), 140.8 (C7a), 139.0 (C3), 129.9 (d, J = 
7.8 Hz, C4’), 128.8 (C5’), 127.7 (d, J = 11.6 Hz, C1’), 124.8 (d, J = 3.8 Hz, C6’), 121.7 (C3a), 116.7 (d, J = 
20.1 Hz, C3’), 44.7 (C4), 34.2 (C5), 21.8 (d, J = 4.7 Hz, C7), 20.4 (C6); m/z (ES+) 232.11 ([M+H]+, 100 %).  
 
(R)-1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-amine (16) 
 
Prepared from (R)-N-((R)-1-(2-fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)-2-methylpropane-2-
sulfinamide 14 (1.4 g, 4.2 mmol, 1.0 eq.) using general method B. The title product 16 was obtained 
as a pale yellow oil (0.86 g, 90%), which did not require further purification. 1H NMR (500 MHz, 
Chloroform-d) δ 7.74 (s, 1H, C3-H), 7.51 – 7.41 (m, 1H, C5’-H), 7.42 – 7.34 (m, 1H, C4’-H), 7.25 – 7.18 
(m, 2H, C6’-H, C3’-H), 4.12 – 4.03 (m, 1H, C4-H), 2.59 – 2.39 (m, 2H, C7-H2), 2.10 – 2.02 (m, 1H, C5-
H2), 2.02 – 1.93 (m, 1H, C6-H2), 1.82 – 1.69 (m, 1H, C6-H2), 1.64 – 1.51 (m, 1H, C5-H2);
 13C NMR (101 
MHz, Chloroform-d) δ 156.4 (d, J = 251.6 Hz, C1’), 140.9 (C7a), 139.0 (C3), 129.9 (d, J = 7.8 Hz, C4’), 
128.7 (C5’), 127.7 (d, J = 11.6 Hz, C1’), 124.8 (d, J = 3.9 Hz, C6’), 121.7 (C3a), 116.7 (d, J = 20.0 Hz, 
C3’), 44.7 (C4), 33.9 (C5), 21.8 (d, J = 4.6 Hz, C7), 20.3 (C6); m/z (ES+) 231.09 ([M+H]+, 100 %).  
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(S)-N-(1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)picolinamide; (-)-MJ05 (1) 
 
Prepared from (S)-1-(2-fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-amine 15 (0.66 g, 2.87 mmol, 
1.0 eq.) and 2–picolinic acid (0.71 g, 5.74 mmol, 2.0 eq.) using general method A. Purified via the 
Biotage SP4 (silica-packed SNAP column 50 g; 20-50% EtOAc/hexanes) to give the title product (-)-
MJ05 (1) as a white solid (0.84 g, 88%). Chiral HPLC analysis Chiralpak AD-H (5% IPA/hexane, 1 mL 
min-1, 254 nm, 30 C) tR (major) 35.5, tR (minor) 31.5, >99% ee; * +D
2 = -71.8 (c 0.1, CHCl3); mp 116-
118 °C; IR (KBr) ν max: 3443 (NH), 3288, 2922, 1658 (C=O), 1530; 
1H NMR (500 MHz, Chloroform-d) δ 
8.47 (dd, J = 4.7, 0.6 Hz, 1H, C6’’-H), 8.19 (m, 2H, NH, C3’’-H), 7.81 (td, J = 7.7, 1.6 Hz, 1H, C4’’-H), 
7.62 (s, 1H, C3-H), 7.47 – 7.27 (m, 3H, C5’-H, C4’-H, C5’’-H), 7.29 – 7.13 (m, 2H, C6’-H, C3’-H), 5.36 – 
5.25 (m, 1H, C4-H), 2.63 – 2.42 (m, 2H, C7-H2), 2.18 – 2.03 (m, 1H, C5-H2), 1.97 – 1.73 (m, 3H, C5-H2, 
C6-H2);
 13C NMR (126 MHz, Chloroform-d) δ 163.7 (CO), 156.3 (d, J = 251.5 Hz, C1’), 149.9 (C2’’), 
148.1 (C6’’), 141.8 (C7a), 139.4 (C3), 137.4 (C4’’), 130.0 (d, J = 7.7 Hz, C4’), 128.6 (C5’), 127.4 (d, J = 
11.8 Hz, C1’), 126.2 (C5’’), 124.8 (d, J = 3.9 Hz, C6’), 122.3 (C3’’), 118.0 (C3a), 116.7 (d, J = 20.1 Hz, 
C3’), 42.4 (C4), 30.1 (C5), 21.6 (d, J = 4.7 Hz, C7), 20.1 (C6); m/z (ES+) 358.89 ([M+Na]+, 100 %); HRMS 
(ES+) Calcd for C19H18N4ONa [M+Na]
+: 359.1284, found 359.1276. 
 
(R)-N-(1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)picolinamide; (+)-MJ05 (1) 
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Prepared from (R)-1-(2-fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-amine 16 (0.86 g, 3.72 mmol, 
1.0 eq.) and 2–picolinic acid (0.91 g, 7.44 mmol, 2.0 eq.) using general method A. Purified via the 
Biotage SP4 (silica-packed SNAP column 100 g; 20-50% EtOAc/hexanes) to give the title product (+)-
MJ05 (1) as a white solid (1.16 g, 93%). Chiral HPLC analysis Chiralpak AD-H (5% IPA/hexane, 1 mL 
min-1, 254 nm, 30 C) tR (minor) 35.9, tR (major) 31.3, 98% ee; * +D
2 = +72.4 (c 0.1, CHCl3); mp 117-
119 °C; IR (KBr) ν max: 3443 (NH), 3291, 2946, 1661 (C=O), 1530;
 1H NMR (500 MHz, Chloroform-d) δ 
8.47 (dd, J = 4.7, 0.6 Hz, 1H, C6’’-H), 8.19 (m, 2H, NH, C3’’-H), 7.81 (td, J = 7.7, 1.6 Hz, 1H, C4’’-H), 
7.62 (s, 1H, C3-H), 7.47 – 7.27 (m, 3H, C5’-H, C4’-H, C5’’-H), 7.29 – 7.13 (m, 2H, C6’-H, C3’-H), 5.36 – 
5.25 (m, 1H, C4-H), 2.63 – 2.42 (m, 2H, C7-H2), 2.18 – 2.03 (m, 1H, C5-H), 1.97 – 1.73 (m, 3H, C5-H, 
C6-H2);
 13C NMR (126 MHz, Chloroform-d) δ 163.7 (CO), 156.3 (d, J = 251.5 Hz, C2’), 149.9 (C2’’), 
148.1 (C6’’), 141.8 (C7a), 139.4 (C3), 137.4 (C4’’), 130.0 (d, J = 7.7 Hz, C4’), 128.6 (C5’), 127.4 (d, J = 
11.8 Hz, C1’), 126.2 (C5’’), 124.8 (d, J = 3.9 Hz, C6’), 122.3 (C3’’), 118.0 (C3a), 116.7 (d, J = 20.1 Hz, 
C3’), 42.4 (C4), 30.1 (C5), 21.6 (C7), 20.1 (C6); m/z (ES+) 359.12 ([M+Na]+, 100 %); HRMS (ES+) Calcd 
for C19H18N4ONa [M+Na]
+: 359.1284, found 359.1281. 
 
(S)-N-((R)-1-(2-Fluorophenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)-2-methylpropane-2-sulfinamide 
(17) 
 
1-(2-Fluorophenyl)-6,7-dihydro-1H-indazol-4(5H)-one 5 (4.64 g, 20.1 mmol, 1.0 eq.) was added to a 
solution of (SS)-2-methyl-2-propanesulfinamide 7 (2.44 g, 20.1 mmol, 1.0 eq.) and Ti(OEt)4 (8.4 mL, 
40.2 mmol, 2.0 eq.) in THF (40 mL) at room temperature. The mixture was heated at 75 °C for 12 
hours. The mixture was cooled to -48 °C and L-Selectride (60.3 mL, 1 M in THF, 3.0 eq.) was added 
dropwise. After 2 hours, the reaction was warmed to 0 °C and MeOH was added dropwise until gas 
evolution was no longer observed. The crude reaction mixture was poured into an equal volume of 
brine while being vigorously stirred. The resulting suspension was filtered through a plug of Celite, 
and the filter cake was washed with EtOAc. The filtrate was washed with brine (30 mL), and the 
brine layer was extracted with EtOAc (3  20 mL). The combined organic extracts were dried over 
MgSO4, filtered, concentrated in vacuo and purified via the Biotage SP4 (silica-packed SNAP column 
180 g; 20-70% EtOAc/hexanes) to give the title product 17 as a white solid (4.89 g, 73%). * +D
2 = 
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+27.7 (c 0.35, CHCl3); mp 112-114 °C; IR (KBr) ν max: 3433 (NH), 3201, 2963, 1514, 1031;
 1H NMR 
(500 MHz, Chloroform-d) δ 7.65 (s, 1H, C3-H), 7.47 – 7.42 (m, 1H, C5’-H), 7.42 – 7.36 (m, 1H, C4’-H), 
7.27 – 7.24 (m, 1H, C6’-H), 7.24 – 7.18 (m, 1H, C3’-H), 4.53 – 4.49 (m, 1H, C4-H), 3.37 (d, J = 9.4 Hz, 
1H, NH), 2.59 – 2.44 (m, 1H, C7-H2), 2.34 – 2.23 (m, 1H, C5-H2), 2.00 – 1.89 (m, 1H, C6-H2), 1.89 – 
1.76 (m, 2H, C5-H2, C6-H2), 1.26 (s, 9H, (CH3)3); 
13C NMR (101 MHz, Chloroform-d) δ 156.4 (d, J = 
251.5 Hz, C2’), 141.5 (C7a), 139.4 (C3), 130.1 (d, J = 7.8 Hz, C4’), 128.7 (C5’), 127.4 (d, J = 11.7 Hz, 
C1’), 124.9 (d, J = 4.0 Hz, C6’), 119.2 (C3a), 116.8 (d, J = 19.9 Hz, C3’), 56.3 (C(CH3)3)), 50.8 (C4), 33.3 
(C5), 22.9 ((CH3)3), 21.6 (d, J = 4.5 Hz, C7), 20.3 (C6); m/z (ES
+) 357.84 ([M+Na]+, 100 %); HRMS (ES+) 
Calcd for C17H22N3OSFNa [M+Na]
+: 358.1365, found 358.1366. 
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6 Overall Conclusions 
Protein-protein interaction modulation has developed as an attractive molecular target for novel 
cancer therapies and as a powerful research tool in chemical biology to advance our understanding 
of the underlying mechanisms involved in carcinogenesis. In this thesis, a range of screening 
approaches were utilised to identify modulators of PPIs which are implicated in oncogenesis.  
 
The diverse range of multiprotein complexes involved in cellular regulation, signalling and 
pathophysiology mediated by the AAA+ protein reptin, has identified it as a promising but untapped 
therapeutic target. Virtual screening coupled with an in vitro PPI assay facilitated the identification of 
two modulators of the peptide binding function of reptin. A SAR optimisation study guided by 
molecular modelling and biological assessment provided Liddean (Figure 6.1), a promising chemical 
tool to study reptin’s intricate protein interactome. A peptide phage display screen of Liddean (48) 
bound reptin identified the tumour suppressor protein p53 as a new interacting partner, which could 
potentially provide a novel therapeutic target for anticancer agents. Extensive research is continuing 
to dissect reptin’s cellular functions and towards the optimisation of the cell permeable drug lead 13 
(see Chapter 2) (Figure 6.1). 
 
Nature’s extensive repertoire of bioactive molecules has been underexploited in the hunt for PPI 
modulators due to the difficulties associated with screening the natural extract libraries against a 
target PPI. The increasing enthusiasm for PPI modulators combined with technological advances in 
screening methods has refocused attention on nature’s plentiful store of drug leads. JBIR-22 (4) was 
identified from a screen of 123,599-natural product extract library as a potent inhibitor of PAC3 
homodimerisation, a promising approach by which to inhibit the generation of the proteasomal 
machinery. JBIR-22 (4) is a member of a subfamily of the ubiquitous collection of bioactive natural 
products containing a tetramic acid core. A short asymmetric synthesis of the unnatural 4,4-
disubstituted glutamic acid provided a synthetically versatile masked tetramic acid which could be 
modified by attachment of a range of side chains. Validation of this approach as a general route to 
this subfamily of tetramic acids was provided by the first total synthesis of the plant growth 
promoting agent harzianic acid (19) and its diastereomers (19b-d, see Chapter 3) with a longest 
linear sequence of only 6 steps (Figure 6.1). Subsequent utilisation of this synthetic approach 
facilitated the first total synthesis of JBIR-22 diastereomers 4a and 4b with a LLS of only 10 steps 
(Figure 6.1). Preliminary investigations indicate that the development of an alternative synthetic 
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approach containing a late stage chiral catalyst-controlled diastereoselective Diels-Alder reaction 
could be possible. This would provide the opportunity to access a diverse library of JBIR-22 (4) 
derivatives via a late stage Diels-Alder cyclisation of a range of polyene substituted tetramic acids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Summary of the PPI modulators developed in this thesis 
 
 
Disease Indications 
Cancer, neurodegenerative 
disorders and microbial 
pathogenesis 
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The design of small molecule peptidomimetics of the binding epitope of one of the partners of a 
protein complex has been a fruitful source of PPI modulators. In particular, indole based 
peptidomimetics have been shown to successfully inhibit a range of PDZ domain mediated PPIs. A 
PDZ domain containing protein of significant therapeutic interest is PICK1, a scaffolding protein 
involved in the clustering and shuttling of its protein partners. Two series of peptidomimetic 
inhibitors of the PICK1 PDZ domain were designed by analysis of known PICK1-peptide coupling 
partners in conjugation with molecular modelling studies. Biological assessment of the 16 
synthesised analogues identified 16a and 33c (see Chapter 4) (Figure 6.1), which had low micromolar 
binding affinities for the PICK1 PDZ domain. These novel peptidomimetics are on a par with the most 
active PDZ domain inhibitors in the literature, and provide a potential mechanism by which to 
investigate the PICK1’s PPI with the dominant breast cancer drug target HER2. In addition, 16a and 
33c are promising lead compounds for the development of nanomolar inhibitors of PICK1’s PDZ 
domain, with potential as therapies for neurodegenerative disorders. 
 
Mutation or unregulated degradation of the p53 tumour suppressor protein plays a pivotal role in 
cancer development and progression. As a result, modulation of the protein interactions involved in 
the regulation of the expression and degradation of p53 is thought to be a promising approach by 
which to target carcinogenesis. (±)-MJ05 (1) (see Chapter 5) was identified as a selective p53 
activator from a forward chemical genetics screen of 20,000 drug-like compounds. (±)-MJ05 (1) was 
selected for further evaluation based on its promising therapeutic window and its potential 
mechanism of action via inhibition of the MDM2/MDM4 PPI complex involved in p53 degradation. 
An asymmetric synthesis of both enantiomers of (±)-MJ05 (1) revealed that (R)-MJ05 (1) was the 
active constituent of the racemate (Figure 6.1). (R)-MJ05 (1) is currently undergoing preclinical 
evaluation as a potential adjuvant therapy in combination with Nilotinib for the treatment of CML. 
 
Despite their pivotal role in carcinogenesis, the interest in PPIs as drug targets has historically been 
tempered by the pervasive view that they are intractable drug targets. The urgent need for new, 
efficacious and non-toxic therapies for the treatment of complex diseases has highlighted the 
potential of PPI modulators as novel drug leads. The development of innovative screening methods 
has provided the opportunity to exploit this potentially rich source of drug leads. The application of a 
range of such screening approaches in this research, to successfully identify PPI modulators targeting 
a diverse range of proteins supports the changing perception regarding the druggability of disease 
relevant PPIs.  
 
Bibliography 
 
237 
 
7 Bibliography 
(1)  Milroy, L.-G.; Grossmann, T. N.; Hennig, S.; Brunsveld, L.; Ottmann, C. Chem. Rev. 2014, 114, 
4695–4748. 
(2)  Loh, S. N. ACS Chem. Biol. 2008, 3, 140–141. 
(3)  Zinzalla, G.; Thurston, D. E. Future Med. Chem. 2009, 1, 65–93. 
(4)  White, A. W.; Westwell, A. D.; Brahemi, G. Expert Rev. Mol. Med. 2008, 10. 
(5)  Hanahan, D.; Weinberg, R. A. Cell 2000, 100, 57–70. 
(6)  Martin, G. S. Cancer Cell 2003, 4, 167–174. 
(7)  Hanahan, D.; Weinberg, R. A. Cell 2014, 144, 646–674. 
(8)  Arkin, M. Curr. Opin. Chem. Biol. 2005, 9, 317–324. 
(9)  Ryan, D. P.; Matthews, J. M. Curr. Opin. Struct. Biol. 2005, 15, 441–446. 
(10)  Ivanov, A. A.; Khuri, F. R.; Fu, H. Trends Pharmacol. Sci. 2013, 34, 393–400. 
(11)  Nero, T. L.; Morton, C. J.; Holien, J. K.; Wielens, J.; Parker, M. W. Nat. Rev. Cancer 2014, 14, 
248–262. 
(12)  Wells, J. A.; McClendon, C. L. Nature 2007, 450, 1001–1009. 
(13)  Arkin, M. R.; Wells, J. A. Nat. Rev. Drug. Discov. 2004, 3, 301–317. 
(14)  Falchi, F.; Caporuscio, F.; Recanatini, M. Future Med. Chem. 2014, 343–357. 
(15)  Ferrari, S.; Pellati, F.; Costi, M. P. In Disruption of Protein-Protein Interfaces: In Search of New 
Inhibitors; Mangani, S., Ed.; Springer: Berlin, Heidelberg, 2013; Vol. Chapter 2, pp. 31–60. 
(16)  Jubb, H.; Higueruelo, A. P.; Winter, A.; Blundell, T. L. Trends Pharmacol. Sci. 2012, 33, 241–
248. 
(17)  Tzakos, A. G.; Fokas, D.; Johannes, C.; Moussis, V.; Hatzimichael, E.; Briasoulis, E. Molecules 
2011, 16, 4408–4427. 
(18)  Tanaka, T.; Rabbitts, T. H. Cell cycle 2008, 7, 1569–1574. 
(19)  Clackson, T.; Wells, J. A. Science 1995, 267, 383–386. 
(20)  Bogan, A. A.; Thorn, K. S. J. Mol. Biol. 1998, 280, 1–9. 
(21)  Van Roey, K.; Uyar, B.; Weatheritt, R. J.; Dinkel, H.; Seiler, M.; Budd, A.; Gibson, T. J.; Davey, 
N. E. Chem. Rev. 2014. 
(22)  Thiel, P.; Kaiser, M.; Ottmann, C. Angew. Chem. Int. Ed. Engl. 2012, 51, 2012–2018. 
(23)  Lee, G. M.; Craik, C. S. Science 2009, 324, 213–215. 
(24)  Ray-Coquard, I.; Blay, J.-Y.; Italiano, A.; Le Cesne, A.; Penel, N.; Zhi, J.; Heil, F.; Rueger, R.; 
Graves, B.; Ding, M.; Geho, D.; Middleton, S. A.; Vassilev, L. T.; Nichols, G. L.; Bui, B. N. Lancet 
Oncol. 2012, 13, 1133–1140. 
(25)  Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J.-J.; Zhao, C.; Glenn, K.; 
Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B. ACS Med. Chem. Lett. 2013, 4, 466–
469. 
(26)  Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Khaira, D.; Hann, 
C. L.; McKeegan, E. M.; Litvinovich, E.; Hemken, P. M.; Dive, C.; Enschede, S. H.; Nolan, C.; 
Chiu, Y.-L.; Busman, T.; Xiong, H.; Krivoshik, A. P.; Humerickhouse, R.; Shapiro, G. I.; Rudin, C. 
M. J. Clin. Oncol. 2011, 29, 909–916. 
(27)  Yuriev, E.; Ramsland, P. A. J. Mol. Recognit. 2013, 26, 215–239. 
(28)  Villoutreix, B. O.; Bastard, K.; Sperandio, O.; Fahraeus, R.; Poyet, J.-L.; Calvo, F.; Déprez, B.; 
Miteva, M. Curr. Pharm. Biotechnol. 2008, 9, 103–122. 
(29)  Villoutreix, B. O.; Kuenemann, M. A.; Poyet, J.-L.; Bruzzoni-Giovanelli, H.; Labbé, C.; Lagorce, 
D.; Sperandio, O.; Miteva, M. A. Mol. Inform. 2014, 33, 414–437. 
(30)  Ewing, T. A.; Makino, S.; Skillman, A. G.; Kuntz, I. J. Comput. Aided. Mol. Des. 2001, 15, 411–
428. 
(31)  Nikolovska-Coleska, Z.; Xu, L.; Hu, Z.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R.; Fang, X.; Guo, R.; 
Zhang, M.; Lippman, M. E.; Yang, D.; Wang, S. J. Med. Chem. 2004, 47, 2430–2440. 
(32)  Reddy, T. R. K.; Li, C.; Fischer, P. M.; Dekker, L. V. ChemMedChem 2012, 7, 1435–1446. 
Bibliography 
 
238 
 
(33)  Voet, A.; Zhang, K. Y. J. Curr. Pharm. Des. 2012, 18, 4586–4598. 
(34)  Phipps, K. D.; Surette, A. P.; O’Connell, P. A.; Waisman, D. M. Cancer Res. 2011, 71 , 6676–
6683. 
(35)  Shang, J.; Zhang, Z.; Song, W.; Zhou, B.; Zhang, Y.; Li, G.; Qiu, S. Tumor Biol. 2013, 34, 3785–
3790. 
(36)  Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. J. Mol. Biol. 1997, 267, 727–748. 
(37)  Murali, R.; Cheng, X.; Berezov, A.; Du, X.; Schön, A.; Freire, E.; Xu, X.; Chen, Y. H.; Greene, M. I. 
Proc. Natl. Acad. Sci. USA 2005, 102, 10970–10975. 
(38)  Berezov, A.; Cai, Z.; Freudenberg, J. A.; Zhang, H.; Cheng, X.; Thompson, T.; Murali, R.; Greene, 
M. I.; Wang, Q. Oncogene 2012, 31, 1938–1948. 
(39)  McMillan, K.; Adler, M. Proc. Natl. Acad. Sci. 2000, 97, 1506–1511. 
(40)  Reynolds, K. A.; McLaughlin, R. N.; Ranganathan, R. Cell 2011, 147, 1564–1575. 
(41)  Motlagh, H. N.; Hilser, V. J. Proc. Natl. Acad. Sci. 2012. 
(42)  Rosenbaum, J.; Baek, S.; Dutta, A. Sci. Signal. 2013, 6, 1–6. 
(43)  Jha, S.; Dutta, A. Mol. Cell 2009, 34, 521–533. 
(44)  Huen, J.; Kakihara, Y.; Ugwu, F.; Cheung, K. L. Y.; Ortega, J.; Houry, W. A. Biochem. cell Biol. 
2010, 40, 29–40. 
(45)  Nano, N.; Houry, W. A. Philos. Trans. R. Soc. B Biol. Sci. 2013, 368 . 
(46)  Shen, X.; Mizuguchi, G.; Hamiche, A.; Wu, C. Nature 2000, 406, 541–544. 
(47)  Jonsson, Z. O.; Dhar, S. K.; Narlikar, G. J.; Auty, R.; Wagle, N.; Pellman, D.; Pratt, R. E.; 
Kingston, R.; Dutta, A. J. Biol. Chem. 2001, 276, 16279–16288. 
(48)  Ikura, T.; Ogryzko, V. V; Grigoriev, M.; Groisman, R.; Wang, J.; Horikoshi, M.; Scully, R.; Qin, J.; 
Nakatani, Y. Cell 2000, 102, 463–473. 
(49)  Doyon, Y.; Selleck, W.; Lane, W. S.; Tan, S.; Cote, J. Mol. Cell Biol. 2004, 24, 1884–1896. 
(50)  Krogan, N. J.; Keogh, M. C.; Datta, N.; Sawa, C.; Ryan, O. W.; Ding, H.; Haw, R. A.; Pootoolal, J.; 
Tong, A.; Canadien, V.; Richards, D. P.; Wu, X.; Emili, A.; Hughes, T. R.; Buratowski, S.; 
Greenblatt, J. F. Mol. Cell 2003, 12, 1565–1576. 
(51)  Cai, Y.; Jin, J.; Florens, L.; Swanson, S. K.; Kusch, T.; Li, B.; Workman, J. L.; Washburn, M. P.; 
Conaway, R. C.; Conaway, J. W. J. Biol. Chem. 2005, 280, 13665–13670. 
(52)  Kanemaki, M.; Kurokawa, Y.; Matsu-ura, T.; Makino, Y.; Masani, A.; Okazaki, K.; Morishita, T.; 
Tamura, T. J. Biol. Chem. 1999, 274 , 22437–22444. 
(53)  Izumi, N.; Yamashita, A.; Iwamatsu, A.; Kurata, R.; Nakamura, H.; Saari, B.; Hirano, H.; 
Anderson, P.; Ohno, S. Sci. Signal. 2010, 3, ra27. 
(54)  Wood, M. A.; McMahon, S. B.; Cole, M. D. Mol. Cell 2000, 5, 321–330. 
(55)  Bauer, A.; Chauvet, S.; Huber, O.; Usseglio, F.; Rothbacher, U.; Aragnol, D.; Kemler, R.; Pradel, 
J. EMBO J. 2000, 19, 6121–6130. 
(56)  Kim, J. H.; Kim, B.; Cai, L.; Choi, H. J.; Ohgi, K. A.; Tran, C.; Chen, C.; Chung, C. H.; Huber, O.; 
Rose, D. W.; Sawyers, C. L.; Rosenfeld, M. G.; Baek, S. H. Nature 2005, 434, 921–926. 
(57)  Venteicher, A. S.; Meng, Z.; Mason, P. J.; Veenstra, T. D.; Artandi, S. E. Cell 2008, 132, 945–
957. 
(58)  Matias, P. M.; Gorynia, S.; Donner, P.; Carrondo, M. A. J. Biol. Chem. 2006, 281, 35918–35929. 
(59)  Gorynia, S.; Bandeiras, T. M.; Pinho, F. G.; McVey, C. E.; Vonrhein, C.; Round, A.; Svergun, D. 
I.; Donner, P.; Matias, P. M.; Carrondo, M. A. J. Struct. Biol. 2011, 176, 279–291. 
(60)  Petukhov, M.; Dagkessamanskaja, A.; Bommer, M.; Barrett, T.; Tsaneva, I.; Yakimov, A.; 
Quéval, R.; Shvetsov, A.; Khodorkovskiy, M.; Käs, E.; Grigoriev, M. Structure 2012, 20, 1321–
1331. 
(61)  Torreira, E.; Jha, S.; López-Blanco, J. R.; Arias-Palomo, E.; Chacón, P.; Cañas, C.; Ayora, S.; 
Dutta, A.; Llorca, O. Structure 2008, 16, 1511–1520. 
(62)  López-Perrote, A.; Muñoz-Hernández, H.; Gil, D.; Llorca, O. Nucleic Acids Res. 2012, 40, 
11086–11099. 
(63)  Hanson, P. I.; Whiteheart, S. W. Nat. Rev. Mol. Cell Biol. 2005, 6, 519–529. 
Bibliography 
 
239 
 
(64)  Cheung, K. L. Y.; Huen, J.; Houry, W. A.; Ortega, J. Biochem. Cell Biol. 2010, 88, 77–88. 
(65)  Maslon, M. M.; Hrstka, R.; Vojtesek, B.; Hupp, T. R. J. Mol. Biol. 2010, 404, 418–438. 
(66)  Niewiarowski, A.; Bradley, A. S.; Gor, J.; McKay, A. R.; Perkins, S. J.; Tsaneva, I. R. Biochem. J. 
2010, 429, 113–125. 
(67)  Huber, O.; Ménard, L.; Haurie, V.; Nicou, A.; Taras, D.; Rosenbaum, J. Cancer Res. 2008, 68, 
6873–6876. 
(68)  Grigoletto, A.; Lestienne, P.; Rosenbaum, J. Biochim. Biophys. Acta 2011, 1815, 147–157. 
(69)  Blanc, J. F.; Lalanne, C.; Plomion, C.; Schmitter, J. M.; Bathany, K.; Gion, J. M.; Bioulac-Sage, P.; 
Balabaud, C.; Bonneu, M.; Rosenbaum, J. Proteomics 2005, 5, 3778–3789. 
(70)  Rousseau, B.; Ménard, L.; Haurie, V.; Taras, D.; Blanc, J.-F.; Moreau-Gaudry, F.; Metzler, P.; 
Hugues, M.; Boyault, S.; Lemière, S.; Canron, X.; Costet, P.; Cole, M.; Balabaud, C.; Bioulac-
Sage, P.; Zucman-Rossi, J.; Rosenbaum, J. Hepatology 2007, 46, 1108–1118. 
(71)  Etard, C.; Gradl, D.; Kunz, M.; Eilers, M.; Wedlich, D. Mech. Dev. 2005, 122, 545–556. 
(72)  Coste, A. de La; Romagnolo, B.; Billuart, P.; Renard, C.-A.; Buendia, M.-A.; Soubrane, O.; 
Fabre, M.; Chelly, J.; Beldjord, C.; Kahn, A.; Perret, C. Proc. Natl. Acad. Sci. 1998, 95 , 8847–
8851. 
(73)  Haurie, V.; Ménard, L.; Nicou, A.; Touriol, C.; Metzler, P.; Fernandez, J.; Taras, D.; Lestienne, 
P.; Balabaud, C.; Bioulac-Sage, P.; Prats, H.; Zucman-Rossi, J.; Rosenbaum, J. Hepatology 2009, 
50, 1871–1883. 
(74)  Ménard, L.; Taras, D.; Grigoletto, A.; Haurie, V.; Nicou, A.; Dugot-Senant, N.; Costet, P.; 
Rousseau, B.; Rosenbaum, J. J. Hepatol. 2010, 52, 681–689. 
(75)  Matias, P. M.; Gorynia, S.; Donner, P.; Carrondo, M. A. J. Biol. Chem. 2006, 281, 38918–38929. 
(76)  Hann, M. M.; Oprea, T. I. Curr. Opin. Chem. Biol. 2004, 8, 255–263. 
(77)  Sauton, N.; Lagorce, D.; Villoutreix, B. O.; Miteva, M. BMC Bioinformatics 2008, 9, 184. 
(78)  Taylor, P.; Blackburn, E.; Sheng, Y. G.; Harding, S.; Hsin, K.-Y.; Kan, D.; Shave, S.; Walkinshaw, 
M. D. Br. J. Pharmacol. 2008, 153, S55–67. 
(79)  Wang, R.; Lu, Y.; Wang, S. J. Med. Chem. 2003, 46, 2287–2303. 
(80)  Houston, D. R.; Walkinshaw, M. D. J. Chem. Inf. Model. 2013, 53, 384–390. 
(81)  Neudert, G.; Klebe, G. J. Chem. Inf. Model. 2011, 51, 2731–2745. 
(82)  Thomas Sander (Actelion Pharmaceuticals Ltd.). OSIRIS Property Explorer 
http://www.organic-chemistry.org/prog/peo/. 
(83)  Brissette, R.; Goldstein, N. In Cancer Genomics and Proteomics SE  - 13; Fisher, P., Ed.; 
Methods in MolecularbiologyTM; Humana Press, 2007; Vol. 383, pp. 203–213. 
(84)  Kehoe, J. W.; Kay, B. K. Chem. Rev. 2005, 105, 4056–4072. 
(85)  Smith, G. P.; Petrenko, V. A. Chem. Rev. 1997, 97, 391–410. 
(86)  Arap, M. A. Genet. Mol. Biol. 2005, 28, 1–9. 
(87)  Hertveldt, K.; Beliën, T.; Volckaert, G. In Bacteriophages SE  - 19; Clokie, M. J.; Kropinski, A., 
Eds.; Methods in Molecular BiologyTM; Humana Press, 2009; Vol. 502, pp. 321–339. 
(88)  Molek, P.; Strukelj, B.; Bratkovic, T. Molecules 2011, 16, 857–887. 
(89)  Tompa, P. Nat. Chem. Biol. 2012, 8, 597–600. 
(90)  Tucker, T.; Marra, M.; Friedman, J. M. Am. J. Hum. Genet. 2009, 85, 142–154. 
(91)  Ten Bosch, J. R.; Grody, W. W. J. Mol. Diagn. 2008, 10, 484–492. 
(92)  Masoudi-Nejad, A.; Narimani, Z.; Hosseinkhan, N. In Next Generation Sequencing and 
Sequence Assembly SE  - 2; SpringerBriefs in Systems Biology; Springer New York, 2013; Vol. 4, 
pp. 11–39. 
(93)  Grada, A.; Weinbrecht, K. J Invest Dermatol 2013, 133, e11. 
(94)  Bailey, T. L.; Williams, N.; Misleh, C.; Li, W. W. Nucleic Acids Res. 2006, 34, W369–73. 
(95)  Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J. J. Mol. Biol. 1990, 215, 403–
410. 
(96)  Thompson, L. A.; Ellman, J. A. Chem. Rev. 1996, 96, 555–600. 
(97)  Waldmann, H.; Janning, P. Chemical Biology; Wiley, 2009; pp. 0–340. 
Bibliography 
 
240 
 
(98)  Gordon, E. M.; Kerwin Jr, J. F. Combinatorial Chemistry and Molecular Diversity in Drug 
Discovery; Wiley, 1998. 
(99)  Franzén, R. G. J. Comb. Chem. 2000, 2, 195–214. 
(100)  An, H.; Cook, P. D. Chem. Rev. 2000, 100, 3311–3340. 
(101)  Dalinger, I. L.; Vatsadse, I.; Shevelev, S.; Ivachtchenko, A. V. J. Comb. Chem. 2005, 7, 236–245. 
(102)  Katsuyama, I.; Ogawa, S.; Yamaguchi, Y. Synthesis (Stuttg). 1997, 1321–1324. 
(103)  Danheiser, R. L.; Miller, R. F.; Brisbois, R. G.; Park, S. Z. J. Org. Chem. 1990, 55, 1959–1964. 
(104)  Recknagel, R. O.; Glende Jr., E. A.; Dolak, J. A.; Waller, R. L. Pharmacol. Ther. 1989, 43, 139–
154. 
(105)  Evans, W. F. J.; Puckrin, E. Geophys. Res. Lett. 1996, 23, 1769–1772. 
(106)  Gutekunst, W. R.; Baran, P. S. Chem. Soc. Rev. 2011, 40, 1976–1991. 
(107)  Verrier, C.; Lassalas, P.; Théveau, L.; Quéguiner, G.; Trécourt, F.; Marsais, F.; Hoarau, C. 
Beilstein J. Org. Chem. 2011, 7, 1584–1601. 
(108)  Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chemie Int. Ed. 2009, 48, 5094–5115. 
(109)  Ferrins, L.; Rahmani, R.; Sykes, M. L.; Jones, A. J.; Avery, V. M.; Teston, E.; Almohaywi, B.; Yin, 
J.; Smith, J.; Hyland, C.; White, K. L.; Ryan, E.; Campbell, M.; Charman, S. A.; Kaiser, M.; Baell, 
J. B. Eur. J. Med. Chem. 2013, 66, 450–465. 
(110)  Zhuravlev, F. A. Tetrahedron Lett. 2006, 47, 2929–2932. 
(111)  Holler, M. G.; Campo, L. F.; Brandelli, A.; Stefani, V. J. Photochem. Photobiol. A Chem. 2002, 
149, 217–225. 
(112)  Myllymäki, M. J.; Koskinen, A. M. P. Tetrahedron Lett. 2007, 48, 2295–2298. 
(113)  Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2012, 75, 311–335. 
(114)  Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2007, 70, 461–477. 
(115)  Li, J. W.-H.; Vederas, J. C. Science 2009, 325, 161–165. 
(116)  Kodadek, T. Chem. Commun. 2011, 47, 9757–9763. 
(117)  Over, B.; Wetzel, S.; Grütter, C.; Nakai, Y.; Renner, S.; Rauh, D.; Waldmann, H. Nat. Chem. 
2013, 5, 21–28. 
(118)  Koehn, F. E.; Carter, G. T. Nat. Rev. Drug Discov. 2005, 4, 206–220. 
(119)  Reindl, W.; Yuan, J.; Krämer, A.; Strebhardt, K.; Berg, T. Chem. Biol. 2008, 15, 459–466. 
(120)  Duncan, S. J.; Grüschow, S.; Williams, D. H.; McNicholas, C.; Purewal, R.; Hajek, M.; Gerlitz, 
M.; Martin, S.; Wrigley, S. K.; Moore, M. J. Am. Chem. Soc. 2001, 123, 554–560. 
(121)  Lepourcelet, M.; Chen, Y.-N. P.; France, D. S.; Wang, H.; Crews, P.; Petersen, F.; Bruseo, C.; 
Wood, A. W.; Shivdasani, R. A. Cancer Cell 2014, 5, 91–102. 
(122)  Hashimoto, J.; Watanabe, T.; Seki, T.; Karasawa, S.; Izumikawa, M.; Seki, T.; Iemura, S.-I.; 
Natsume, T.; Nomura, N.; Goshima, N.; Miyawaki, A.; Takagi, M.; Shin-Ya, K. J. Biomol. Screen. 
2009, 14, 970–979. 
(123)  Izumikawa, M.; Hashimoto, J.; Hirokawa, T.; Sugimoto, S.; Kato, T.; Takagi, M.; Shin-Ya, K. J. 
Nat. Prod. 2010, 73, 628–631. 
(124)  Hirano, Y.; Hayashi, H.; Iemura, S.-I.; Hendil, K. B.; Niwa, S.-I.; Kishimoto, T.; Kasahara, M.; 
Natsume, T.; Tanaka, K.; Murata, S. Mol. Cell 2006, 24, 977–984. 
(125)  Finley, D. Annu. Rev. Biochem. 2009, 78, 477–513. 
(126)  Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. Leukemia 2007, 21, 838–842. 
(127)  Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Science 1995, 
268, 726–731. 
(128)  Adams, J.; Palombella, V.; Sausville, E. Cancer Res. 1999, 2615–2622. 
(129)  Murata, M.; Matsuoka, S.; Matsumori, N.; Paul, G. K.; Tachibana, K. J. Am. Chem. Soc. 1999, 
121, 870–871. 
(130)  Royles, B. J. L. Chem. Rev. 1995, 95, 1981–2001. 
(131)  Jeong, Y.-C.; Moloney, M. G. J. Org. Chem. 2011, 76, 1342–1354. 
(132)  Schobert, R.; Schlenk, A. Bioorg. Med. Chem. 2008, 16, 4203–4221. 
(133)  Gromak, V. V; Avakyan, V. G.; Lakhvich, O. F. J. Appl. Spectrosc. 2000, 67, 205–215. 
Bibliography 
 
241 
 
(134)  Steyn, P. S.; Wessels, P. L. Tetrahedron Lett. 1978, 19, 4707–4710. 
(135)  Nolte, M. J.; Steyn, P. S.; Wessels, P. L. J. Chem. Soc., Perkin Trans. 1 1980, 1057–1065. 
(136)  Athanasellis, G.; Igglessi-Markopoulou, O.; Markopoulos, J. Bioinorg. Chem. Appl. 2010, 2010, 
315056. 
(137)  Schobert, R. Naturwissenschaften 2007, 94, 1–11. 
(138)  Fisch, K. M. RSC Adv. 2013, 3, 18228. 
(139)  Staunton, J.; Weissman, K. J. Nat. Prod. Rep. 2001, 18, 380–416. 
(140)  Sims, J. W.; Fillmore, J. P.; Warner, D. D.; Schmidt, E. W. Chem. Commun. (Camb). 2005, 186–
188. 
(141)  Campbell, C. D.; Vederas, J. C. Biopolymers 2010, 93, 755–763. 
(142)  Oikawa, H.; Tokiwano, T. Nat. Prod. Rep. 2004, 21, 321–352. 
(143)  Stocking, E. M.; Williams, R. M. Angew. Chem. Int. Ed. Engl. 2003, 42, 3078–3115. 
(144)  Kelly, W. L. Org. Biomol. Chem. 2008, 6, 4483–4493. 
(145)  Kim, H. J.; Ruszczycky, M. W.; Choi, S.; Liu, Y.; Liu, H. Nature 2011, 473, 109–112. 
(146)  Ose, T.; Watanabe, K.; Mie, T.; Honma, M.; Watanabe, H.; Yao, M.; Oikawa, H.; Tanaka, I. 
Nature 2003, 422, 185–189. 
(147)  Serafimov, J. M.; Gillingham, D.; Kuster, S.; Hilvert, D. J. Am. Chem. Soc. 2008, 130, 7798–
7799. 
(148)  Watanabe, K.; Mie, T.; Ichihara, A.; Oikawa, H.; Honma, M. J. Biol. Chem. 2000, 275 , 38393–
38401. 
(149)  Guimarães, C. R. W.; Udier-Blagovid, M.; Jorgensen, W. L. J. Am. Chem. Soc. 2005, 127, 3577–
3588. 
(150)  Kaufmann, G. F.; Sartorio, R.; Lee, S.-H.; Rogers, C. J.; Meijler, M. M.; Moss, J. a; Clapham, B.; 
Brogan, A. P.; Dickerson, T. J.; Janda, K. D. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 309–314. 
(151)  Kaufmann, G. F.; Sartorio, R.; Lee, S.-H.; Mee, J. M.; Altobell, L. J.; Kujawa, D. P.; Jeffries, E.; 
Clapham, B.; Meijler, M. M.; Janda, K. D. J. Am. Chem. Soc. 2006, 128, 2802–2803. 
(152)  Waters, C. M.; Bassler, B. L. Annu. Rev. Cell Dev. Biol. 2005, 21, 319–346. 
(153)  Lowery, C. A.; Park, J.; Gloeckner, C.; Meijler, M. M.; Mueller, R. S.; Boshoff, H. I.; Ulrich, R. L.; 
Barry  Clifton E.; Bartlett, D. H.; Kravchenko, V. V; Kaufmann, G. F.; Janda, K. D. J. Am. Chem. 
Soc. 2009, 131, 14473–14479. 
(154)  Sengoku, T.; Nagae, Y.; Ujihara, Y.; Takahashi, M.; Yoda, H. J. Org. Chem. 2012, 77, 4391–
4401. 
(155)  Spengler, J.; Schedel, H.; Sieler, J.; Quaedflieg, P. J. L. M.; Broxterman, Q. B.; Duchateau, A. L. 
L.; Burger, K. Synthesis (Stuttg). 2001, 2001, 1513,1518. 
(156)  Lacey, R. N. J. Chem. Soc. 1954, 850–854. 
(157)  Poncet, J.; Jouin, P.; Castro, B.; Nicolas, L.; Boutar, M.; Gaudemer, A. J. Chem. Soc. Perkin 
Trans. 1 1990, 611. 
(158)  Burke, L. T.; Dixon, D. J.; Ley, S. V; Rodríguez, F. Org. Biomol. Chem. 2005, 3, 274–280. 
(159)  Burke, L. T.; Dixon, D. J.; Ley, S. V.; Rodríguez, F. Org. Lett. 2000, 2, 3611–3613. 
(160)  Kawada, M.; Yoshimoto, Y.; Kumagai, H. J. Antibiot. (Tokyo). 2004, 57, 2–4. 
(161)  Hazalin, N. A. M. N.; Ramasamy, K.; Lim, S. M.; Cole, A. L. J.; Majeed, A. B. A. Phytomedicine 
2012, 19, 609–617. 
(162)  Yang, S.-W.; Mierzwa, R.; Terracciano, J.; Patel, M.; Gullo, V.; Wagner, N.; Baroudy, B.; Puar, 
M.; Chan, T.-M.; McPhail, A. T.; Chu, M. J. Nat. Prod. 2006, 69, 1025–1028. 
(163)  Yang, S.; Mierzwa, R.; Terracciano, J.; Patel, M.; Gullo, V.; Wagner, N.; Baroudy, B.; Puar, M.; 
Chan, T.; Chu, M. J. Antibiot. (Tokyo). 2007, 60, 524–528. 
(164)  Vinale, F.; Flematti, G.; Sivasithamparam, K.; Lorito, M.; Marra, R.; Skelton, B. W.; Ghisalberti, 
E. L.; School. J. Nat. Prod. 2009, 72, 2032–2035. 
(165)  Vinale, F.; Nigro, M.; Sivasithamparam, K.; Flematti, G.; Ghisalberti, E. L.; Ruocco, M.; Varlese, 
R.; Marra, R.; Lanzuise, S.; Eid, A.; Woo, S. L.; Lorito, M. FEMS Microbiol. Lett. 2013. 
(166)  Daferner, M.; Anke, T.; Sterner, O. Tetrahedron 2002, 58, 7781–7784. 
Bibliography 
 
242 
 
(167)  Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. Science 1996, 272, 872–877. 
(168)  Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. 
A. Science 1996, 272, 1955–1958. 
(169)  Palani, A.; Tagat, J. R. J. Med. Chem. 2006, 49, 2851–2857. 
(170)  Maeda, K.; Das, D.; Nakata, H.; Mitsuya, H. Expert Opin. Emerg. Drugs 2012, 17, 135–145. 
(171)  Gilliam, B. L.; Riedel, D. J.; Redfield, R. R. J. Transl. Med. 2011, 9 Suppl 1, S9. 
(172)  Sawa, R.; Mori, Y.; Iinuma, H. J. Antibiot. (Tokyo). 1994, 47, 731–732. 
(173)  Vinale, F.; Sivasithamparam, K.; Ghisalberti, E. L.; Marra, R.; Woo, S. L.; Lorito, M. Soil Biol. 
Biochem. 2008, 40, 1–10. 
(174)  Lorito, M.; Woo, S. L.; Harman  Gary E.; Monte, E. Annu. Rev. Phytopathol. 2010, 48, 395–417. 
(175)  Barton, L. L.; Hemming, C. B. Iron Chelation in Plants and Soil Microorganisms; Academic 
Press, New York, 1993. 
(176)  Neilands, J. B. J. Biol. Chem. 1995, 270 , 26723–26726. 
(177)  Hider, R. C.; Kong, X. Nat. Prod. Rep. 2010, 27, 637–657. 
(178)  Biersack, B.; Diestel, R.; Jagusch, C.; Sasse, F.; Schobert, R. J. Inorg. Biochem. 2009, 103, 72–
76. 
(179)  Kaufmann, G. F.; Sartorio, R.; Lee, S.-H.; Rogers, C. J.; Meijler, M. M.; Moss, J. a; Clapham, B.; 
Brogan, A. P.; Dickerson, T. J.; Janda, K. D. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 309–314. 
(180)  Baldwin, S.; Long, A. Org. Lett. 2004, 6, 1653–1656. 
(181)  Helaine, V.; Bolte, J. Tetrahedron: Asymmetry 1998, 9, 3855–3861. 
(182)  He, V.; Rossi, È.; Gefflaut, T.; Alaux, Â.; Bolte, J. Adv. Synth. Catal. 2001, 0–5. 
(183)  Polt, R.; Seebach, D. J. Am. Chem. Soc. 1989, 111, 2622–2632. 
(184)  Alderweireldt, F.; Jadot, J.; Casimir, J.; Loffet, A. Biochim. Biophys. Acta - Gen. Subj. 1967, 136, 
89–94. 
(185)  Jadot, J.; Casimir, J.; Loffet, A. Biochim. Biophys. Acta - Gen. Subj. 1967, 136, 79–88. 
(186)  Meier, L. K.; Sorensen, H. Phytochemistry 1979, 18, 1173–1175. 
(187)  Bu’Lock, J. D. Biosynthesis; A specialist periodical report. Biosynthesis; Royal Society of 
Chemistry, 1980; pp. 155–178. 
(188)  Liu, G.; Cogan, D. A.; Ellman, J. A. J. Am. Chem. Soc. 1997, 119, 9913–9914. 
(189)  Robak, M. T.; Herbage, M. A.; Ellman, J. A. Chem Rev 2010, 110, 3600–3740. 
(190)  Xu, H.-C.; Chowdhury, S.; Ellman, J. A. Nat. Protoc. 2013, 8, 2271–2280. 
(191)  Trost, B. M.; Brindle, C. S. Chem. Soc. Rev. 2010, 39, 1600–1632. 
(192)  Evans, D. A.; Bartroli, J.; Shih, T. L. J. Am. Chem. Soc. 1981, 103, 2127–2129. 
(193)  Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1974, 39, 1615–1621. 
(194)  Gathergood, N.; Juhl, K.; Poulsen, T. B.; Thordrup, K.; Jørgensen, K. A. Org. Biomol. Chem. 
2004, 2, 1077–1085. 
(195)  Kochi, T.; Tang, T.; Ellman, J. J. Am. Chem. Soc. 2002, 6518–6519. 
(196)  Kochi, T.; Tang, T. P.; Ellman, J. J. Am. Chem. Soc. 2003, 125, 11276–11282. 
(197)  Reddy, L.; Gupta, A.; Liu, Y. J. Org. Chem. 2011, 3409–3415. 
(198)  Zimmerman, H. E.; Traxler, M. D. J. Am. Chem. Soc. 1957, 79, 1920–1923. 
(199)  Colyer, J. T.; Andersen, N. G.; Tedrow, J. S.; Soukup, T. S.; Faul, M. M. J. Org. Chem. 2006, 71, 
6859–6862. 
(200)  Robak, M. T.; Herbage, M. A.; Ellman, J. A. Chem. Rev. 2010, 110, 3600–3740. 
(201)  Gribble, G. W. Org. Process Res. Dev. 2006, 10, 1062–1075. 
(202)  W. Gribble, G. Chem. Soc. Rev. 1998, 27, 395. 
(203)  Borch, R. F.; Bernstein, M. D.; Durst, H. D. J. Am. Chem. Soc. 1971, 93, 2897–2904. 
(204)  Robak, M. T.; Herbage, M. A.; Ellman, J. A. Chem. Rev. 2010, 110, 3600–3740. 
(205)  Staunton, J.; Weissman, K. J. Nat. Prod. Rep. 2001, 18, 380–416. 
(206)  Ley, S. V.; Woodward, P. R. Tetrahedron Lett. 1987, 28, 3019–3020. 
(207)  Booth, P. M.; Broughton, H. B.; Ford, M. J.; Fox, C. M. J.; Ley, S. V.; Slawin, A. M. Z.; Williams, 
D. J.; Woodward, P. R. Tetrahedron 1989, 45, 7565–7580. 
Bibliography 
 
243 
 
(208)  Fox, C. M. J.; Ley, S. V; Slawin, A. M. Z.; Williams, D. J. J. Chem. Soc., Chem. Commun. 1985, 
1805–1806. 
(209)  Clarke, T.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1 1987, 131–135. 
(210)  Booth, P. M.; Fox, C. M. J.; Ley, S. V. Tetrahedron Lett. 1983, 24, 5143–5146. 
(211)  Booth, P. M.; Fox, C. M. J.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1 1987, 121–129. 
(212)  Ley, S. V.; Smith, S. C.; Woodward, P. R. Tetrahedron 1992, 48, 1145–1174. 
(213)  Ley, S.; Smith, S.; Woodward, P. Tetrahedron Lett. 1988, 29, 5829–5832. 
(214)  Ley, S.; Woodward, P. Tetrahedron Lett. 1987, 28, 345–346. 
(215)  Lipson, V. V; Gorobets, N. Y. Mol. Divers. 2009, 13, 399–419. 
(216)  Ivanov, A. S. Chem. Soc. Rev. 2008, 37, 789–811. 
(217)  Schreiber, S.; Claus, R.; Reagan, J. Tetrahedron Lett. 1982, 23, 3867–3870. 
(218)  Uchida, K.; Ogawa, T.; Yasuda, Y.; Mimura, H.; Fujimoto, T.; Fukuyama, T.; Wakimoto, T.; 
Asakawa, T.; Hamashima, Y.; Kan, T. Angew. Chem. Int. Ed. Engl. 2012, 51, 12850–12853. 
(219)  Thompson, S. K.; Heathcock, C. H. J. Org. Chem. 1990, 55, 3386–3388. 
(220)  Lambert, T. H.; Danishefsky, S. J. J. Am. Chem. Soc. 2006, 128, 426–427. 
(221)  Wilson, R. M.; Jen, W. S.; Macmillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 11616–11617. 
(222)  Ahrendt, K.; Borths, C. J.; Macmillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243–4244. 
(223)  Evans, D.; Chapman, K.; Bisaha, J. Tetrahedron Lett. 1984, 7–10. 
(224)  Paintner, F. F.; Bauschke, G.; Polborn, K. Tetrahedron Lett. 2003, 44, 2549–2552. 
(225)  Merino, P.; Marqués-López, E.; Tejero, T.; Herrera, R. Synthesis (Stuttg). 2009, 2010, 1–26. 
(226)  Kumpulainen, E. T. T.; Koskinen, A. M. P.; Rissanen, K. Org. Lett. 2007, 9, 5043–5045. 
(227)  Jacobs, W. C.; Christmann, M. Synlett 2008, 2, 247–251. 
(228)  Gaich, T.; Baran, P. S. J. Org. Chem. 2010, 75, 4657–4673. 
(229)  Hendrickson, J. B. J. Am. Chem. Soc. 1975, 97, 5784–5800. 
(230)  Bertz, S. H. J. Am. Chem. Soc. 1982, 104, 5801–5803. 
(231)  Mulzer, J. Nat. Prod. Rep. 2014, 31, 595–603. 
(232)  Newhouse, T.; Baran, P. S.; Hoffmann, R. W. Chem. Soc. Rev. 2009, 38, 3010–3021. 
(233)  Könning, D.; Hiller, W.; Christmann, M. Org. Lett. 2012, 14, 5258–5261. 
(234)  De Figueiredo, R. M.; Voith, M.; Fröhlich, R.; Christmann, M. Synlett 2007, 2007, 391–394. 
(235)  Ma, S. M.; Li, J. W.-H.; Choi, J. W.; Zhou, H.; Lee, K. K. M.; Moorthie, V. a; Xie, X.; Kealey, J. T.; 
Da Silva, N. a; Vederas, J. C.; Tang, Y. Science 2009, 326, 589–592. 
(236)  Devos, M.; Patte, F.; Rouault, J.; Lafort, P.; Van Gemert, L. J. Standardized Human Olfactory 
Thresholds; Oxford Press, 1990; p. 118. 
(237)  Chen, M.; Roush, W. R. Org. Lett. 2012, 14, 426–428. 
(238)  Shimshock, S. J.; Waltermire, R. E.; DeShong, P. J. Am. Chem. Soc. 1991, 113, 8791–8796. 
(239)  DeShong, P.; Ramesh, S.; Elango, V.; Perez, J. J. J. Am. Chem. Soc. 1985, 107, 5219–5224. 
(240)  Pronin, S. V; Kozmin, S. a. J. Am. Chem. Soc. 2010, 132, 14394–14396. 
(241)  Du, H.; Ding, K. ChemInform 2010, 1, 1–57. 
(242)  Corey, E. J. Angew. Chemie Int. Ed. 2002, 41, 1650–1667. 
(243)  Takao, K.; Munakata, R.; Tadano, K. Chem. Rev. 2005, 105, 4779–4807. 
(244)  Furuta, K.; Kanematsu, A.; Yamamoto, H.; Takaoka, S. Tetrahedron Lett. 1989, 30, 7231–7232. 
(245)  Iwasawa, N.; Sugimori, J.; Kawase, Y.; Narasaka, K. Chem. Lett. 1989, 18, 1947–1950. 
(246)  Evans, D.; Miller, S.; Lectka, T.; von Matt, P. J. Am. Chem. Soc. 1999, 121, 7559–7573. 
(247)  Evans, D.; Johnson, J. J. Org. Chem. 1997, 62, 786–787. 
(248)  Corey, E. J.; Loh, T. P. J. Am. Chem. Soc. 1991, 113, 8966–8967. 
(249)  Simsek, S.; Horzella, M.; Kalesse, M. Org. Lett. 2007, 9, 5637–5639. 
(250)  Evans, D.; Miller, S.; Lectka, T. J. Am. Chem. Soc. 1993, 12, 6460–6461. 
(251)  Evans, D.; Kozlowski, M.; Tedrow, J. Tetrahedron Lett. 1996, 37, 7481–7484. 
(252)  Desimoni, G.; Faita, G.; Jørgensen, K. A. Chem. Rev. 2006, 106, 3561–3651. 
(253)  Owens, T.; Hollander, F. J. Am. Chem. Soc. 2001, 1539–1540. 
(254)  Ellman, J. A.; Owens, T. D.; Tang, T. P. Acc. Chem. Res. 2002, 35, 984–995. 
Bibliography 
 
244 
 
(255)  Evans, D. a.; Johnson, J. S. J. Org. Chem. 1997, 62, 786–787. 
(256)  Corey, E.; Ishihara, K. Tetrahedron Lett. 1992, 33, 6807–6810. 
(257)  Raithby, P. R.; Shields, G. P.; Allen, F. H.; Motherwell, W. D. S. Acta Crystallogr. Sect. B 2000, 
56, 444–454. 
(258)  Eya, B. K.; Toshikazu, O.; Isao, K.; Wood, D. L. Tetrahedron 1990, 46, 2695–2706. 
(259)  Snider, B. B.; Lu, Q. J. Org. Chem. 1996, 61, 2839–2844. 
(260)  Lygo, B.; Hirst, D. J. Synthesis (Stuttg). 2005, 3257–3262. 
(261)  Grauer, A.; König, B. European J. Org. Chem. 2009, 2009, 5099–5111. 
(262)  Floris, M.; Moro, S. Mol. Inform. 2012, 31, 12–20. 
(263)  Kharb, R.; Rana, M.; Sharma, P. C.; Yar, M. S.; Delhi, N. J. Chem. Pharm. Res. 2011, 3, 173–186. 
(264)  Vagner, J.; Qu, H.; Hruby, V. J. Curr. Opin. Chem. Biol. 2008, 12, 292–296. 
(265)  Karatas, H.; Townsend, E. C.; Cao, F.; Chen, Y.; Bernard, D.; Liu, L.; Lei, M.; Dou, Y.; Wang, S. J. 
Am. Chem. Soc. 2012, 135, 669–682. 
(266)  Patel, A.; Vought, V. E.; Dharmarajan, V.; Cosgrove, M. S. J. Biol. Chem. 2008, 283 , 32162–
32175. 
(267)  Cao, F.; Townsend, E. C.; Karatas, H.; Xu, J.; Li, L.; Lee, S.; Liu, L.; Chen, Y.; Ouillette, P.; Zhu, J.; 
Hess, J. L.; Atadja, P.; Lei, M.; Qin, Z. S.; Malek, S.; Wang, S.; Dou, Y. Mol. Cell 2014, 53, 247–
261. 
(268)  Rew, Y.; Sun, D.; Gonzalez-Lopez De Turiso, F.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, 
A.; Chow, D.; Deignan, J.; Fox, B. M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.; 
Kopecky, D. J.; Li, Y.; Lo, M.-C.; Long, A. M.; Michelsen, K.; Oliner, J. D.; Osgood, T.; Ragains, 
M.; Saiki, A. Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, 
J.; Medina, J. C.; Olson, S. H. J. Med. Chem. 2012, 55, 4936–4954. 
(269)  Moll, U. M.; Petrenko, O. Mol. Cancer Res. 2003, 1 , 1001–1008. 
(270)  You, L.; Xu, Z.; Punchihewa, C.; Jablons, D. M.; Fujii, N. Mol. Cancer Ther. 2008, 7, 1633–1638. 
(271)  Vogrig, A.; Dorr, L.; Bouzidi, N.; Boucherle, B.; Wattiez, A.-S.; Cassier, E.; Vallon, G.; Ripoche, I.; 
Abrunhosa-Thomas, I.; Marin, P.; Nauton, L.; Thery, V.; Courteix, C.; Lian, L.-Y.; Ducki, S. ACS 
Chem. Biol. 2013, 8, 2209–2216. 
(272)  Fujii, N.; Shelat, A.; Hall, R. a; Guy, R. K. Bioorg. Med. Chem. Lett. 2007, 17, 546–548. 
(273)  Mahindroo, N.; Punchihewa, C.; Bail, A. M.; Fujii, N. Bioorg. Med. Chem. Lett. 2008, 18, 946–
949. 
(274)  Mayasundari, A.; Ferreira, A. M.; He, L.; Mahindroo, N.; Bashford, D.; Fujii, N. Bioorg. Med. 
Chem. Lett. 2008, 18, 942–945. 
(275)  Hammond, M. C.; Harris, B. Z.; Lim, W.; Bartlett, P. Chem. Biol. 2006, 13, 1247–1251. 
(276)  Jeleo, F.; Oleksy, A.; Smietana, K.; Otlewski, J. Acta Biochim. Pol. 2003, 50, 985–1017. 
(277)  Pan, L.; Wu, H.; Shen, C.; Shi, Y.; Jin, W.; Xia, J.; Zhang, M. EMBO J 2007, 26, 4576–4587. 
(278)  Dev, K. K. Nat. Rev. Drug Discov. 2004, 3, 1047–1056. 
(279)  Dev, K. K. Curr. Top. Med. Chem. 2007, 7, 3–20. 
(280)  Wang, C. Extended PDZ Domain Database http://bcz102.ust.hk/pdzex/. 
(281)  Aarts, M.; Liu, Y.; Liu, L.; Besshoh, S.; Arundine, M.; Gurd, J. W.; Wang, Y.-T.; Salter, M. W.; 
Tymianski, M. Science 2002, 298, 846–850. 
(282)  Joshi, M.; Vargas, C.; Boisguerin, P.; Diehl, A.; Krause, G.; Schmieder, P.; Moelling, K.; Hagen, 
V.; Schade, M.; Oschkinat, H. Angew. Chem. Int. Ed. Engl. 2006, 45, 3790–3795. 
(283)  Fujii, N.; You, L.; Xu, Z.; Uematsu, K.; Shan, J.; He, B.; Mikami, I.; Edmondson, L. R.; Neale, G.; 
Zheng, J.; Guy, R. K.; Jablons, D. M. Cancer Res. 2007, 67, 573–579. 
(284)  Subbaiah, V. K.; Kranjec, C.; Thomas, M.; Banks, L. Biochem. J. 2011, 439, 195–205. 
(285)  Thorsen, T. S.; Madsen, K. L.; Rebola, N.; Rathje, M.; Anggono, V.; Bach, A.; Moreira, I. S.; 
Stuhr-Hansen, N.; Dyhring, T.; Peters, D.; Beuming, T.; Huganir, R.; Weinstein, H.; Mulle, C.; 
Strømgaard, K.; Rønn, L. C. B.; Gether, U. Proc. Natl. Acad. Sci. USA 2010, 107, 413–418. 
(286)  Bolia, A.; Gerek, Z. N.; Keskin, O.; Banu Ozkan, S.; Dev, K. K. Proteins 2012, 80, 1393–1408. 
Bibliography 
 
245 
 
(287)  Perez, J. L.; Khatri, L.; Chang, C.; Srivastava, S.; Osten, P.; Ziff, E. B. J. Neurosci. 2001, 21, 5417–
5428. 
(288)  Zhang, B.; Cao, W.; Zhang, F.; Zhang, L.; Niu, R.; Niu, Y.; Fu, L.; Hao, X.; Cao, X. Cancer Sci. 
2010, 101, 1536–1542. 
(289)  Dev, K. K.; Henley, J. M. Trends Pharmacol. Sci. 2006, 27, 574–579. 
(290)  Hanley, J. G. Pharmacol Ther. 2008, 118, 152–160. 
(291)  Xia, J.; Zhang, X.; Staudinger, J.; Huganir, R. L. Neuron 1999, 22, 179–187. 
(292)  Jaulin-Bastard, F.; Saito, H.; Le Bivic, A.; Ollendorff, V.; Marchetto, S.; Birnbaum, D.; Borg, J. P. 
J. Biol. Chem. 2001, 276, 15256–15263. 
(293)  Hudis, C. A. N. Engl. J. Med. 2007, 357, 39–51. 
(294)  Bach, A.; Stuhr-Hansen, N.; Thorsen, T. S.; Bork, N.; Moreira, I. S.; Frydenvang, K.; Padrah, S.; 
Christensen, S. B.; Madsen, K. L.; Weinstein, H.; Gether, U.; Strømgaard, K. Org. Biomol. 
Chem. 2010, 8, 4281–4288. 
(295)  Fujii, N.; Haresco, J. J.; Novak, K. a P.; Stokoe, D.; Kuntz, I. D.; Guy, R. K. J. Am. Chem. Soc. 
2003, 125, 12074–12075. 
(296)  Fujii, N.; Haresco, J. J.; Novak, K. a P.; Gage, R. M.; Pedemonte, N.; Stokoe, D.; Kuntz, I. D.; 
Guy, R. K. Bioorg. Med. Chem. Lett. 2007, 17, 549–552. 
(297)  Vogrig, A.; Boucherle, B.; Deokar, H.; Thomas, I.; Ripoche, I.; Lian, L.-Y. Y.; Ducki, S. Bioorg. 
Med. Chem. Lett. 2011, 21, 3349–3353. 
(298)  Elkins, J. M.; Papagrigoriou, E.; Berridge, G.; Yang, X.; Phillips, C.; Gileadi, C.; Savitsky, P.; 
Doyle, D. A. Protein Sci. 2007, 16, 683–694. 
(299)  Madsen, K. L.; Beuming, T.; Niv, M. Y.; Chang, C.-W.; Dev, K. K.; Weinstein, H.; Gether, U. J. 
Biol. Chem. 2005, 280, 20539–20548. 
(300)  Shi, Y. Biochemistry 2010, 49, 4432–4439. 
(301)  Xu, J.; Xia, J. Neurosignals. 2007, 15, 190–201. 
(302)  Dougherty, D. A. Science 1996, 271, 163–168. 
(303)  Burley, S. K.; Petsko, G. A. FEBS Lett. 1986, 203, 139–143. 
(304)  Gallivan, J. P.; Dougherty, D. A. Proc. Natl. Acad. Sci. 1999, 96 , 9459–9464. 
(305)  Crowley, P. B.; Golovin, A. Proteins Struct. Funct. Bioinforma. 2005, 59, 231–239. 
(306)  Zhong, W.; Gallivan, J. P.; Zhang, Y.; Li, L.; Lester, H. A.; Dougherty, D. A. Proc. Natl. Acad. Sci. 
1998, 95 , 12088–12093. 
(307)  Bissantz, C.; Kuhn, B.; Stahl, M. J. Med. Chem. 2010, 53, 5061–5084. 
(308)  Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Proteins Struct. Funct. 
Bioinforma. 2003, 52, 609–623. 
(309)  Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V; Mee, R. P. J. Comput. Aided Mol. 
Des. 1997, 11, 425–445. 
(310)  Salonen, L. M.; Bucher, C.; Banner, D. W.; Haap, W.; Mary, J. L.; Benz, J.; Kuster, O.; Seiler, P.; 
Schweizer, W. B.; Diederich, F. Angew. Chem. Int. Ed. Engl. 2009, 48, 811–814. 
(311)  Ma, J. C.; Dougherty, D. A. Chem. Rev. 1997, 97, 1303–1324. 
(312)  Jesús Ezquerra; Ezquerra, J.; Pedregal, C.; Lamas, C.; Barluenga, J.; Pérez, M.; García-Martín, 
M. A.; González, J. M. J. Org. Chem. 1996, 61, 5804–5812. 
(313)  Pelkey, E.; Gribble, G. Synthesis (Stuttg). 1999, 7, 1117–1122. 
(314)  Roy, S. S.; Gribble, G. W. Tetrahedron Lett. 2008, 49, 1531–1533. 
(315)  Çalimsiz, S.; Organ, M. G. Chem. Commun. (Camb) 2011, 47, 5181–5183. 
(316)  Han, C.; Buchwald, S. L. J. Am. Chem. Soc. 2009, 131, 7532–7533. 
(317)  Tamao, K.; Kiso, Y.; Sumitani, K.; Kumada, M. J. Am. Chem. Soc. 1972, 94, 9268–9269. 
(318)  Hayashi, T.; Konishi, M.; Kobori, Y.; Kumada, M.; Higuchi, T.; Hirotsu, K. J. Am. Chem. Soc. 
1984, 106, 158–163. 
(319)  Dreher, S. D.; Dormer, P. G.; Sandrock, D. L.; Molander, G. A. J. Am. Chem. Soc. 2008, 130, 
9257–9259. 
(320)  Joshi-Pangu, A.; Ganesh, M.; Biscoe, M. R. Org. Lett. 2011, 13, 1218–1221. 
Bibliography 
 
246 
 
(321)  Zhang, F.; Zhao, Y.; Sun, L.; Ding, L.; Gu, Y.; Gong, P. Eur. J. Med. Chem. 2011, 46, 3149–3157. 
(322)  Ray, S.; Patra, A.; Mal, D. Tetrahedron 2008, 64, 3253–3267. 
(323)  Nakamura, K.; Inoue, K.; Ushio, K.; Oka, S.; Ohno, A. J. Org. Chem. 1988, 53, 2589–2593. 
(324)  Roznyatovskiy, V.; Lynch, V.; Sessler, J. L. Org. Lett. 2010, 12, 4424–4427. 
(325)  Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, D. V. 
S.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S. Nat. Rev. 
Drug Discov. 2011, 10, 188–195. 
(326)  Mayr, L. M.; Fuerst, P. J. Biomol. Screen. 2008, 13 , 443–448. 
(327)  Liu, B.; Li, S.; Hu, J. Am. J. Pharmacogenomics 2004, 4, 263–276. 
(328)  Cesa, L. C.; Patury, S.; Komiyama, T.; Ahmad, A.; Zuiderweg, E. R. P.; Gestwicki, J. E. ACS Chem. 
Biol. 2013, 8, 1988–1997. 
(329)  Heeres, J. T.; Hergenrother, P. J. Chem. Soc. Rev. 2011, 40, 4398–4410. 
(330)  Lokey, R. S. Curr. Opin. Chem. Biol. 2003, 7, 91–96. 
(331)  Choi, H.; Kim, J.-Y.; Chang, Y.; Nam, H. In Arabidopsis Protocols SE  - 21; Sanchez-Serrano, J. J.; 
Salinas, J., Eds.; Methods in Molecular Biology; Humana Press, 2014; Vol. 1062, pp. 393–404. 
(332)  Haggarty, S. J.; Schreiber, S. L. In Chemical Biology; Wiley-VCH Verlag GmbH, 2008; pp. 299–
354. 
(333)  Das, R. K.; Samanta, A.; Ghosh, K.; Zhai, D.; Xu, W.; Su, D.; Leong, C.; Young-Tae, C. Interdiscip. 
Bio Cent. 2011, 3, 1–18. 
(334)  Ares, J.; Durán-Peña, Maj.; Hernández-Galán, R.; Collado, I. Phytochem. Rev. 2013, 12, 895–
914. 
(335)  McCarthy, A. R.; Hollick, J. J.; Westwood, N. J. Semin. Cancer Biol. 2010, 20, 40–45. 
(336)  Berkson, R. G.; Hollick, J. J.; Westwood, N. J.; Woods, J. A.; Lane, D. P.; Lain, S. Int. J. Cancer 
2005, 115, 701–710. 
(337)  Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; 
Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J. R.; 
Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Cancer Cell 2008, 13, 454–463. 
(338)  Soussi, T. EMBO Rep. 2010, 11, 822–826. 
(339)  Lane, D. P. Nature 1992, 358, 15–16. 
(340)  Vogelstein, B.; Lane, D.; Levine, A. J. Nature 2000, 408, 307–310. 
(341)  Vousden, K. H.; Prives, C. Cell 2009, 137, 413–431. 
(342)  Zilfou, J. T.; Lowe, S. W. Cold Spring Harb. Perspect. Biol. 2009, 1, a001883. 
(343)  Marine, J. C.; Dyer, M. A.; Jochemsen, A. G. J. Cell Sci. 2007, 120, 371–378. 
(344)  Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Nature 1997, 387, 296–299. 
(345)  Brooks, C. L.; Gu, W. Mol. Cell 2006, 21, 307–315. 
(346)  Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P. Nat. Rev. Cancer 2009, 9, 862–873. 
(347)  Shangary, S.; Wang, S. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 223–241. 
(348)  Wade, M.; Li, Y.-C.; Wahl, G. M. Nat. Rev. Cancer 2013, 13, 83–96. 
(349)  Khosravi, R.; Maya, R.; Gottlieb, T.; Oren, M.; Shiloh, Y.; Shkedy, D. Proc. Natl. Acad. Sci. U S A 
1999, 96, 14973–14977. 
(350)  Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, 
U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. Science 2004, 303, 844–848. 
(351)  Nigro, J. M.; Baker, S. J.; Preisinger, A. C.; Jessup, J. M.; Hostetter, R.; Cleary, K.; Bigner, S. H.; 
Davidson, N.; Baylin, S.; Devilee, P.; et al. Nature 1989, 342, 705–708. 
(352)  Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. Science 1991, 253, 49–53. 
(353)  Lain, S.; Lane, D. Eur. J. Cancer. 2003, 39, 1053–1060. 
(354)  Muller, P. Y.; Milton, M. N. Nat. Rev. Drug Discov. 2012, 11, 751–761. 
(355)  Ma, Q.; Lu, A. Y. Pharmacol. Rev. 2011, 63, 437–459. 
(356)  Claramunt, R. M.; López, C.; Pérez-Medina, C.; Pinilla, E.; Torres, M. R.; Elguero, J. 
Tetrahedron 2006, 62, 11704–11713. 
Bibliography 
 
247 
 
(357)  Hoefle, M. L.; Short, F. Antiinflammatory 1-phenyl-1H-indazole-4-acetic acids. US 3657270 A, 
1972. 
(358)  Tanuwidjaja, J.; Peltier, H. M.; Ellman, J. A. J. Org. Chem. 2007, 72, 626–629. 
(359)  Borg, G.; Cogan, D. A.; Ellman, J. A. Tetrahedron Lett. 1999, 40, 6709–6712. 
(360)  Weber, J. D. Genes Dev. 2000, 14, 2358–2365. 
(361)  Bai, Y.; Lu, Z.; Lin, Y.; Sun, B. Oncol. Res. Featur. Preclin. Clin. Cancer Ther. 2013, 21, 23–1. 
(362)  Williams, R. T.; Sherr, C. J. Cold Spring Harb. Symp. Quant. Biol. 2008, 73 , 461–467.  
Appendices 
 
248 
 
Appendix A: The 31 hits selected for testing in the reptin-AGR2 
peptide binding assay (Chapter 2). 
Visual analysis of the top 100 hits identified the presence of 15 different groups of compounds. 
Groups 1-13 were classified based on a similar structural core. 1-3 analogues were purchased from 
each group for testing depending on the size and structural diversity of the group. Group 14 
contained the remaining analogues that did not contain a common structural core, of which 7 were 
purchased for testing. 
Group 10 Group 11 Group 12 Group 15 (singular)
Group 13 Group 14
Group 6 Group 7 Group 8 Group 9
Group 5Group 1 Group 2 Group 3 Group 4
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Appendix B: 1H NMR spectra provided for the purchased analogues of 
hits 17 and 13 (Chapter 2). 
1H NMR spectra provided by Chembridge. 
Compound 37: 
 
Compound 38: 
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Compound 39: 
 
 
 
Compound 40: 
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Compound 41: 
 
 
Compound 3: 
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Compound 61: 
 
 
 
Compound 62: 
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Appendix C: 1H and 13C NMR spectra of (R,R)-Harzianic acid (19) in 
CDCl3 and MeOD (Chapter 3) 
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Appendix D: 1H and 13C NMR spectra of (S,R)-5’epiHarzianic acid (19b) 
in CDCl3 and MeOD (Chapter 3) 
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Appendix E: NOE analysis, 1H and COSY NMR spectras of (±)-68 
(Chapter 3) 
 
 
 
 
(1) In CDCl3 at room temperature the (±)-68 exists as a (3 : 1) keto : enol mixture. NOE analysis of the 
major keto tautomer is shown. (2) An NOE was observed between C1-H and C2’-H2, C2-H and C4a-H, 
demonstrating C1-H, C2-H and C4a-H are cofacial. (3) An NOE was observed between C2-H and C1-H, 
C2’-H2, C2-CH3 and C3-H, confirming the presence of C1-H and C2-H on the same face of the decalin 
ring. (4) An NOE was observed between C2-CH3 and C2-H, C2’-H2, C8a-H and C3-H, demonstrating 
C2-CH3 and C8a-H are cofacial. The NOE analysis confirms the formation of the predicted endo-
diastereomer of (±)-68. Relative stereochemistry of (±)-68 is shown.  
 
 
 
C2’-H2 C1-H C2-H C2-CH3 
C4a-H 
C8a-H 
C3-H 
(1) 
(3) 
(2) 
(4) 
(5) 
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m.
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Appendix F: 1H and 13C NMR spectra of JBIR-22 diastereomeric 
mixture 4a/b (Chapter 3) 
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Appendix G: Full GC chromatograms of (±)-90, 90a and 90b (Chapter 
3) 
 
Full GC traces of (±)-90, 90a and 90b. GC analyses were obtained on a Shimadzu GC consisting of a 
Shimadzu AOC-20i auto injector and a Shimadzu GC-2025 gas chromatograph. Analysis was 
performed using Shimadzu GCsolution v2.41 software and separation was achieved using an Agilent 
Cyclosil-B column. The minor diastereomers of 90a and 90b can be observed with retention times 
between 20-22 minutes. 
 
 
 
 
(±)-90 
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90a 
90b 
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Appendix H: 1H and 13C NMR spectra of 4a and 4b (Chapter 3) 
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Appendix I: 1H NMR spectrum of a sample of the isolated JBIR-22 (4) 
(Chapter 3) 
 
1H NMR spectrum of an authentic sample (0.5 mg) of JBIR-22 (4) obtained from Dr Kazuo Shin-ya, 
National Institute of Advanced Industrial Science (AIST), Japan. Spectrum was obtained in acetone-d6 
using a 1.75 mm probe. 
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Appendix J: NMR spectra of the product resulting from the achiral 
catalysed cycloaddition of 65 (Chapter 3) 
 
1H NMR spectrum of the crude reaction mixture of the IMDA cycloaddition of 65. 
 
13C NMR spectrum of crude reaction mixture in acetone-d6. Two sections of the NMR spectrum are 
magnified to highlight the characteristic doubling of the carbon signals resulting from the formation 
of a mixture of diastereomers (77a/b). 
 
1H NMR 
Acetone-d6 
500 MHz 
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Appendix K: GoldScore of a selection of the docked PICK1 series 1 
inhibitors (Chapter 4) 
 
No. R1 R2 R3 GoldScore 
1 methyl ethylbenzene ethyl 57.86 
2 sec-butyl ethylbenzene propyl 57.75 
3 2-methylpentane ethylbenzene ethyl 57.73 
4 sec-butyl ethylbenzene cyclopropyl 57.74 
5 iso-propyl ethylbenzene iso-butyl 58.79 
6 methyl n-butyl ethylbenzene 58.18 
7 iso-propyl n-butyl ethyl 54.95 
8 methyl n-butyl benzyl 52.38 
9 iso-propyl n-butyl iso-butyl 56.72 
10 methyl iso-butyl ethylbenzene 55.17 
11 iso-propyl iso-butyl iso-propyl 54.82 
12 iso-propyl iso-butyl ethyl 53.97 
13 methyl iso-butyl iso-butyl 48.68 
14 methyl iso-propyl benzyl 48.32 
15 iso-propyl iso-propyl ethyl 48.64 
16 iso-propyl iso-propyl iso-propyl 49.57 
17 methyl benzyl iso-propyl 50.31 
18 iso-propyl benzyl ethyl 55.55 
19 iso-propyl benzyl iso-butyl 56.65 
20 methyl ethyl phenyl 49.72 
21 iso-propyl ethyl ethyl 51.53 
22 iso-propyl ethyl benzyl 58.92 
23 iso-propyl N,N-dimethylethylamine ethylbenzene 62.74 
24 iso-propyl N,N-dimethylethylamine ethyl 53.69 
25 iso-propyl N,N-dimethylethylamine iso-butyl 57.67 
 
A selection of the compounds docked into the PDZ domain of the X-ray crystal structure of PICK1 
[PDB: 3HPK] after extraction of the GluR2 (-EVKI) ligand. Only compounds which docked in the PICK1 
PDZ domain and mimicked the pose of the natural peptide (-VKI) are reported.  
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Appendix L: Crystal Data and Structural Refinement of Small Molecule 
X-ray of 46 (Chapter 3) 
 
Empirical Formula C14H23NO5S 
Formula Weight 317.40 
Crystal Color, Habit colorless, prism 
Crystal Dimensions 0.120 X 0.050 X 0.050 mm 
Crystal System orthorhombic 
Lattice Type Primitive 
Lattice Parameters a =  5.5980(11) Å 
 b =  15.959(4) Å 
 c =  18.735(4) Å 
 V = 1673.8(6) Å3 
Space Group P212121 (#19) 
Z value 4 
Dcalc 1.259 g/cm3 
F000 680.00 
μ(MoKα) 2.124 cm-1 
Diffractometer XtaLAB P200 
Radiation MoKα (λ = 0.71075 Å) 
 multi-layer mirror monochromated 
Voltage, Current 45kV, 66mA 
Temperature -180.0oC 
Detector Aperture 83.8 x 70.0 mm 
Data Images 439 exposures 
Pixel Size 0.172 mm 
2θmax 50.7o 
No. of Reflections Measured Total: 7588 
 Unique: 3006 (Rint = 0.0403) 
 Parsons quotients (Flack x parameter): 935 
Corrections Lorentz-polarization 
  Absorption 
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  (trans. factors: 0.733 - 0.989) 
Structure Solution Direct Methods (SIR2011) 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.0000 . P)2  
  + 0.0000 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 50.7o 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All reflections) 3006 
No. Variables 194 
Reflection/Parameter Ratio 15.49 
Residuals: R1 (I>2.00σ(I)) 0.0239 
Residuals: R (All reflections) 0.0273 
Residuals: wR2 (All reflections) 0.0547 
Goodness of Fit Indicator 0.542 
Flack parameter (Parsons' quotients = 935) 0.03(4) 
Max Shift/Error in Final Cycle 0.001 
Maximum peak in Final Diff. Map 0.18 e‑/Å3 
Minimum peak in Final Diff. Map   -0.19 e‑/Å3 
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Appendix M: Crystal Data and Structural Refinement of Small 
Molecule X-ray of 91a (Chapter 3) 
 
Empirical Formula C12H18O2 
Formula Weight 194.27 
Crystal Color, Habit colorless, platelet 
Crystal Dimensions 0.150 X 0.150 X 0.010 mm 
Crystal System tetragonal 
Lattice Type Primitive 
Lattice Parameters a =   7.8129(11) Å 
 c =  35.798(6) Å 
 V = 2185.2(6) Å3 
Space Group P43212 (#96) 
Z value 8 
Dcalc 1.181 g/cm3 
F000 848.00 
μ(CuKα) 6.232 cm-1 
Diffractometer XtaLAB P100 
Radiation CuKα (λ = 1.54187 Å) 
 multi-layer mirror monochromated 
Voltage, Current 40kV, 30mA 
Temperature -100.0oC 
Detector Aperture 83.8 x 33.5 mm 
Data Images 3983 exposures 
Pixel Size 0.172 mm 
2θmax 136.3o 
No. of Reflections Measured Total: 23076 
 Unique: 2000 (Rint = 0.0544) 
 Parsons quotients (Flack x parameter): 692 
Corrections Lorentz-polarization 
  Absorption 
  (trans. factors: 0.800 - 0.994) 
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Structure Solution Direct Methods (SIR2011) 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.0725 . P)2  
  + 0.0550 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 136.3o 
Anomalous Dispersion All non-hydrogen atoms 
 
No. Observations (All reflections) 2000 
No. Variables 132 
Reflection/Parameter Ratio 15.15 
Residuals: R1 (I>2.00σ(I)) 0.0373 
Residuals: R (All reflections) 0.0387 
Residuals: wR2 (All reflections) 0.1000 
Goodness of Fit Indicator 1.085 
Flack parameter (Parsons' quotients = 692) -0.04(9) 
Max Shift/Error in Final Cycle 0.000 
Maximum peak in Final Diff. Map 0.21 e‑/Å3 
Minimum peak in Final Diff. Map   -0.20 e‑/Å3 
Appendices 
 
271 
 
Appendix N: Crystal Data and Structural Refinement of Small Molecule 
X-ray of 91b (Chapter 3) 
 
Empirical Formula C12H18O2 
Formula Weight 194.27 
Crystal Color, Habit colorless, platelet 
Crystal Dimensions 0.300 X 0.140 X 0.030 mm 
Crystal System tetragonal 
Lattice Type Primitive 
Lattice Parameters a =   7.8135(7) Å 
 c =  35.790(4) Å 
 V = 2185.0(4) Å3 
Space Group P41212 (#92) 
Z value 8 
Dcalc 1.181 g/cm3 
F000 848.00 
μ(CuKα) 6.232 cm-1 
Diffractometer XtaLAB P100 
Radiation CuKα (λ = 1.54187 Å) 
 multi-layer mirror monochromated 
Voltage, Current 40kV, 30mA 
Temperature -100.0oC 
Detector Aperture 83.8 x 33.5 mm 
Data Images 3983 exposures 
Pixel Size 0.172 mm 
2θmax 136.2o 
No. of Reflections Measured Total: 23224 
 Unique: 1994 (Rint = 0.0614) 
 Parsons quotients (Flack x parameter): 703 
Corrections Lorentz-polarization 
  Absorption 
  (trans. factors: 0.755 - 0.981) 
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Structure Solution Direct Methods (SIR2011) 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.0723 . P)2  
  + 0.1083 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 136.2o 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All reflections) 1994 
No. Variables 132 
Reflection/Parameter Ratio 15.11 
Residuals: R1 (I>2.00σ(I)) 0.0405 
Residuals: R (All reflections) 0.0414 
Residuals: wR2 (All reflections) 0.1063 
Goodness of Fit Indicator 1.104 
 
Flack parameter (Parsons' quotients = 703) -0.03(9) 
Max Shift/Error in Final Cycle 0.000 
Maximum peak in Final Diff. Map 0.24 e‑/Å3 
Minimum peak in Final Diff. Map   -0.20 e‑/Å3 
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Appendix O: Crystal Data and Structural Refinement of Small Molecule 
X-ray of (SSR)-17 (Chapter 5) 
 
Empirical Formula C17H22FN3OS 
Formula Weight 335.44 
Crystal Color, Habit colorless, prism 
Crystal Dimensions 0.200 X 0.100 X 0.030 mm 
Crystal System hexagonal 
Lattice Type Primitive 
Lattice Parameters a =  11.3879(17) Å 
 c =  22.909(4) Å 
 V = 2572.9(7) Å3 
Space Group P65 (#170) 
Z value 6 
Dcalc 1.299 g/cm3 
F000 1068.00 
μ(MoKα) 2.060 cm-1 
Diffractometer Mercury70 
Radiation MoKα (λ = 0.71075 Å) 
Voltage, Current 50kV, 16mA 
Temperature -180.0oC 
Detector Aperture 70.0 x 70.0 mm 
Pixel Size 0.068 mm 
2θmax 50.6o 
No. of Reflections Measured Total: 16327 
 Unique: 3130 (Rint = 0.0377) 
 Parsons quotients (Flack x parameter): 1370 
Corrections Lorentz-polarization 
  Absorption 
  (trans. factors: 0.867 - 0.994) 
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Structure Solution Direct Methods (SIR2004) 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.0517 . P)2  
  + 0.5035 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 50.6o 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All reflections) 3130 
No. Variables 212 
Reflection/Parameter Ratio 14.76 
Residuals: R1 (I>2.00σ(I)) 0.0350 
Residuals: R (All reflections) 0.0369 
Residuals: wR2 (All reflections) 0.0902 
Goodness of Fit Indicator 1.040 
Flack parameter (Parsons' quotients = 1370) -0.00(3) 
Max Shift/Error in Final Cycle 0.000 
Maximum peak in Final Diff. Map 0.59 e‑/Å3 
Minimum peak in Final Diff. Map   -0.24 e‑/Å3 
